stemcellwellbeinginternationalscams

Behind the Investment: Where Does Wellbeing International Foundation's Money Go?

Sun, 11 Oct 2026 09:29:46 GMT

The Wellbeing Illusion — Chapter Nine

A scientific breakthrough can attract attention. A compelling patient story can inspire hope. An international network of clinics can create confidence.

But when an organisation begins raising private investment, an entirely different set of questions becomes necessary.

Questions that cannot be answered by patient testimonials, scientific biographies or photographs of medical facilities.

Who receives the money? Who controls the business? What assets support its valuation? And what does an investor actually own?

These questions now sit at the centre of our investigation into Wellbeing International Foundation, the organisation promoting a biological intervention known as Cell-Free Therapy, or CFT.

For several chapters, we have examined the organisation's clinical network, German laboratory arrangements, scientific history, clinical evidence and historical intellectual-property connections.

We found a complex picture involving independent medical providers, external laboratory relationships and an earlier biotechnology company associated with some of the scientific personnel now connected with Wellbeing.

None of those findings establishes financial misconduct.

But they make the next stage of the investigation particularly important.

Because in March 2026, Wellbeing publicly announced that it had closed the first tranche of a private capital-raising round.

The announcement marked a significant moment.

The organisation was no longer simply presenting a medical programme to prospective patients.

It was also describing an opportunity for private capital to support its future development.

And that raises a question every prospective investor should be able to answer.

What exactly is the investment funding, and who stands to benefit?

The Capital-Raising Announcement

Wellbeing's March 2026 announcement stated that the opening tranche of its capital round had closed.

The organisation described the investment as supporting continued scientific work, documentation, operating capacity and expansion of its clinical relationships.

It also indicated that the wider fundraising process remained open.

Specific investment amounts, financial terms and participating investors were not publicly identified.

Wellbeing explained that detailed financial information was handled separately through its legal and finance team.

There is nothing inherently unusual about that arrangement.

Private companies frequently disclose sensitive financial information directly to prospective investors rather than publishing it openly.

Investment agreements, valuations and shareholder details may be subject to confidentiality.

However, there is an important difference between announcing a successful fundraising milestone and demonstrating the financial condition of a business.

A capital-raising announcement does not establish profitability.

It does not establish the company's valuation.

It does not show the amount of money held in the bank.

And it does not reveal what percentage of the organisation has been sold.

Those questions require financial documents.

The announcement is therefore evidence of what Wellbeing publicly reported about its fundraising activity, not independent proof of the financial merits of the investment.

First Identify the Company

The first difficulty in assessing a private investment is often surprisingly basic.

Which legal entity is actually issuing the investment?

Wellbeing International Foundation is the name presented publicly.

Its website identifies a headquarters in Hamilton, Bermuda.

But a public-facing organisation and the legal company issuing shares or other investment instruments are not necessarily the same entity.

A business may operate through a holding company, subsidiaries, affiliated companies or separate commercial vehicles.

That structure can be entirely legitimate.

It can also make investment analysis considerably more complicated.

An investor may believe they are acquiring an interest in an international biotechnology operation.

But the rights attached to that investment depend on the specific company issuing it.

Does that company own the intellectual property?

Does it receive the patient revenue?

Does it control the laboratory agreements?

Does it hold the clinical contracts?

Does it own shares in the operating companies?

Or is it primarily an entity through which investment is collected and allocated?

The answers determine what the investor is buying.

A percentage of one company does not automatically provide ownership of every business associated with the same commercial network.

Before considering potential returns, an investor needs a complete understanding of the corporate structure.

Three Different Sources of Funding

Wellbeing's public explanation of its financial model identifies three broad sources of support.

Private investment.

Patient revenue.

Selective philanthropic engagement.

These sources serve different purposes and create different financial obligations.

Patient revenue is generated when individuals purchase treatment-related services.

Investment capital is contributed under specific financial arrangements, potentially in exchange for shares or other economic rights.

Philanthropic support may be provided to advance a mission without creating an ownership interest.

There is nothing inherently problematic about combining these sources.

Research-oriented businesses sometimes depend on investment while generating commercial revenue and receiving external support.

But the accounting treatment and legal rights attached to each source matter.

Patient payments should not be confused with investor contributions.

Investment proceeds should not automatically be treated as operating revenue.

And philanthropic contributions should not be assumed to create shareholder rights.

The organisation's use of the word Foundation also deserves clarification.

The name alone does not establish that the relevant legal entity is a registered charity, a nonprofit organisation or prohibited from distributing profits.

Those matters depend on its registration and governing documents.

For anyone considering investment, the distinction is fundamental.

What We Learned About Patient Pricing

Historical material obtained during our investigation provides an indication of the commercial scale of Wellbeing's treatment programme.

During consultations recorded in 2020 and 2021, prospective patients were quoted substantial amounts for treatment arrangements.

One historical discussion referred to an initial programme costing approximately $40,000, with subsequent infusions discussed at a substantially lower price.

Another involved an American prospective patient being quoted approximately $48,000 for a two-treatment arrangement.

These figures must be understood in context.

They were historical quotations.

They are not verified current prices.

They do not establish how many patients purchased treatment.

And they are not proof that the quoted sums were ultimately received.

Nevertheless, they demonstrate that the programme has historically been marketed as a high-value medical service.

That matters because a business charging tens of thousands of dollars per patient may generate significant gross revenue.

But the treatment price is only the beginning of the financial calculation.

The Difference Between Revenue and Profit

A patient paying $40,000 does not mean Wellbeing earns $40,000 in profit.

The treatment pathway involves multiple services and potentially multiple businesses.

There may be charges for medical consultations, blood collection, biological-material transportation, laboratory processing, quality control, storage and clinical administration.

There are also ordinary operating expenses.

Staff salaries.

Professional fees.

Insurance.

Marketing.

Research.

Administration.

Regulatory and legal advice.

And the costs associated with maintaining an international commercial network.

The central question is how much revenue remains after these costs.

Consider a purely illustrative example.

If 100 patients each paid $40,000, the total amount billed would be $4 million.

That sounds substantial.

But it would not establish that Wellbeing itself received all $4 million.

It would not establish the company's profit.

And it would not tell us whether the business was financially sustainable.

The payment arrangements between the patient, laboratory, clinical provider and coordinating organisation would determine how the revenue was distributed.

Without those agreements and the relevant accounts, any calculation of profitability would be speculation.

Following the Payment Through the Treatment Network

The international structure examined in earlier chapters becomes particularly relevant when we consider the financial pathway.

A patient may receive a consultation in one country.

Their blood may be collected by an independent practitioner.

The sample may be transported by a specialist courier.

Processing may take place at a German laboratory.

The finished preparation may then be administered at another medical facility.

Each stage may involve a separate legal entity.

Who invoices the patient?

Who collects the full treatment fee?

Does the laboratory invoice Wellbeing or the patient?

Does the treating physician receive a fixed fee or a percentage of the treatment price?

Does the clinical facility charge separately?

Are referral payments involved?

Which organisation retains the remaining commercial margin?

These questions are not allegations.

They are the basic mechanics of understanding a distributed healthcare business.

A company can coordinate a valuable international service without receiving every payment generated by the network.

The financial statements should therefore distinguish the revenue of the central organisation from the wider economic activity associated with its partners.

The Physician Programme and Its Commercial Incentives

Wellbeing's published physician partnership programme offers another insight into its financial strategy.

The programme is aimed at established medical practitioners, including those already involved in regenerative procedures.

It promotes opportunities associated with premium services, patient acquisition, repeat infusions and cell banking.

This is a commercial proposition as well as a medical one.

The organisation is encouraging practitioners to incorporate its programme into existing businesses.

For a physician, the attraction may include additional patient services and new revenue opportunities.

For Wellbeing, the arrangement may provide access to patients and clinical facilities without requiring the organisation to establish its own clinics in every location.

That can be a commercially efficient strategy.

But it creates questions about financial incentives.

Are physicians paid for administering treatment?

Are they rewarded for referring patients?

Are they offered revenue-sharing arrangements?

Do they receive recurring income from repeat procedures or biological-material storage?

And what safeguards ensure that commercial incentives do not interfere with independent medical judgment?

We have not established the contractual answers.

The point is that the financial structure of a medical partnership can be as important as its clinical structure.

Patients should be able to understand who is responsible for their care.

Investors should be able to understand who receives the revenue.

The Attraction of Repeat Treatment

One aspect of Wellbeing's business model deserves particular attention.

Repeat infusions and cell banking.

From a commercial perspective, repeat business can be extremely valuable.

A patient who purchases one treatment generates a single transaction.

A patient who returns for additional procedures may generate revenue over several years.

If biological material is stored for future use, ongoing storage fees may create another source of income.

This could make the business less dependent on continually recruiting new patients.

But projected recurring revenue is not the same as demonstrated recurring revenue.

The relevant figures would include the number of active storage customers, repeat-treatment rates, annual revenue per patient and the percentage of customers who discontinue the service.

Those are measurable indicators.

Without them, it is difficult to determine whether the model produces predictable income or merely offers the possibility of doing so.

An investor should distinguish between the commercial opportunities described in marketing material and the actual financial performance recorded in the accounts.

Who Controls the Organisation?

Wellbeing's leadership structure includes chairman Max Lewinsohn, chief executive Andrew Chancellor and scientific personnel associated with the development of its treatment programme.

Its public materials also identify members of the Lewinsohn family in senior commercial roles.

Family participation in a private business is not inherently unusual or inappropriate.

Many established companies are controlled by founders and their relatives.

But investors need to understand the difference between management, ownership and control.

A director may manage a company without owning a majority of its shares.

A shareholder may possess substantial economic rights without managing daily operations.

And voting arrangements may allow one group to retain control even after new investors contribute capital.

The questions are therefore straightforward.

Who holds the voting shares?

Who can appoint or remove directors?

Who approves major expenditure?

Who determines executive remuneration?

Who can authorise the sale of company assets?

And what rights do new investors receive?

These questions become especially important when minority investors may have limited influence over management decisions.

Related-Party Transactions: Why They Matter

In any privately controlled business, related-party transactions deserve careful examination.

A related-party transaction may involve a company paying a director, shareholder, family member or another business connected with them.

Such transactions can be entirely legitimate.

They may include salaries, consultancy fees, loans, property arrangements or payments for specialist services.

But they should be appropriately authorised, recorded and disclosed where required.

Why does this matter?

Because the amount of money entering a company does not necessarily tell investors how much value will remain for shareholders.

A business may generate revenue while incurring substantial management expenses.

It may pay consultants.

It may repay loans.

It may purchase services from connected businesses.

None of these payments is automatically improper.

But investors should understand their nature, amounts and commercial justification.

We have not established that Wellbeing has made improper related-party payments.

Nor have we established the remuneration of its directors.

The question is whether prospective investors receive sufficient financial disclosure to assess the company's expenditure and governance arrangements.

The Scientific Assets and the Financial Valuation

The ownership questions raised in Chapter Eight now become financially significant.

Our earlier investigation identified a historical microvesicle patent family associated with Lydac Neuroscience Ltd.

Stephen Ray was named as an inventor.

Lydac was the original patent applicant and assignee.

The company subsequently entered administration, liquidation and dissolution.

We did not establish that Wellbeing's present CFT technology uses those patents.

Nor did we establish that any intellectual-property transfer was improper.

But the history illustrates an important principle.

A biotechnology company's valuation depends partly on the rights it actually owns or controls.

If a business owns valuable patents, those rights may contribute to its worth.

If it licenses technology, the terms of the licence matter.

If its processes are protected through confidential know-how, the legal arrangements controlling that knowledge matter.

And if the technology depends heavily on an individual scientist or an external laboratory, investors need to understand the commercial consequences of that dependency.

Scientific experience can be valuable.

But it is not automatically a company-owned asset.

How Much Is Wellbeing Worth?

This is the question at the centre of any investment round.

What valuation has been placed on the company?

And how was that valuation calculated?

A biotechnology business might be valued using current financial performance, projected revenue, proprietary technology, clinical data, commercial contracts or anticipated future growth.

But each method carries assumptions.

A business generating reliable profits can be assessed differently from one that remains dependent upon external capital.

A company with exclusive intellectual-property rights may have a different competitive position from one operating through non-exclusive partnerships.

And a treatment supported by large, controlled clinical trials may have a different risk profile from one supported primarily by exploratory research.

Wellbeing's 2026 capital announcement does not publicly disclose the valuation or the securities issued.

That does not mean prospective investors cannot obtain the information privately.

But without those details, an outside observer cannot determine whether the investment price is reasonable.

The Clinical Evidence Still Matters

The financial investigation cannot be separated from the scientific one.

Wellbeing's peer-reviewed pilot study, published in Frontiers in Aging in June 2026, provides early human research data.

It is an important addition to the organisation's published evidence.

But it was a small, open-label, single-arm study without a control group.

Sixteen participants were enrolled and fourteen completed the programme.

The intervention involved several components, including lifestyle measures, supplements and two infusions of autologous conditioned media.

That design limits the conclusions that can be drawn about the independent effects of CFT.

The study does not establish clinical efficacy through a controlled comparison.

It does, however, provide a basis for further investigation.

For investors, this distinction matters.

A promising pilot study may support additional research.

It does not guarantee regulatory acceptance, widespread clinical adoption or future commercial success.

Further trials may require significant funding.

And the results may not confirm the expectations created by early observations.

That uncertainty is a central feature of biotechnology investment.

Where Will the New Capital Be Spent?

Wellbeing's announcement identifies research, documentation, operational capacity and clinical-network expansion as areas supported by the 2026 fundraising.

Those categories cover a wide range of possible expenditure.

Scientific research may involve laboratory experiments, analytical testing, clinical studies or work with independent institutions.

Documentation may involve technical reports, regulatory submissions or scientific publications.

Operational development may include personnel, administration, systems and infrastructure.

Network expansion may involve recruiting physicians, establishing new partnerships and marketing services.

All can be legitimate uses of capital.

But investors need a budget.

How much is allocated to each category?

What milestones are expected?

What evidence will demonstrate that the expenditure has achieved its purpose?

How long will the capital last?

And what happens if the organisation requires another round of investment before those milestones are reached?

These are ordinary questions in private-company finance.

Without a detailed use-of-funds statement, it is difficult to judge whether the amount being raised is appropriate for the proposed development programme.

The Risk of Future Dilution

An investor acquiring shares in a private company must also consider what happens when additional capital is raised.

If the company issues more shares, an existing shareholder's percentage ownership may decrease.

This is known as dilution.

Dilution is not inherently unfair.

It is a common consequence of financing growth.

But the effect depends on the terms.

Does the investor have pre-emption rights?

Can they participate in future rounds?

Are there convertible instruments that may become shares?

Do any existing investors hold preferential rights?

Could a future fundraising round take place at a lower valuation?

And what happens if an investor cannot contribute additional capital?

These questions can substantially affect the eventual return.

Owning a percentage of a business today does not guarantee retaining the same percentage indefinitely.

Bermuda and the Question of Investor Protection

Wellbeing identifies Bermuda as its headquarters.

Bermuda is an established international corporate jurisdiction.

Its use does not imply wrongdoing.

But the jurisdiction governing an investment affects shareholder rights, reporting obligations, dispute resolution and insolvency procedures.

An investor based in the United Kingdom or Europe should not assume that the protections familiar from domestic company law automatically apply.

The relevant rights depend on the actual issuing entity, its constitutional documents, the investment agreement and applicable law.

Where are disputes resolved?

Can minority shareholders inspect financial records?

What information must directors provide?

Are shares transferable?

Can investors require an exit?

What happens if the business is sold?

And how are shareholder interests treated if the company becomes insolvent?

These matters should be established before funds are transferred.

The Documents That Matter More Than Marketing

By this stage, the investigation reaches a clear conclusion.

The most important unanswered financial questions cannot be resolved through promotional material.

They require documentation.

A prospective investor should be able to examine the identity of the issuing company, its corporate structure, the investment terms, the capitalisation table and the rights attached to the securities offered.

They should also understand the financial statements, liabilities, related-party arrangements and proposed use of funds.

Where technology forms a substantial part of the valuation, the relevant intellectual-property rights and manufacturing agreements should be examined.

And where future revenue depends upon patient treatments, investors should receive reliable financial information about pricing, costs, margins and repeat business.

This is not an extraordinary standard.

It is conventional commercial due diligence.

Private information does not necessarily have to be published to the world.

But it should be available to those being asked to place capital at risk.

What the Public Record Does Not Establish

Our investigation has identified Wellbeing's reported 2026 fundraising activity and several features of its commercial model.

We have examined historical patient pricing discussions, its physician partnership programme, its international treatment pathway and the earlier corporate history associated with its scientific personnel.

But the public information examined does not establish the complete financial position of the investment entity.

We cannot independently confirm the total capital raised.

We cannot establish the valuation used.

We cannot identify the complete shareholder structure.

We cannot calculate the company's profitability.

We cannot determine the distribution of patient revenue among the participating businesses.

And we cannot establish the economic interests of every person or entity connected with the organisation.

Those limitations are important.

They do not establish financial impropriety.

They do not prove that investors have been misled.

And they do not mean the company lacks commercial value.

They mean that the public evidence is insufficient to reach reliable conclusions about the investment's financial merits.

Who Really Benefits?

The answer may involve several groups.

Patients may benefit if the treatment produces meaningful clinical results.

Physicians may receive income from providing medical services.

The laboratory may earn revenue from processing biological material.

Wellbeing may receive commercial revenue from coordinating and supplying the programme.

Employees and consultants may receive remuneration.

Shareholders may benefit if the company becomes more valuable.

And investors may eventually receive financial returns if the business succeeds and their investment terms provide for them.

These outcomes are not mutually exclusive.

A commercially successful healthcare business can create benefits for multiple participants.

But the distribution of financial rewards depends upon contracts, ownership rights and actual financial performance.

Without those records, identifying the ultimate beneficiaries would require assumptions that the evidence does not support.

The Difference Between a Medical Opportunity and an Investment Opportunity

This is the distinction that prospective investors must understand.

A medical intervention may be scientifically interesting without being clinically proven.

A company may generate substantial revenue without producing substantial profit.

A commercial network may operate across numerous countries without owning the facilities involved.

And a business may possess valuable expertise without owning every element of the intellectual property associated with its scientific history.

Each of these distinctions affects valuation.

Each affects risk.

And each matters when private capital is being raised.

The financial proposition must therefore be assessed independently of the scientific narrative.

Investors are not simply purchasing belief in a treatment.

They are acquiring contractual and economic rights in a particular legal entity.

Those rights determine whether they benefit from the company's success.

And they determine their exposure if the business fails.

The Final Question

Our investigation into Wellbeing International Foundation began with its scientific and medical claims.

It moved through the international clinical network, the German laboratory, historical patient experiences, published research and the intellectual-property trail.

Now it has reached the financial structure.

The organisation has publicly reported raising private capital.

It has described a commercial model supported by patient revenue, investment and selective philanthropic engagement.

And it has outlined plans for continued scientific and operational development.

But the public record does not provide enough information to establish the valuation, profitability, ownership structure or financial risk of the investment.

Those matters require documents that cannot be replaced by testimonials, scientific biographies or fundraising announcements.

This does not mean Wellbeing cannot be a legitimate commercial enterprise.

It means that its commercial merits must be demonstrated through the same evidence expected of any serious private investment.

Who owns the assets?

Who controls the company?

Where does the revenue go?

What rights do investors receive?

And what happens if the anticipated commercial success never arrives?

Until those questions are answered with verifiable financial and legal records, the investment proposition remains impossible to assess independently from the public material alone.

The most important lesson is therefore not that private biotechnology investment should be avoided.

It is that scientific promise and financial value are two different things.

A compelling story may explain why someone becomes interested.

Only proper due diligence can establish what they are actually buying.

Coming Next — The Investment Test: What Happens When We Ask for the Documents?

Our investigation now turns to the evidence that could resolve the remaining questions.

The company registrations.

The shareholder structure.

The financial statements.

The intellectual-property agreements.

The laboratory contracts.

And the terms of the investment itself.

Because the real test of an investment proposition is not how impressive it appears in a presentation.

It is whether the documents support the value being placed upon it.

Public reference material

Editorial note: Historical patient quotations are distinguished from verified current prices and financial results. This article examines public disclosures and unanswered due-diligence questions; it does not allege that Wellbeing or its personnel have engaged in financial misconduct.

The Patent Trail: The Failed Biotechnology Company Behind Wellbeing's Scientific History

Sun, 11 Oct 2026 09:24:24 GMT

The Wellbeing Illusion — Chapter Eight, Part Two | Alternative Edition

The search for Wellbeing International Foundation's physical assets led us to an unexpected conclusion.

The most important asset behind its international medical operation might not be a clinic, a laboratory or a building.

It might be something far less visible.

The legal ownership of the science.

In Part One, we examined Wellbeing's international partner clinics, its German laboratory arrangements and its network of independent medical practitioners.

We found a business model that appears to depend substantially on relationships with external providers.

Such an arrangement can be entirely legitimate. Many biotechnology businesses outsource manufacturing and clinical services while retaining ownership of valuable scientific technology.

But that model creates an essential question.

If the clinics are partners and the laboratory is a partner, what proprietary technology does the central organisation actually control?

To investigate, we turned away from medical facilities and began examining patent records, company registrations, historical directorships and insolvency documents.

The records led us to a British biotechnology company whose name rarely features in the public story surrounding Wellbeing International Foundation.

Lydac Neuroscience Ltd.

The company had a documented connection to Stephen Ray, a scientist associated with Wellbeing's research history.

It was also connected, at a later date, to Andrew Chancellor, Wellbeing's chief executive.

And its history included something that made the ownership question considerably more important.

Lydac entered administration, subsequently moved into liquidation and was eventually dissolved.

That does not establish that anything improper happened to its intellectual property.

But it does create a question that deserves a documented answer.

What happened to the scientific rights associated with the earlier company, and do any of those rights form part of Wellbeing's present commercial technology?

The Patent That Opened the Investigation

Our investigation began with a patent family relating to microvesicles.

The European patent, identified as EP2240189B1 and titled Microvesicles, names Stephen Ray as an inventor.

The original applicant and assignee was Lydac Neuroscience Ltd.

The patent family traces its earliest priority to January 2008, with an international application published in 2009.

These are not claims taken from promotional material.

They are details recorded in publicly accessible patent documents.

The patent concerns biological methods involving microvesicles and related cellular processes.

Its subject matter is relevant to the broader scientific field in which Wellbeing describes its work.

But the existence of the patent does not establish that the invention became a clinically effective treatment.

Nor does it prove that Wellbeing's current Cell-Free Therapy, or CFT, uses the same patented process.

That distinction is essential.

A patent can establish that an invention was described and legally claimed. It does not establish that a medical intervention works in patients.

Nevertheless, the records provide a concrete historical link between Stephen Ray, microvesicle research and a separate biotechnology company.

And that link takes us into the question of ownership.

The Scientist Who Invented It Was Not Necessarily the Person Who Owned It

Patent law distinguishes between inventorship and ownership.

The inventor is the person credited with making the invention.

The owner is the person or legal entity holding the relevant patent rights.

Sometimes they are the same.

Often they are not.

A scientist may develop an invention while working for a company that owns the resulting intellectual property.

Alternatively, rights may be assigned through an agreement or transferred later.

The original patent records identify Lydac Neuroscience as the applicant and assignee.

They do not identify Wellbeing International Foundation as the original owner.

That matters because a scientist's expertise can continue from one commercial organisation to another without the underlying patent rights automatically moving with them.

An inventor can leave a company.

They can establish another business.

They can continue researching similar technology.

They can develop entirely new methods.

But none of those events, by itself, transfers ownership of an earlier company's intellectual property.

If the present Wellbeing treatment depends on technology once owned by Lydac, there would need to be a legal explanation for the rights involved.

That might be a patent assignment, a licence, an asset purchase or another enforceable arrangement.

Equally, the present treatment may have developed independently and may not require those historical patent rights at all.

The public record examined in this investigation does not resolve which explanation applies.

Who Was Lydac Neuroscience?

Lydac Neuroscience Ltd was incorporated in England and Wales on 12 September 2007.

Its company number was 06369154.

The company's history can be traced through Companies House, the United Kingdom's official corporate register.

Stephen Ray was appointed a director when Lydac was incorporated.

His directorship ended in July 2012.

Andrew Chancellor was appointed a director in November 2014.

This chronology is important.

The two men were associated with the same company at different times, but the recorded appointments do not establish that they served together as directors.

We should not exaggerate the connection.

Nevertheless, it is a documented corporate relationship between two individuals subsequently associated with the Wellbeing story.

And it connects them to an earlier biotechnology enterprise with an identifiable patent history.

The significance lies not simply in their names appearing on company records.

It lies in what those records may tell us about the commercial development of the scientific technology.

The Harley Street Connection

Lydac's corporate history contains another detail.

In June 2015, the company's registered office moved to 10 Harley Street in London.

The address later appeared in the company's insolvency documentation.

During our separate historical investigation, consultations connected with Wellbeing were recorded at 10 Harley Street during 2020 and 2021.

The overlap is noteworthy.

But it must be interpreted carefully.

Harley Street contains numerous medical and professional consulting facilities. Organisations can use the same address at different times without having the same ownership, directors or legal identity.

The address alone does not establish that Wellbeing was a successor to Lydac.

Nor does it demonstrate that intellectual property moved between the two organisations.

What it does establish is another historical connection worth examining alongside the corporate and scientific records.

The same medical address appears at different points in the histories of the earlier biotechnology company and the later Wellbeing-related activity.

It is a connection, not proof of legal succession.

When the Biotechnology Company Ran Into Financial Trouble

The next stage of Lydac's history is documented in formal insolvency records.

Administrators were appointed to Lydac Neuroscience in December 2018.

The company subsequently entered creditors' voluntary liquidation in November 2019.

It was dissolved on 9 April 2025.

That sequence is significant, but it should not be sensationalised.

Biotechnology companies face substantial financial risks.

Research can be expensive.

Scientific development may take years.

Commercialisation may require further investment.

And promising technologies do not always generate sufficient revenue to sustain a business.

A company entering administration is not, by itself, evidence of misconduct.

Nor does a failed biotechnology venture prove that its scientific work was invalid.

However, insolvency creates an important issue concerning company property.

What happened to the assets?

And, more specifically, what happened to any patents, licences, research rights or proprietary methods held by Lydac?

What Happens to Patents When a Company Fails?

Intellectual property can form part of a company's assets.

That may include patents, patent applications, registered trademarks, contractual rights and commercially valuable technical knowledge.

When a company enters administration or liquidation, those assets may be examined and dealt with as part of the insolvency process.

Depending on the circumstances, intellectual property can be sold, licensed, assigned, abandoned or allowed to expire.

Some assets may have little value.

Others may be worth substantial sums.

But ownership does not automatically pass to a former director or inventor simply because the company ceases trading.

This is why the Lydac history is relevant.

If the earlier microvesicle technology remained commercially important, what happened to the rights attached to it?

Were they sold during the insolvency proceedings?

Had they already been transferred?

Were they licensed to another organisation?

Did the patents cease to be commercially useful?

Or did later scientific developments make them unnecessary?

These are different possibilities.

We have not established which, if any, connects the historical patents to Wellbeing's present CFT programme.

The answer requires documentary evidence.

What the Patent Register Actually Shows

The publicly accessible European patent record identifies Lydac Neuroscience as the original assignee associated with the microvesicle invention.

Google Patents currently describes the European patent as not in force.

However, legal-status information in patent databases carries qualifications and should not be treated as a definitive determination of every legal right.

Patent protection can vary between jurisdictions.

Individual national validations may have different histories.

Assignments may require examination of official registers.

And an expired or lapsed patent does not necessarily eliminate the value of related know-how.

There is also another important distinction.

A patent becoming unenforceable may allow others to practise the disclosed invention, subject to any other applicable rights or restrictions.

That is not the same as acquiring ownership of the patent.

And neither situation establishes ownership of later improvements or confidential manufacturing processes.

Consequently, the historical patent record cannot be used on its own to determine the ownership of Wellbeing's current technology.

It establishes a starting point for investigation, not a completed chain of title.

The German Laboratory Adds Another Layer

In Part One, we examined Wellbeing's historical relationship with a German laboratory.

Recorded discussions from 2021 described a longstanding arrangement in which Stephen Ray was associated with the design of scientific protocols while the German laboratory carried out processing and quality-related work.

This historical evidence is important because it raises questions about the relationship between scientific development and manufacturing.

A protocol may be designed by one person.

It may be refined by another.

A laboratory may develop practical techniques that improve consistency or efficiency.

An organisation may finance further development.

And a separate business may commercialise the final product.

The resulting intellectual-property position can be complicated.

Who owns the original method?

Who owns subsequent improvements?

Who has the right to reproduce the process?

Who controls the manufacturing documentation?

Can the protocol be transferred to another laboratory?

Can the scientist use the same method for another organisation?

Could the laboratory offer similar services to other customers?

The answers depend on contracts and applicable law.

They cannot be established simply by knowing who designed the original protocols or who performed the processing.

This matters because Wellbeing's commercial proposition depends upon its ability to continue providing a distinctive biological intervention.

If that ability relies on intellectual property or know-how controlled by third parties, the relevant agreements become central to the organisation's value.

Does Current CFT Actually Use the Lydac Patents?

This is perhaps the most important scientific qualification in the investigation.

The earlier patent family concerns microvesicles and associated biological methods.

Wellbeing's present treatment materials describe an autologous, blood-derived biological preparation involving conditioned media.

There are broad scientific themes that warrant comparison.

But a resemblance between descriptions is not proof that one process practises the claims of a particular patent.

To determine whether the present CFT process uses the patented invention, investigators would need detailed technical information.

That would include the actual processing steps, biological materials, relevant cell populations, harvesting methods and composition of the finished preparation.

Those details would then need to be compared with the specific patent claims.

We have not established that comparison.

Therefore, we cannot conclude that Wellbeing uses the Lydac patent.

We cannot conclude that a licence to that patent is required.

And we cannot conclude that any intellectual property has been used without authorisation.

But this uncertainty cuts both ways.

If the present CFT process is genuinely different from the earlier invention, the question becomes who developed the new technology and who owns it.

That ownership history is just as important.

Twenty Years of Research Does Not Necessarily Mean Twenty Years of Company-Owned Research

Wellbeing describes a scientific background extending more than twenty years.

The experience of an individual researcher can legitimately contribute to such a history.

A scientist may spend decades studying a particular field while working for different institutions, companies and research programmes.

That experience may be valuable.

But the research history of an individual is not necessarily the asset history of the organisation currently employing or consulting with that individual.

This distinction becomes particularly important when scientific history is used to support commercial credibility.

Consider three different statements.

A scientist has worked in a field for twenty years.

A treatment method has evolved through twenty years of scientific development.

A company owns twenty years' worth of proprietary research and intellectual property.

Those statements are not interchangeable.

Each requires different evidence.

The first may be supported by a professional biography.

The second requires a documented scientific development history.

The third requires evidence of legal ownership or control.

Without those distinctions, a long research narrative can create an impression of corporate assets that has not actually been demonstrated.

Why Ownership Matters to Investors

The intellectual-property question becomes more significant in light of Wellbeing's 2026 private capital round.

The organisation announced in March 2026 that it had closed an opening tranche of investment, with the wider round continuing.

Its stated objectives included further research, documentation, operational development and expansion of clinical relationships.

Those may be legitimate investment purposes.

But an investor must understand what the investment entity actually owns.

If the company owns valuable patents, those rights may support its valuation.

If it holds an exclusive licence, the duration and terms of that licence matter.

If its principal technology is protected by confidential know-how, investors need to understand how that knowledge is controlled.

If manufacturing depends on an external laboratory, contractual continuity matters.

And if the business relies heavily on a particular scientist, the arrangements governing that person's expertise and intellectual-property contributions may be commercially critical.

The existence of a scientific history is not enough.

The investment entity must have identifiable rights that allow it to benefit from the technology.

The Missing Documentary Bridge

Our investigation has established a series of historical facts.

There was an earlier British biotechnology company.

That company was associated with a microvesicle patent family.

Stephen Ray was named as an inventor.

Lydac Neuroscience was the original patent applicant and assignee.

Stephen Ray served as a director during the company's early history.

Andrew Chancellor became a director later.

Lydac subsequently entered insolvency proceedings and was dissolved.

Historical material also documents scientific and laboratory relationships involving personnel associated with Wellbeing.

But these facts do not, on their own, establish a legal transfer of intellectual property into Wellbeing's current commercial structure.

There may be agreements that answer the question.

They may be private.

They may involve later developments rather than the original patent family.

Or the current technology may not depend upon those earlier patents at all.

What remains unresolved is the documented relationship, if any, between the historical intellectual property and the present commercial process.

This is not evidence that Wellbeing lacks the necessary rights.

It is a gap in what can presently be independently verified.

The Documents That Would Settle the Ownership Question

A proper intellectual-property review would examine the relevant patent assignments and licences, together with the contracts governing scientific development and laboratory manufacturing.

It would also identify the legal entity that currently owns or controls the CFT protocols.

If the technology has evolved independently of the Lydac patents, the review would establish how and when that later technology was developed.

It would identify the ownership of subsequent improvements and the contractual rights held by Wellbeing.

It would also consider whether the business has sufficient rights to transfer manufacturing, license the process or prevent unauthorised commercial use.

These are ordinary questions in biotechnology due diligence.

They are not accusations.

They are the documents needed to distinguish scientific experience from legally owned technology.

A Failed Company Does Not Mean Failed Science

One conclusion must be avoided.

The dissolution of Lydac Neuroscience does not establish that the underlying science was worthless.

Nor does it establish that its former directors acted improperly.

Companies can fail for reasons unrelated to the scientific merit of their research.

And technologies can continue to develop after the original company disappears.

Scientific expertise can survive corporate failure.

New inventions can emerge.

Legitimate licensing and asset-transfer arrangements can preserve commercial rights.

But that does not eliminate the need to establish ownership.

In fact, it makes the ownership history more important.

When an earlier company has entered insolvency, assumptions about continuity are particularly unreliable.

The proper question is not whether the same individuals remain involved.

It is whether the relevant legal rights can be traced.

The Central Finding

The investigation into Wellbeing's intellectual-property history has not established unlawful conduct.

It has not demonstrated that the present CFT process infringes an earlier patent.

It has not proved that patents were improperly transferred.

And it has not shown that Wellbeing lacks legitimate rights to its technology.

What it has established is a documented historical patent and corporate trail that is relevant to understanding the scientific and commercial history presented by the organisation.

That trail leads to Lydac Neuroscience.

It connects to Stephen Ray.

It connects, at a later point, to Andrew Chancellor.

It includes a Harley Street address associated with later Wellbeing-related consultations.

And it ends with the earlier company's dissolution.

The current ownership of Wellbeing's CFT technology cannot be determined solely from that history.

But neither can it be assumed.

That is the distinction at the heart of this investigation.

What Is the Real Asset Behind Wellbeing?

After examining the clinics, laboratory, historical patents and scientific relationships, the central question becomes clearer.

Perhaps Wellbeing's greatest value lies in its international network.

Perhaps it lies in proprietary manufacturing know-how.

Perhaps it lies in exclusive commercial agreements.

Perhaps it lies in new technology developed independently of the earlier patents.

Or perhaps its value is distributed across several different rights and relationships.

Any of these possibilities could support a legitimate commercial enterprise.

But each produces a different financial picture.

An organisation that owns enforceable intellectual property is not economically identical to an organisation that licenses technology from another party.

A business with exclusive manufacturing rights is not the same as one dependent on a non-exclusive service provider.

And a company with a proprietary clinical process is not necessarily equivalent to a company coordinating treatments through independent practitioners.

Those distinctions determine how resilient the business is, how easily competitors can enter the market and what an investor might actually acquire.

The Question That Remains

The most revealing part of this investigation is not the existence of a failed biotechnology company.

It is the difference between a scientific story and a legal ownership story.

A scientist can have decades of experience.

A laboratory can possess sophisticated equipment.

A company can coordinate international medical services.

Patients can provide sincere testimonials.

And a business can raise investment to finance future development.

All of those things may be genuine.

But none of them independently establishes ownership of the scientific technology.

For that, we need documentary evidence.

The relevant patent rights.

The assignments.

The licences.

The contracts.

The identity of the entity that controls the technology today.

Until those matters are established, the historical patent trail remains an important but incomplete part of Wellbeing's commercial story.

And that brings us to the next stage of the investigation.

Because if the clinics operate through partnerships, the laboratory is an external relationship and the historical intellectual-property trail requires further examination, a prospective investor faces a much broader question.

What exactly is the company worth?

Not what the scientific story suggests.

Not what the international network appears to represent.

But what its actual assets, contracts, revenue and legal rights justify.

That question cannot be answered by examining patents alone.

It requires following the money.

Coming Next — Follow the Money: Who Really Benefits From the Wellbeing Investment?

Wellbeing has publicly announced a private capital round in 2026.

Its business model includes patient revenue, clinical partnerships and specialist laboratory processing.

But the financial position of the investment entity cannot be established simply from those descriptions.

In the next investigation, we examine the distinction between patient fees and company profit, the structure of private investment, the significance of related-party transactions, and the financial documents needed to understand what investors are actually buying.

Because the ultimate question is no longer just who developed the science.

It is who owns the commercial value — and who carries the financial risk.

Public reference material

Editorial note: The historical corporate and patent connections described in this article are distinguished from unverified questions about present-day intellectual-property ownership. No finding of misconduct, unlawful transfer or patent infringement is made.

Behind the Global Network: What Does Wellbeing International Foundation Actually Own?

Sun, 11 Oct 2026 09:20:23 GMT

The Wellbeing Illusion — Chapter Eight, Part One | Alternative Edition

An international network of medical clinics. A specialist laboratory in Germany. Doctors across multiple countries. A sophisticated biological treatment process. More than twenty years of scientific development.

Taken together, these are the ingredients of what appears to be a substantial international biotechnology operation.

They are also central to the public presentation of Wellbeing International Foundation, the organisation promoting a treatment known as Cell-Free Therapy, or CFT.

But behind the international reach and scientific language lies a basic business question that deserves considerably more attention.

How much of this medical infrastructure actually belongs to Wellbeing International Foundation?

It is a question about ownership, operational control and the commercial substance of the organisation.

Because there is an enormous difference between owning a medical facility and having an agreement with one. There is a difference between employing a specialist and working with an independent practitioner. And there is a difference between operating a laboratory and commissioning a laboratory to carry out a proprietary process.

All are legitimate business arrangements. But they represent very different assets, obligations and risks.

Our investigation set out to establish which of these arrangements lies behind Wellbeing's international medical network.

The International Image

Wellbeing International Foundation presents itself as an organisation with access to an extensive international clinical network.

Its published materials describe 23 partner clinics, specialist laboratory processing in Germany and medical relationships spanning multiple jurisdictions.

The organisation also promotes an approach in which a patient's biological material is collected, transported, processed and subsequently administered as part of its CFT programme.

For someone unfamiliar with the business, the presentation can suggest a substantial medical infrastructure extending across the world.

But an international presence does not necessarily mean international ownership.

A company can coordinate medical services in numerous countries while owning relatively little physical infrastructure.

Indeed, some of the world's most successful healthcare businesses operate through external providers, licensing agreements and specialist contractors.

The question is not whether such an arrangement is legitimate.

The question is whether the scale of the organisation's commercial relationships is being confused with the scale of its owned assets.

And in Wellbeing's case, that distinction is particularly important.

The Significance of One Word: Partner

Wellbeing's description of its network repeatedly uses the term partner clinic.

It may sound like a minor detail.

It is not.

A partner clinic is not necessarily a subsidiary, branch or property owned by the organisation referring patients to it.

It may be an entirely independent medical practice that has agreed to provide particular services.

That arrangement could involve collecting blood samples, administering an infusion, conducting consultations or providing clinical supervision.

The clinic may have its own medical licence, professional insurance, employees and patient-record systems.

Wellbeing may coordinate the treatment while the clinic provides the medical environment in which it takes place.

This is an entirely plausible operating model.

But it means that counting partner clinics tells us relatively little about the organisation's physical assets.

A business claiming relationships with 23 clinics has not thereby demonstrated ownership of 23 clinics.

To establish ownership, we would need to identify the individual facilities, their legal operators and their relationship with Wellbeing.

That information would also help answer another important question: how secure are those relationships?

An independent clinic may be able to terminate its arrangement. It may work with competing providers. Its medical personnel may change.

Unless there are enforceable agreements providing otherwise, access to a network can be more fragile than ownership of the infrastructure itself.

Following the Treatment From Patient to Laboratory

Wellbeing's published treatment process provides an insight into the organisation's operational structure.

The pathway begins with patient assessment and the collection of a blood sample at an approved location.

The biological material is then transported to Germany for specialist processing.

Following processing and quality checks, the preparation is returned for administration at an approved clinical site.

At first glance, this appears to be a seamless medical programme.

Operationally, however, it involves several potentially separate businesses.

There may be a medical practitioner responsible for collecting the blood, a transport company handling biological samples, a laboratory carrying out the processing, and another medical professional responsible for administering the final preparation.

Each stage carries its own legal, clinical and commercial responsibilities.

Who holds the patient's medical records?

Who is responsible for the biological material during transport?

Which organisation holds the relevant laboratory authorisations?

Who releases the processed preparation?

Which clinician assumes responsibility for administering it?

And if something goes wrong, which organisation is legally accountable?

These questions cannot be answered simply by describing the overall process as Wellbeing's treatment programme.

The treatment pathway may be coordinated centrally, but that does not establish central ownership of every component.

Germany: The Laboratory at the Centre of the Business

The German laboratory occupies a particularly important position in Wellbeing's commercial model.

Without the processing stage, the treatment cannot proceed in the manner publicly described.

The laboratory is therefore more than a peripheral supplier.

It is central to the delivery of the intervention.

That makes its ownership and contractual relationship with Wellbeing especially significant.

Does Wellbeing own the facility? Does it employ the laboratory personnel? Does it possess the manufacturing equipment? Or does it contract an independent specialist laboratory to process the biological material?

Wellbeing's public materials describe a laboratory partnership.

That wording does not establish company ownership.

Our historical investigation uncovered further evidence of how the relationship operated.

During a recorded discussion obtained in 2021, representatives connected with Wellbeing and the German laboratory discussed a working relationship stretching back approximately a decade.

The conversation described a division of responsibilities between scientific protocol development and laboratory processing.

One representative explained that Stephen Ray designed the protocols used by the programme.

The laboratory representative described the German facility's role as carrying out those protocols and handling process and quality-control responsibilities.

This historical material supports the existence of a substantive laboratory relationship.

But it does not establish that Wellbeing owned the laboratory.

In fact, the division of responsibilities raises a more interesting commercial question.

If the scientific methods are developed by one party and the manufacturing work is carried out by another, who owns the process itself?

That is not necessarily the same question as who owns the building.

And it may be considerably more important.

What Happens if the Laboratory Relationship Ends?

Consider the practical implications of relying upon an external laboratory.

If the arrangement is exclusive, long-term and protected by comprehensive contracts, it could provide Wellbeing with considerable commercial security.

If the relationship is non-exclusive or terminable, the organisation may face different risks.

Could another laboratory take over the processing?

Would Wellbeing have the right to transfer the protocols?

Would a replacement facility need to undergo technical validation?

Who owns improvements developed during years of manufacturing?

Who controls the documentation necessary to reproduce the preparation consistently?

Could the existing laboratory work with other companies offering similar biological services?

These questions are especially relevant when a business's principal offering depends upon a specialist manufacturing process.

A laboratory agreement can be commercially valuable.

But its value depends upon the rights it grants.

An investor assessing such a business would need to examine the agreement rather than simply assume that the laboratory represents an asset owned by the central organisation.

The GMP Question

Wellbeing's public material also refers to GMP-related laboratory standards.

Good Manufacturing Practice is an important concept in the manufacture and quality control of medical and biological products.

But claims about GMP require precision.

A facility operating according to GMP principles is not necessarily making the same statement as a facility holding a particular regulatory manufacturing authorisation.

The precise meaning depends upon the documentation, issuing authority, activities covered and regulatory framework.

During our historical investigation, a German laboratory representative described operations conducted according to GMP standards.

Wellbeing's present-day material refers to a GMP-certified laboratory.

These descriptions may reflect different periods or different aspects of the laboratory's quality arrangements.

They do not, by themselves, establish the precise scope of certification.

To independently verify the position, the relevant questions would include which legal entity holds the certification, which facility it covers and whether its scope includes the particular biological preparation involved in CFT.

The issue is not whether the laboratory is capable of sophisticated processing.

It is whether the regulatory claims can be matched to identifiable authorisations and responsible legal entities.

For a treatment involving the collection, international transportation, processing and administration of human biological material, that distinction matters.

Harley Street: An Address Is Not a Medical Institution

Another part of the investigation took us to 10 Harley Street in London.

Harley Street has a longstanding association with private medicine, specialist consultations and prestigious clinical practices.

It is an address that can carry considerable reputational weight.

Historical investigative material established that Wellbeing-related consultations took place at 10 Harley Street during 2020 and 2021.

But the presence of consultations at a medical address does not establish ownership of a medical clinic.

Independent practitioners and commercial organisations can legitimately use consulting rooms, shared premises or sessional facilities.

A prestigious address can provide access to a professional environment without representing a substantial property asset.

The important questions are therefore operational rather than geographical.

Was Wellbeing running a permanent clinic at the premises?

Was it using rooms provided by another operator?

Were consultations conducted by independent practitioners?

Who held responsibility for the clinical service?

And which entity maintained the patient records?

The available historical evidence establishes the connection with the address, but not the ownership of a permanent Wellbeing-operated medical facility there.

Harley Street also has another significance in this investigation.

Its connection with an earlier biotechnology company will become important when we examine the history of the scientific technology.

A Network Built Around Independent Physicians

Wellbeing's physician partnership programme provides perhaps the clearest indication of its broader commercial strategy.

The programme invites medical practitioners, including those already involved in regenerative procedures, to incorporate CFT into their practices.

It describes opportunities involving premium treatment services, patient acquisition, repeat infusions and biological-material banking.

This is a recognisable business-development model.

Rather than building a medical clinic in every city, an organisation can work with practitioners who already possess the premises, equipment, professional registrations and clinical infrastructure needed to treat patients.

The central organisation provides access to its programme and coordinates the specialist components.

Such a structure can allow rapid geographical expansion without the enormous expense of establishing and staffing company-owned facilities across multiple countries.

It can also be commercially attractive.

But it raises an important question about what is being counted when an organisation describes its international reach.

Is it counting facilities it owns?

Facilities with exclusive agreements?

Independent practices that have agreed to participate?

Or clinical locations capable of providing services when required?

The public description of a partner network does not, on its own, resolve these distinctions.

The Difference Between Access and Control

This is the central issue.

Access to a medical facility can be commercially useful.

Control over that facility can be more valuable.

Ownership may provide a different level of security again.

A company may have access to a network of independent clinics but limited influence over their staffing, operating hours, financial stability or long-term participation.

It may coordinate an international laboratory process without owning the manufacturing facility.

It may rely upon individual scientific consultants without owning every element of their earlier research.

None of these arrangements is necessarily problematic.

But together, they create a business that may depend heavily upon contracts and personal relationships.

The durability of those arrangements becomes essential to understanding its value.

If a key partner leaves, can the service continue?

If the scientific adviser departs, does the company retain the rights and technical knowledge required to manufacture the preparation?

If a laboratory relationship ends, can production be transferred?

If independent clinicians withdraw, can replacement providers be recruited without disrupting patients?

These are questions about commercial resilience.

And they are particularly relevant when an organisation is promoting a medical intervention that requires coordination across international borders.

What Assets Could Actually Make Wellbeing Valuable?

There is an important possibility that should not be overlooked.

Perhaps the most valuable part of Wellbeing's business is not its physical infrastructure at all.

In biotechnology, a company can have relatively few buildings and still possess considerable commercial value.

That value may reside in intellectual property.

A patented invention.

A proprietary biological-processing method.

Exclusive manufacturing rights.

Confidential scientific know-how.

Research data.

Or contractual rights that competitors cannot easily reproduce.

If Wellbeing possesses strong, enforceable rights to a distinctive technology, those rights could be considerably more important than owning clinics or laboratory equipment.

But that brings us to a different kind of ownership question.

Not where the treatment is delivered.

Not where the blood is processed.

But who owns the scientific process being commercialised.

And whether the organisation has the legal right to use, license, develop and protect it.

What the Investigation Has Established

The evidence examined so far supports a picture of an international programme operating through multiple clinical and laboratory relationships.

Wellbeing publicly describes a network of partner clinics.

Its treatment process involves collection, transportation, laboratory processing and clinical administration.

Historical investigative material documents a longstanding German laboratory relationship.

The organisation's physician programme promotes cooperation with established medical practitioners.

And consultations associated with Wellbeing historically took place at a recognised Harley Street medical address.

These are meaningful operational connections.

They should not be dismissed.

But they do not, by themselves, establish ownership of the underlying facilities.

We have not independently verified that Wellbeing owns its advertised partner clinics.

We have not established that it owns the German laboratory.

We have not examined the contracts governing the clinical network.

And we have not established the complete asset position of the legal entity operating the commercial programme.

That does not mean the relevant contracts or assets do not exist.

It means the public presentation is insufficient to determine the extent of ownership and control.

The distinction is essential.

Because an organisation can appear international in scale while remaining dependent upon external businesses for much of its operational infrastructure.

The Discovery That Changed Our Direction

By this stage, our investigation had reached a crossroads.

We had followed the patient pathway.

We had examined the clinic network.

We had traced the German laboratory relationship.

We had revisited the Harley Street consultations.

And we had looked at the organisation's strategy for recruiting independent physicians.

The same question kept returning.

If so much of the infrastructure operates through relationships, where does the organisation's distinctive commercial value actually reside?

The answer might lie in something that cannot be photographed.

Something that does not require an impressive medical address.

Something that may be far more valuable than a building or a laboratory.

Intellectual property.

So we began searching patent records.

We examined the historical scientific work associated with Stephen Ray.

We searched British company filings.

We followed earlier corporate appointments.

And we uncovered a biotechnology company whose history reaches back to the scientific foundations of the Wellbeing story.

The company was called Lydac Neuroscience Ltd .

Its name appears in historical microvesicle patent records.

Stephen Ray was a director during its early years.

Andrew Chancellor became a director later.

The company subsequently entered administration and liquidation before being dissolved.

Those facts do not establish that Wellbeing acquired its intellectual property, nor do they prove that the present CFT process uses the earlier patented methods.

But they introduce a crucial question that the clinic and laboratory investigation could never answer.

Who legally owns the science behind the treatment?

That question leads us away from medical addresses and into the records of patents, companies, directors and intellectual-property rights.

And the story becomes considerably more complicated.

Coming Next — Who Owns the Science? The Patents, the Failed Biotechnology Company and the Missing Ownership Trail

The investigation continues with the historical patent records, Lydac Neuroscience, Stephen Ray and Andrew Chancellor.

We examine what the corporate documents establish, what happened to the earlier company and why the legal ownership of scientific technology matters to anyone assessing Wellbeing's commercial claims.

Because access to a laboratory is one thing.

Having a scientist on your team is another.

But owning the technology on which a business depends is something entirely different.

And it is that distinction we investigate next.

Public reference material

Editorial note: This article distinguishes documented corporate and historical connections from questions of ownership that remain unverified. References to recorded historical conversations are based on material obtained during the investigation; confidential sources are not identified.

The Clinical Trial Question: Why Did Formal Human Research Come So Late?

Sun, 04 Oct 2026 09:01:18 GMT

The Wellbeing Illusion — Chapter Seven

For six chapters we have followed the trail backwards.

The clinics.

The doctors.

The German laboratory.

The protocols.

The scientific history.

The patients.

And finally the evidence those patients should have generated.

Now we can put dates against that story.

And the dates create perhaps the most uncomfortable question so far.

Wellbeing International Foundation presents a scientific history stretching over more than twenty years.

Our historical investigation found patients discussing treatment years ago.

We found longstanding laboratory relationships.

We found protocols already being used.

We found discussions of repeat infusions.

We found claims of extensive patient experience.

And yet the peer-reviewed human pilot study that Wellbeing now cites did not begin until August 2024 .

The study completed in March 2025 .

The ClinicalTrials.gov record associated with it was first submitted in December 2025 and publicly posted in January 2026 .

The peer-reviewed paper appeared in June 2026 .

Put those dates on a single line and something becomes immediately obvious.

The patients came first.

The formal published clinical research came much later.

And when we followed that chronology one step further, we found something that leads directly into the most important chapter of this investigation so far.

Start With What Wellbeing Says Today

There is now a genuine peer-reviewed study associated with Wellbeing's intervention.

That fact needs to be stated clearly.

The study was published in Frontiers in Aging in June 2026 under the title:

“A multi-modal longevity protocol integrating lifestyle, supplements, and autologous pro-regenerative cell-conditioned media: a pilot study.”

Read the published study

It involved sixteen healthy adults, fourteen of whom completed the programme.

The study was small.

It was open-label.

It had no control group.

And Cell-Free Therapy was only one part of a much larger programme involving lifestyle changes and supplementation.

We examined those limitations in Chapter Five.

But the existence of the study itself matters.

Wellbeing now has published human research associated with its intervention.

The question is not whether it exists.

The question is:

Why did it arrive so late?

Because the Patients Were Already There

Our confidential historical material takes us back years before the pilot.

Recorded consultations from 2020 and 2021 describe a functioning patient pathway.

Prospective patients were discussing medical conditions.

Blood collection was discussed.

Sending blood to Germany was discussed.

Laboratory processing was explained.

Intravenous administration was discussed.

Repeat treatment was discussed.

Prices were discussed.

And previous patient experience was repeatedly referenced.

This was not a conversation about an intervention still waiting to be tried in humans.

People were already apparently receiving it.

Wellbeing's own historical case studies also describe patients receiving versions of the intervention years before the 2024 pilot.

So there is an unavoidable gap in the chronology.

Human treatment appears substantially earlier than the formal study Wellbeing now cites.

Treating Patients Is Not Clinical Research

This distinction is essential.

There is nothing inherently unusual about clinical experience preceding formal research.

Medical innovations can develop through laboratory work, physician experience, compassionate use and observational practice before becoming the subject of rigorous trials.

But those activities are not interchangeable.

Treating someone is not automatically conducting research.

Observing somebody after treatment is not automatically a clinical study.

Collecting a testimonial is not clinical research.

A scientist believing an intervention works is not clinical proof.

Formal human research introduces something different.

A protocol.

Defined participants.

Predefined outcomes.

Eligibility criteria.

Safety monitoring.

Research consent.

Structured data collection.

Statistical analysis.

And ideally, registration before researchers know what the results will be.

That framework exists for a reason.

It makes the evidence testable.

So When Did Formal Research Actually Begin?

The study associated with the 2026 publication began on:

5 August 2024.

Its primary completion date was:

15 December 2024.

The study itself completed on:

20 March 2025.

The associated ClinicalTrials.gov identifier is:

NCT07322224.

The study is titled:

Multi-Modal Longevity Protocol Including Autologous Cell-Free Conditioned Media.

Those dates give us something we haven't had before.

A point at which the formal human research programme becomes publicly traceable.

And that point is remarkably recent compared with the much longer history being described around the technology.

This Wasn't a Large Therapeutic Trial

It is also important to understand what kind of study this was.

It wasn't a Phase III clinical trial.

It wasn't a large randomized trial involving hundreds of patients.

It wasn't designed to demonstrate that CFT treated cancer, neurological disease, orthopaedic injury or another named medical condition.

The participants were generally healthy adults interested in longevity.

There was one intervention group.

No placebo group.

No untreated control group.

No randomisation between CFT and no CFT.

No masking.

And CFT was combined with multiple other interventions.

The registered study describes its primary purpose as Basic Science and its phase as Not Applicable .

That makes sense for exploratory research.

But after a scientific history said to extend beyond twenty years, it also tells us something important.

The formal public clinical evidence still appears to be at an exploratory stage.

Why Start With Healthy Adults?

This creates another interesting contrast.

The historical story contains discussions involving people with serious medical conditions.

There are neurological patients in Wellbeing's public history.

There are injured professional athletes.

There are people seeking regenerative benefits.

There are repeat patients.

There are years of claimed experience.

Yet the peer-reviewed pilot Wellbeing now cites involved generally healthy adults participating in a longevity programme.

That doesn't make the study inappropriate.

It simply means it doesn't answer many of the questions raised by the historical patient population.

It doesn't tell us whether CFT helped the historical knee patients.

It doesn't tell us whether it changed neurological disease progression.

It doesn't tell us whether injured athletes recovered faster because of CFT.

And it doesn't explain what happened to the hundreds of historical patients referred to in earlier material.

Those questions remain open.

Then We Looked at the Registration Timeline

This is where Chapter Seven becomes considerably more interesting.

The study began in August 2024.

It completed in March 2025.

But according to the public registration chronology associated with NCT07322224, the ClinicalTrials.gov submission came later — in December 2025 — with the record appearing publicly in January 2026.

In other words, according to that chronology:

the study had already been completed before its ClinicalTrials.gov registration was publicly submitted and posted.

That requires careful wording.

It does not mean the research didn't have a protocol before it began.

It does not prove that endpoints were altered.

It does not mean the study was fabricated.

And it does not automatically invalidate the eventual peer-reviewed publication.

But it does mean the public registry record appears to have been created retrospectively rather than prospectively.

And scientifically, that distinction matters.

Why Register a Study Before It Starts?

Clinical-trial registration isn't merely administrative bureaucracy.

It serves an important scientific purpose.

Before researchers know the outcome, they publicly state what they intend to investigate.

What is the intervention?

Who will participate?

How many participants?

What is the primary outcome?

What are the secondary outcomes?

When will measurements occur?

What is the study design?

That creates a timestamp.

Then, when the results are eventually published, researchers and readers can compare:

What did you say you were going to measure?

with:

What did you eventually report?

That helps protect against selective reporting.

Imagine Measuring Twenty Things

The reason is easy to understand.

Imagine a study measures twenty biological markers.

Seventeen show no meaningful change.

Three improve.

If the researchers subsequently publish only those three, the results can appear much more impressive than the experiment actually was.

Prospective registration helps outsiders see that twenty things were originally being measured.

The unsuccessful results remain visible in the research design.

That is one of the safeguards against researchers unconsciously — or deliberately — selecting the most attractive outcomes after seeing the data.

Retrospective registration cannot provide exactly the same protection.

Because by then the results may already be known.

Again, we are not alleging that happened here .

We have no evidence establishing that it did.

The point is simply that the chronology matters.

The Paper Was Still Peer Reviewed

This should not be overlooked.

The study was eventually published in a peer-reviewed journal.

Its methodology can be examined.

Its limitations are discussed.

Its affiliations are disclosed.

Its results are available for other researchers to scrutinise.

That is valuable.

And the authors themselves are cautious about what can be concluded.

They acknowledge the small sample.

They acknowledge the absence of a control group.

They acknowledge the open-label design.

They acknowledge that the multimodal intervention prevents the contribution of each individual component from being isolated.

And they call for larger controlled research.

That is how exploratory science should progress.

But peer review doesn't change the dates.

The Dates Are the Story

Put everything we have discovered so far into chronological order.

There is a scientific story said to extend over more than twenty years.

There are laboratory relationships extending back well over a decade.

There were protocols.

There were patients.

There were repeat treatments.

There were claims of extensive experience.

There were testimonials.

There were discussions about outcomes.

Then, much later:

August 2024 — the pilot begins.

March 2025 — the study completes.

December 2025 — the ClinicalTrials.gov record is first submitted.

January 2026 — the record becomes publicly available.

June 2026 — the peer-reviewed paper is published.

The gap between those two histories is striking.

The commercial and patient history appears old.

The public formal clinical-research history appears much younger.

Why Wasn't This Done Earlier?

That is the obvious question.

If hundreds of patients had already received versions of the intervention, why wasn't a structured prospective study undertaken earlier?

If there was extensive experience with knees, why not study knee patients?

If professional athletes repeatedly received treatment, why not construct a sports-injury cohort?

If neurological patients were receiving repeated infusions, why not systematically record progression?

If biological material was being processed through the same laboratory relationship for years, why not connect laboratory variables with patient outcomes?

If the intervention produced results as impressive as some historical conversations suggested, formal research could potentially have demonstrated that.

There may be perfectly reasonable explanations.

Perhaps funding wasn't available.

Perhaps research wasn't the organisation's original priority.

Perhaps earlier research exists but was never published.

Perhaps the technology changed so substantially that older data were no longer comparable.

Perhaps the necessary infrastructure wasn't in place.

We don't know.

And where the documents don't answer the question, we won't invent an answer.

But the chronology itself remains.

There Is Another Difference Between the Old Claims and the New Study

The historical consultations could be remarkably confident.

We have already examined the statement concerning knee patients:

“I can't think of a patient that hasn't shown improvement.”

Another representative responded:

“There hasn't been one.”

Now compare that with the language of the 2026 scientific paper.

The published researchers are much more cautious.

They describe signals.

Associations.

Limitations.

Subgroups.

Hypotheses.

The need for larger controlled trials.

That difference is revealing.

Not necessarily because one side was dishonest.

But because science forces certainty to shrink .

Once you start counting everybody, measuring everybody and analysing everybody, the story becomes more complicated.

And that is precisely why formal research matters.

Not Everyone in the Pilot Responded the Same Way

The pilot itself illustrates this perfectly.

Participant responses varied.

The paper describes larger responders and smaller or non-responders in relation to biological-age measurements.

That is normal.

Biology is messy.

People differ.

Responses vary.

And it demonstrates why a handful of spectacular patient stories can never tell us how an intervention performs across an entire population.

Clinical research introduces the denominator.

It forces us to count the people who didn't produce the headline.

The Study Wasn't Independent Replication Either

There is another limitation.

The paper's declarations identify organisational relationships between its authors and the groups involved with the programme, including Wellbeing and xLongevity.

Again, this does not invalidate the research.

Commercial organisations routinely investigate their own technologies.

What matters is transparency.

But it means the study is not yet independent replication .

That would require other researchers, independent of the organisations involved, to test the intervention and reproduce the findings.

That remains another important step.

What Would the Decisive Trial Look Like?

The next study could answer much more.

Take CFT itself.

Define the preparation precisely.

Prospectively register the protocol before the first participant is enrolled.

Select a meaningful population.

Randomise participants.

Create an appropriate comparator.

Blind outcome assessment wherever possible.

Predefine the primary endpoint.

Track adverse events.

Follow participants long enough to determine whether any effect persists.

And publish the results regardless of whether they are positive or negative.

If the biological effect is substantial, rigorous research should make it easier to demonstrate.

If there is no meaningful effect, rigorous research should reveal that too.

That is the bargain science makes.

But While Following the Trial, We Found Something Else

This is where our investigation changes direction.

Initially, we were interested in the trial because we wanted to understand the evidence.

When did it start?

How many people participated?

What did it measure?

When was it registered?

What did it find?

But the study record contains more than scientific information.

It contains organisations.

A sponsor.

Collaborators.

Researchers.

A study location.

Responsibilities.

And once we began examining those details alongside everything uncovered in the previous six chapters, a much larger question appeared.

Because Wellbeing is not operating in isolation.

Throughout this investigation we have repeatedly encountered other components.

Partner clinics.

Independent physicians.

A German laboratory partner.

External scientific literature.

A separate lead study sponsor.

Collaborating organisations.

A distributed clinical network.

And historical companies connected to the people and science.

None of that is inherently improper.

Modern biotechnology frequently depends upon outsourcing and partnerships.

But it means we have been asking the wrong question.

Stop Asking What Wellbeing Has Access To

Having access to something is not the same as owning it.

A company can use a laboratory without owning the laboratory.

It can refer patients to doctors without employing those doctors.

It can operate through clinics without owning those clinics.

It can use scientific protocols without necessarily owning the underlying intellectual property.

It can cite scientific literature without having conducted that research.

It can collaborate on a clinical study without sponsoring it.

It can use a Harley Street location without owning a hospital.

It can maintain relationships across twenty countries without owning twenty international medical facilities.

Again:

None of those arrangements is inherently improper.

But they become extremely important when trying to understand what the organisation actually is.

And even more important when investors are being invited to put money into it.

Because Investors Are Not Buying “Access”

This is where Chapter Eight becomes unavoidable.

Wellbeing announced in 2026 that it had closed the opening tranche of a capital round.

Investment changes the question completely.

A patient may principally care whether the treatment is safe and effective.

An investor needs to understand something else as well.

What does the company actually own?

Not what can it access.

Not who does it know.

Not which scientists advise it.

Not which laboratories process material.

Not which doctors can administer infusions.

Not which independent research papers support the biological theory.

What assets belong to the organisation receiving the investment?

That is a very different question.

Follow the Assets

After seven chapters, we can now place almost every part of the Wellbeing proposition into a category.

The clinics.

Are they owned?

Or partners?

The physicians.

Employees?

Contractors?

Independent practitioners?

The German laboratory.

Owned?

Controlled?

Or contracted?

The protocols.

Who owns them?

The intellectual property.

Where is it?

The patents.

Who owns them?

The historical patient data.

Who controls it?

The banked biological material.

Who is its legal custodian?

The clinical study.

Who sponsored it?

The research.

Who paid for it?

The scientific know-how.

Does it belong to Wellbeing, individual scientists, the laboratory, or another entity?

The brand.

The website.

The patient relationships.

The clinical network.

The commercial agreements.

The revenue.

The investment capital.

For the first time, all of those questions can now be placed on the same table.

And once we do that, something becomes obvious.

We need to stop following the claims.

We need to follow the ownership.

Seven Chapters Have Brought Us to One Question

This investigation began by asking where Wellbeing actually was.

Then we followed its clinic network.

We followed the people treating the patients.

We followed the blood to Germany.

We followed the scientific history.

We searched for twenty years of research.

We searched for the historical patient outcomes.

And now we have followed the clinical trial.

Every road has brought us to the same place.

Ownership.

Because an organisation can appear enormous when everything surrounding it is placed together.

Twenty-three partner clinics.

A German laboratory.

Doctors.

Scientists.

Hundreds of scientific papers.

Patients around the world.

Professional athletes.

Clinical research.

Decades of experience.

But the critical due-diligence question is not how impressive that combined ecosystem appears.

It is much simpler.

Which parts of that ecosystem actually belong to Wellbeing International Foundation?

That question matters to patients.

It matters to doctors.

It matters to regulators.

But most of all, it matters to anybody being invited to invest.

Because Chapter Eight is no longer about whether Cell-Free Therapy sounds scientifically plausible.

It is about something considerably more concrete.

Assets.

Ownership.

Control.

Intellectual property.

Contracts.

Infrastructure.

And ultimately:

What is the investor actually buying?

Next: Chapter Eight — What Does Wellbeing Actually Own?

This is where the investigation changes.

We have followed the clinics, the physicians, the German laboratory, the scientific protocols, the research history, the patients and the clinical trial.

Now we strip the entire proposition down to its assets.

Which clinics does Wellbeing own? Does it own the German laboratory? Who owns the Cell-Free Therapy protocol? Where is the intellectual property? Who owns the patents behind the earlier science? Who controls the patient data and banked biological material? What contracts secure the clinical network? And what assets actually sit inside the organisation receiving investors' money?

Because access is not ownership.

Partnership is not ownership.

Scientific history is not ownership.

And when investment money enters the story, there is one question that matters above almost everything else:

What, exactly, are you buying?

Before the Trial: What Happened to Years of Patient Outcomes?

Sun, 04 Oct 2026 08:57:41 GMT

The Wellbeing Illusion — Chapter Six

In Chapter Five, we followed Wellbeing International Foundation's claim of more than twenty years of science.

We found something important.

The scientific history appears to be genuinely old.

The laboratory relationships appear to be old.

The protocols appear to have evolved over many years.

And people were apparently receiving versions of the intervention long before the peer-reviewed pilot published in 2026.

That creates a problem — but also potentially an extraordinary scientific opportunity.

Because every patient leaves evidence.

A medical history.

A reason for treatment.

A biological sample.

A laboratory record.

An infusion.

A response.

Perhaps another infusion.

Perhaps improvement.

Perhaps no improvement.

Perhaps an adverse reaction.

Perhaps nothing happened at all.

After years of treating patients, those individual experiences should begin forming something much more important than a collection of testimonials.

They should begin forming a dataset.

So this chapter asks a very simple question:

What happened to everybody?

The Patients Came Before the Published Study

This is the first fact we need to establish.

The peer-reviewed pilot associated with Wellbeing was conducted much later than the patient activity documented in our historical investigation.

Our covert archive contains recorded consultations from 2020 and 2021 discussing blood collection, laboratory processing in Germany, intravenous administration and repeat treatments.

The conversations don't sound like people discussing a hypothetical therapy that might one day be offered.

They describe an intervention already being provided.

Wellbeing's own published history also contains patient stories predating the 2026 paper by years.

So when the formal study eventually arrived, it did not mark the beginning of human exposure to the intervention.

Patients had apparently come first.

And that means those patients potentially represent years of information.

Our Investigation Found Claims of Hundreds of Clients

Historical investigative material reviewed for this series contains claims that Wellbeing had already dealt with hundreds of clients .

One historical figure recorded during the investigation referred to more than 600.

We have not independently audited patient files to verify that number, so we are not presenting 600 as an established total.

But the claim itself matters.

Because even if the true number were substantially lower, a significant historical patient population should have created an enormous amount of information.

If the number really was in the hundreds, the opportunity becomes even more significant.

Imagine 600 properly documented patient histories.

Six hundred baseline assessments.

Six hundred treatment records.

Six hundred sets of follow-up data.

Potentially thousands of individual infusions.

That could begin answering questions a testimonial page never can.

Who Improved?

This is the obvious question.

But it isn't enough.

Scientific outcome data require a denominator.

It isn't enough to identify ten patients who say they improved.

We need to know whether those ten came from:

twelve patients;

one hundred patients;

or one thousand patients.

Those would represent completely different outcomes.

The question therefore isn't simply:

How many success stories exist?

It is:

What percentage of everyone treated experienced an objectively measurable improvement?

And then:

What happened to everyone else?

Our Covert Recordings Contain an Extraordinary Historical Claim

During one covert consultation concerning a knee injury, a senior member of Wellbeing's scientific team discussed previous experience with knees.

Professional American football and ice-hockey players were mentioned.

The representative said:

“we've got a lot of experience with knees in particular”

Then came a remarkable statement:

“I can't think of a patient that hasn't shown improvement.”

Another representative present during the conversation responded:

“There hasn't been one.”

Read that again.

Not one.

If supported by systematically collected clinical data, that would be an extraordinary result.

Potentially an extremely important one.

But the statement immediately creates questions.

How many knee patients were there?

What qualified as improvement?

Pain reduction?

Mobility?

MRI findings?

Return to sport?

Reduced medication?

Avoidance of surgery?

Who assessed the improvement?

How long did it last?

And most importantly:

Where are those results?

“Improvement” Needs a Definition

This matters enormously.

Imagine somebody enters treatment saying their knee pain is eight out of ten.

Three months later they say it is four.

That is useful information.

But even then, we need context.

Did they also undergo physiotherapy?

Lose weight?

Stop playing sport temporarily?

Receive steroid injections?

Take anti-inflammatory medication?

Have surgery?

Change training?

Did the pain later return?

Now imagine something much stronger.

Every knee patient undergoes the same validated assessment before treatment.

Pain score.

Range of movement.

Strength.

Imaging.

Functional testing.

Medication.

Previous interventions.

Then the same measurements are repeated after treatment.

Now the word improvement begins to mean something scientifically.

Without a standardized starting point, however, it becomes difficult to determine exactly what changed.

Our Recordings Raise Questions About Baseline Medical Information

Another historical recording becomes important here.

A senior scientific representative was questioned directly about the medical records patients supplied.

His answer was:

“Sometimes they are extensive from their own doctors. Sometimes they are less so.”

He explained that his role was primarily to explain the science rather than provide the medical treatment.

That distinction is important and should be respected.

It does not prove that no physician subsequently assessed the patient.

It doesn't prove that proper medical supervision was absent.

But from a research perspective, the statement creates an obvious problem.

If medical records varied substantially between patients, how consistent were the baseline measurements?

Because without knowing precisely where a patient started, determining how far they improved becomes difficult.

Another Consultation Revealed the Same Problem

In another historical conversation, a prospective patient discussing a serious previous illness asked whether records from previous doctors would be required.

The response indicated that the patient could complete the medical-history information himself, with particular emphasis placed on listing medication.

Again, one historical conversation cannot establish the process used for every patient.

Nor does it prove that further medical documentation wasn't subsequently obtained.

But it reinforces the same research question.

Was there a standardized baseline dataset for historical patients?

If there was, it could be extremely valuable today.

Testimonials Only Show One Side of the Population

This is where testimonial evidence becomes dangerous if misunderstood.

A testimonial may be completely genuine.

The patient may sincerely believe the intervention changed their life.

But testimonials naturally select unusual or successful experiences.

Someone who experiences a dramatic improvement is likely to tell people.

They may remain in contact with the organisation.

They may agree to be interviewed.

They may provide photographs.

They may recommend the treatment.

But consider another patient.

They pay for the intervention.

Nothing noticeable happens.

They don't return.

They don't provide a testimonial.

They simply disappear.

Unless every patient is systematically followed, that person can vanish from the evidence.

The website gradually fills with success stories while the non-responders become invisible.

That is why clinical research requires denominators.

Wellbeing Itself Now Acknowledges This

The current Wellbeing website makes an important distinction.

Its patient testimonials and case studies are described as patient-reported experiences rather than evidence establishing efficacy.

That is scientifically appropriate.

Wellbeing International Foundation — About

But it creates another question.

If the testimonials aren't evidence of efficacy, where is the systematic outcome information from the wider historical patient population?

Because those are the patients who could potentially tell us whether the testimonials are typical.

One Published Case Demonstrates the Problem Perfectly

One of Wellbeing's published case studies concerns a patient with Motor Neurone Disease.

According to Wellbeing's account, the patient was diagnosed in 2017 and subsequently received regular infusions over approximately three and a half years.

The family believed the intervention helped slow progression.

That experience is understandably powerful.

But Wellbeing's own case study contains an extremely important acknowledgement:

“We have no data to prove the difference the therapy made…”

That sentence should not be buried.

Scientifically, it is one of the most important statements in the entire case.

Because it recognises the difference between:

“We believe it helped.”

and:

“We can demonstrate that it helped.”

Those are completely different propositions.

But Why Wasn't There Data?

This is where the case becomes even more interesting.

According to Wellbeing's own account, the patient received repeat infusions approximately every three months over several years.

That potentially represents numerous opportunities for structured follow-up.

What happened at those intervals?

Was respiratory function measured?

Mobility?

Speech?

Muscle strength?

Weight?

Medication?

Quality of life?

Hospital admissions?

Neurological progression?

Were recognised disease-progression scales used?

If objective measurements were collected repeatedly, then there may actually be meaningful longitudinal data.

If they weren't, an extraordinary research opportunity may have been lost.

The Athletes Present an Even Greater Opportunity

Wellbeing's history also contains numerous elite athletes.

That population is particularly interesting because professional athletes generate enormous amounts of objective data.

Injury dates.

Imaging.

Strength testing.

Training load.

Performance statistics.

Return-to-play dates.

Surgery.

Rehabilitation.

Medication.

Days unavailable for competition.

If substantial numbers of professional athletes received the intervention, retrospective analysis could potentially be extremely informative.

How long did comparable injuries normally take to recover?

How long did they take after CFT?

Did recurrence rates change?

Did objective performance change?

Did imaging change?

How many athletes reported no benefit?

How many required surgery anyway?

Those are measurable questions.

They are far more powerful than:

“I felt better.”

Follow the Patient, Not the Testimonial

This investigation therefore takes a different approach.

Take every patient.

Start at the beginning.

Why did they seek treatment?

What was their diagnosis or reason for treatment?

What was their baseline condition?

What medical evidence existed?

What preparation did they receive?

Which version of the protocol?

How many infusions?

What other treatments occurred simultaneously?

What happened after one month?

Three months?

Six months?

One year?

Did they improve?

Stay the same?

Deteriorate?

Return?

Stop treatment?

Experience an adverse event?

Die?

Become lost to follow-up?

Every one of those outcomes matters.

Not just the success stories.

What Happened to the People Who Never Came Back?

This may be one of the most important unanswered questions.

Repeat patients are easy to observe.

Satisfied clients remain visible.

Professional athletes may maintain contact.

But the patient who receives one treatment and disappears is scientifically important.

Why didn't they return?

Perhaps one treatment was sufficient.

Perhaps they couldn't afford another.

Perhaps they moved.

Perhaps they experienced no improvement.

Perhaps their condition deteriorated.

Perhaps they received conventional treatment elsewhere.

Perhaps they died.

We don't know.

And that is exactly the point.

In clinical research, a patient lost to follow-up doesn't simply cease to matter.

They become part of the analysis.

Then There Is Safety

Efficacy is only half the equation.

The other half is:

What went wrong?

Wellbeing currently describes CFT as autologous and cell-free and presents the intervention as having a favourable safety profile.

The 2026 pilot reported no adverse events among its small participant population.

That is encouraging.

But a small pilot cannot establish the safety profile of an intervention reportedly used across a much larger historical population.

If hundreds of patients have received the intervention over many years, the historical safety database could be considerably more informative.

How many total infusions have been administered?

How many immediate reactions occurred?

How many delayed reactions?

How many infections?

How many hospitalisations?

How many unexpected inflammatory responses?

How many events were considered unrelated?

How many were considered possibly related?

Perhaps the answer is almost none.

If so, that would itself be valuable evidence.

But safety becomes scientifically meaningful when there is a denominator.

For example:

Three adverse events across 2,000 infusions.

That tells us something.

Simply saying serious problems have not generally been seen tells us much less.

The Laboratory Should Already Have Part of the Record

There is another reason this question matters.

The treatment process itself requires documentation.

Blood is collected.

The sample is identified.

It is transported.

It reaches the laboratory.

It is processed.

Quality checks are performed.

The preparation is released.

It is returned.

It is administered.

Wellbeing's current process describes controlled transport, chain of custody, laboratory processing, quality testing and optional cell banking.

Wellbeing International Foundation — The Process

That creates a documentary trail.

And our historical covert investigation contains another intriguing detail.

During one recorded conversation, a senior Wellbeing representative discussed biological material stored in preservation tanks in Germany.

He claimed some stored material dated back to around 2010 and was periodically checked.

We have not independently inspected those storage records and therefore cannot verify that historical claim.

But if correct, it suggests that the biological archive itself could extend back many years.

That should mean identifiers.

Dates.

Storage records.

Processing records.

Release records.

Quality records.

And potentially repeat use involving the same patient.

Now connect those laboratory records with patient outcomes.

Suddenly, something extremely interesting becomes possible.

The Dataset May Already Exist

This is the possibility we cannot ignore.

Perhaps Wellbeing has far more evidence than is publicly visible.

Perhaps the information sits across different systems.

Patient files.

Laboratory records.

Clinical notes.

Follow-up calls.

Emails.

Infusion records.

Stored samples.

Questionnaires.

Medical records.

Repeat-treatment histories.

If those sources can be linked and properly anonymised, Wellbeing may already possess a substantial real-world dataset.

It could potentially answer questions that the current pilot cannot.

Which patients responded?

Which didn't?

How long did effects last?

Did repeat treatment produce different outcomes?

Did protocol changes alter results?

Were certain patient characteristics associated with stronger responses?

How frequently did adverse events occur?

That would not replace randomized controlled trials.

But it could provide an enormously useful foundation for designing them.

Or Perhaps the Dataset Doesn't Exist

There is another possibility.

Years of patients may have been treated without systematic research-grade follow-up.

Medical histories may have varied.

Outcomes may have been collected informally.

Successful patients may have remained visible.

Non-responders may have disappeared.

Testimonials may have accumulated while structured outcome data did not.

If that happened, years of patient experience may have produced surprisingly little scientifically usable evidence.

We cannot currently establish which explanation is correct.

But the difference between them is enormous.

One possibility means an important historical dataset is waiting to be analysed.

The other means an extraordinary research opportunity may have been lost.

The 2026 Pilot Shows What Was Possible

This is why the recent pilot matters beyond its results.

For those participants, researchers established a structured protocol.

There were baseline measurements.

There were defined outcomes.

There was a defined intervention period.

There was laboratory documentation.

There was analysis.

There was a scientific paper.

Whatever its limitations, that is research.

Now compare that with the years before it.

If structured measurements could be collected in 2024 and 2025, why weren't comparable systems apparently producing published evidence much earlier?

Perhaps they were.

If so, where are the results?

That question leads directly into the next stage of this investigation.

The Missing Denominator Changes Everything

After six chapters, this may be one of the simplest and most important questions we have asked.

How many people were actually treated?

Without that number, virtually every success claim loses context.

Suppose 90 out of 100 patients improved.

That would demand serious scientific attention.

Suppose 90 out of 10,000 improved.

That tells a very different story.

Suppose virtually everyone improved, as one historical consultation appeared to suggest for knee patients.

Then publish the cohort.

That could be extraordinary.

But without knowing the denominator, we simply cannot know what the visible success stories represent.

We Need the Failures as Much as the Successes

This is perhaps the greatest difference between marketing and science.

Marketing asks:

Who can tell our best story?

Science asks:

What happened to everybody?

The people who improved matter.

The people who didn't improve matter.

The people who deteriorated matter.

The people who stopped responding matter.

The people who never came back matter.

The people who experienced adverse events matter.

And the people who received treatment and experienced absolutely nothing matter.

In fact, scientifically, some of those failures may ultimately teach us more than the successes.

Because they help establish when an intervention doesn't work.

Years of Patients Should Have Created More Than Stories

This investigation isn't claiming that historical patient data were deliberately hidden.

We have not established that.

Nor have we established that no comprehensive patient database exists.

It may exist.

But after examining the public material and the historical evidence available to us, we have not located a comprehensive published analysis of the entire historical patient population.

That leaves a remarkable gap.

Because Wellbeing's own story tells us the patients were there.

Our covert investigation tells us treatments were being discussed and provided years ago.

The laboratory history tells us biological processing was already established.

The testimonials tell us some people returned repeatedly.

And the current organisation tells us follow-up forms part of the clinical journey.

The missing piece is what happened when all those individual experiences were put together.

This Is Bigger Than Testimonials

The question isn't:

Can Wellbeing find patients who say they benefited?

Clearly it can.

The question is:

When every patient is counted, what does the complete picture show?

That is where efficacy signals begin to emerge.

That is where safety signals appear.

That is where non-responders become visible.

That is where extraordinary claims either become more compelling or begin to weaken.

And that is where years of commercial treatment can begin transforming into scientific evidence.

If the records exist, they may contain some of the most important evidence Wellbeing possesses.

If they don't, the question becomes much more difficult.

Because patients appear to have been receiving the intervention long before formal published human research arrived.

And that means our investigation now has to put dates against the science.

When exactly did treatment begin?

When did systematic research begin?

When was the first formal human study conducted?

When was it registered?

And was that registration made before the researchers knew the results — or afterwards?

Those dates matter.

A great deal.

Because in the next chapter, the timeline finally becomes visible.

And once it does, the gap between years of patients and formal clinical research becomes impossible to ignore.

Next: Chapter Seven — The Clinical Trial Question: Why Did Formal Human Research Come So Late?

Patients appear in the story years before the clinical trial. Laboratory protocols appear years before the clinical trial. Claims of extensive experience appear years before the clinical trial. In Chapter Seven we put the dates side by side — treatment, study commencement, study completion, trial registration and publication — and ask why the formal evidence arrived so late in a scientific story said to stretch back more than twenty years.

Twenty Years of Science — But Where Is the Evidence Trail?

Sun, 04 Oct 2026 08:53:29 GMT

The Wellbeing Illusion — Chapter Five

There is a phrase that appears repeatedly around Wellbeing International Foundation's scientific story:

More than twenty years of research.

It is a powerful statement.

For a prospective patient, twenty years suggests maturity.

For a doctor, it suggests an established body of evidence.

And for a potential investor, it can suggest that the underlying science has been developed and tested over a substantial period.

But there is another way of looking at twenty years of research.

Twenty years should leave twenty years of footprints.

Publications.

Clinical studies.

Research programmes.

Patient cohorts.

Laboratory results.

Conference presentations.

Protocols.

Collaborating institutions.

Outcome data.

Safety data.

And eventually, independent researchers attempting to reproduce the findings.

So we decided to stop looking at the number.

And start looking for the footprints.

What we found is much more complicated.

Because there is unquestionably real science surrounding extracellular vesicles, conditioned media and cellular signalling.

There is also evidence that the scientific relationships surrounding Wellbeing's technology stretch back many years.

And now, in 2026, there is a genuine peer-reviewed human pilot study.

But those three things are not necessarily the same as twenty years of clinical evidence for Wellbeing's Cell-Free Therapy .

That distinction is where this investigation begins.

What Does “Twenty Years of Research” Actually Mean?

This sounds like a simple question.

It isn't.

Research can mean many different things.

It can mean laboratory experiments.

Protocol development.

Studying published papers.

Developing methods for processing biological material.

Observing patients.

Treating patients.

Animal studies.

Human studies.

Clinical trials.

Or formal controlled research designed to determine whether an intervention actually works.

All of those activities may legitimately form part of scientific development.

But they do not carry the same evidential weight.

A scientist spending twenty years studying extracellular vesicles is not the same thing as Cell-Free Therapy undergoing twenty years of clinical trials.

A laboratory developing protocols for twenty years is not the same thing as twenty years of human efficacy data.

And treating patients for twenty years does not automatically create twenty years of clinical research.

This distinction becomes particularly important when we look at Wellbeing's scientific material today.

There Is a Huge Amount of Science Around Extracellular Vesicles

This point should be acknowledged immediately.

Extracellular vesicles are not some invented biological concept.

They are the subject of extensive international scientific research.

Researchers around the world are investigating their role in cellular communication, inflammation, regeneration, ageing, neurological disease and many other biological processes.

Wellbeing has assembled a substantial Research Library containing scientific papers across related fields.

That is useful.

But there is a crucial distinction.

Most of that scientific literature was not produced by Wellbeing.

It is research conducted by universities, hospitals, laboratories and scientists around the world.

That literature can help explain the biological rationale behind an intervention.

It does not automatically demonstrate that Wellbeing's particular preparation works clinically.

Imagine a company developing a new cancer drug.

There may be 50,000 scientific papers explaining cancer biology.

Those papers do not prove that company's drug works.

The drug requires evidence of its own.

The same principle applies here.

The real question isn't:

Is there scientific literature about extracellular vesicles?

There clearly is.

The question is:

Where is the historical research specifically demonstrating what Wellbeing's intervention does in humans?

Our Covert Investigation Asked That Question Years Ago

This is where our confidential archive becomes important.

Years before the publication of Wellbeing's current pilot study, investigators posing as prospective patients were already asking the organisation about the evidence behind what was being offered.

Their identities will remain confidential.

But the recorded answers provide a rare historical snapshot of the scientific position at the time.

During one recorded conversation in 2021, a prospective patient questioned a senior member of Wellbeing's scientific team about evidence relating to cancer.

The answer was remarkably candid.

The representative explained that the biological secretions had originally been developed around regeneration and tissue repair.

Then came an important admission.

There had been:

“never any primary research, original research on anti-cancer effects.”

Instead, he referred to a limited number of scientific papers elsewhere suggesting possible effects and characterised that evidence as preliminary.

When directly asked whether the intervention cured cancer, his answer was:

“no, in my opinion.”

He also explained that cancer was not something the organisation specialised in.

That is an important historical conversation.

And in fairness to the scientific representative, it was a considerably more cautious answer than simply promising a desperate patient that the intervention would work.

But scientifically, it tells us something else.

When specifically challenged about research in that area, the evidence being discussed wasn't a Wellbeing clinical trial.

It was scientific literature produced elsewhere.

That distinction is fundamental.

Another Recording Told Us Something Different

In another recorded encounter, the scientific basis of the intervention was challenged more directly.

Why did they believe it worked?

The response was:

“Based on the research we've actually done.”

That statement immediately interested us.

Because it implies the existence of a separate body of internal research.

The representative described a technology that had evolved over years.

Earlier work had involved cells obtained from fat.

Later development moved towards the blood-derived approach associated with the intervention today.

That supports something we have increasingly discovered throughout this investigation.

The scientific story behind Wellbeing appears to be genuinely old.

There were earlier technologies.

There were laboratory experiments.

There were evolving protocols.

There were patients.

There were relationships with scientists and laboratories.

There appears to have been a gradual transition from earlier cell-based techniques towards what would eventually become the modern cell-free proposition.

But that creates another question.

Where is the research generated during that evolution?

The German Laboratory Takes Us Back More Than a Decade

Our covert material provides another piece of the historical puzzle.

During a recorded discussion in 2021, a senior Wellbeing representative described a relationship with the German laboratory connection stretching back to approximately 2010 or 2011 .

The laboratory representative remembered the collaboration potentially beginning even earlier.

The Wellbeing representative described its senior scientific figure as central to the development of the protocols.

His words were clear:

“Steve designs all the protocols that we use.”

The German laboratory representative then said:

“We carry out the protocols of Wellbeing International.”

He described his responsibilities as including quality control and process control.

This matters.

It provides evidence of a long-running scientific and laboratory relationship.

It supports the idea that the technology didn't suddenly appear in 2024 or 2026.

Something was being developed.

Something was being processed.

Protocols existed.

Laboratory relationships existed.

And people were apparently receiving versions of the intervention.

But once again:

scientific history is not automatically clinical evidence.

A Protocol Is Not Proof

This distinction is easy to lose.

A laboratory can perfect a method of producing something.

That demonstrates manufacturing capability.

It doesn't establish that the finished preparation produces a meaningful clinical benefit.

A scientist can develop a sophisticated biological theory.

That demonstrates scientific reasoning.

It doesn't prove the intervention works in humans.

Patients can receive an intervention.

That demonstrates clinical experience.

It doesn't establish efficacy.

And patients can report improvements.

Those experiences can be genuine and important.

But testimonials cannot determine whether the intervention caused the improvement.

That requires structured research.

Which brings us back to those twenty years.

Where Is the Research Timeline?

If the scientific programme really extends across more than two decades, it should be possible to reconstruct it.

Not necessarily perfectly.

But enough to understand what happened.

What was being researched twenty years ago?

What experiments were performed?

What were the results?

What happened around 2010?

What role did the German laboratory play?

When were the first human patients treated?

What exactly were they receiving?

When did the intervention change from earlier cell-based approaches to conditioned media?

How many people received each version?

Were outcomes systematically recorded?

Were unsuccessful outcomes recorded?

Were adverse events documented?

When was the first prospective human study?

When was the first controlled study?

When was the first peer-reviewed clinical publication?

Those questions are not attacks.

They are how a scientific development history is established.

Yet the public material currently available does not allow us to reconstruct a complete twenty-year clinical research programme for the intervention now described as Cell-Free Therapy.

That does not prove the research didn't happen.

It means we have not yet found the public evidence trail showing what it consisted of.

Then Something Important Happened in 2026

This investigation also has to acknowledge when the evidence changes.

And in 2026, it did.

On 25 June 2026, Frontiers in Aging published:

A multi-modal longevity protocol integrating lifestyle, supplements, and autologous pro-regenerative cell-conditioned media: a pilot study.

Read the study in Frontiers in Aging

This is important.

It is original research.

It is peer reviewed.

And it involves an autologous conditioned-media intervention associated with Wellbeing.

Sixteen healthy adults aged 46 to 72 entered the study.

Fourteen completed it.

The programme lasted 17 weeks.

Participants received a multimodal intervention combining lifestyle optimisation, targeted supplementation and two intravenous infusions of autologous pro-regenerative cell-derived conditioned media.

The researchers reported reductions in two measures of biological age, alongside changes in some biomarkers. No adverse events were reported during the study. Frontiers

This is real evidence.

But understanding what it proves — and what it doesn't — is critical.

The Study Wasn't Testing Cell-Free Therapy Alone

This is the first major limitation.

Participants weren't simply given the conditioned-media preparation.

They were simultaneously placed on an extensive health programme.

That included dietary intervention.

Physical-activity guidance.

Sleep optimisation.

Intermittent fasting.

Individual coaching.

And a substantial supplement programme including NMN, collagen peptides, glycine, N-acetylcysteine, creatine, taurine, curcumin, CoQ10 and nucleotides.

They also received the biological intervention. Frontiers

So when biological-age measurements changed, there was an obvious problem.

Which intervention caused the change?

The diet?

Exercise?

Fasting?

Improved sleep?

Supplements?

Conditioned media?

Or some combination of them?

The study cannot answer that.

Importantly, the researchers themselves acknowledge this.

They state that because the intervention was multimodal, the study cannot isolate the contribution of each individual component. Frontiers

That is an important limitation.

There Was No Control Group

There is another.

The study was:

single-arm;

open-label;

and had no control or sham comparator .

Everyone knew they were participating.

Everyone received the programme.

There was no equivalent group receiving lifestyle changes and supplements without the conditioned-media infusion.

There was no group receiving the infusion without the lifestyle programme.

And there was no placebo-infusion group.

The authors explicitly acknowledge that without randomized comparison, the changes could potentially reflect factors including regression to the mean, expectancy, behavioural changes associated with participating in a study or other influences unrelated to a specific component of the programme. Frontiers

That doesn't make the study worthless.

It makes it what the title says it is:

a pilot study.

Fourteen People Are a Beginning, Not a Conclusion

Pilot studies are supposed to be exploratory.

They help researchers determine whether something interesting may be happening.

They can identify possible signals.

They can reveal unexpected problems.

They can help design the next study.

But fourteen completers cannot establish that Cell-Free Therapy reverses ageing.

They cannot establish efficacy for neurological disease.

They cannot establish tissue regeneration across multiple conditions.

And because the study combined so many interventions, it cannot determine how much of the observed change was caused by the conditioned-media component.

The authors themselves describe their findings as hypothesis-generating and call for larger randomized, controlled studies. Frontiers

That is exactly what should happen next.

The Results Were Interesting — But They Were Not Uniform

There is another finding that deserves attention.

The participants did not all respond identically.

The researchers identified substantial variation in epigenetic-age response.

A larger-response subgroup showed an average reduction of around 5.1 years.

The smaller/no-response subgroup showed an average reduction of only around 0.2 years. Frontiers

That is scientifically interesting.

It also demonstrates why individual testimonials can be so misleading.

People respond differently.

One dramatic response doesn't tell us what the next patient should expect.

And that is precisely why larger cohorts, controls and proper denominators matter.

The Researchers Themselves Recognise What Comes Next

The discussion section of the paper is important.

The researchers acknowledge the absence of a control group.

They acknowledge the small sample size.

They acknowledge the open-label design.

They acknowledge that the multimodal intervention prevents the effect of individual components from being separated.

And they call for larger randomized, double-blind clinical trials with multiple study arms. Frontiers

That is how science should progress.

The pilot asks a question.

A larger trial attempts to answer it.

This Wasn't Independent Confirmation

There is another distinction worth making.

The study was peer reviewed.

But peer review and independent replication are different things.

The paper states that two authors were employed by Wellbeing International Foundation and three were employed by xLongevity. Frontiers

That does not invalidate the research.

Companies and researchers connected with technologies routinely conduct legitimate studies of their own products and interventions.

The relationships are disclosed in the paper.

But it means the study is not independent replication.

Independent confirmation would require researchers outside the organisations involved to reproduce the findings.

That remains an important future step.

The Study Contains Another Important Clue

The paper describes how the conditioned media were produced.

It says preparations were produced individually by an independent internationally accredited facility using a standardized, batch-controlled workflow.

It describes chain-of-identity and chain-of-custody records, processing documentation, extracellular-vesicle output measurements, acceptance criteria, deviation handling and retained samples for confirmatory testing. Frontiers

That is precisely the sort of documentation we have been looking for.

It shows that detailed data can exist around the manufacturing process.

Which immediately raises another question.

If this level of documentation exists for the 2024–25 pilot, what documentation exists for the many years of patients who apparently came before it?

The Historical Patients Become More Important

Our covert archive demonstrates that prospective patients were discussing treatment years before this pilot.

Historical conversations discussed repeat infusions.

Laboratory processing.

Medical conditions.

Expected outcomes.

Stored biological material.

And years of accumulated experience.

So where is the data from those people?

Were they systematically followed?

Were baseline measurements taken?

Were objective outcomes recorded?

Were adverse events captured?

Were non-responders recorded?

Did anybody analyse the entire patient population?

If so, that historical dataset could be extremely valuable.

If not, decades of patient experience may have generated remarkably little scientifically usable evidence.

Testimonials Cannot Fill That Gap

Wellbeing has published compelling patient stories.

Some involve professional athletes.

Others involve people confronting serious health problems.

Their experiences deserve to be heard.

But testimonials cannot answer the central scientific question.

A patient saying:

“I improved.”

is fundamentally different from researchers being able to say:

“Out of 300 comparable patients, this percentage improved by this predefined measurement, this percentage experienced no measurable change, this percentage deteriorated, and these adverse events occurred.”

The first is a story.

The second is data.

Both may matter.

But they are not interchangeable.

There Is Potentially an Extraordinary Dataset Somewhere

This may ultimately become one of the most important findings of this entire investigation.

Suppose Wellbeing and the organisations around it really have treated substantial numbers of people over many years.

Suppose detailed laboratory records exist.

Suppose patient histories were collected.

Suppose biological material was banked.

Suppose repeat infusions were documented.

Suppose outcomes were followed.

Then somewhere inside this network may exist a remarkable body of real-world evidence.

It could potentially show which patients appeared to respond.

Which didn't.

How long effects lasted.

Whether outcomes changed as protocols evolved.

Whether particular biomarkers predicted response.

Whether repeat infusions produced different results.

And what adverse events occurred across the entire historical population.

That wouldn't replace randomized trials.

But it could provide important evidence.

The question is whether the data exist in a form capable of being analysed.

This Is Where “Twenty Years” Becomes Testable

Twenty years is no longer simply a marketing phrase once records exist.

It becomes something that can be audited.

Show the development timeline.

Show the protocols.

Show the patient cohorts.

Show the research programmes.

Show the outcome data.

Show the safety records.

Show the unsuccessful cases.

Show the publications.

Show how the intervention changed.

Show why it changed.

And show which scientific findings caused those changes.

That would allow outsiders to distinguish between:

twenty years of scientific history

and

twenty years of evidence for Cell-Free Therapy.

They are not necessarily the same thing.

The Evidence Has Moved Forward

It would be unfair to finish this chapter without acknowledging that.

There is now a genuine peer-reviewed pilot.

The methodology is described.

The limitations are openly discussed.

The researchers report no adverse events in the study.

The data produced interesting biological-age signals.

And the authors themselves call for substantially stronger trials.

That is progress.

But it also exposes the historical gap more clearly.

Because the first question is no longer:

Is there any published human research?

There is.

The question has become:

Why does the formal published evidence appear so recent when the scientific and patient story is said to be so old?

And that is where this investigation goes next.

Twenty Years Should Leave Twenty Years of Footprints

There is genuine science surrounding extracellular vesicles.

There is evidence of longstanding scientific and laboratory relationships.

There is historical evidence of protocol development.

There were patients.

And there is now a genuine peer-reviewed pilot study.

None of those facts should be dismissed.

But neither should they be combined into something they do not necessarily establish.

Independent research into extracellular vesicles is not automatically research into Wellbeing's CFT.

Laboratory development is not a clinical trial.

Patient experience is not controlled evidence.

A testimonial is not an outcome dataset.

And one small multimodal pilot published in 2026 cannot, by itself, explain a scientific history extending more than twenty years.

The strongest evidence Wellbeing could produce now would therefore be remarkably simple.

Not another celebrity testimonial.

Not another library of papers written by other scientists.

Not another explanation of extracellular-vesicle biology.

The historical research itself.

Because after more than twenty years, the question should no longer be whether the science exists somewhere.

It should be possible to follow it.

Year by year.

Study by study.

Patient by patient.

Result by result.

And once we began putting dates against that history, another problem emerged.

The patients appear much earlier than the formal clinical research.

And that changes the investigation completely.

Next: Chapter Six — Before the Trial: What Happened to Years of Patient Outcomes?

People were apparently receiving versions of the intervention long before the recent peer-reviewed pilot. So in Chapter Six we stop following scientific papers and start following the patients. How many were treated? What happened to them? Were failures recorded alongside successes? Were adverse events systematically captured? And after years of treatment, does a comprehensive patient dataset exist somewhere that the public has never seen?

Inside the German Laboratory: Who Actually Makes Wellbeing’s Cell-Free Therapy?

Sun, 27 Sep 2026 07:34:27 GMT

The Wellbeing Illusion — Chapter Four

If there is one physical location that appears indispensable to Wellbeing International Foundation's Cell-Free Therapy, it is not Bermuda.

It is not Harley Street.

It is not one of the 23 partner clinics.

It is the laboratory in Germany.

Wellbeing's current website describes it as a “GMP-certified laboratory” and says every Cell-Free Therapy preparation is processed there. The patient gives approximately 150ml of blood at an approved collection point; that sample is transported to Germany, where cells are isolated and conditioned, the cell-free output is harvested and tested, and the resulting preparation can later be returned for intravenous administration. Wellbeing International Foundation

Wellbeing's About page goes further, calling it the organisation's:

“German GMP-certified laboratory partner.” Wellbeing International Foundation

That final word is important.

Partner.

It indicates that the laboratory sits alongside Wellbeing rather than necessarily being a facility owned by Wellbeing itself.

So we started looking behind the phrase “German laboratory.”

And what we found takes the Wellbeing story back more than a decade.

The Laboratory Is the Manufacturing Heart of the Process

Forget the marketing for a moment and follow the biology.

Without the German laboratory, there appears to be no CFT preparation.

Wellbeing's current process says the patient's blood is sent there under monitored conditions.

The cells are isolated.

They are placed under controlled conditions.

Wellbeing says those conditions stimulate the cells' natural signalling response.

The cell-free output is collected.

It undergoes quality testing.

Material may then be stored.

Eventually it is made available for infusion. Wellbeing International Foundation

Whatever view one takes of the claimed biological effects, the laboratory is therefore performing one of the most important physical functions in the entire Wellbeing system.

The clinic doesn't manufacture the preparation.

The CEO doesn't manufacture it.

The patient coordinator doesn't manufacture it.

Germany does.

So who exactly is Germany?

The Public Website Doesn't Name the Laboratory

This is where things become interesting.

Wellbeing's current Contact page identifies:

Germany (Laboratory)

and describes a:

“State-of-the-art GMP-certified laboratory for cell-free preparation processing.” Wellbeing International Foundation

But the page does not name the laboratory company.

It doesn't provide its address.

And it doesn't identify the certification number or certification scope on that page.

The Regulatory page similarly says Wellbeing uses an:

“EU-compliant, GMP-certified laboratory in Germany”

with full traceability, batch testing and quality assurance. Wellbeing International Foundation

Again, the laboratory isn't identified there by corporate name.

So we went back into the historical evidence.

And there, the picture becomes considerably clearer.

A Prospective Patient Was Introduced Directly to the Laboratory

In January, an investigator posing as a prospective patient asked Wellbeing to explain what happened to his blood in Germany.

Andrew Chancellor arranged a video meeting.

The people on that call included Chancellor and a representative of a German laboratory business called Ad Lentus .

At the beginning of the meeting Chancellor introduced the German participant as the person running Ad Lentus and described it as the laboratory Wellbeing worked with. 4. MR Stem Cell report.

This is significant.

This wasn't information inferred from a company directory.

The introduction came from Wellbeing's CEO during a discussion specifically arranged to explain the laboratory that would process the prospective patient's biological material.

The Relationship Went Back Years

The conversation then became even more interesting.

Chancellor explained that the German laboratory relationship was not new.

He recalled working with the laboratory connection from around 2010 or 2011 .

The German representative remembered the relationship as potentially extending even further back.

Chancellor also described Stephen Ray as being central to the scientific side of the arrangement, saying:

“Steve designs all the protocols that we use.”

2. UC TL (1)

This is an extremely important piece of the Wellbeing structure.

Because it begins to separate three distinct functions.

Wellbeing — coordination and commercial organisation.

Stephen Ray — scientific protocol.

German laboratory — physical processing, quality and process control.

And according to the participants themselves, versions of that relationship existed long before the current Wellbeing website.

The Laboratory Representative Explained His Role

The German representative then described what his laboratory did.

He said:

“We carry out the protocols of Wellbeing International.”

He also described responsibility for:

“quality control”

and:

“process control.”

1. Ad lentus (1)

That distinction matters.

It suggests the laboratory was not necessarily inventing the entire Wellbeing process independently.

According to the recorded discussion, protocols were associated with Ray and Wellbeing, while the laboratory implemented the process and controlled its execution.

That raises an important question for today's CFT:

Who owns the current manufacturing protocol?

Is it Wellbeing?

Ray?

The laboratory?

Another legal entity?

Or is it governed through a licence or contractual arrangement?

Wellbeing's public pages reviewed for this article do not answer that question.

What Actually Happened to the Patient's Cells?

The 2021 conversation provides a rare historical description from inside the processing relationship.

The prospective patient asked whether drugs or other substances were being added.

The German representative said they were not.

He described cells being isolated and then subjected to the protocol.

The objective, as he explained it, was to stimulate them so biological signalling substances accumulated in the surrounding liquid.

Among the substances he specifically mentioned were:

cytokines;

microvesicles;

and:

growth factors.

He described the resulting material as coming from the patient's own biological starting material. 6. Max Robert Lewinsohn

This is broadly recognisable alongside the biological principles Wellbeing describes publicly today, although the organisation's current process and terminology should not simply be assumed to be identical to the 2021 method.

Processes evolve.

Protocols change.

Regulatory requirements change.

That distinction is important.

But the historical continuity is difficult to miss.

Then Comes the Word “GMP”

Today Wellbeing uses unequivocal language.

It says the laboratory is:

“GMP-certified.” Wellbeing International Foundation

But during the 2021 recorded conversation, the German representative used slightly different wording.

He said:

“we have a laboratory, according to GMP standards.”

2. UC TL (1)

Those statements are not necessarily contradictory.

A facility can change status over time.

The speaker may have been using informal English rather than regulatory terminology.

A different facility or corporate entity may now perform the work.

Or the laboratory may indeed have held relevant certification at the time and the speaker simply described it imprecisely.

We therefore cannot responsibly conclude from those words that the facility was not GMP-certified in 2021.

But neither should “according to GMP standards” and “GMP-certified” automatically be treated as interchangeable without examining the underlying documentation.

GMP Is Not Just a Marketing Term

This distinction matters because GMP — Good Manufacturing Practice — is not simply another way of saying a laboratory is clean or professionally run.

The meaningful questions concern the actual regulatory documentation.

Which legal entity holds the relevant authorisation or certificate?

Which physical premises does it cover?

Which regulatory authority issued or inspected it?

What activities are included within its scope?

What products or manufacturing processes are authorised?

When was the facility last inspected?

And does that scope encompass the specific processing being performed for Wellbeing's CFT preparations?

Those are documentary questions.

And Wellbeing itself says detailed regulatory documentation is available from its team. Wellbeing International Foundation

For this investigation, seeing that documentation would resolve a significant part of the uncertainty.

Ad Lentus Is a Real German Biotechnology Business

This is another important distinction.

Our investigation is not suggesting that Ad Lentus is an invented laboratory.

It isn't.

Ad Lentus GmbH has a public presence in Germany.

Its own website identifies the company as:

Ad Lentus GmbH

at:

Magirus-Deutz-Str. 18 D
89077 Ulm
Germany.

Its legal notice identifies the business in the Ulm commercial register under HRB 731330 and names Jörn Steiger and Cornelia Ludwig as managing directors. Ad Lentus GmbH

Its website describes specialist analytical laboratory services involving the isolation and analysis of human cell types and cytokines.

It also advertises expertise in process development, method transfer, automation, GMP compliance , quality-management systems and pharmaceutical production development. Ad Lentus GmbH

Those are substantial biotechnology activities.

But something else emerged from the public corporate record.

There Is More Than One Ad Lentus Company

Public German corporate information also identifies a separate company:

Ad Lentus Laboratories GmbH.

It was registered in 2019 and has an address in Laichingen.

Its publicly recorded business purpose includes pharmaceutical project development, biotechnology, cell-based products, regenerative medicine, quality assurance and GMP systems. Company House

This distinction becomes important.

Because saying simply “Ad Lentus” does not necessarily tell us which legal entity performed a particular activity at a particular time.

Was Wellbeing's historical laboratory relationship with Ad Lentus GmbH?

Ad Lentus Laboratories GmbH?

Did the relationship migrate between entities?

Which company actually received patient samples?

Which company invoiced for processing?

Which company employed the laboratory personnel?

And most importantly today:

Which legal entity holds the certification Wellbeing relies upon when it describes its current laboratory as GMP-certified?

We have not yet established those answers.

The Current Laboratory May Not Be the Historical Laboratory

This is another point where we need to be careful.

The 2021 evidence connects Wellbeing's historical processing arrangement with Ad Lentus.

The current Wellbeing website says it has a German GMP-certified laboratory partner. Wellbeing International Foundation

But from the current public Wellbeing pages reviewed for this chapter, we have not independently established that Ad Lentus remains the current CFT processing laboratory in September 2026 .

That distinction matters enormously.

It would be tempting to simply write:

“Wellbeing's laboratory is Ad Lentus.”

The historical evidence supports that description for the arrangement discussed in 2021.

It does not, by itself, prove the current arrangement is unchanged.

So we asked the harder question instead.

Who processes CFT today?

There Is Another Geographic Puzzle

Our historical evidence contains another intriguing detail.

In a separate recorded conversation, Chancellor was asked whether an infusion could take place in Germany.

He replied that it could.

When asked where the laboratory was, he described it as being in eastern Germany and referred to Dresden .

He also said biological material was stored in the German laboratory in preservation tanks and claimed some stored material dated back to 2010 and was periodically checked. 7. SR meeting Part 1

But the public Ad Lentus businesses identified today are associated with Ulm and Laichingen , in Baden-Württemberg — not Dresden. Ad Lentus GmbH

That does not establish a contradiction.

Wellbeing may have had multiple facilities.

Storage and processing may have occurred in different places.

A partner facility may have existed in Dresden.

The arrangement may have changed.

Or Chancellor may simply have been referring to a clinical location rather than the same processing facility.

The evidence currently available does not resolve this.

But it gives us another question that deserves an answer:

Where, physically, was the patient's biological material being processed and stored?

The Storage Claim Is Particularly Important

Consider what Chancellor's historical statement implies.

If biological material derived from patients was being stored for years, there should be a substantial documentary framework surrounding that activity.

Patient consent.

Sample identification.

Storage conditions.

Traceability.

Retention periods.

Release procedures.

Quality checks.

Destruction procedures.

Data protection.

Chain of custody.

And a legal entity responsible for maintaining the material.

Wellbeing's current process continues to advertise optional cell banking , meaning material can be stored for future use. Wellbeing International Foundation

So this is not merely an historical curiosity.

Storage appears to remain part of the modern business model.

Which means another simple question emerges:

Who legally holds the patient's banked biological material?

Wellbeing Says Traceability Is Complete

Its current regulatory page makes strong quality-control claims.

Wellbeing says the German laboratory provides:

full traceability;

batch testing;

and:

quality assurance.

It says there is complete tracking from patient sample to final preparation. Wellbeing International Foundation

Those are exactly the systems we would expect to see around this type of process.

And they should create documentation.

A patient's blood doesn't simply become “CFT.”

There should be records showing what happened.

When the sample arrived.

Who received it.

What identifier it was given.

What process occurred.

Which protocol version was used.

What equipment was involved.

What quality tests were performed.

Whether the batch passed.

Who released it.

What was stored.

What was shipped.

And where it ultimately went.

That documentary trail may be one of the most important pieces of evidence in the entire Wellbeing system.

Then There Is Stephen Ray

The laboratory investigation also brings us back to the scientific ownership question.

Chancellor's recorded statement was remarkably clear:

“Steve designs all the protocols that we use.”

2. UC TL (1)

That was 2021.

Wellbeing today identifies Stephen Ray as its Senior Scientific Consultant and describes more than 30 years of academic and commercial cell-therapy research. Wellbeing International Foundation

So what exactly is Ray's relationship to the present CFT manufacturing protocol?

Did he personally develop it?

Does Wellbeing own it?

Was it assigned to Wellbeing?

Is it licensed?

Does the German laboratory receive a controlled manufacturing protocol from Wellbeing?

Does the laboratory have discretion to modify it?

Who approves modifications?

Who owns improvements developed inside the laboratory?

Those may sound like corporate-law questions.

They are not.

They are central to understanding what Wellbeing actually possesses.

Because the Laboratory May Hold More Than the Buildings

Imagine that Wellbeing owns no laboratory.

That doesn't necessarily matter.

Many successful biotechnology companies outsource manufacturing.

But if manufacturing is outsourced, the organisation normally needs something else.

A proprietary protocol.

A patent.

A licence.

Protected know-how.

Validated processes.

Exclusive manufacturing rights.

Contracts.

Data.

Or some other defensible intellectual asset.

Otherwise, an investor needs to understand precisely what prevents another organisation from reproducing the commercial model.

This becomes especially important because Wellbeing announced a new private capital round in 2026 and said the money would support research, documentation, operating capacity and expansion of its clinical-relationship network. ( wellbeingint.com )

If investors are funding biotechnology, the ownership and control of the underlying biotechnology matter.

What We Have Established

At this stage, the evidence supports several conclusions.

Wellbeing currently says CFT preparations are processed at a GMP-certified laboratory in Germany. Wellbeing International Foundation

Wellbeing describes that facility as a laboratory partner , rather than publicly presenting it on the pages reviewed as a Wellbeing-owned laboratory. Wellbeing International Foundation

Historical evidence establishes that Wellbeing had a processing relationship with Ad Lentus in 2021. 4. MR Stem Cell report.

The German laboratory representative said the laboratory carried out Wellbeing protocols and handled quality and process control. 1. Ad lentus (1)

Chancellor said Stephen Ray designed the protocols used at the time. 2. UC TL (1)

And Ad Lentus is a real German biotechnology business publicly advertising analytical laboratory, cell, cytokine, process-development and GMP-compliance expertise. Ad Lentus GmbH

Those are facts we can document.

What We Have Not Established

There are equally important things we cannot yet say.

We have not independently established that Ad Lentus is Wellbeing's current 2026 CFT processing laboratory .

We have not obtained the current GMP certificate relied upon by Wellbeing.

We therefore have not independently verified its holder, physical site, issuing authority or precise scope.

We have not established whether the historical Dresden reference concerned processing, storage, infusion or another partner facility.

We have not established who legally owns Wellbeing's current CFT manufacturing protocol.

And we have not established the contractual relationship governing intellectual property between Wellbeing, Ray and the current laboratory partner.

Those are not reasons to declare the laboratory illegitimate.

They are reasons to obtain the documents.

The Laboratory Behind the Curtain

Chapter Two showed us that Wellbeing's international clinic network appears to operate largely through relationships.

Chapter Three showed that clinical responsibility can involve different professionals and organisations.

Now Chapter Four reveals the same pattern at the scientific centre of the operation.

The laboratory appears to be a partner .

Historically, the protocol was described as being designed outside the laboratory and executed inside it.

The patients were elsewhere.

The doctors were elsewhere.

The commercial organisation was elsewhere.

The biological material moved between them.

That may be an entirely workable biotechnology model.

But it makes the contractual and documentary relationships between those components absolutely fundamental.

Because somewhere inside Germany is the place where a tube of blood stops being simply a patient's blood and becomes the preparation Wellbeing calls Cell-Free Therapy.

And if we want to understand Wellbeing International Foundation, that transformation may be the single most important part of the entire operation to investigate.

We therefore end with four questions:

Who owns the laboratory?

Who certifies the process?

Who owns the protocol?

And ultimately:

Who actually makes CFT?

Next: Chapter Five — Twenty Years of Research: Where Is It?

Wellbeing describes a scientific programme extending over more than two decades. In Chapter Five we stop following the businesses and start following the science. We search the publications, clinical trials, patents, research institutions and named investigators behind those twenty years — and separate documented research from commercial history.

Who Is Actually Treating the Patient? Inside Wellbeing’s Clinical Chain

Sun, 27 Sep 2026 07:28:34 GMT

The Wellbeing Illusion — Chapter Three

There is a point in this investigation where company structures, clinic networks and biotechnology stop being abstract.

A patient sits down.

They discuss their health.

Someone considers whether Cell-Free Therapy is appropriate.

Blood is taken.

That blood crosses an international border.

A laboratory processes material derived from it.

Weeks later, a biological preparation is infused back into the patient's body.

At that point, one question matters more than almost anything else:

Who is actually treating the patient?

Chapter Two examined Wellbeing International Foundation's claim of a global network of partner clinics.

What emerged was not the conventional structure many readers might imagine.

Wellbeing's own current material describes a distributed system: an initial consultation with its clinical team, blood collection at an “approved collection point,” transportation to a laboratory in Germany, and eventual infusion at an “approved clinical location” by a qualified medical professional. Wellbeing International Foundation

There is nothing inherently improper about medicine being delivered through different specialist organisations.

But it creates a chain.

And when we began reconstructing that chain using Wellbeing's current disclosures alongside historical patient consultations obtained during this investigation, an important question emerged:

At what point does somebody become medically responsible for the patient?

Start With Wellbeing's Current Process

Today Wellbeing describes the beginning of the CFT journey as an:

“Initial Consultation.”

Its website says:

“Speak with the WIF clinical team about your goals and health history.”

Blood collection comes afterwards.

Approximately 150ml is taken at an approved collection point and transported under controlled temperature conditions to Germany.

After cell isolation, conditioning, collection of the cell-free biological output and quality testing, the preparation can eventually be administered intravenously at an approved clinical location. Wellbeing International Foundation

On paper, that appears straightforward.

But look more closely at the first stage.

Who is the “WIF clinical team” ?

And what exactly happens during that initial consultation?

Is it an information session?

A sales conversation?

A scientific consultation?

A medical assessment?

A formal clinical evaluation?

And most importantly:

Who decides that this particular patient should proceed?

Someone Has to Make the Medical Decision

This distinction matters.

There is nothing unusual about non-doctors speaking to prospective patients.

Healthcare organisations employ patient coordinators, receptionists, scientists, nurses, commercial directors and administrators.

Each can legitimately play a role.

But their roles are different.

Explaining how a technology works is not the same as diagnosing somebody.

Collecting medical records is not the same as interpreting them.

Discussing price is not the same as determining medical suitability.

And explaining scientific research is not the same as accepting clinical responsibility for an individual patient.

So we went back to the historical evidence.

And one recorded consultation is particularly revealing.

Inside a Wellbeing Consultation

An investigator posing as a prospective patient attended a Wellbeing consultation at 10 Harley Street, London .

We are deliberately withholding the investigator's identity.

The investigator presented with a supposed knee injury.

According to the contemporaneous recording, Stephen Ray did much of the talking.

Medical history and the proposed treatment were discussed.

Ray asked questions including the prospective patient's age and occupation.

The proposed process was then explained: blood would be collected, sent to Germany, processed and later returned for intravenous administration. WIFL Claims (Covert) Dr. X notes…

The investigator's contemporaneous summary records that Ray anticipated the supposed patient might require two or three infusions and that approximately ten vials could potentially be produced, with material remaining available for future use. WIFL Claims (Covert) Dr. X notes…

The quoted overall cost at that historical consultation was approximately $40,000.

This was not simply someone reading a webpage.

It was an individual sitting in Harley Street discussing their supposed medical history and a proposed biological intervention.

So who was providing the medical assessment?

Stephen Ray Provides an Important Answer

This investigation subsequently obtained another recorded exchange with Stephen Ray.

Ray was directly asked whether he was a medical doctor.

His response was clear:

“No, I'm a PHD doctor.”

He described himself as a neuroscientist and Wellbeing's Chief Scientist. A:181220:1142 telephone call tr…

Later in the exchange he made the distinction even clearer:

“I don't do the medical treatment cause I'm not a doctor.”

Ray explained his role differently.

He said:

“My job is to advise patients for what these things can do and what they can't do.”

WIFL - USA

That distinction is important.

Ray himself was not claiming to be the treating physician in that exchange.

He was explicitly distinguishing his scientific role from medical treatment.

But that immediately produces the next question.

If Ray wasn't making the medical decision, who was?

Medical Records Were Not Always the Same

The exchange also gives us some insight into the information available during these consultations.

When challenged about medical records, Ray said:

“Sometimes they are extensive from their own doctors. Sometimes they are less so.”

He then explained:

“My job is really to explain the science to them and then it is up to them if they want to go ahead or not.”

WIFL - USA

That sentence deserves careful treatment.

It would be wrong to interpret it as proof that no doctor assessed Wellbeing patients.

The historical consultation itself involved another person described at the time as a medical doctor.

Nor does Ray saying the decision was “up to them” necessarily mean that patients could proceed without medical clearance.

But it does leave an important gap in the documented historical pathway.

Who gave the clinical approval?

That is what we need to establish.

The Current Wellbeing Team Is More Clearly Defined

Wellbeing's present website provides more information about its clinical personnel than was readily apparent from older material.

It identifies named clinical staff.

For example, Wellbeing describes Chris Icamina as Senior Clinical Consultant and says he performs both blood draws and infusions while working alongside partner physicians beginning to deliver CFT.

It describes Melanie Scaggs as Senior Nursing Consultant and says she performs blood draws and infusions and participates in follow-up afterwards. Wellbeing International Foundation

Those are meaningful clinical functions.

But Wellbeing's own wording also reinforces something important.

Icamina works:

“alongside partner physicians.” Wellbeing International Foundation

Which takes us directly back to the network uncovered in Chapter Two.

The physician may belong to the partner clinic.

The nurse may perform the infusion.

The laboratory may be a separate German organisation.

And Wellbeing may coordinate the system.

So where does medical responsibility sit?

The Doctor May Not Work for Wellbeing

This is perhaps the most important consequence of the partner-network model.

Wellbeing's physician programme actively recruits established practitioners, including high-volume PRP practices.

It promotes CFT as a premium addition to an existing regenerative-medicine practice and offers training, scientific access, commercial modelling, cell-banking revenue opportunities and marketing support. Wellbeing International Foundation

That strongly suggests that at least some physicians delivering CFT can be independent practitioners joining the Wellbeing network.

Again, there is nothing inherently unusual about this.

But consider what it means from the patient's perspective.

The organisation introducing CFT may be Wellbeing.

The scientific explanation may come from Wellbeing.

The laboratory protocol may be associated with Wellbeing.

The preparation may be produced through Wellbeing's German laboratory relationship.

But the person putting the IV into the patient's arm may work for an entirely different medical practice.

So:

Who is the physician of record?

Follow the Patient Instead of the Company

This is where the investigation becomes clearer if we stop following company names and follow one hypothetical patient.

They contact Wellbeing.

Stage One: Consultation

Someone discusses their health history and objectives.

Who conducts that consultation?

And is it clinical or informational?

Stage Two: Suitability

Someone must decide whether there is any medical reason why the patient should not proceed.

Who makes that decision?

Stage Three: Blood Collection

Approximately 150ml of blood is collected.

Who orders that procedure?

Who verifies the patient's identity?

Who records the collection?

Stage Four: Transportation

The sample leaves the collection point and travels to Germany.

Wellbeing says chain of custody and temperature monitoring are maintained. Wellbeing International Foundation

Who legally assumes custody?

Stage Five: Laboratory Processing

Cells are isolated and conditioned.

The cell-free biological output is collected and tested.

Who authorises the release of that preparation?

Stage Six: Return

The resulting material is made available for infusion.

Who receives it?

Stage Seven: Infusion

A qualified medical professional administers it intravenously. Wellbeing International Foundation

Who prescribed or authorised that administration?

Stage Eight: Follow-Up

If the patient develops an unexpected reaction hours or days later, who is responsible for investigating it?

One organisation?

The partner doctor?

The laboratory?

Wellbeing?

Or some combination of them?

These are basic clinical-governance questions.

The Laboratory Has Responsibility Too

There is another important participant in this chain.

Germany.

Wellbeing currently says every preparation is processed at a single GMP-certified laboratory in Germany. Wellbeing International Foundation

Its Contact page describes a:

“State-of-the-art GMP-certified laboratory for cell-free preparation processing.” Wellbeing International Foundation

And the treatment-process page says the biological output undergoes quality testing before release. Wellbeing International Foundation

But the laboratory isn't simply a courier destination.

It is where the patient's biological material is transformed into the preparation eventually infused.

That means laboratory responsibility is central to the patient journey.

Who operates it?

Who is the responsible scientific or medical officer?

What precisely does its certification cover?

What release criteria must a preparation satisfy?

What happens if a batch fails?

Who reports that to the patient?

Those questions become even more important when collection, processing and administration occur in different countries.

Wellbeing's Current Claims Have Become More Careful

There is another development worth acknowledging.

Wellbeing's current website now contains unusually explicit language about what it says CFT does not claim .

It says CFT:

“is not offered as a treatment for any named condition.”

It further states that CFT is:

“not intended to diagnose, treat, cure, or prevent any disease.” Wellbeing International Foundation

Wellbeing also says the peer-reviewed pilot published in 2026 is the only clinical study it cites and that testimonials and case studies are patient-reported accounts rather than evidence of efficacy. Wellbeing International Foundation

That is important context.

But it creates an interesting question for the patient consultation.

If CFT isn't offered as treatment for a named condition, what exactly determines whether a particular person is an appropriate candidate?

“Can It Help My Knee?” Is Still a Medical Question

Imagine somebody contacts Wellbeing because they have a damaged knee.

Or neurological symptoms.

Or chronic pain.

Or age-related decline.

They aren't interested in the abstract biology of extracellular vesicles.

They want to know:

Will this help me?

That is where marketing, science and medicine can begin to overlap.

A scientist can explain what extracellular vesicles are.

A CEO can explain how the company works.

A patient coordinator can explain logistics.

A nurse can explain what happens during an infusion.

But when discussion moves to whether a particular person's medical circumstances make an intervention appropriate, the question becomes clinical.

And somebody needs to own that decision.

The Historical Consultation Shows Why This Matters

Return to Harley Street in 2020.

The investigator's supposed knee injury was discussed.

Ray did much of the scientific explanation.

The process was explained.

Potential numbers of infusions were discussed.

The prospective patient was given an approximate price.

And at the end of the consultation, the division of responsibilities was summarised.

The investigator was told that clinical questions could be directed to those present at the consultation, while financial questions would go to Andrew Chancellor. WIFL Claims (Covert) Dr. X notes…

That suggests there was an intended distinction between clinical and commercial functions.

Good.

But it still leaves us needing to identify precisely who held the medical responsibility.

Not who explained the science.

Not who organised the payment.

Not who physically drew the blood.

The doctor responsible for deciding:

This patient is medically suitable to receive this preparation.

What We Have Not Established

Precision is essential here.

We have not established that Wellbeing patients receive treatment without medical supervision.

We have not established that the current partner physicians are unqualified.

We have not established that blood draws or infusions are being performed improperly.

We have not established that Stephen Ray represented himself as the treating medical physician in the exchange examined here. In fact, the recorded evidence contains Ray explicitly stating that he was not a medical doctor and that he did not perform the medical treatment. WIFL - USA

And we have not established that Wellbeing's current clinical-governance arrangements are identical to those operating in 2020.

The organisation has evolved.

Those distinctions matter.

Our question is narrower.

Can a patient clearly identify who holds medical responsibility at every stage?

Wellbeing Could Answer This Very Easily

There is a straightforward way to resolve the issue.

For every patient, identify:

the clinician conducting the formal medical assessment;

the physician responsible for approving CFT;

the legal medical provider;

the professional registration of that physician;

the organisation responsible for the blood collection;

the laboratory legal entity responsible for processing;

the clinician authorising administration;

the professional administering the infusion;

the organisation retaining the medical record;

and the organisation responsible for adverse-event reporting and follow-up.

That information need not undermine Wellbeing's distributed model.

It would strengthen it.

Because patients would know exactly who is responsible for them.

The Question Isn't Whether Wellbeing Has Doctors

That would be far too simplistic.

Wellbeing works with medical professionals.

Its current material identifies clinical personnel and explicitly refers to partner physicians. Wellbeing International Foundation

The real question is more sophisticated.

Where does medical responsibility sit inside a network where the consultation, blood collection, laboratory processing and infusion may involve different people, organisations and countries?

That is the question patients need answered.

It is also the question prospective physician partners should ask before joining the network.

And it is something investors examining the scalability of the model should understand.

Because a global medical network is not merely a collection of relationships.

It is a chain of responsibility.

From Harley Street to Germany and Back Again

Our investigation started with a patient sitting in Harley Street.

It then followed their hypothetical blood.

Out of their arm.

Into a collection system.

Across an international border.

Into a German laboratory.

Through a biological processing protocol.

Into storage and quality control.

Back into the clinical network.

And eventually into an IV line.

At every stage somebody is doing something.

At every stage somebody owns responsibility for that action.

But the patient shouldn't have to conduct an investigation to discover who those people are.

That information should be obvious.

Because when a person agrees to have a biological preparation manufactured from their own blood and subsequently infused back into their body, the most important person in the entire network isn't the CEO.

It isn't the scientist.

It isn't the investor.

It isn't the laboratory partner.

And it isn't the person who built the website.

It's the patient.

And that patient deserves a clear answer to one extraordinarily simple question:

Doctor — who is actually responsible for me?

Next: Chapter Four — Inside the German Laboratory: Who Actually Makes Cell-Free Therapy?

The patient may begin with Wellbeing, but their blood travels elsewhere. In Chapter Four we follow it to Germany. Who operates the laboratory? What does “GMP-certified” actually cover? Who designed the processing protocols, who performs the quality-control release, and what is the legal relationship between the laboratory and Wellbeing International Foundation?

The Invisible Clinic Network: Where Are Wellbeing International Foundation’s 23 Partner Clinics?

Sun, 27 Sep 2026 07:24:19 GMT

The Wellbeing Illusion — Chapter Two

Twenty-three partner clinics.

More than twenty delivery locations.

A German laboratory.

Operations spanning the United States, Europe, the Middle East, Africa and the Pacific.

That is the international footprint presented today by Wellbeing International Foundation.

On its current website, Wellbeing describes itself as operating through a worldwide network of 23 partner clinics , supported by a single German laboratory. It lists locations stretching from Los Angeles and New York to London, Monaco, Dubai, Johannesburg and New Zealand. Wellbeing International Foundation

It sounds substantial.

But there is an obvious problem for anybody attempting to investigate that network.

Wellbeing doesn't publicly identify those 23 partner clinics on the page where it makes the claim.

It identifies places .

And a place is not a clinic.

That distinction takes us directly into one of the most important questions surrounding Wellbeing International Foundation:

What exactly does Wellbeing mean when it says it has 23 partner clinics?

Twenty-Three Clinics — But Which Clinics?

Wellbeing's current About page lists its geographical presence as follows.

In the United States:

Austin, Dallas, Detroit, Los Angeles, Louisville, New Orleans, New York, Philadelphia, Reno, San Francisco, Seattle, St Louis and Virginia Beach.

In Europe:

Dresden, Faro, Lisbon, London, Monaco and Nice.

Elsewhere:

Dubai, Johannesburg and New Zealand. Wellbeing International Foundation

Count them.

There are 22 named geographical locations .

Yet further down the same page, Wellbeing describes a:

“delivery network of 23 partner clinics.” Wellbeing International Foundation

That is not necessarily a contradiction.

There could be two partner clinics in one listed location.

The location list may be illustrative rather than exhaustive.

A newly added clinic may not yet appear in the geographical list.

But the discrepancy produces an extremely simple question:

What are the names and addresses of the 23 clinics?

We searched for that answer.

We could not find a complete public directory on Wellbeing's current website identifying all 23 clinics by clinic name, street address and responsible physician.

A City Is Not a Clinic

This sounds obvious, but it matters.

“New York” doesn't tell a prospective patient where treatment takes place.

“Los Angeles” doesn't identify the medical provider.

“London” doesn't tell us which regulated clinic is involved.

And “New Zealand” does not even identify a city.

For a medical network, those details matter because they establish considerably more than geography.

They allow a patient to identify who is actually treating them.

They allow somebody to check professional registration.

They allow inspection of regulatory records.

They establish which legal entity operates the premises.

They help establish who carries clinical responsibility.

And they allow a patient to distinguish between a facility owned by Wellbeing and an independent medical practice that provides services to Wellbeing patients.

Those are completely different things.

Wellbeing Actually Gives Us an Important Clue

Read Wellbeing's own language carefully.

It doesn't generally describe these locations as a chain of Wellbeing-owned hospitals or medical centres.

It calls them:

“partner clinics.” Wellbeing International Foundation

That word changes the picture considerably.

A partner clinic could be an entirely independent medical business.

It could have its own doctors.

Its own premises.

Its own licences.

Its own insurance.

Its own patients.

Its own medical records.

Wellbeing might simply have a commercial or clinical relationship allowing CFT patients to use the facility.

There is nothing inherently unusual about that model.

Medicine routinely operates through partnerships, referral networks and contracted providers.

But it means that saying an organisation has a presence in 23 clinics is very different from saying it owns or operates 23 clinics .

And Wellbeing's own current physician-recruitment programme provides further insight into how this network is apparently being constructed.

Wellbeing Is Actively Recruiting Existing Doctors

Wellbeing currently has an entire section of its website devoted to recruiting physicians.

It specifically targets practitioners already involved with PRP and regenerative medicine.

The proposition is not simply scientific.

It is also commercial.

Wellbeing tells prospective physician partners that CFT can become a “premium service offering” , discusses recurring revenue from cell banking, repeat infusions and marketing and patient-acquisition support. Wellbeing International Foundation

It offers three partnership tiers:

Team Physicians

Academic & Research Physicians

and:

High-Volume PRP Practitioners. Wellbeing International Foundation

The last category is particularly revealing.

Wellbeing describes these as established regenerative practices ready for premium positioning and offers them a revenue model, projections, patient-outcome data access, brand association and marketing support. Wellbeing International Foundation

This looks considerably less like a conventional company opening 23 of its own clinics around the world.

It looks more like a distributed partnership network built around existing independent practitioners .

Again, that isn't inherently a criticism.

But it is a fundamentally different business structure.

And It Helps Explain How Treatment Can Happen Almost Anywhere

Our investigation uncovered historical conversations that make considerably more sense when viewed through this modern partnership model.

During a recorded conversation with a prospective American patient, Andrew Chancellor was asked how treatment could be organised in the United States.

His answer was striking.

He explained that the blood could be taken:

“pretty much anywhere”

and that the infusion could similarly be organised in many places.

When the prospective patient referred to their doctor administering the treatment, Chancellor corrected the assumption:

“Well not your doctor, we can find a doctor for you.”

The discussion indicated that Wellbeing would organise both the physician and the medical courier.

That conversation took place years before the present website's description of 23 partner clinics.

But viewed from 2026, the underlying model suddenly becomes much easier to understand.

The important component may never have been a chain of buildings carrying a Wellbeing sign.

The important component may have been the network .

The Patient, the Clinic and the Laboratory Can All Be Somewhere Different

Wellbeing's current published treatment process effectively confirms this distributed structure.

The patient begins with a consultation with the Wellbeing clinical team.

Approximately 150ml of blood is then drawn at an:

“approved collection point.”

The sample is transported under controlled conditions to the laboratory in Germany.

Processing takes place there.

The final preparation is subsequently administered at an:

“approved clinical location”

by qualified medical professionals. Wellbeing International Foundation

Notice the terminology.

Not necessarily a Wellbeing clinic.

An approved collection point .

An approved clinical location .

And a laboratory in another country.

The consultation, blood collection, biological processing and infusion therefore do not necessarily need to occur within the same organisation or even the same jurisdiction.

That is a very different architecture from what most people might imagine when they read about an international organisation with 23 clinics.

So What Does Wellbeing Actually Own?

This becomes the central question.

Does Wellbeing own any of the 23 clinics?

We have not established that it does.

Does it employ the physicians working inside them?

We have not established that for the entire network either.

Does it lease dedicated clinical rooms?

Does it contract independent physicians?

Are some clinics simply authorised to perform blood draws and infusions?

Are there different arrangements in different countries?

The public website does not provide enough information to answer those questions across all 23 locations.

Wellbeing's wording instead consistently points towards partnerships and clinical relationships .

Even its March 2026 investment announcement says new capital is supporting expansion of its:

“clinical-relationship network”

in the United States and Europe. Wellbeing International Foundation

That is unusually useful wording.

Not clinic acquisitions.

Not new Wellbeing hospitals.

Not construction of treatment centres.

Expansion of clinical relationships .

Follow the Blood

Perhaps the simplest way of understanding the organisation is to stop following the clinic map and follow the patient's blood instead.

A patient could begin in one country.

A local practitioner takes approximately 150ml of blood.

The biological sample is transported internationally.

It reaches Germany.

Cells are isolated and processed.

Wellbeing says the resulting cell-free preparation contains extracellular vesicles, growth factors, cytokines and other signalling molecules. Wellbeing International Foundation

Material can be banked.

A preparation is eventually returned for administration.

The patient attends an approved clinical location.

A medical professional performs the infusion.

That means the Wellbeing product or service appears to depend upon a chain of organisations and individuals , rather than necessarily one vertically integrated medical institution.

And every link in that chain matters.

Who Is Responsible for the Patient?

Imagine something goes wrong.

Who holds the medical record?

Who conducted the medical assessment?

Who decided the patient was suitable?

Who prescribed or authorised the procedure, where applicable?

Who collected the blood?

Who became responsible for it during international transportation?

Who accepted it in Germany?

Who processed it?

Who performed quality-control release?

Who authorised its return?

Who received it at the destination?

Who performed the infusion?

And who is clinically responsible if an adverse event occurs afterwards?

Those questions are not allegations.

They are the ordinary questions produced by a distributed medical-delivery model.

The more organisations involved in delivering a biological preparation, the more important the chain of responsibility becomes.

Wellbeing Now Names Some Clinical Personnel

There has been an important development here.

Wellbeing's current website provides substantially more information about its clinical team than older versions did.

For example, it identifies Chris Icamina as Senior Clinical Consultant and says he performs both blood draws and infusions while working alongside partner physicians as they begin delivering CFT.

It identifies Melanie Scaggs as Senior Nursing Consultant and says she performs blood draws and infusions. Wellbeing International Foundation

That is useful disclosure.

But it still doesn't answer the wider question.

Who are the responsible physicians at the 23 partner clinics ?

Why Not Publish the Directory?

This is perhaps the simplest question in this chapter.

If the network consists of 23 established medical clinics operating across multiple countries, why not publish:

clinic name;

full address;

responsible physician;

professional registration;

services performed there;

and whether the clinic is owned, contracted or independently partnered?

There may be perfectly reasonable explanations for not publishing such a directory.

Relationships change.

Some facilities may value patient privacy.

Certain locations may operate by appointment only.

Contracts may differ.

But for an organisation placing “Transparency” among its stated core principles, a public clinic directory would remove considerable ambiguity. Wellbeing International Foundation

The German Laboratory Raises the Same Question

The clinic network isn't the only part of the organisation described geographically rather than corporately.

Wellbeing's Contact page identifies:

Bermuda — Headquarters

and:

Germany — Laboratory.

The laboratory is described as a:

“State-of-the-art GMP-certified laboratory for cell-free preparation processing.” Wellbeing International Foundation

But the Contact page itself does not name the laboratory's operating company or give its street address.

Again, that does not establish that anything is wrong.

But it means a prospective patient cannot use that page alone to independently verify the facility processing their biological material.

And our investigation has uncovered evidence that the German laboratory relationship goes back much further than the current 23-clinic network.

Behind Closed Doors, the History Was More Revealing

In a recorded 2021 discussion concerning the German processing facility, Chancellor described the relationship as longstanding.

He said that he and Stephen Ray had worked with the German laboratory connection since approximately 2010 or 2011.

The laboratory representative himself remembered the relationship as potentially extending even further back.

More importantly, the conversation revealed how responsibilities were divided.

Chancellor described Ray as designing the protocols.

The German representative said the laboratory carried out Wellbeing's protocols and was responsible for quality and process control.

This is important because it suggests the distributed model is not something recently created to support the current 23-clinic expansion.

The underlying structure appears to have existed for years.

Science and protocols in one place.

Laboratory processing in another.

Patients elsewhere.

Clinical administration through separate medical locations.

The Website Has Changed — But the Architecture Looks Familiar

Wellbeing's current website is more explicit than its earlier public material.

It identifies partner clinics.

It identifies clinical personnel.

It describes the collection process.

It explains transportation.

It acknowledges that the German facility is part of the processing chain.

It now also explicitly states that testimonials and case studies are patient-reported accounts and are not offered as evidence of efficacy , while describing its peer-reviewed pilot as the clinical study it cites. Wellbeing International Foundation

Those disclosures matter and should be acknowledged.

But underneath the new presentation, the same fundamental question remains.

What is Wellbeing itself?

Perhaps We Have Been Looking for the Wrong Thing

Maybe searching for 23 buildings with Wellbeing International Foundation signs above their doors misses the point entirely.

Perhaps there aren't supposed to be 23 conventional Wellbeing clinics.

Perhaps Wellbeing is better understood as the organisation sitting between the different components.

Between patient and practitioner.

Between practitioner and laboratory.

Between laboratory and infusion location.

Between scientific protocol and clinical delivery.

Between biological material and international logistics.

Between independent physicians operating across multiple jurisdictions.

If that is the model, then the real asset isn't necessarily the buildings.

It is the network .

And that would explain a great deal.

But Networks Need Transparency Too

An asset-light medical model isn't automatically inferior to an organisation owning hospitals and laboratories.

In some circumstances it can be considerably more efficient.

But outsourcing physical infrastructure doesn't outsource the need for accountability.

In fact, it can make transparency more important.

Patients should be able to understand which organisation performs each stage of the procedure.

Investors should be able to distinguish assets owned by Wellbeing from services purchased from third parties.

Physicians considering joining the network should understand where responsibility begins and ends.

And regulators should be able to identify which legal entity performs which regulated activity.

That requires more than dots on a map.

Twenty-Three Clinics May Be the Wrong Number to Focus On

After investigating Wellbeing's global footprint, we are beginning to think the headline number may actually distract from the more important story.

Whether the current number is 22, 23 or eventually 50 isn't the central issue.

The central issue is:

What constitutes a Wellbeing partner clinic?

If an independent PRP practitioner joins the partnership programme, does that practitioner's existing medical practice become another Wellbeing partner clinic?

If so, the network could expand rapidly without Wellbeing purchasing a single new building.

Its physician page actively markets exactly such an expansion strategy, including revenue opportunities, cell banking, repeat infusions and patient acquisition. Wellbeing International Foundation

That could be a commercially effective model.

But it is not the same thing as building an international chain of regenerative-medicine centres.

And patients and investors should understand the distinction.

The Questions Wellbeing Could Answer Immediately

There is a straightforward way for Wellbeing International Foundation to settle most of this.

Publish the 23 clinics.

Name them.

Identify their responsible physicians.

Explain which are owned and which are independent partners.

Identify the German laboratory legal entity and the certification covering the relevant processing.

Explain which organisation has responsibility for the patient at each stage.

Explain who owns and stores the clinical records.

Explain who receives payment for the medical procedure.

And explain precisely what Wellbeing means when it says somebody is treated through its worldwide network.

Those answers would transform this investigation.

Because they would replace inference with documentation.

The Invisible Network

So where are Wellbeing International Foundation's 23 clinics?

We now have a more nuanced answer than when we began.

Wellbeing publicly identifies a large international geographical footprint .

It publicly states that there are 23 partner clinics . Wellbeing International Foundation

It openly recruits existing physicians into its network. Wellbeing International Foundation

It describes a process in which blood can be collected at an approved collection point, processed in Germany and administered at an approved clinical location. Wellbeing International Foundation

And its investment announcement describes the underlying structure as a clinical-relationship network . Wellbeing International Foundation

Put those pieces together and Wellbeing begins to look less like an international chain of conventional clinics and more like a central organisation coordinating a distributed network of independent clinical relationships around a single biological-processing system .

That may be exactly what Wellbeing intends.

But if it is, then patients and investors deserve to see the network clearly.

Not merely the cities.

Not merely the map.

Not merely the number 23 .

The clinics.

The doctors.

The laboratory.

The contracts.

And the chain of responsibility connecting them all.

Because when biological material leaves one medical location, crosses international borders, enters a laboratory in another country and eventually returns to a patient through another practitioner, the most important question isn't how many dots appear on a map.

It is:

Who is responsible at every step?

Next: Chapter Three — Who Is Actually Treating the Patient?

We follow the clinical chain from the first Wellbeing consultation to blood collection, German laboratory processing and the final infusion. Who assesses the patient? Who makes the medical decision? Who is the physician of record? And where does Wellbeing's responsibility end and the independent doctor's begin?

Where Is Wellbeing? Searching for the Organisation Behind Cell-Free Therapy

Sat, 19 Sep 2026 15:16:06 GMT

Behind Wellbeing — Chapter One

Wellbeing International Foundation describes more than twenty years of research, a German GMP-certified laboratory and an international network of partner clinics. But when you strip away the website, the scientific language and the global map, what does Wellbeing itself physically own and operate? This new investigation starts with a simple question that turns out to be surprisingly difficult to answer: where, exactly, is Wellbeing?

Sometimes the most revealing questions are the simplest.

For months, I have investigated the people behind Wellbeing International Foundation.

I have followed Andrew Chancellor.

Stephen Ray.

The patents.

Lydac Neuroscience.

The science.

The investment proposition.

But while researching the organisation, another question kept returning.

Where is Wellbeing?

Not where its website can be accessed.

Not where a patient can apparently receive an infusion.

Not where one of its partners operates.

I mean something much more literal.

Where is the organisation?

Where are its offices?

Where are its laboratories?

Where are its clinics?

Where are its doctors?

Where are its researchers?

And which of those facilities does Wellbeing International Foundation actually own, lease, operate or control?

That question begins a completely new investigation.

What Wellbeing Presents to the World

Wellbeing's current website presents an international regenerative-medicine organisation.

Its About page states:

20+ years of research.

20+ delivery locations.

A GMP-certified laboratory .

And a worldwide network of 23 partner clinics .

It lists locations across the United States including Austin, Dallas, Detroit, Los Angeles, Louisville, New Orleans, New York, Philadelphia, Reno, San Francisco, Seattle, St Louis and Virginia Beach.

European locations include Dresden, Faro, Lisbon, London, Monaco and Nice.

Dubai, Johannesburg and New Zealand are also listed. ( Wellbeing International Foundation )

At first glance, that is an impressive international footprint.

But look more carefully at the terminology.

It doesn't say:

23 Wellbeing clinics.

It says:

23 partner clinics.

That is a very different proposition.

A Network Is Not Necessarily an Estate

There is nothing inherently wrong with operating through partners.

Modern businesses do it constantly.

A company can build a large international operation without owning every building from which its service is delivered.

Indeed, an asset-light business can sometimes scale much faster precisely because it doesn't need to purchase clinics, employ every physician or construct laboratories in every country.

But if that is Wellbeing's model, patients and prospective investors should understand it accurately.

Because there is an enormous difference between saying:

“We operate internationally through 23 partner clinics.”

and creating the impression of an organisation possessing an international estate of clinical facilities.

The first question of this investigation is therefore simple:

How much of Wellbeing's international footprint actually belongs to Wellbeing?

Start at Headquarters

Wellbeing's current contact page identifies its headquarters as:

Hamilton, Bermuda.

Interestingly, that page currently provides no street address for the headquarters. It simply gives the organisation's name, Hamilton, Bermuda and an email address. ( Wellbeing International Foundation )

Elsewhere in Wellbeing's public history, Williams House in Hamilton has been associated with the organisation.

That gives us somewhere to investigate.

But finding an address is only the beginning.

A corporate address does not automatically tell us the nature of the operation conducted there.

It could be a substantial operational headquarters.

It could contain executives and administrative staff.

It could be a serviced office.

It could be a shared business centre.

It could primarily provide corporate administration or correspondence facilities.

All of those arrangements can be perfectly legitimate.

What matters is establishing which description is accurate.

What Actually Happens in Bermuda?

This is where the questions begin.

How many Wellbeing employees work from Bermuda?

Does Andrew Chancellor routinely work from the Hamilton headquarters?

Does the scientific team operate there?

Are patients ever seen there?

Is any CFT processing performed there?

Is biological material stored there?

Are clinical records maintained there?

Is there laboratory infrastructure?

Or is Bermuda primarily the corporate and administrative centre of the organisation?

None of those possibilities should be assumed.

They should be documented.

Because when an organisation presents itself internationally, the difference between its registered presence and its operational presence matters.

Then Look for the Clinics

Wellbeing makes the position clearer on its own website.

Its current About page says it delivers through:

“a network of more than twenty partner clinics”

and later describes:

“a delivery network of 23 partner clinics.” ( Wellbeing International Foundation )

This is significant.

Wellbeing isn't presently describing these locations as an estate of clinics it owns.

It is describing a network.

That immediately changes the question.

Instead of asking:

Where are Wellbeing's 23 clinics?

we need to ask:

Who owns the 23 clinics through which Wellbeing operates?

The Treatment Process Provides Another Clue

Wellbeing's own description of the CFT journey says a patient's blood draw takes place at an:

“approved collection point.”

The sample is then transported under controlled conditions to the GMP laboratory in Germany. ( Wellbeing International Foundation )

Again, the terminology is important.

Approved collection point.

Not necessarily:

Wellbeing clinic.

This begins to reveal a potentially very different organisation from the conventional image of an international medical group.

It may be a distributed network connecting separate components.

Patients.

Collection sites.

A laboratory partner.

Independent clinics.

Physicians.

Logistics.

And a central organisation coordinating the process.

If that is the model, there is nothing inherently improper about it.

But that is the model we need to investigate.

Wellbeing Is Actively Recruiting Existing Clinics

The physician section of Wellbeing's website provides perhaps the clearest indication of how this network is being expanded.

Wellbeing markets CFT directly to practitioners who already provide PRP and regenerative services.

It describes CFT as a premium addition to an existing PRP practice.

Its partnership programme includes a tier specifically aimed at:

“High-Volume PRP Practitioners.”

The business benefits promoted to potential partners include a premium service offering, recurring annual revenue through cell banking, repeat infusions and marketing and patient-acquisition support. ( Wellbeing International Foundation )

That is commercially interesting.

It suggests Wellbeing can potentially expand its geographical reach without building a new Wellbeing clinic in every city.

Instead, an established clinic joins the network.

From a business perspective, that could be extremely efficient.

From an investigative perspective, however, it means the phrase “global presence” requires some unpacking.

Twenty-Three Locations Does Not Necessarily Mean Twenty-Three Wellbeing Facilities

Imagine an independent regenerative-medicine clinic in California.

It already has doctors.

Treatment rooms.

Nurses.

Insurance.

Patients.

PRP equipment.

Clinical licences.

It then becomes a Wellbeing partner and begins offering CFT.

Wellbeing can now legitimately have a clinical relationship in that city.

But the bricks and mortar still belong to somebody else.

The clinicians may work for somebody else.

The medical licences may belong to somebody else.

The clinic's patient database may belong to somebody else.

The treatment rooms belong to somebody else.

That doesn't make the partnership meaningless.

But it means we need to distinguish between:

reach

and:

ownership.

Those are not the same thing.

So Who Actually Treats a Wellbeing Patient?

This becomes one of the most important questions.

A patient contacts Wellbeing.

They go through an initial consultation.

Blood is collected.

The sample travels to Germany.

It is processed.

The resulting preparation returns.

The patient receives an intravenous administration.

But who medically treats that patient?

Who is the physician of record?

Who employs the physician?

Who carries professional indemnity?

Who determines whether the patient is medically suitable?

Who stores the clinical notes?

Who reports an adverse reaction?

Who provides emergency care if something goes wrong?

And under whose clinical licence is the procedure performed?

Those questions become especially important when medical services cross company and national boundaries.

Then We Reach Germany

If the partner clinics form one side of the Wellbeing model, the German laboratory appears to form another.

Wellbeing's contact page currently describes:

“Germany (Laboratory)”

followed by:

“State-of-the-art GMP-certified laboratory for cell-free preparation processing.” ( Wellbeing International Foundation )

Its About page is more revealing.

It says day-to-day operations are coordinated between Wellbeing's central team, the:

“German GMP-certified laboratory partner”

and the clinician network. ( Wellbeing International Foundation )

That single word matters.

Partner.

This appears to indicate that the German laboratory is a laboratory partner , rather than establishing from the website that Wellbeing itself owns the facility.

If so, that is not necessarily a problem.

Biotechnology companies frequently outsource manufacturing and processing to specialist facilities.

But now we need to know who that partner is.

What Is the German Laboratory Called?

This is one of the most obvious questions raised by the public website.

On the pages reviewed for this article, Wellbeing repeatedly refers to the German GMP-certified laboratory.

But the current contact page doesn't identify its corporate name or street address. ( Wellbeing International Foundation )

So let's find it.

What company operates it?

Where in Germany is it?

Who owns it?

Which regulatory authority oversees it?

What GMP certificate does it hold?

What exactly is the scope of that certification?

Does the certification specifically cover the processes relevant to CFT?

How many people work there?

And what contractual relationship exists between the laboratory and Wellbeing?

These questions are not peripheral.

The laboratory appears to be one of the most important physical components in the entire CFT process.

“GMP Certified” Is Not the End of the Question

GMP means Good Manufacturing Practice.

It is an important concept in pharmaceutical and biological manufacturing.

But simply seeing the letters GMP should not end an investigation.

Certification has a scope.

Facilities have authorised activities.

Certificates have issuing authorities.

Inspections have dates.

Products and processes can fall into different regulatory categories.

Therefore we should be able to move beyond:

“GMP-certified laboratory in Germany.”

We should be able to identify the actual facility and examine the documentation supporting that description.

That will be one of the next stages of this series.

Now Look at the Research

Wellbeing currently says it has invested:

“20+ years of ongoing research into autologous biological preparations.” ( Wellbeing International Foundation )

Its Research Library is substantial.

At the time of this investigation it contained 235 papers across 11 fields of research , including work on extracellular vesicles, ageing, orthopaedics, manufacturing and related regenerative biology. ( Wellbeing International Foundation )

But there is an important distinction.

A research library demonstrates that a scientific field has a literature.

It does not mean Wellbeing conducted all of that research.

Much of the library consists of papers produced by independent researchers around the world. ( Wellbeing International Foundation )

So another part of this investigation will separate three different things:

research about extracellular-vesicle biology;

research involving Wellbeing personnel;

and:

clinical research specifically testing Wellbeing's CFT.

Those categories should never be treated as interchangeable.

There Is Now a Clinical Study

This point also needs to be corrected carefully because the public record has developed.

It would be wrong to say Wellbeing has no clinical study .

Wellbeing currently identifies the protocol registration NCT07322224 and cites a peer-reviewed pilot published in Frontiers in Aging in June 2026. ( Wellbeing International Foundation )

The study involved a 17-week multimodal longevity programme.

Sixteen healthy adults enrolled.

Fourteen completed it.

It was single-arm and open-label.

Most importantly, the programme combined several interventions:

lifestyle optimisation;

supplementation;

and intravenous administration of autologous pro-regenerative cell-conditioned media.

Wellbeing itself correctly acknowledges that the reported changes reflect the entire multimodal programme , not CFT in isolation. ( Wellbeing International Foundation )

That is an important scientific limitation.

Wellbeing Makes an Interesting Admission

Its current About page contains a particularly useful statement.

Wellbeing says:

“The peer-reviewed pilot named above is the only clinical study we cite.” ( Wellbeing International Foundation )

That deserves attention.

The same organisation describes:

20+ years of research.

Yet its current public position identifies one clinical study that it cites.

That doesn't mean twenty years of research didn't occur.

Laboratory research is research.

Preclinical research is research.

Method development is research.

Scientific observation is research.

But clinical trials are a particular form of research .

And treating patients over many years is not automatically equivalent to conducting controlled clinical trials.

That distinction will become central to this series.

Testimonials Are Not Clinical Evidence

Interestingly, Wellbeing itself now makes this distinction.

Its About page says its testimonials and case studies are patient-reported accounts and explicitly says they are not offered as evidence of efficacy. ( Wellbeing International Foundation )

That is an appropriate distinction.

A patient can sincerely report feeling dramatically better.

An athlete can sincerely believe treatment transformed their recovery.

Those experiences may be important to the individuals concerned.

But they don't substitute for controlled clinical evidence.

So if Wellbeing refers to years of clinical experience, we need to understand exactly what evidence was generated during those years.

Where Are the Researchers?

Then comes another surprisingly basic question.

Where does Wellbeing's research actually happen?

At the German laboratory?

At universities?

At independent research organisations?

At partner clinics?

Through consultants?

Through collaborations?

Wellbeing describes Stephen Ray as its Senior Scientific Consultant and describes a wider team and research programme. ( Wellbeing International Foundation )

But if we want to understand the physical substance behind the organisation, we need to identify where that scientific work takes place.

Does Wellbeing operate its own research laboratory?

Does it employ laboratory scientists directly?

Does it own research equipment?

Does it maintain dedicated scientific facilities?

Or is the research function itself largely collaborative and outsourced?

Once again, neither structure is automatically problematic.

But they represent very different kinds of biotechnology organisation.

Perhaps We Have Been Looking at Wellbeing the Wrong Way

This investigation may ultimately reveal something relatively straightforward.

Perhaps Wellbeing isn't intended to resemble a traditional clinic group at all.

Perhaps it is essentially a coordinating organisation .

A central team.

A scientific protocol.

A laboratory partnership.

A network of clinicians.

Independent treatment facilities.

Logistics.

Patient relationships.

Research collaborations.

And intellectual know-how.

That could be a viable business model.

Indeed, it could explain how an organisation can develop a presence across numerous cities without constructing clinics around the world.

But it would also mean that when evaluating Wellbeing, we shouldn't measure the size of the organisation simply by counting pins on a map.

We should measure what it actually owns and controls .

This Becomes Extremely Important for Investors

This investigation follows directly from our previous examination of Wellbeing's 2026 capital round.

Wellbeing confirmed in March 2026 that private capital is supporting continued research, expansion of its clinical-relationship network, documentation work and operational capacity. ( Wellbeing International Foundation )

Now consider the investment proposition alongside what we are beginning to discover.

If the clinics are independently owned...

if the laboratory is a partner...

if key scientists are consultants...

if treatment is delivered by independent clinicians...

then investors need to understand what assets actually reside inside the entity receiving their money.

That doesn't automatically make it a weak investment.

Some extraordinarily successful companies own relatively little physical infrastructure.

But their value usually rests somewhere else:

proprietary technology;

patents;

exclusive licences;

software;

data;

contracts;

brands;

trade secrets;

or highly defensible intellectual property.

Which brings us straight back to the question we raised in the previous series.

What does Wellbeing actually own?

Compare That With a Conventional Medical Research Institution

Later in this series we will make a proper comparison.

Not an emotional one.

Not:

big hospital good, small company bad.

That would tell us very little.

Instead, we will compare verifiable infrastructure.

When examining an established clinical research institution, we can often identify:

research facilities;

laboratories;

principal investigators;

trial sponsors;

ethics approvals;

registered clinical studies;

manufacturing infrastructure;

medical staff;

clinical sites;

published results;

and institutional ownership.

Then we will apply exactly the same categories to Wellbeing.

The objective isn't to declare that every biotechnology organisation should look like a hospital or university.

It is to determine what kind of organisation Wellbeing actually is.

Twenty-Three Clinics: Let's Identify Every One

Wellbeing has given us an excellent starting point.

It says there are 23 partner clinics.

So let's find them.

One by one.

For each location we can ask:

What is the clinic called?

Who owns it?

Who is the responsible physician?

Does the clinic advertise CFT independently?

When did it join the network?

Is CFT regularly available there?

Does Wellbeing have an exclusive agreement?

Is it simply an infusion location?

Who invoices the patient?

Who carries clinical responsibility?

And what part of the patient's payment remains with the clinic?

By the end of that exercise, we should have a much clearer picture of what “23 partner clinics” actually means.

Then We Find the Laboratory

The same applies to Germany.

Find the company.

Find the facility.

Find the regulator.

Find the certificate.

Find the authorised activities.

Find the ownership.

Find the directors.

Find the relationship with Wellbeing.

And determine exactly what happens to a patient's blood between arrival at the laboratory and departure of the final preparation.

That could become one of the most important chapters in this entire investigation.

Then We Find the Research

Twenty-plus years.

Let's document it.

Not the 235 papers written throughout the wider scientific field.

Wellbeing's own research lineage.

Which experiments?

Which institutions?

Which researchers?

Which publications?

Which clinical protocols?

Which patient cohorts?

Which registered studies?

Which ethics approvals?

Which datasets?

Which results?

And which of those records can be independently verified?

Again, the answer may be substantial.

But the evidence should tell us.

What We Have Established So Far

At this stage, the public record supports several important facts.

Wellbeing identifies Hamilton, Bermuda as its headquarters. ( Wellbeing International Foundation )

It describes a German GMP-certified laboratory, and its own About page refers to that facility as a laboratory partner . ( Wellbeing International Foundation )

It describes its international treatment presence as a network of 23 partner clinics , rather than stating that it owns 23 clinics. ( Wellbeing International Foundation )

Its treatment process uses approved collection points and sends samples to Germany. ( Wellbeing International Foundation )

Its physician programme actively recruits established practitioners and promotes CFT as a premium service offering with recurring cell-banking and repeat-infusion revenue opportunities. ( Wellbeing International Foundation )

It has a peer-reviewed human pilot associated with its programme, while explicitly acknowledging that the results apply to the entire multimodal protocol rather than CFT alone. ( Wellbeing International Foundation )

And Wellbeing itself currently says that this pilot is the only clinical study it cites. ( Wellbeing International Foundation )

Those are facts.

The conclusions come later.

What We Have Not Established

We have not established that Wellbeing is merely a virtual organisation.

We have not established that its headquarters is only a registered address.

We have not established that its partner clinics are improperly described.

We have not established that the German laboratory lacks appropriate certification.

We have not established that Wellbeing lacks genuine scientific infrastructure.

We have not established that its distributed business model is inappropriate.

And we have not established that its claimed research history is false.

Those questions require further evidence.

That is precisely what this series will investigate.

Questions for Wellbeing

There is a straightforward way for Wellbeing International Foundation to clarify much of this.

What is the complete legal identity and registration number of Wellbeing International Foundation?

What physical premises does Wellbeing itself currently own or lease?

How many people work from its Bermuda headquarters?

What operations are actually conducted there?

Does Wellbeing own any of the 23 partner clinics?

Can Wellbeing identify all 23 clinics publicly?

Who owns and operates the German GMP-certified laboratory?

What is the laboratory's full legal name and address?

Which authority issued its GMP certification?

What precisely does that certification cover?

Does Wellbeing operate its own research laboratory anywhere?

How many scientists does Wellbeing employ directly rather than engage as consultants or collaborators?

Which clinical studies specifically investigating CFT have been conducted during the claimed research history?

And which physical and intellectual assets are actually owned by Wellbeing itself?

Clear answers would substantially improve public understanding of the organisation.

Conclusion: Find the Organisation

This investigation isn't about whether an organisation needs a marble headquarters or its own hospital.

It doesn't.

It isn't about suggesting that outsourcing is suspicious.

It isn't.

And it isn't about arguing that a biotechnology company must own every laboratory or clinic it uses.

Many don't.

The question is much simpler.

What is Wellbeing International Foundation?

Is it principally a biotechnology research company?

A medical-services organisation?

An intellectual-property business?

A treatment-network coordinator?

A licensing operation?

A research foundation?

A commercial patient-services network?

Or some combination of these?

Twenty-three partner clinics can create an impressive international map.

But partner clinics are not necessarily company-owned clinics.

A laboratory partnership provides access to sophisticated infrastructure.

But access is not necessarily ownership.

Twenty years of research can represent an enormous body of work.

But research in the wider scientific field is not necessarily research conducted by the organisation itself.

And an address in Bermuda establishes a corporate presence.

It does not, by itself, tell us what happens behind the door.

So this new investigation will do something very simple.

We are going to find Wellbeing.

Building by building.

Clinic by clinic.

Scientist by scientist.

Study by study.

Contract by contract.

And laboratory by laboratory.

Because before patients put their trust in an organisation—and before investors put their money into it—they should be able to answer one extraordinarily basic question:

What physically exists behind the name Wellbeing International Foundation?

Next: Chapter Two — The Clinics That Aren't Wellbeing Clinics

Wellbeing says its international reach includes 23 partner clinics. In Chapter Two, we start identifying them. Who owns them? Who employs the doctors? Which clinics publicly advertise Cell-Free Therapy? Which are collection points, which administer infusions, and which are something else entirely? Most importantly: when Wellbeing says it has a global clinical network, how much of that network does Wellbeing itself actually own or control?

Follow the Investment: Where Does Your Money Actually Go?

Sat, 19 Sep 2026 15:12:35 GMT

The Men Behind Wellbeing — Chapter Twelve

Wellbeing International Foundation is raising private capital to fund research, clinical relationships and international expansion. Chapter Eleven asked what investors are actually buying. Now we ask the question that should come immediately afterwards: once the money has been transferred, where does it actually go—and who ultimately owns what that money creates?

Investment stories usually begin with potential.

How large could the market become?

How valuable could the technology become?

How many patients could eventually be treated?

How many countries could the organisation enter?

But there is another way to investigate an investment.

Start with the money.

Take away the projections.

Forget the future valuation.

Forget what the company might eventually become.

Imagine an investor transferring £100,000 into the 2026 Wellbeing International Foundation capital round.

Then ask:

Where does that £100,000 actually go?

Not metaphorically.

Not according to a presentation.

Not according to a future business plan.

Legally and financially.

That question takes us somewhere very different.

Wellbeing Has Confirmed It Is Raising Capital

Wellbeing announced in March 2026 that it had completed the opening tranche of its 2026 capital round.

The organisation said that the round remained open and that capital would support continuing research, expansion of its clinical-relationship network, documentation work and the operating capacity required to support its existing patient population.

Wellbeing also said its historical funding model had combined private investment, patient revenue and selective philanthropic engagement.

Importantly, it stated that specific amounts, terms and participating investors were private matters handled through its legal and finance team.

That means we can establish that money is being raised.

What the public information doesn't provide is the complete route that money takes once it enters the organisation.

And that route matters.

Start With the Receiving Bank Account

Before transferring investment capital, there is an extraordinarily simple question an investor should ask:

What is the exact legal name attached to the bank account receiving my money?

Not the trading name.

Not the website name.

Not simply:

Wellbeing International Foundation.

The complete legal entity.

Its jurisdiction.

Its registration number.

Its legal form.

And its relationship to the organisation whose science and commercial potential have been presented to the investor.

This matters because investing in a brand and investing in a legal entity are two completely different things.

Only one of them gives you enforceable rights.

Which Wellbeing Are You Investing In?

Wellbeing publicly identifies Bermuda as its headquarters and describes itself as a privately held organisation. Its public-facing material also describes operations and relationships extending across multiple countries.

International structures are completely normal.

A biotechnology organisation might legitimately have:

a holding company in one jurisdiction;

research activity in another;

laboratory processing somewhere else;

clinical partners across several countries;

and intellectual property held by yet another entity.

That structure isn't inherently concerning.

But it makes the corporate diagram extraordinarily important.

An investor needs to know:

Which box on that diagram am I buying into?

Follow the £100,000

Let's continue with our hypothetical investment.

The investor transfers £100,000.

Some of that money might support research.

Some might pay laboratory expenses.

Some might support employees or consultants.

Some might pay lawyers and accountants.

Some might fund marketing.

Some might finance clinical-network expansion.

Some might fund data collection, scientific documentation or regulatory work.

Some might simply support ordinary operating expenses.

There is nothing inherently problematic about any of those uses.

That is what investment capital is for.

But the investor should be able to see a use-of-funds schedule showing how management expects the capital to be deployed.

Because “research and expansion” is a strategy.

It isn't an accounting breakdown.

Who Gets Paid?

This is the next layer.

If Wellbeing pays for scientific work, who receives the money?

If it pays for laboratory processing, which company receives it?

If it pays clinical partners, who are those partners?

If it pays consultants, who are they?

If it funds research, which organisation performs that research?

If it pays licensing fees, who owns the licensed asset?

And are any recipients connected to directors, shareholders, consultants or senior figures within the organisation?

Again, payments to connected parties are not automatically problematic.

Related-party transactions occur throughout legitimate business.

But investors should know about them.

Related-Party Transactions Matter

Suppose an investor puts £100,000 into Company A.

Company A then pays £30,000 to Company B for laboratory services.

If Company B is completely independent, that is one commercial relationship.

If Company B is owned or controlled by somebody connected to Company A, that is another.

It may still be entirely legitimate.

But the investor needs disclosure.

They need to understand:

who owns the supplier;

what service is being provided;

how the price was determined;

whether alternative suppliers exist;

and whether the transaction was negotiated on ordinary commercial terms.

This is why sophisticated investors ask for a schedule of related-party transactions before investing.

Then Follow the Patient Money

Wellbeing's own capital announcement says its historical funding has included patient revenue .

That introduces another extremely important question.

Which legal entity receives the patient's money?

Imagine an investor owns shares in Company A.

But patients pay Company B.

Company C owns the laboratory.

Company D owns the intellectual property.

And Company E contracts with the clinicians.

That could represent a perfectly legitimate international corporate structure.

But the value of Company A depends upon the contractual relationships connecting those companies.

If an investor believes they are buying exposure to the entire commercial ecosystem, they need to establish that the investment entity actually receives the economic benefit from that ecosystem.

Who Invoices the Patient?

This should be straightforward to establish.

When a patient purchases Cell-Free Therapy:

Who sends the invoice?

Who appears on the credit-card statement?

Who receives the bank transfer?

Does the partner clinic charge the patient?

Does Wellbeing charge the patient?

Does another organisation charge the patient?

Does the clinic retain a percentage?

Does Wellbeing receive a fee?

Does the laboratory receive a separate processing charge?

Without understanding that transaction, it is difficult to understand the business model.

And without understanding the business model, it is difficult to value the investment.

The Partner-Clinic Model Makes This More Important

Wellbeing currently describes its international clinical presence as a network of partner clinics .

Its treatment information refers to approved collection points and approved clinical locations rather than describing every treatment location as a Wellbeing-owned clinic.

Its physician programme also invites existing practitioners to join the network.

That suggests an asset-light or distributed model may form an important part of the business.

There is nothing inherently wrong with that.

It can actually be highly efficient.

But from an investment perspective, it creates a distinction between:

owning an asset

and:

having contractual access to somebody else's asset.

Those are not economically identical.

The German Laboratory Becomes Critical

Wellbeing repeatedly describes CFT preparations as being processed through a GMP-certified laboratory in Germany.

That laboratory therefore appears to be an important component of the treatment pathway.

So an investor should establish:

Does Wellbeing own it?

Does a Wellbeing subsidiary own it?

Is it independently owned?

Does Wellbeing simply contract with it?

Is the agreement exclusive?

How long does the agreement last?

Can either party terminate it?

Who owns the processing protocols?

Who owns improvements developed during processing?

Could Wellbeing transfer production to another laboratory?

And what happens to the business if that relationship ends?

This isn't a minor operational issue.

If the therapy depends upon specialised processing, the entity controlling that processing may hold an important part of the commercial value chain.

Now Follow the Intellectual Property

This is where the previous chapters become relevant again.

We established that Stephen Ray's historical microvesicle work produced a patent family originally associated with Lydac Neuroscience.

We also established that Wellbeing's modern CFT proposition involves autologous biological material associated with extracellular-vesicle biology.

But similarity doesn't establish that the old Lydac patents and modern CFT are legally or technically identical.

Modern CFT may involve later developments.

Different processes.

Trade secrets.

New know-how.

Licensing arrangements.

Or technology that falls outside those earlier patent claims.

What remains important for investors is this:

Who owns the technology being developed with their money?

Imagine Investor Money Creates the Next Breakthrough

Suppose some of the 2026 capital funds research.

That research produces an improvement to CFT.

Perhaps researchers discover a better conditioning process.

A better isolation technique.

A more effective preparation method.

A new biomarker.

A new clinical protocol.

Or something sufficiently novel to patent.

Who owns it?

The investment company?

Stephen Ray?

The laboratory?

The researcher who developed it?

A research partner?

A separate IP company?

Or several parties jointly?

That question should already be answered contractually.

Because investor capital can fund the creation of extremely valuable intellectual property.

The investor needs to know whether that value remains inside the entity they funded.

The Same Applies to Clinical Data

Data can become an important biotechnology asset.

Suppose investor money funds patient monitoring and clinical research.

Hundreds of patients eventually generate biological measurements, treatment histories, outcomes and follow-up information.

Who controls the resulting dataset?

Who has the right to analyse it?

Who can publish it?

Who can use it commercially?

Can another company access it?

What happens to it if a commercial relationship ends?

And what rights does the investment entity have over research funded using its shareholders' capital?

These are questions sophisticated biotechnology investors routinely investigate.

Now Follow the Scientists

There is another form of capital that doesn't appear neatly on a balance sheet.

Knowledge.

Stephen Ray remains central to Wellbeing's scientific narrative.

If important elements of CFT depend upon his knowledge and experience, then investors need to understand how that knowledge has been secured within the company.

Does Wellbeing own documented protocols?

Are inventions automatically assigned?

Does Ray have an exclusive agreement?

Could he work with another organisation?

What happens if he retires?

What happens if the relationship ends?

Could another scientific team reproduce the process without him?

This is known as key-person risk .

It doesn't imply anything negative about the individual concerned.

It simply recognises that a business becomes more vulnerable when substantial value depends upon a small number of people.

Now Follow the Research

Wellbeing says some investment capital supports continuing research.

We know that a peer-reviewed longevity pilot associated with Wellbeing has now been published.

But the study was small.

It was open-label.

It was single-arm.

And it evaluated a multimodal programme rather than isolating CFT as the only intervention.

Wellbeing itself says that this is the clinical study it currently cites and acknowledges the need for further research.

So investors should ask another financial question:

How much additional capital will be required to generate substantially stronger clinical evidence?

Because research programmes rarely end after one pilot study.

Research Has a Price

A larger controlled clinical study requires money.

Potentially substantial amounts of it.

Participants must be recruited.

Investigators paid.

Sites organised.

Samples processed.

Data collected.

Statistics performed.

Safety monitored.

Documentation maintained.

Results analysed.

Regulatory requirements satisfied.

And if multiple indications are investigated, the process can repeat.

Therefore an investor shouldn't simply ask:

How much has Wellbeing raised?

They should ask:

How much will Wellbeing ultimately need?

Those are very different questions.

Which Brings Us to Cash Runway

One of the most important figures in an early-stage investment is surprisingly simple.

How many months until the money runs out?

That is the company's runway.

If Wellbeing raises a particular amount and spends a particular amount every month, an investor should be able to estimate when additional financing might be required.

Without management accounts, cash balances and expenditure figures, we cannot calculate that from the public information.

But an investor with access to the private investment documentation should.

Because another financing round introduces another risk.

Dilution

Suppose an investor purchases 5% of a company.

The company later requires considerably more capital.

New shares are issued.

If the original investor doesn't participate—or lacks appropriate protections—their percentage can fall.

That doesn't necessarily mean they lose money.

If the company becomes substantially more valuable, a smaller percentage could still be worth much more.

But dilution needs to be understood.

Investors should therefore know:

What pre-emption rights exist?

What share classes exist?

Can new preferred shares be created?

Who approves future capital raises?

Can convertible instruments dilute existing shareholders?

What happens in a down-round?

And how much future funding does management currently anticipate?

Then Ask the Question Nobody Wants to Ask

What happens if another funding round doesn't happen?

Not because we are predicting that outcome.

Because responsible investment analysis examines downside as well as upside.

Suppose research takes longer than expected.

Suppose patient growth is slower.

Suppose regulatory requirements increase.

Suppose clinical expansion costs more.

Suppose another round is required during difficult financial conditions.

And suppose sufficient capital cannot be raised.

What happens?

This is where the earlier questions about ownership become extremely important.

If Everything Stops Tomorrow, What Is Left?

Imagine Wellbeing stopped trading tomorrow.

Again, this is a hypothetical stress test—not a prediction.

What would remain?

Cash?

Laboratory equipment?

Property?

Patents?

Licences?

Research data?

Clinical contracts?

Patient receivables?

Trade secrets?

Software?

Brand value?

Or would a substantial proportion of the company's perceived value depend upon relationships, future research, future patient revenue and continued access to external infrastructure?

This is where investors discover the difference between:

potential value

and:

recoverable value.

Lydac Neuroscience Demonstrates Why This Matters

The historical Lydac story makes this question impossible to ignore.

Lydac was involved in biotechnology.

Stephen Ray was an early director.

His microvesicle inventions became associated with Lydac's patent portfolio.

Andrew Chancellor later became a director.

And Lydac eventually entered administration before moving into creditors' voluntary liquidation and ultimately dissolution.

None of that establishes misconduct.

Nor does it predict Wellbeing's future.

But it demonstrates something extremely relevant to investors.

Companies can disappear while science survives.

People survive.

Knowledge survives.

Patents can survive.

Research can survive.

Commercial ideas can survive.

But shareholders own rights in a particular legal entity.

That distinction becomes painfully important when a company becomes insolvent.

This Is Why Investors Must Follow Assets, Not Personalities

An investor might have enormous confidence in Andrew Chancellor.

Or Stephen Ray.

Or the science.

Or the extracellular-vesicle field.

But investment ownership doesn't attach itself to confidence.

It attaches itself to legal rights.

If a scientist leaves, the investor doesn't own the scientist.

If a partner clinic leaves, the investor doesn't own the clinic.

If an independent laboratory terminates a contract, the investor doesn't own the laboratory.

If intellectual property belongs to another entity, the investor doesn't automatically own that either.

What matters is what the investment company owns and what it can enforce contractually.

What I Would Ask to See

Before transferring money, I would want a documentary map of the entire structure.

Not a presentation.

Not a brochure.

Not a scientific explanation.

A legal and financial map showing the investment entity, shareholders, subsidiaries, associated companies, laboratory relationships, clinical partners and intellectual-property ownership.

Then I would want the financial information.

Current cash.

Revenue.

Patient revenue specifically.

Monthly operating expenditure.

Debt.

Liabilities.

Amounts owed to connected parties.

Expected research expenditure.

Laboratory expenditure.

Management remuneration.

Consultancy expenditure.

Marketing expenditure.

And projected cash runway.

Then I would want the contractual information.

Laboratory agreement.

Clinical-network agreements.

Key consultant agreements.

IP assignments.

Licences.

Research agreements.

Data ownership.

And related-party contracts.

Only then can an investor properly answer:

Where does my money go?

The Public Record Cannot Give Us All Those Answers

This needs to remain clear.

Wellbeing has explicitly said that detailed investment information is handled privately with legitimate interested parties rather than published through its news pages.

Therefore, the fact that we cannot answer these questions from its website does not establish that Wellbeing cannot answer them.

The documents may exist.

Investors may already receive them.

Contracts may comprehensively protect the organisation.

Financial information may be supplied under confidentiality agreements.

We simply cannot assume either way.

The appropriate response isn't accusation.

It is:

Show the documents.

Questions for Wellbeing

For the purposes of this investigation, I would invite Wellbeing International Foundation to clarify the following.

What precise legal entity receives capital from the 2026 investment round?

Which bank-account entity receives those funds?

What investment instrument is being issued?

Which entity receives patient revenue?

Does Wellbeing own the German laboratory used to process CFT?

If not, who owns it and what contractual relationship exists?

Does Wellbeing own any of the partner clinics?

What proportion of investment capital is expected to fund research?

What proportion funds operating expenditure?

Are material payments made to related parties?

Who owns intellectual property created through investor-funded research?

Who owns clinical data generated through that research?

What contractual rights does Wellbeing hold over Stephen Ray's existing and future CFT-related intellectual property?

What is Wellbeing's current monthly cash expenditure?

What runway does the present funding round provide?

When does management currently anticipate requiring additional capital?

And ultimately:

If Wellbeing failed to secure additional funding, what assets would remain inside the company for investors?

What We Are Not Claiming

We have found no evidence in this investigation establishing that investment funds are being misused.

We have not established improper payments to related parties.

We have not established that patient revenue is being diverted.

We have not established that Wellbeing doesn't own or legitimately control its technology.

We have not established that Wellbeing is financially distressed.

We have not established that another financing round will be unsuccessful.

And we have certainly not established that investors will lose their money.

Those would be conclusions requiring evidence we do not possess.

What we are establishing is something different.

There are fundamental questions concerning the movement of capital, ownership of assets and allocation of future value that cannot presently be answered from the public material we have examined.

For an organisation seeking private investment, those answers matter.

Conclusion: Follow the Money

A biotechnology investment can sound enormously complicated.

Extracellular vesicles.

Cell signalling.

Autologous conditioned media.

Biological ageing.

Regenerative medicine.

GMP processing.

International clinical networks.

But investment due diligence eventually becomes surprisingly simple.

Money enters.

Money leaves.

Assets are created.

Someone owns those assets.

Someone owns the intellectual property.

Someone receives the patient revenue.

Someone controls the laboratory relationship.

Someone owns the clinical data.

Someone gets paid.

And investors receive particular legal rights in return for their capital.

So follow those things.

Don't begin with the projected valuation.

Begin with the bank account.

Then follow every significant payment.

Follow the patient revenue.

Follow the laboratory fees.

Follow the research expenditure.

Follow the intellectual property.

Follow the contracts.

Follow the data.

And finally ask where all of those roads lead.

Because an investor isn't buying a scientific story.

They are buying legal and economic rights in a business.

And before transferring a single pound, dollar or euro, there are two questions that deserve unequivocal answers:

Where does my money actually go?

And:

What do I legally own when it gets there?

What Exactly Are Investors Buying?

Sat, 19 Sep 2026 15:08:13 GMT

The Men Behind Wellbeing — Chapter Eleven

Wellbeing International Foundation has confirmed that it is raising private investment to fund research, clinical relationships and its continuing operations. But after following the people, patents and corporate history behind the organisation, a much more basic question emerges: before an investor transfers their money, what exactly are they buying?

By Steven

There is a point in almost every biotechnology story where science becomes finance.

The language changes.

Research becomes opportunity.

Experiments become potential.

Clinical networks become scalability.

Intellectual property becomes valuation.

And people who were previously being asked to believe in the science are suddenly being asked to put money behind it.

Wellbeing International Foundation reached that point publicly in March 2026.

The organisation announced that it had closed the opening tranche of its 2026 capital round. It also confirmed that the round remained open at the time of the announcement. Wellbeing said the money would support its research programme, expansion of clinical relationships in the United States and Europe, documentation work and the operational capacity required to support its existing patient population. ( Wellbeing International Foundation )

There is nothing unusual about a biotechnology organisation raising private capital.

Research costs money.

Scientists cost money.

Laboratories cost money.

Clinical studies cost money.

Regulatory work costs money.

International expansion costs money.

The important question isn't why Wellbeing is raising investment.

It is:

What does the investor actually receive in return?

We Know a Funding Round Exists

Wellbeing's announcement is unusually clear about what it does not publicly disclose.

The organisation says that the specific terms, amounts and participating investors are private and held by its legal and finance team. It says detailed investor communication is handled separately from its public news pages and provided directly to parties with a legitimate interest. ( Wellbeing International Foundation )

For a privately held organisation, confidentiality around investment terms isn't inherently unusual.

But it creates a limitation for anyone attempting to assess the proposition from the public record.

From Wellbeing's public announcement alone, we cannot establish:

the amount raised;

the valuation applied;

the identity of the investors;

the percentage of ownership issued;

the precise investment instrument;

the rights attached to that investment;

or the financial projections used to support the valuation.

Those answers may exist in private investor documents.

But without those documents, an outside observer cannot properly evaluate the transaction.

And that is where due diligence must begin.

First Question: What Legal Entity Are You Investing In?

Before considering the science, an investor should ask something far more mundane.

What is the exact legal name of the entity receiving my money?

Wellbeing describes itself publicly as privately held, founded in 2015 and headquartered in Bermuda. Its LinkedIn profile identifies Williams House in Bermuda as its primary location. ( LinkedIn )

Its website also identifies Hamilton, Bermuda as its headquarters. ( Wellbeing International Foundation )

But a brand name and an investment vehicle are not necessarily the same thing.

A prospective investor needs the legal entity's full registration details and constitutional documents.

Then comes the next question.

What is being issued?

Ordinary shares?

Preference shares?

Convertible securities?

Debt?

Some other contractual economic interest?

Until that is known, saying someone has “invested in Wellbeing” tells us remarkably little about what they actually own.

Then Comes the Valuation

Suppose an investor is offered shares.

What is the company worth?

More importantly:

How was that valuation calculated?

Biotechnology valuations can incorporate future potential because early-stage companies may have relatively little current revenue compared with what investors hope their technology could eventually produce.

But that makes the assumptions behind the valuation extremely important.

An investor needs to understand how much value is attributed to:

existing revenue;

the clinical network;

scientific know-how;

intellectual property;

research data;

future treatments;

international expansion;

and future scientific validation.

Without the valuation methodology, an investor is being shown the price without necessarily being able to examine the foundations underneath it.

Intellectual Property Becomes Crucial

This investigation has already uncovered something that becomes considerably more important once money enters the story.

Stephen Ray's historical microvesicle work entered the patent system through Lydac Neuroscience.

Those patents described autologous microvesicle-related biological technology.

Today, Wellbeing describes Cell-Free Therapy as an autologous preparation involving regenerative signalling material, including extracellular-vesicle biology. ( Wellbeing International Foundation )

Similarity does not establish that the historical patents cover today's CFT.

It does not establish infringement.

And it does not establish that Wellbeing lacks legitimate rights to its current technology.

But our earlier investigation did not locate, in the public patent material examined, a documented assignment establishing that the historical Lydac patent family was transferred to Wellbeing.

That leaves an obvious investor question:

What proprietary scientific assets does the company being funded actually own?

Perhaps the Old Patents Don't Matter

There is another perfectly plausible possibility.

Perhaps the historical Lydac patents simply aren't commercially important to modern Cell-Free Therapy.

Technology changes.

Patents expire or cease to remain in force.

Manufacturing techniques develop.

New knowledge emerges.

And twenty years of scientific development can make an earlier patent relatively unimportant.

If that's the answer, investors should establish what replaced it.

Is modern CFT protected by newer patents?

Trade secrets?

Confidential processing protocols?

Exclusive licences?

Laboratory agreements?

Proprietary datasets?

Clinical know-how?

Or some combination of these?

Because somewhere inside an investable biotechnology proposition should normally be an answer to a fundamental question:

What stops somebody else doing the same thing?

If the Asset Is Know-How, Who Owns the Know-How?

This becomes particularly important because Stephen Ray remains central to Wellbeing's scientific story.

Wellbeing publicly identifies him as its Senior Consultant Scientist. ( Wellbeing International Foundation )

The word consultant deserves attention from an investment perspective.

Not because consultancy is unusual.

It isn't.

But if a significant proportion of the organisation's scientific value resides in knowledge held by an individual consultant, investors should understand the contractual arrangements surrounding that knowledge.

Does Wellbeing own the protocols?

Are inventions automatically assigned?

Does it have exclusive rights to Ray's work?

Who owns improvements?

What happens to the technology if the relationship ends?

Can the knowledge be transferred to another scientific team?

Those are not allegations.

They are basic key-person and intellectual-property questions.

Then Look at the Evidence

Wellbeing now has genuine peer-reviewed human research associated with its programme.

Its 2026 Frontiers in Aging paper studied a 17-week multimodal longevity programme. Sixteen participants enrolled and fourteen completed it.

But the study was single-arm and open-label.

Importantly, the intervention didn't test Cell-Free Therapy by itself.

Participants underwent lifestyle optimisation and supplementation alongside intravenous administration of autologous conditioned media. Wellbeing itself acknowledges that the reported results reflect the complete multimodal programme rather than CFT in isolation. ( Wellbeing International Foundation )

That distinction is extremely important for investors.

The paper demonstrates that research is taking place.

It does not, on its own, establish the independent clinical effect or eventual commercial success of CFT.

Wellbeing's current website goes further and explicitly says this peer-reviewed pilot is the only clinical study it cites . ( Wellbeing International Foundation )

That gives investors something concrete to assess.

But it also demonstrates how early the publicly cited clinical evidence remains.

A Scientific Field Is Not the Same as a Proprietary Product

Wellbeing maintains an extensive research library covering extracellular vesicles, ageing, regenerative signalling and related biology. ( Wellbeing International Foundation )

That literature can establish that the underlying scientific field is real and actively researched.

But papers written by independent researchers do not automatically establish that Wellbeing owns commercially defensible technology.

This distinction matters.

There are really two questions:

Is extracellular-vesicle biology scientifically interesting?

and:

Does Wellbeing own something proprietary and commercially defensible within that field?

Those are not the same question.

An investor should not confuse evidence supporting an area of science with evidence establishing ownership of a particular commercial opportunity.

What Does Wellbeing Physically Control?

There is another issue we are now investigating separately.

Wellbeing describes a global presence built around a GMP-certified laboratory in Germany and a delivery network of 23 partner clinics. ( Wellbeing International Foundation )

Again, the terminology matters.

Partner clinics.

The investment question is therefore not simply how large the network appears.

It is what Wellbeing owns or contractually controls.

Does Wellbeing own the German laboratory?

Does it own any of the clinics?

Are the clinical relationships exclusive?

How long do those contracts last?

Could a partner leave?

Who owns the patient relationship?

Which entity receives patient revenue?

An asset-light network can be extremely valuable.

But access to infrastructure and ownership of infrastructure are different things.

Investors need to understand which they are paying for.

Now Add the Corporate History

There is another reason for asking these questions.

The earlier chapters of this investigation established a documented connection between Stephen Ray's historical scientific work and Lydac Neuroscience.

Ray was an early director.

Andrew Chancellor became a director later.

Lydac subsequently entered administration.

That history does not establish misconduct by either man.

Nor does the failure of one biotechnology business predict the future of another.

But it does demonstrate why ownership matters.

When a company is successful, investors focus on valuation.

When a company fails, everybody suddenly wants to know:

Who owns the patents?

Who owns the equipment?

Who owns the contracts?

Who owns the data?

Who gets paid first?

And what assets are actually left?

That is why those questions should be asked before investing rather than afterwards.

Wellbeing Says This Is Not a One-Off Funding Event

There is another sentence in Wellbeing's announcement that deserves attention.

The organisation says the 2026 round forms part of a longer-term funding cadence and that historically its funding has combined private investment, patient revenue and selective philanthropic engagement. ( Wellbeing International Foundation )

That isn't inherently concerning.

Biotechnology companies frequently require multiple financing rounds.

But repeated fundraising introduces another investor risk:

dilution.

If additional shares are issued later, an existing investor's percentage ownership can decrease unless they have appropriate participation or pre-emption rights.

That makes several questions essential.

How much capital will Wellbeing require after this round?

How long does the present capital last?

What milestones must be achieved before another round?

What happens if those milestones aren't achieved?

And what protections do existing investors have if new capital is raised on different terms?

The Question Nobody Likes Asking

Investment presentations naturally concentrate on what happens if everything works.

The science progresses.

Clinical evidence strengthens.

The network expands.

More patients arrive.

Revenue grows.

New markets open.

The company becomes more valuable.

But proper due diligence requires the opposite thought experiment.

What happens if it doesn't?

Suppose the scientific evidence develops more slowly than anticipated.

Suppose commercial adoption disappoints.

Suppose regulatory requirements become more expensive.

Suppose a laboratory or clinical relationship ends.

Suppose a key scientist leaves.

Suppose another financing round becomes necessary but cannot be completed on attractive terms.

What does the investor own then?

That question is uncomfortable.

It is also one of the most important questions in private investment.

Could an Investor Lose Everything?

Yes—in principle, an investor in a private early-stage or speculative biotechnology venture can lose their entire investment.

That statement isn't specific to Wellbeing.

It is a fundamental characteristic of high-risk private investment.

What we cannot responsibly say from the public information currently available is that Wellbeing investors will lose their money, or that such an outcome is likely.

We do not possess the private investor pack.

We do not have the complete financial statements supplied to investors.

We do not know the investment valuation.

We do not know its cash position.

We do not know its complete contractual asset base.

We do not know the terms investors have negotiated.

Those documents could materially change the assessment.

But that is precisely why they matter.

Don't Invest in the Story. Invest in the Documents.

An investor considering Wellbeing should be able to obtain a comprehensive due-diligence package.

I would want to see the precise legal identity of the investment entity, its constitutional documents, current capitalisation table, investment agreement, share or security class, valuation, financial statements, management accounts, liabilities, cash position, monthly expenditure and expected runway.

Then I would want the scientific assets.

The complete intellectual-property schedule.

Patent ownership.

Patent assignments.

Licences.

Trade-secret arrangements.

Laboratory contracts.

Agreements covering Stephen Ray's existing and future scientific work.

Ownership of future inventions.

Clinical data rights.

Then the commercial assets.

Patient revenue.

Clinic agreements.

Laboratory relationships.

Material related-party transactions.

Revenue projections.

And finally the downside provisions.

Voting rights.

Pre-emption rights.

Preference rights.

Dilution.

Liquidation rights.

And what happens if another funding round cannot be completed.

That's not excessive scrutiny.

That is what investing in an emerging biotechnology proposition demands.

There Is a Simple Way for Wellbeing to Answer This

Wellbeing could remove much of the uncertainty by answering a relatively short series of questions.

Which precise legal entity received the 2026 investment?

What security or economic interest did investors receive?

What valuation was applied?

What assets does that entity own?

Which intellectual property does it own or exclusively license?

Does it own the German laboratory?

Does it own any of the partner clinics?

Which entity receives patient revenue?

How much cash runway does the 2026 round provide?

What future capital requirements are anticipated?

What rights protect existing investors against dilution?

And:

If the business ceased operating, what assets would remain inside the investment entity?

If comprehensive answers are already contained in Wellbeing's private investor materials, prospective investors should examine them carefully.

What We Are Not Saying

There is an important distinction between unanswered questions and evidence of wrongdoing.

This investigation has not established that Wellbeing's valuation is unreasonable.

It has not established that investors have been misled.

It has not established that Wellbeing lacks legitimate intellectual-property rights.

It has not established that investor funds are being improperly used.

It has not established that Wellbeing is financially distressed.

And it has not established that investors will lose their money.

What we can establish publicly is narrower.

Wellbeing is raising private capital.

The organisation says the amount, terms and participants are private. ( Wellbeing International Foundation )

Its publicly cited clinical evidence presently includes a small, uncontrolled, multimodal pilot rather than a large controlled CFT-specific trial. ( Wellbeing International Foundation )

And important questions concerning the precise investment structure, asset ownership and intellectual-property position cannot be answered completely from the public material we have examined.

That is where the investment risk becomes worthy of scrutiny.

Conclusion: What Exactly Are You Buying?

There may ultimately be excellent answers to every question in this chapter.

Perhaps Wellbeing has comprehensive IP agreements.

Perhaps its investor documents contain detailed financial accounts.

Perhaps the laboratory contracts are extremely strong.

Perhaps its clinical network is secured through long-term agreements.

Perhaps its valuation is supported by revenue and assets we cannot see publicly.

If so, prospective investors should be shown that evidence.

Because an investment decision this complex shouldn't depend upon what somebody believes Wellbeing might eventually become.

It should begin with what exists today .

What does the company own?

What does it control?

What does it earn?

What does it owe?

What rights does the investor receive?

And what remains if the optimistic scenario never happens?

A scientific story can be exciting.

A market opportunity can be enormous.

A management team can be confident.

A treatment can be promising.

None of those things, individually or collectively, eliminates investment risk.

Before investing in the future, establish ownership of the present.

Because if everything doesn't go according to plan, the most important question isn't what Wellbeing might have become.

It is what the investor actually owns.

Next: Chapter Twelve — Follow the Investment: Where Does Your Money Actually Go?

In Chapter Twelve, we stop looking at the investment from the outside and follow the money itself. Which legal entity receives it? Where does patient revenue go? Who is paid for laboratory services, research and clinical work? Which assets are created with investor capital—and who ultimately owns them? Because before asking how much an investment could return, there is another question worth answering: where did the money go in the first place?

Following the Patent Trail: From Lydac Neuroscience to Wellbeing International Foundation

Sun, 13 Sep 2026 09:07:52 GMT

The Men Behind Wellbeing — Chapter Ten

The earlier chapters established that Stephen Ray’s microvesicle research entered the patent system through Lydac Neuroscience. Today, Wellbeing International Foundation promotes an autologous Cell-Free Therapy built around extracellular-vesicle biology. This chapter follows the patents themselves and asks the question that now matters most: where is the legal and technical bridge between the old intellectual property and the treatment being commercialised today?

At some point, every investigation reaches the stage where biographies stop being useful.

People can describe their history in different ways.

Companies can change their branding.

Scientific terminology can evolve.

But patents are different.

They leave dates.

They identify inventors.

They identify applicants and assignees.

They show which jurisdictions were pursued.

And, crucially, they can reveal whether intellectual property moved from one legal owner to another.

That is why this chapter returns to Stephen Ray’s original microvesicle patent family.

Because if Wellbeing International Foundation’s present Cell-Free Therapy genuinely developed from that scientific lineage, the patent record may help us establish what happened between:

Stephen Ray’s early research

and:

the commercial treatment being promoted today.

The Patent Story Begins in 2008

The earliest priority date I have identified for the microvesicle invention is:

4 January 2008.

A second British priority application followed on:

17 March 2008.

Then, on 2 January 2009 , the invention entered the international patent system through:

PCT/GB2009/000004.

That application became:

WO2009087361 — Microvesicles.

The inventor is identified as:

Stephen Ray.

The original assignee is:

Lydac Neuroscience Limited.

Google Patents — WO2009087361 Microvesicles

This is the starting point.

Not Wellbeing.

Not a modern longevity programme.

Not an investment round.

A biotechnology company called Lydac Neuroscience , and a patent application concerning microvesicles.

What Did Stephen Ray’s Patent Actually Describe?

The patent is technical, but its central concept can be explained without oversimplifying it.

It describes the production and use of microvesicles released by cells.

The invention includes methods in which one population of cells is influenced or induced, microvesicles produced by those cells are harvested, and those vesicles or their contents may then be used in relation to another population of cells.

Importantly, the patent discusses:

autologous microvesicles.

In other words, biological material originating from the same individual.

The specification also discusses potential therapeutic applications.

European Patent EP2240189B1 — Microvesicles

That terminology matters because Wellbeing today also describes its Cell-Free Therapy as autologous.

But similarity in scientific language does not automatically establish legal identity.

What Wellbeing Describes Today

Wellbeing International Foundation now describes Cell-Free Therapy as a process in which blood is taken from the patient, white blood cells are isolated, and biological material produced under controlled conditions is subsequently returned to that same patient.

Wellbeing describes the resulting material as containing:

extracellular vesicles;

growth factors;

and:

cytokines.

Wellbeing International Foundation — Cell-Free Therapy

Its science material also describes extracellular vesicles as small membrane-bound structures involved in cell-to-cell signalling and capable of carrying proteins, RNA and other biological material.

Wellbeing International Foundation — The Science

So the comparison becomes obvious.

Historical patent:

autologous microvesicles.

Current CFT:

autologous biological material containing extracellular vesicles.

Same scientist.

Same broad scientific field.

But not necessarily the same legal invention.

Microvesicles and Extracellular Vesicles Are Related — But Not Identical Terms

This distinction deserves particular care.

Extracellular vesicles are a broad category of membrane-bound particles released by cells.

Microvesicles are generally considered one class within that broader field.

Wellbeing’s own research library includes scientific literature discussing exosomes, microvesicles and other extracellular-vesicle categories.

Wellbeing International Foundation — Research Library

That means it would be misleading to pretend the two scientific concepts have nothing to do with one another.

But it would be equally misleading to say that every modern extracellular-vesicle process is therefore covered by Ray’s original microvesicle patent.

Patent protection depends upon the actual claims.

And technologies can evolve significantly over time.

The Patent Family Went International

The invention did not remain confined to Britain.

The international filing generated patent activity across several jurisdictions, including:

Europe

the United States

Canada

Australia

and:

New Zealand.

International patent family — WO2009087361

This is important because patent rights are territorial.

There is no single worldwide patent that automatically applies everywhere.

A right may remain active in one jurisdiction while lapsing in another.

Ownership records may also differ.

That means any serious ownership investigation has to follow the patent family jurisdiction by jurisdiction.

Europe: The Lydac Patent Reaches Grant

The European application ultimately became:

EP2240189B1 — Microvesicles.

The record identifies:

Stephen Ray — Inventor

and:

Lydac Neuroscience Limited — Original Assignee.

The patent reached grant on:

30 December 2015.

Google Patents — EP2240189B1

That date is particularly interesting in the corporate timeline.

Andrew Chancellor had become a director of Lydac in November 2014 .

So when the European patent reached grant, Chancellor was directing the company recorded as original assignee.

That does not make Chancellor the inventor.

It does not make him the personal owner.

But it places him inside the corporate structure during an important period in the patent’s life.

The European Patent Is Now Shown as Not in Force

The current Google Patents record lists EP2240189B1 as:

Not-in-force.

It also continues to display Lydac Neuroscience as both original and current assignee.

EP2240189B1 — Current database record

But caution is essential.

Google Patents itself warns that its legal-status and assignee information should not be treated as definitive legal advice.

National validations, renewals, lapses, assignments and other factors can complicate the true legal position.

So we cannot responsibly say:

“Lydac remained the legal owner of every European right until the end.”

But we can say something narrower.

I have not yet found a public European assignment record transferring this patent to Wellbeing International Foundation.

That is an important difference.

The United States Patent Trail Continues

The US side of the family is also worth examining.

A microvesicle application was published in 2011 as:

US20110014251.

Stephen Ray is named as inventor.

Lydac Neuroscience Limited is identified as applicant.

Justia Patents — US20110014251 Microvesicles

But the US history continues beyond that filing.

Later publications associated with Stephen Ray include:

US20160032322 — Microvesicles

and:

US20180112236 — Microvesicles.

Justia Patents — Stephen Ray inventor records

That suggests the patent prosecution continued through multiple generations of applications.

And one date becomes particularly interesting.

December 2017 Deserves Attention

The later US filing associated with the 2018 publication was filed on:

21 December 2017.

Now compare that with Wellbeing’s own historical account.

Its Paul Cook case study says Cook met Stephen Ray in November 2017 and subsequently began a cell-free treatment programme involving extracellular vesicles derived from his own cells.

Wellbeing International Foundation — Paul Cook Case Study

Those dates are close.

But we need to be very careful.

The timing does not prove that the December 2017 patent filing covered Cook’s treatment.

Continuation and divisional patent applications can arise from older filings for technical patent-prosecution reasons.

A later filing does not necessarily represent a newly invented treatment.

Still, the overlap makes 2017 a critical period for understanding the relationship between:

Ray’s historical patent activity;

the treatment programme later described by Wellbeing;

and:

the ownership of the technology at that time.

Who Owned the Rights in 2017?

This question has become increasingly important.

Lydac was still in existence.

It had not yet entered administration.

Stephen Ray was no longer one of its directors.

Andrew Chancellor was.

Wellbeing’s own account says Ray was involved in an autologous extracellular-vesicle treatment programme.

And related microvesicle patent activity was still occurring.

So:

Who owned the relevant commercial rights at that moment?

Was it Lydac?

Was the technology licensed?

Had an assignment occurred?

Was another organisation involved?

Or had Ray’s work progressed beyond the original patent claims?

Those possibilities are very different.

And we still need the evidence to distinguish between them.

Inventorship Is Not Ownership

This remains one of the most important principles in the investigation.

Stephen Ray being the inventor does not mean Stephen Ray personally owned all of the resulting patent rights.

The original patent records identify Lydac Neuroscience as assignee.

Likewise, Andrew Chancellor becoming a director of Lydac did not mean he personally owned Lydac’s patents.

A company is legally separate from its directors.

If a company owns intellectual property, that asset remains with the company until it is:

sold;

assigned;

licensed;

allowed to lapse;

or otherwise dealt with legally.

That is why the later Wellbeing connection requires documentation.

The Same Principle Applies to Wellbeing

Ray later joining or advising Wellbeing does not automatically take the historical patent rights with him.

Chancellor later becoming CEO of Wellbeing does not automatically transfer assets from a company he previously directed.

If Wellbeing acquired rights, there should be a legal basis.

Potentially:

an assignment;

a purchase;

a licence;

or:

later independent intellectual property.

So far, I have not found a public patent record reviewed for this chapter showing the original WO2009087361 / EP2240189 family assigned directly from Lydac Neuroscience to Wellbeing International Foundation.

Again, that does not mean no rights exist.

It means the public bridge has not yet been established.

Perhaps the Old Patent No Longer Matters

There is another possibility that could resolve much of this.

Perhaps Wellbeing simply does not depend upon Ray’s original patent family anymore.

The European patent is currently shown as not in force.

Modern CFT may rely on later discoveries.

Newer protocols.

Manufacturing know-how.

Trade secrets.

Subsequent inventions.

Or a process that falls outside the original patent claims entirely.

That would be commercially plausible.

But it changes the due-diligence question.

Instead of asking:

Which old patents does Wellbeing own?

we would need to ask:

What newer proprietary technology protects the business today?

Patent Protection and Know-How Are Different Assets

A company can possess valuable technology without a current patent.

Some manufacturing methods are deliberately kept secret.

A patent requires disclosure.

Trade secrets do not.

So Wellbeing could potentially rely upon proprietary know-how involving:

cell conditioning;

culture conditions;

timing;

concentration;

purification;

processing;

quality control;

or:

other laboratory techniques.

That might provide significant commercial value.

But then the ownership question simply moves elsewhere.

Who owns the know-how?

If Stephen Ray Is the Know-How, Investors Should Understand That

Suppose the real competitive advantage is largely Stephen Ray’s scientific expertise.

That creates a different type of business risk.

Is his knowledge contractually assigned to Wellbeing?

Is he an employee?

A consultant?

What happens to intellectual property created during his work?

Who owns improvements?

Does Wellbeing have exclusivity?

Can Ray work with another organisation?

What happens if he leaves?

These are not questions about Ray personally.

They are questions about whether Wellbeing’s scientific advantage is legally embedded within the company—or primarily dependent upon one individual.

For investors, that distinction could be substantial.

Wellbeing’s Website Copyright Does Not Answer the Question

Wellbeing’s Terms of Service contain a conventional intellectual-property clause relating to its website materials.

It covers things such as:

text;

logos;

graphics;

images;

and software.

Wellbeing International Foundation — Terms

That is normal.

But website copyright does not establish ownership of the underlying biotechnology.

It doesn't tell us who owns:

the CFT production method;

the relevant extracellular-vesicle technology;

the laboratory protocols;

or:

Ray’s historical inventions.

Those require separate documentation.

Scientific Papers Are Not Proprietary Rights Either

Wellbeing has assembled an extensive research library covering extracellular-vesicle science, secretome biology, ageing and other subjects.

That demonstrates that the wider field is real and scientifically active.

But those papers are independent research.

They do not belong to Wellbeing simply because Wellbeing links to them.

Wellbeing International Foundation — Research Library

This distinction is important for prospective investors.

The existence of a large scientific literature demonstrates a research field.

It does not create exclusive commercial rights for one company operating within that field.

The Real Investor Question Is Different

An investor should therefore not ask only:

“Is extracellular-vesicle science legitimate?”

The better question is:

“What part of this technology does Wellbeing uniquely control?”

That could mean:

patents;

exclusive licences;

trade secrets;

manufacturing protocols;

clinical data;

specialist know-how;

or proprietary methods.

Then comes the next question:

Which legal entity owns those assets?

And:

Are those assets inside the company or structure receiving my investment?

Those questions go directly to value.

What About the 2026 Investment Round?

This matters because Wellbeing has publicly announced the opening tranche of a 2026 capital round.

It says the funding is supporting research, operating capacity and expansion.

Wellbeing — 2026 Investment Round Announcement

That makes ownership of future intellectual property important as well.

If investors fund new research:

Who owns what the research produces?

Wellbeing International Foundation?

Stephen Ray?

A laboratory partner?

Another corporate entity?

Are inventions automatically assigned?

Will patents be filed?

Will investor capital finance technology that sits inside the investment vehicle—or outside it?

These are questions serious investors normally examine before investing.

The Patent Timeline We Can Establish

At this stage, the documentary sequence is becoming clear.

2008

British priority applications are filed.

2009

PCT/GB2009/000004 enters the international patent system.

Stephen Ray is inventor.

Lydac Neuroscience is assignee.

2009

WO2009087361 — Microvesicles is published.

2010–2015

The patent family progresses into national and regional jurisdictions.

2015

European patent EP2240189B1 is granted.

2016

A further US microvesicle publication appears.

November 2017

Wellbeing’s historical account places Ray in an autologous extracellular-vesicle treatment programme.

December 2017

Another US microvesicle application associated with Ray is filed.

December 2018

Lydac Neuroscience enters administration.

November 2019

Lydac enters creditors’ voluntary liquidation.

April 2025

Lydac is dissolved.

Today

Wellbeing promotes an autologous Cell-Free Therapy involving extracellular vesicles.

What remains missing is the documentary bridge connecting those stages.

Four Possible Explanations

At this point, I see several realistic possibilities.

Wellbeing Acquired or Licensed the Relevant Rights

There may be a legitimate assignment or licence that is not apparent in the public records reviewed so far.

The Original Patents Became Irrelevant

Modern CFT may have evolved sufficiently far beyond the old claims that Wellbeing does not require those rights.

The Commercial Value Lies in Know-How

The old patents may be less important than confidential manufacturing methods, scientific expertise or trade secrets.

Another Entity Holds the Rights

A separate company may own patents, protocols or licences used by Wellbeing.

Any one of those explanations could be entirely lawful.

We simply need to establish which one is true.

What Would Resolve the Question?

The evidence we need is now very specific.

The full assignment history for the Ray microvesicle patent family.

USPTO assignment records.

European Patent Register ownership records.

Canadian and other national ownership records.

Lydac’s insolvency asset-sale documentation.

Any licensing agreements involving the relevant technology.

And Wellbeing’s present intellectual-property schedule.

Put those documents together and we should finally be able to see whether there is a legal chain connecting the early science with the present commercial operation.

Questions for Wellbeing International Foundation

At this stage, I would invite Wellbeing to answer several straightforward questions.

Does CFT use any technology covered by, derived from or substantially related to WO2009087361 or EP2240189B1?

Does Wellbeing own any member of that patent family?

Has it ever licensed those rights?

Did Wellbeing or any connected organisation acquire intellectual property from Lydac Neuroscience?

What intellectual property protected the 2017 treatment programme described by Wellbeing?

Which patents, if any, currently protect CFT?

If CFT is primarily protected by proprietary know-how rather than patents, which entity legally owns that know-how?

And:

which entity will own new intellectual property developed using current investment capital?

These should be answerable questions.

What We Are Not Claiming

This investigation has not established patent infringement .

It has not established unauthorised use of Lydac technology .

It has not established that Andrew Chancellor or Stephen Ray improperly transferred intellectual property .

It has not established that Wellbeing lacks valid commercial rights .

And it has not established that current CFT is identical to Ray’s 2008 invention .

Those would be much stronger conclusions than the evidence currently supports.

What we have established is enough to justify a serious ownership investigation.

There is a historical patent family.

There is a documented inventor.

There is a documented original assignee.

There is a later therapy involving related science.

There are overlapping people.

And there is no complete public ownership chain yet identified between those points.

Conclusion: The Patent Trail Is Real. The Ownership Trail Is Still Incomplete.

At the beginning of this investigation, one question was whether Stephen Ray genuinely had a historical scientific footprint in this field.

The patent record answers that.

He did.

His microvesicle intellectual property reaches back to 2008.

It entered multiple jurisdictions.

It described autologous microvesicles with potential therapeutic applications.

And Lydac Neuroscience appears as the original corporate assignee.

Today, Wellbeing promotes an autologous treatment involving extracellular vesicles and identifies Ray as a central scientific figure.

That does not prove the old patent became CFT.

But it does create a legitimate question of provenance.

How did we get from one to the other?

If there was an assignment, find it.

If there was a licence, identify it.

If the old technology became obsolete, establish when and why.

If later technology replaced it, identify the newer intellectual property.

And if Wellbeing’s real competitive advantage is know-how rather than patents, then investors deserve to understand exactly what that know-how is, who owns it, and how it is protected.

Because investors are not investing in the existence of extracellular-vesicle science.

That science belongs to an entire research field.

They are investing in whatever Wellbeing uniquely and legally controls within that field.

And until that asset is clearly identified, one fundamental question remains open:

What exactly does Wellbeing own that another organisation cannot legally or practically reproduce?

Next: Chapter Eleven — What Exactly Are Investors Buying?

The patent investigation has brought us directly back to the investment proposition. In Chapter Eleven, we examine the entity receiving investment, the assets inside it, what investors actually receive, how intellectual property is represented, and whether the scientific assets being used to support Wellbeing’s future valuation genuinely belong to the company being funded.

The Missing Asset: Does Wellbeing Actually Own the Science Behind Cell-Free Therapy?

Sun, 13 Sep 2026 09:01:14 GMT

The Men Behind Wellbeing — Chapter Nine

Lydac Neuroscience is gone. Stephen Ray’s science continued. Today, Ray and former Lydac director Andrew Chancellor are together again at Wellbeing International Foundation, where Cell-Free Therapy is promoted around extracellular-vesicle science. That creates a question that matters enormously to patients and prospective investors: where is the documented bridge between the old science and the technology being commercialised today?

By Steven

For the last three chapters, this investigation has followed a trail that began almost twenty years ago.

Stephen Ray.

Microvesicles.

Patents.

Lydac Neuroscience.

Andrew Chancellor.

Administration.

Liquidation.

Dissolution.

But it is important not to become lost in the history.

We started investigating all of this for one reason:

Wellbeing International Foundation.

Today, Wellbeing presents Cell-Free Therapy as an advanced biological treatment involving material produced from a patient's own cells.

Its scientific explanation places extracellular vesicles, growth factors and cytokines at the centre of that process.

And one of the principal scientific figures behind the organisation is Stephen Ray.

That is the same Stephen Ray whose earlier microvesicle research led us to patents originally assigned to Lydac Neuroscience.

The same Lydac that Andrew Chancellor subsequently directed.

The same Lydac that later became insolvent and disappeared.

So Chapter Nine asks the question we have been moving towards:

What exactly does Wellbeing own?

Start With What Wellbeing Says CFT Is

To understand the question, we first need to understand the treatment.

Wellbeing describes Cell-Free Therapy as an autologous process.

In broad terms, blood is taken from the patient.

White blood cells are isolated.

Those cells are placed under controlled conditions.

The resulting biological material contains components including extracellular vesicles, growth factors and cytokines.

That material is then administered back to the same patient.

The important words for our investigation are:

autologous

and:

extracellular vesicles.

Because those words take us straight back into Stephen Ray's earlier patent history.

Go Back to 2008

The patent family we have been examining begins with priority applications filed in 2008.

The international application became:

WO2009087361 — Microvesicles.

Stephen Ray is named as inventor.

Lydac Neuroscience Limited is identified as the original assignee.

The patent describes methods involving microvesicles and specifically discusses immunologically matched autologous microvesicles and their potential therapeutic applications.

Now compare that with Wellbeing's present description.

Historical technology:

autologous microvesicles.

Present-day CFT:

autologous biological material containing extracellular vesicles.

Same scientist.

Related biological mechanisms.

Related terminology.

But potentially different technology.

And that final distinction is crucial.

Similarity Is Not Proof

It would be irresponsible to look at those descriptions and simply declare:

“CFT is the old Lydac patent.”

We have not established that.

Extracellular-vesicle science has developed considerably since 2008.

Microvesicles form part of the wider extracellular-vesicle field.

Processes can evolve.

Manufacturing techniques can change.

Later discoveries can create new intellectual property.

And an old patent can become irrelevant even though the scientist behind it continues working in the same field.

Therefore, the question is not whether the words look similar.

The proper question is:

What scientific relationship exists between Ray's Lydac-era microvesicle technology and the CFT process being used today?

And once that relationship is established:

Who owns the relevant rights?

Wellbeing Itself Points Back to Ray's Earlier Science

This question isn't being created solely by outside investigators.

Wellbeing itself presents Stephen Ray's long research history as part of the scientific foundation behind the organisation.

Ray is presented as a senior scientific figure with decades of experience in cell therapy and related research.

That history gives Wellbeing's scientific narrative credibility.

But it also creates a responsibility to distinguish between several different things:

Ray's historical research;

the Lydac-era patented invention;

later scientific development;

and:

the exact CFT process being offered today.

Those are not automatically the same thing.

If Wellbeing wants to rely upon the history, then understanding the transition between those stages becomes important.

The 2017 Date Changes Everything

One date has become particularly interesting.

According to Wellbeing's own published account concerning patient Paul Cook, Cook was introduced to Stephen Ray in November 2017 and subsequently began a cell-free treatment programme involving extracellular vesicles derived from his own cells.

That date deserves attention.

November 2017.

Because Lydac Neuroscience still existed.

It would not enter administration until:

17 December 2018.

That means, according to Wellbeing's own historical account, Ray-associated autologous extracellular-vesicle treatment was already taking place while the company historically associated with Ray's microvesicle intellectual property remained alive.

That does not establish that Lydac owned the 2017 treatment.

But it creates a much more precise question.

Who Owned the Technology Being Used in 2017?

This may prove to be one of the key questions in the entire investigation.

If the 2017 programme substantially relied upon Lydac's patented technology:

what was the commercial arrangement?

Was Lydac involved?

Was the technology licensed?

Had the relevant rights already been assigned elsewhere?

Was another company operating the programme?

Or had Ray's research progressed sufficiently far beyond the old patent that Lydac's intellectual property was no longer relevant?

There may be a perfectly legitimate explanation.

But identifying that explanation could finally establish the bridge we have been looking for.

Science Can Travel. Ownership Doesn't Travel Automatically.

This distinction is fundamental.

Stephen Ray invented the earlier technology.

But the patent records identify Lydac Neuroscience as the original corporate assignee.

Inventorship and ownership are different.

A scientist leaving a company does not automatically take the company's patents with him.

Likewise, Andrew Chancellor subsequently becoming a Lydac director did not make Lydac's patents Chancellor's personal property.

And Ray and Chancellor later appearing together at Wellbeing does not automatically make historical Lydac intellectual property Wellbeing property.

There must be a legal basis for ownership or use where protected rights are involved.

Potentially:

assignment;

purchase;

licence;

new intellectual property;

or:

the expiry or abandonment of earlier rights.

Which applies here?

That is what we need to establish.

What Happened When Lydac Failed?

Chapter Eight brought us directly to this point.

When administrators entered Lydac in December 2018, they were dealing with a biotechnology company historically associated with Ray's intellectual property.

If Lydac still owned commercially valuable patent rights, those rights were potentially company assets.

If it didn't own them anymore, then we need to establish when they had left.

If they had been licensed, those agreements could potentially have value.

If they had become commercially irrelevant, that is also important.

And if the real value was not in patents at all but in scientific know-how, then we need to establish who owned or controlled that know-how.

The insolvency records and patent records therefore need to be examined together.

The European Patent Record Creates Another Question

The European patent EP2240189B1 identifies Stephen Ray as inventor and Lydac Neuroscience as original assignee.

Public patent databases currently display the patent as not in force .

That could mean the patent itself no longer provides meaningful protection today.

But that doesn't erase its historical significance.

For this investigation, we need to know what happened during the period when it was potentially relevant.

Was it assigned?

Was it licensed?

Did later patents replace it?

Did its claims cease to matter to the developing CFT process?

Those are different possibilities with very different implications.

Perhaps Wellbeing Doesn't Need the Lydac Patent at All

This possibility deserves serious consideration.

The answer to this investigation could ultimately be:

the old Lydac patent doesn't matter anymore.

Perhaps Ray continued developing the science.

Perhaps CFT represents a later generation of the technology.

Perhaps modern production methods are materially different.

Perhaps Wellbeing's competitive advantage comes from laboratory protocols rather than patents.

Perhaps the organisation relies upon proprietary know-how developed after the original applications.

There would be nothing inherently suspicious about that.

In fact, biotechnology businesses frequently rely upon combinations of patents, confidential processes, manufacturing expertise and trade secrets.

But if that is Wellbeing's position, another question immediately replaces the patent question.

Who Owns the Know-How?

Suppose the real value behind CFT isn't EP2240189B1.

Suppose it is:

a proprietary cell-conditioning process;

specific laboratory conditions;

timing;

concentrations;

purification;

processing;

quality-control procedures;

or accumulated scientific knowledge developed by Stephen Ray.

That could potentially be commercially valuable.

But who owns it?

Is that knowledge contractually assigned to Wellbeing?

Does Wellbeing possess exclusive rights?

Is Ray an employee or consultant?

What does his agreement say about intellectual property?

Who owns improvements he develops?

Can the technology be used elsewhere?

What happens if Ray leaves?

For investors, these questions can be every bit as important as patents.

A Scientist Is Not an Intellectual-Property Portfolio

This distinction matters particularly when an organisation's scientific identity is strongly associated with one person.

Stephen Ray's presence may provide expertise.

His research history may provide scientific credibility.

His knowledge may be extremely valuable.

But the presence of a scientist inside an organisation does not automatically mean the organisation owns everything that scientist previously invented—or everything he knows.

Ownership depends upon contracts.

Assignments.

Employment terms.

Licences.

And the circumstances under which new intellectual property is created.

This is why investors need documentation rather than assumptions.

Now Bring the Investors Back Into the Story

Wellbeing is not simply discussing experimental science.

It has been raising capital.

That makes intellectual-property ownership commercially important.

A prospective investor should be able to ask:

What am I actually investing in?

A scientific team?

A treatment business?

A research programme?

A proprietary manufacturing process?

Patents?

Licences?

Trade secrets?

Clinical relationships?

Patient revenue?

Or some combination of those things?

There is nothing inherently wrong with any of those business models.

But they have very different values and risks.

Owning the Organisation Doesn't Necessarily Mean Owning the Science

Imagine an investor acquires shares or some other economic interest connected with Wellbeing.

What assets sit inside the entity receiving that investment?

Does that entity own CFT intellectual property?

Does another company own it?

Does Stephen Ray own part of it?

Does Wellbeing operate under licence?

Does a laboratory own aspects of the manufacturing process?

Are rights held elsewhere within a corporate structure?

Those questions matter because investment into one legal entity does not automatically provide economic exposure to assets owned by another.

For biotechnology investors, that distinction can be fundamental.

The Research Library Is Not the Intellectual Property

Wellbeing maintains a substantial research library covering extracellular vesicles, secretome biology, ageing, neurological research and other areas.

That can be useful.

It demonstrates that extracellular-vesicle biology is a serious international field of scientific research.

But independent academic research is not proprietary technology belonging to Wellbeing.

A published scientific paper belongs to the wider evidence base.

It may support biological plausibility.

It may support a scientific hypothesis.

It may inform product development.

But it does not give Wellbeing exclusive commercial ownership of the underlying scientific field.

So investors need to distinguish between:

science supporting the field

and:

intellectual property belonging to the business.

They are not the same thing.

The Question Investors Should Ask

Rather than asking:

“How much research exists around extracellular vesicles?”

an investor should ask:

“What does Wellbeing uniquely control?”

That might include:

patents;

patent applications;

exclusive licences;

trade secrets;

proprietary manufacturing processes;

clinical data;

software;

protocols;

contractual rights;

or specialist know-how.

Then comes the second question:

Which legal entity owns those assets?

And the third:

Are those assets actually included in the company or structure I am investing in?

Those are the questions that determine whether the science has commercial defensibility.

Ask for the Intellectual-Property Schedule

There is a straightforward way to answer much of this.

Prospective investors should request Wellbeing's intellectual-property schedule and supporting documentation.

That should allow them to identify:

which patents are relevant to CFT;

who owns those patents;

which patents remain in force;

whether licences exist;

whether licences are exclusive;

which territories are covered;

who owns proprietary manufacturing protocols;

who owns new inventions created through ongoing research;

and:

whether any relevant rights originated with Lydac Neuroscience.

If the intellectual-property position is straightforward, this documentation should make it straightforward.

Then Ask About Lydac Specifically

The historical connection deserves its own questions.

Did Wellbeing acquire any Lydac intellectual property?

Did Stephen Ray reacquire any rights?

Did Andrew Chancellor or another connected entity acquire rights?

Were any Lydac patents licensed?

Were relevant rights sold during the administration?

Did the CFT process develop independently from the old patent family?

Or did the old patents simply become obsolete?

Any of those answers could resolve the apparent gap.

But without an answer, the gap remains.

Why Patients Should Care Too

This isn't only an investor issue.

Patients are also entitled to understand the scientific provenance of a treatment.

If a therapy is presented alongside decades of scientific history, patients should be able to distinguish between:

decades of research in a field;

decades of work by a particular scientist;

and:

clinical evidence relating specifically to the exact treatment being offered today.

Those are different things.

If CFT evolved through multiple generations of Ray's work, that history could be scientifically interesting.

But the evidence supporting earlier technology should not automatically be treated as evidence supporting every later version.

The exact process being administered matters.

So does the evidence generated specifically around it.

There May Be a Completely Innocent Explanation

This investigation needs to remain open to that possibility.

Perhaps the entire intellectual-property history is straightforward.

Perhaps Lydac's patents ceased to matter years ago.

Perhaps modern CFT is technically distinct.

Perhaps Wellbeing has properly documented rights to later technology.

Perhaps there are licences that aren't visible in public databases.

Perhaps the organisation relies primarily upon confidential know-how.

If so, publishing that explanation would answer many of the questions raised in these chapters.

The objective is not to force the evidence into a predetermined conclusion.

The objective is to establish what actually happened.

What We Can Establish

At this point, we have a documented historical sequence.

Stephen Ray developed microvesicle technology.

Patent records identify him as inventor.

Lydac Neuroscience appears as the original corporate assignee.

Andrew Chancellor subsequently became a director of Lydac.

Wellbeing's own historical account places Ray in an autologous extracellular-vesicle treatment programme by 2017.

Lydac entered administration in 2018.

It subsequently entered liquidation.

Today, Ray and Chancellor are associated with Wellbeing International Foundation.

And Wellbeing promotes Cell-Free Therapy involving autologous extracellular-vesicle-related biological material.

Those facts justify investigating the relationship.

What We Have Not Established

We have not established that CFT is the Lydac invention.

We have not established that Wellbeing uses intellectual property without permission.

We have not established that Lydac intellectual property was improperly transferred.

We have not established that Andrew Chancellor personally acquired Lydac assets.

We have not established that Stephen Ray improperly removed technology from Lydac.

We have not established that Lydac's creditors lost an asset that should have been realised for their benefit.

And we have not established that Wellbeing lacks legitimate intellectual-property rights.

Those would require evidence we do not presently have.

But we have established the question.

And it is now a very specific one.

Conclusion: The Missing Asset May Be the Missing Explanation

We began this part of the investigation looking for an asset.

A patent.

An assignment.

A transaction.

Something showing how Stephen Ray's earlier microvesicle science travelled from Lydac Neuroscience into the world surrounding Wellbeing International Foundation.

But perhaps what is missing isn't necessarily an asset.

Perhaps what is missing is simply the explanation .

There may be a legitimate chain.

There may be no chain because CFT is genuinely different technology.

There may be later intellectual property.

There may be licences.

There may be proprietary know-how.

There may be a perfectly ordinary commercial structure behind everything we have uncovered.

But until that structure is identified, an important question remains unanswered.

Wellbeing uses Stephen Ray's long scientific history as part of its story.

That history leads us directly to Lydac Neuroscience and its microvesicle patents.

Wellbeing today promotes Cell-Free Therapy involving extracellular vesicles.

And Wellbeing is seeking investment to expand its work.

So patients and investors deserve something more precise than a scientific biography.

They deserve the bridge between the history and the product.

Where did the present CFT technology come from?

Who owns it?

And what exactly does Wellbeing control that another organisation cannot simply reproduce?

Until those questions are answered, the missing asset remains at the centre of the story.

Next: Chapter Ten — Following the Patent Trail: From Lydac to Wellbeing

In Chapter Ten, we stop looking at companies and follow the intellectual property itself. We trace Stephen Ray's microvesicle patent family across Britain, Europe, the United States and other jurisdictions, examine later filings and begin looking for assignments, successor rights and the documentary bridge—if one exists—between Lydac Neuroscience and Wellbeing International Foundation.

Inside the Collapse of Lydac Neuroscience: What Happened to the Company — and Its Science?

Sun, 13 Sep 2026 08:58:29 GMT

The Men Behind Wellbeing — Chapter Eight

Lydac Neuroscience once sat at the centre of Stephen Ray’s microvesicle research. Andrew Chancellor later became a director. Then the company entered administration, moved into liquidation and ultimately disappeared. The failure of a biotechnology company is not, by itself, evidence of wrongdoing. But when the people and apparently related science later reappear around Wellbeing International Foundation, one question becomes unavoidable: what happened to Lydac’s intellectual property when the company failed?

Chapter Seven introduced a company that has become increasingly important to this investigation.

Lydac Neuroscience Limited.

It was incorporated in 2007.

Stephen Ray was one of its early directors.

Patent records connect Lydac directly with Ray's work involving microvesicles.

Ray subsequently left the board.

Andrew Chancellor later became a director.

Then, in December 2018, Lydac entered administration.

The company never recovered.

It moved into creditors' voluntary liquidation in 2019 and, after a lengthy winding-up process, was finally dissolved in April 2025.

On its own, that story isn't particularly remarkable.

Biotechnology companies fail.

Research programmes run out of money.

Investments don't always produce commercial products.

Patents don't always become profitable businesses.

None of those things demonstrates misconduct.

But Lydac is different for one reason.

The story appears to continue after the company disappears.

Today, Stephen Ray and Andrew Chancellor are both associated with Wellbeing International Foundation.

And Wellbeing promotes Cell-Free Therapy using a scientific narrative involving extracellular vesicles.

That is why Lydac's insolvency matters.

We need to determine what happened to the company's assets—particularly the intellectual property historically associated with Stephen Ray.

December 2018: Lydac Enters Administration

The critical date is:

17 December 2018.

Official insolvency notices record the appointment of administrators to Lydac Neuroscience Limited.

The administrators were Ian Robert and Christopher Purkiss of Kingston Smith & Partners LLP.

Lydac's business was described as:

“Research and experimental development on biotechnology.”

Its principal trading address was recorded as:

10 Harley Street, London W1G 9PF.

This is an important distinction.

Lydac wasn't simply struck from the Companies House register after being abandoned.

It entered a formal insolvency procedure.

Administrators took control of the company.

That means its financial affairs had to be examined.

Its creditors had to be identified.

Its assets had to be considered.

And for a biotechnology company, those assets potentially included something much more important than office furniture or bank balances.

Intellectual property.

The Strange Position Before Administration

The company's history immediately raises an interesting question.

Before administration, Lydac had filed dormant accounts for financial years ending in 2015, 2016 and 2017.

A dormant company is not necessarily an inactive company in every practical sense.

A company can exist primarily to hold intellectual property.

It can have very limited accounting transactions.

Research or commercial operations can potentially be conducted through other structures.

So dormant accounts are not evidence of anything improper.

But they make the subsequent administration particularly interesting.

A company reporting itself as dormant does not normally require administrators unless liabilities or financial obligations have arisen somewhere.

So what happened?

What did Lydac owe?

Who did it owe money to?

What assets remained?

And:

What value was placed on its intellectual property?

Those questions take us into the insolvency documents.

January 2019: The Statement of Affairs

On 28 January 2019 , a Statement of Affairs was filed.

This is one of the documents I consider particularly important to the next stage of this investigation.

A statement of affairs provides a snapshot of an insolvent company's financial position.

Depending upon the circumstances, it can reveal:

assets;

estimated realisable values;

secured creditors;

preferential creditors;

unsecured creditors;

and the estimated deficiency facing those creditors.

But when the company concerned is a biotechnology business, there is another line we need to look for.

Patents and intellectual property.

Because we already know Lydac had a documented connection with intellectual property.

The Patent Didn't Belong to Stephen Ray Personally

This distinction becomes critical here.

Stephen Ray is named as the inventor of the microvesicle technology we examined in earlier chapters.

But inventor and owner are not the same thing.

The international patent record for WO2009087361 — Microvesicles identifies:

Inventor: Stephen Ray

and:

Original Assignee: Lydac Neuroscience Ltd.

The corresponding European patent, EP2240189B1 , similarly identifies Lydac in the ownership history.

That means the intellectual-property question cannot simply be answered by saying:

“Stephen Ray invented it, so Stephen Ray could take it somewhere else.”

Patent ownership doesn't work like that.

If rights had been assigned to a company, those rights were corporate assets unless subsequently assigned, licensed, expired, abandoned or otherwise dealt with.

And once a company becomes insolvent, that distinction becomes extremely important.

What Did the Administrators Find?

This is where we have to be disciplined.

At present, the existence of the insolvency filings is established.

But we should not pretend that filing titles alone tell us what happened to every Lydac asset.

They don't.

We need the underlying documents.

What we are looking for is very specific.

Did the administrators identify patents?

Were they given a valuation?

Were licences identified?

Was scientific know-how treated as an asset?

Were there research agreements?

Was intellectual property sold?

Was there a purchaser?

Or had the relevant intellectual property already left Lydac before administration?

Each answer would take this investigation in a different direction.

April 2019: A 31-Page Administrator's Proposal

On 9 April 2019 , a much more substantial document was filed:

Statement of Administrator's Proposal.

Thirty-one pages.

This document could be central to reconstructing what happened.

Administrators are required to explain what they intend to achieve and how they propose dealing with the insolvent company's affairs.

For an investigator, this can provide something far more useful than retrospective interviews or company marketing.

It is a professional account created during the insolvency itself.

The questions for us are therefore straightforward:

What caused Lydac's financial failure?

What assets did the administrators identify?

What was recoverable?

What were creditors owed?

And what did they intend to do with any remaining intellectual property?

Then Come the Creditors

On 10 April 2019 , the result of the creditors' decision process was filed.

That matters because administration is ultimately about creditors and assets.

But we need to avoid turning the existence of creditors into something it isn't.

An insolvent company having creditors does not prove that investors were deceived.

It does not prove directors behaved improperly.

It does not prove patient money was lost.

Those would require evidence.

The correct investigative approach is much simpler.

Who were the creditors?

How much were they owed?

What was the estimated deficiency?

Were any creditors connected parties?

Were directors owed money?

Were investors or lenders among them?

Were patent attorneys or scientific suppliers among them?

Those answers could help us understand what Lydac actually was commercially by the time it failed.

July 2019: The Administrators Report Back

On 19 July 2019 , an Administrator's Progress Report was filed.

This is potentially even more revealing.

By then, the administrators had been in control for around seven months.

They had had time to examine records.

Investigate assets.

Deal with creditors.

And potentially attempt to realise whatever value remained.

For this investigation, one question dominates:

Had anything happened to the intellectual property?

If patents were sold, there should potentially be a purchaser.

If rights were licensed, there should potentially be an agreement.

If the intellectual property was regarded as worthless, that too may be documented.

And if Lydac no longer owned relevant rights when the administrators arrived, we then need to move backwards and establish when they left.

November 2019: Lydac Is Not Rescued

Administration did not save Lydac Neuroscience as an operating company.

On 15 November 2019 , Lydac moved from administration into:

creditors' voluntary liquidation.

That tells us something important.

The company itself was not going to continue.

From this point, the objective was winding it up.

But a company disappearing and its intellectual property disappearing are two completely different things.

Intellectual Property Can Outlive the Company

This is perhaps the most important principle in this entire chapter.

Imagine a conventional business failing.

Its assets might include:

vehicles;

machinery;

property;

stock;

cash.

A biotechnology company's valuable assets can be much less visible.

They might include:

patents;

patent applications;

licences;

research data;

laboratory protocols;

manufacturing methods;

trade secrets;

and:

scientific know-how.

Those assets can survive the corporate entity that originally developed or owned them.

They can be purchased from administrators.

They can be assigned before insolvency.

They can be licensed.

They can become part of another business.

Or patents can simply lapse while the underlying scientific knowledge continues to be developed.

That is why the dissolution of Lydac doesn't end this investigation.

It actually creates the next part of it.

Lydac Remained in Liquidation for Years

Lydac's liquidation was not completed quickly.

Further liquidators' statements of receipts and payments were filed over subsequent years.

The process continued until a final winding-up return was filed in 2025.

Then:

9 April 2025 — Lydac Neuroscience Limited was dissolved.

The corporate entity was gone.

But by then, something interesting had already happened elsewhere.

Stephen Ray's science had continued.

And Andrew Chancellor's involvement in biotechnology had continued.

The Same Two Men Appear Again

Today, Stephen Ray is presented by Wellbeing International Foundation as a senior scientific figure.

Andrew Chancellor is its Chief Executive.

That alone proves nothing about Lydac's assets.

People who worked with one company can perfectly legitimately work together again.

But when we combine the people with the science, the historical connection becomes much more relevant.

Lydac's patent history involved:

microvesicles.

Wellbeing's present Cell-Free Therapy involves:

extracellular vesicles.

Lydac's patent history involved:

Stephen Ray.

Wellbeing's scientific narrative involves:

Stephen Ray.

Lydac's later corporate history involved:

Andrew Chancellor.

Wellbeing is now led by:

Andrew Chancellor.

These are documented points of continuity.

What they do not establish is the legal connection between the technology.

And that is precisely what we need to find.

An Even More Important Date: 2017

There is another piece of the chronology that makes the insolvency particularly interesting.

Wellbeing's own account of patient Paul Cook places Stephen Ray in a cell-free treatment programme involving extracellular vesicles derived from Cook's own cells in 2017 .

That date matters.

Because Lydac did not enter administration until December 2018.

So according to Wellbeing's own historical narrative, Ray-associated autologous extracellular-vesicle treatment activity was taking place while Lydac still existed .

This does not establish that the treatment used Lydac intellectual property.

It does not establish patent infringement.

It does not establish that Lydac owned the treatment.

But it does sharpen the question.

Who owned the relevant technology in 2017?

If It Was Lydac's Technology, What Was the Commercial Arrangement?

Suppose, purely for the purpose of investigation, that the 2017 treatment substantially relied upon technology covered by or derived from Lydac's intellectual property.

Then we would need to know:

Was Lydac conducting the programme?

Was the technology licensed?

Was another company authorised to use it?

Had ownership already been transferred?

Or was the process sufficiently different from the patented invention that Lydac's rights were irrelevant?

Those are all possible explanations.

But we need the evidence to distinguish between them.

If It Wasn't Lydac's Technology, That Matters Too

The alternative is equally important.

Perhaps Stephen Ray's science had moved substantially beyond the original microvesicle patents by 2017.

Perhaps CFT represented later work.

Perhaps new techniques had been developed.

Perhaps the relevant competitive advantage lay in know-how rather than patents.

If so, that would help separate Wellbeing's present technology from the old Lydac intellectual property.

That would be a significant finding.

An investigation should be equally prepared to establish separation as connection.

Andrew Chancellor's Role Must Be Treated Fairly

Andrew Chancellor was a director of Lydac when administrators were appointed.

That is relevant.

But it needs to be reported responsibly.

His position as director does not establish that he caused Lydac's insolvency.

It does not establish that he improperly transferred intellectual property.

It does not establish that he acquired company assets.

And it does not establish misconduct.

I have not established any of those things.

The legitimate question is narrower:

What happened to Lydac's assets during the period surrounding its insolvency, and did any of those assets later become connected with Wellbeing?

That is the question the documents should answer.

Stephen Ray's Position Is Different

Ray had left Lydac's board years before administration.

We should therefore not associate him with management of the company when it failed without evidence.

But Ray remains essential to the intellectual-property story because he is the named inventor.

And that creates a fascinating distinction.

The company could fail.

The patent could lapse.

But the scientist still retains his knowledge.

He knows what he discovered.

He knows how the research developed.

He may continue making further discoveries.

He may develop later techniques that are entirely outside the original patent claims.

That makes the boundary between old corporate intellectual property and new scientific know-how particularly important.

Why This Matters to Wellbeing's Investors

And now we return to the present.

Wellbeing is raising investment.

If investors are being asked to fund a biotechnology organisation whose value depends partly upon proprietary science, they need to understand what that proprietary science actually consists of.

Does Wellbeing own patents?

Does it license them?

Does another entity own them?

Does the company instead rely upon trade secrets?

Does its commercial advantage depend heavily upon Stephen Ray personally?

Who owns improvements developed during current research?

What happens if Ray leaves?

And most importantly for our historical investigation:

Did any intellectual property currently used by Wellbeing originate inside Lydac Neuroscience?

These are standard due-diligence questions.

The Insolvency Could Answer the Ownership Question

This is why Chapter Eight matters.

The Lydac insolvency records potentially provide a fixed point in the history.

December 2018.

At that moment, professional insolvency practitioners entered the company.

What did they find?

If Lydac still owned the relevant patents, we should investigate what happened to them.

If it didn't, we need to establish when ownership changed.

If the patents had no value, that matters.

If another company acquired them, that matters.

If the commercially valuable technology wasn't patented at all, that matters.

Whatever the answer, it helps reconstruct the journey from Ray's early science to the technology being promoted today.

What We Know

At this stage, the established chronology is significant.

Lydac Neuroscience was incorporated in 2007 as a biotechnology research company.

Stephen Ray was an early director.

Ray became named inventor on microvesicle intellectual property originally assigned to Lydac.

Andrew Chancellor later became a director.

Lydac subsequently entered administration in December 2018.

A Statement of Affairs was filed.

An Administrator's Proposal followed.

A Progress Report followed.

The company entered creditors' voluntary liquidation in November 2019.

And Lydac was finally dissolved in April 2025.

Those facts provide the framework.

What We Do Not Yet Know

We have not established that Wellbeing acquired Lydac's intellectual property.

We have not established that Andrew Chancellor acquired it.

We have not established that Stephen Ray reacquired it.

We have not established that any asset was improperly transferred.

We have not established that creditors were deprived of intellectual property.

And we have not established that Wellbeing's present Cell-Free Therapy is the same invention described in Lydac's historical patents.

Those distinctions matter.

But so does what remains unanswered.

Where did the intellectual property go?

The Documents That Could Resolve It

The next phase needs to combine two separate documentary trails.

First, the insolvency trail:

the Statement of Affairs;

the Administrator's Proposal;

the Administrator's Progress Reports;

the liquidators' receipts-and-payments statements;

and any asset-sale documentation.

Second, the intellectual-property trail:

the international patent records;

the European Patent Register;

USPTO assignment records;

and the corresponding records in Canada, Australia and New Zealand.

Then we place the two timelines together.

If an intellectual-property transaction occurred, that is where we should begin to see it.

Questions for Andrew Chancellor, Stephen Ray and Wellbeing

There are several straightforward questions that could shorten this investigation considerably.

What intellectual property did Lydac own when it entered administration?

Were any patents, licences, research assets or proprietary processes sold during the administration or liquidation?

Who acquired them?

Did Andrew Chancellor, Stephen Ray, Wellbeing International Foundation or any connected organisation subsequently acquire or license any Lydac intellectual property?

Was the Cell-Free Therapy programme described by Wellbeing in 2017 technically connected to Lydac's microvesicle technology?

And if not:

When and where was the distinct CFT technology developed?

There may be perfectly ordinary answers.

We would welcome them.

Conclusion: The Company Failed. The Question Survived.

Lydac Neuroscience disappeared in April 2025.

But the story surrounding its science did not disappear with it.

Stephen Ray remains involved in extracellular-vesicle-related regenerative medicine.

Andrew Chancellor now leads Wellbeing International Foundation.

And Wellbeing promotes a Cell-Free Therapy that raises legitimate questions about its scientific lineage.

That does not establish wrongdoing.

It establishes something more useful:

a trail worth following.

Because companies disappear.

Patents expire.

Brands change.

Directors move.

Scientists continue their work.

But intellectual-property ownership leaves records.

And if the science now being promoted through Wellbeing genuinely evolved from technology once assigned to Lydac Neuroscience, somewhere between those two organisations there should be an explanation.

A sale.

An assignment.

A licence.

A new invention.

Or a clear technical break between the old science and the new.

Until we establish which one occurred, the collapse of Lydac leaves behind one asset we still cannot account for:

the scientific and legal bridge to what came next.

Next: Chapter Nine — The Missing Asset: Does Wellbeing Actually Own the Science Behind Cell-Free Therapy?

The company disappeared, but apparently related science continued. In Chapter Nine, we return directly to Wellbeing International Foundation and compare its present Cell-Free Therapy with Stephen Ray's earlier microvesicle work. Then we ask the question that matters to patients and investors alike: what does Wellbeing actually own?

The Missing Asset: Does Wellbeing Actually Own the Science Behind Cell-Free Therapy?

Sat, 05 Sep 2026 04:05:42 GMT

The Men Behind Wellbeing — Chapter Nine

We followed Stephen Ray’s science backwards through patents, Lydac Neuroscience and ultimately the company’s insolvency. Now the investigation must return to where it started: Wellbeing International Foundation. If the Cell-Free Therapy being promoted today developed from the same microvesicle science once held by Lydac, where did Wellbeing obtain it — and what intellectual property does it actually own?

For the last several chapters, this investigation has travelled backwards.

We started with Wellbeing International Foundation and its Cell-Free Therapy.

We followed the scientist behind much of its scientific narrative, Stephen Ray.

That led us to patents.

The patents led us to a biotechnology company called Lydac Neuroscience Limited.

Lydac led us to Andrew Chancellor.

And Lydac's eventual collapse led us into administration, liquidation and a company that was finally dissolved in April 2025.

But there is a danger in following corporate records too far backwards.

We can forget why we started looking.

This investigation was never really about Lydac Neuroscience.

It is about Wellbeing International Foundation today .

It is about the scientific provenance of the treatment being offered to patients.

It is about the scientific story being presented around that treatment.

And it is increasingly about what prospective investors are actually being invited to invest in.

Because Wellbeing announced in 2026 that it had closed the opening tranche of a new capital round, with money intended to support research, clinical relationships, documentation and expansion.

That brings us to perhaps the most important question we have asked so far:

If Wellbeing's present Cell-Free Therapy originates from, incorporates, or substantially develops Stephen Ray's earlier microvesicle technology, who owns that technology today?

And specifically:

Does Wellbeing own it?

Start With What Wellbeing Says It Is Doing

Wellbeing describes Cell-Free Therapy as an autologous treatment.

In simplified terms, blood is taken from the patient, white blood cells are isolated and processed under controlled conditions, and biological material is produced containing signalling components including extracellular vesicles, growth factors and cytokines.

Wellbeing places particular importance on extracellular vesicles in explaining the science behind its treatment.

That terminology matters.

Because it brings us directly back to the intellectual property uncovered earlier in this investigation.

Stephen Ray's Earlier Technology Was About Microvesicles

Years before the present Wellbeing organisation was promoting Cell-Free Therapy, Stephen Ray was named as inventor on patent applications dealing specifically with microvesicles .

One of the clearest examples is European patent EP2240189B1 , titled simply:

“Microvesicles.”

The patent record identifies:

Inventor: Stephen Ray

and:

Original Assignee: Lydac Neuroscience Ltd.

The patent concerns methods involving microvesicles, including the production of immunologically matched autologous microvesicles and their potential therapeutic and cosmetic applications.

This is not something we have inferred from Wellbeing's marketing.

It exists in the patent record.

And the underlying priority dates take the technology back to 2008 .

Now Compare the Two Scientific Stories

This is where things become interesting.

The historical patent describes:

autologous microvesicles.

Wellbeing today describes:

autologous biological material containing extracellular vesicles.

Stephen Ray is the inventor associated with the earlier technology.

Stephen Ray is now Wellbeing's Senior Scientific Consultant.

There is therefore an obvious scientific lineage worth investigating.

But there is an equally important warning.

Similarity does not establish legal or technical identity.

We cannot simply declare that the old Lydac patent is Wellbeing's present CFT.

That has not been established.

The terminology surrounding extracellular vesicles has evolved.

The manufacturing process may have changed.

Ray may have made substantial subsequent discoveries.

Wellbeing may possess additional know-how.

There may be newer intellectual property we have not yet identified.

And the claims contained in the old patents may not cover Wellbeing's present process.

Those possibilities have to remain open.

But the similarities are sufficient to ask something Wellbeing should be capable of answering:

What is the relationship between Stephen Ray's Lydac-era microvesicle technology and the Cell-Free Therapy being promoted today?

The Science Has a History

This matters because Wellbeing itself relies upon scientific history.

Its biography of Stephen Ray describes him as having more than 30 years of academic and commercial experience in cell therapy.

That experience is presented as part of the scientific foundation behind the organisation.

And our investigation has actually found documentary evidence supporting the existence of a substantial historical research footprint.

Ray was not suddenly introduced to this area when Wellbeing appeared.

His involvement goes back considerably further.

But that creates another distinction that patients and investors should understand.

Thirty years of a scientist's research experience is not necessarily thirty years of research on the exact commercial therapy being offered today.

Those are different claims.

If present-day CFT evolved from Ray's earlier microvesicle research, that history should be capable of being mapped.

Where did the process begin?

What did the original technology involve?

What changed?

When did it change?

What was patented?

What remained proprietary know-how?

And when did the version currently described as Cell-Free Therapy emerge?

That history could potentially strengthen Wellbeing's scientific narrative.

But it also creates an ownership question.

The Original Patent Holder Wasn't Wellbeing

This is one of the most important facts in the story.

The European patent record does not identify Wellbeing International Foundation as the original owner of Ray's microvesicle patent.

It identifies:

Lydac Neuroscience Limited.

That matters because we now know considerably more about Lydac than we did when this investigation began.

Stephen Ray was a director of Lydac from its incorporation in September 2007 until July 2012.

Andrew Chancellor became a director in November 2014.

The European patent was granted in December 2015.

Lydac subsequently entered administration in December 2018.

It moved into creditors' voluntary liquidation in November 2019.

And after years of winding up, the company was finally dissolved on 9 April 2025 .

The company disappeared.

The science apparently did not.

Two Men Reappear in the Same Story

This is another reason the Lydac investigation matters.

Stephen Ray and Andrew Chancellor were not simultaneously directors of Lydac according to the dates we have established.

Ray had resigned more than two years before Chancellor joined the board.

We should therefore not describe Chancellor as directly “taking over from Ray” without evidence supporting that conclusion.

But both men undeniably appear in the corporate history of the same biotechnology company .

Ray was there when the early microvesicle intellectual property was being developed.

Chancellor subsequently became a director.

Today, the two men are again connected through Wellbeing International Foundation.

Ray is presented as the scientific specialist.

Chancellor is the Chief Executive.

And Wellbeing is promoting Cell-Free Therapy.

That makes the corporate history relevant.

Where Is the Bridge Between Lydac and Wellbeing?

This is where our investigation currently reaches a gap.

If technology belonging to Lydac subsequently became technology used by Wellbeing, there should logically be some mechanism explaining how that happened.

It might have been:

an assignment;

a sale;

a licence;

an acquisition;

a transfer of intellectual property;

a successor patent;

a separate agreement involving Ray;

or an entirely new body of technology developed later.

Any one of those explanations could be legitimate.

But they are not interchangeable.

And so far, we have not established the documentary bridge connecting Lydac's intellectual property with Wellbeing.

That is the missing asset in this story.

Who Owned the Patent When Lydac Failed?

The patent record adds another complication.

Google Patents currently displays Lydac Neuroscience Ltd as both the original assignee and the current assignee for EP2240189B1, while also describing the patent's status as “Not-in-force.”

That must be treated cautiously.

Google Patents itself warns that its legal-status information is not a legal conclusion, and patent ownership can vary between national members of an international patent family.

So this does not prove that Lydac legally owned every relevant patent right when it entered administration.

But neither have we yet identified a public assignment showing this particular European patent moving from Lydac to Wellbeing.

That is precisely why the insolvency documents examined in Chapter Eight matter.

If Lydac still possessed valuable intellectual property when administrators were appointed, we need to know what happened to it.

Was the Technology Sold During the Insolvency?

There are several possibilities.

The administrators may have sold intellectual property.

They may have sold licences.

The patents may have been considered commercially worthless.

Rights may already have expired or lapsed in particular jurisdictions.

The technology may have been transferred before administration.

Or the commercially important knowledge may never have depended entirely upon the patents.

Until the administrator's detailed asset records and patent assignment records are reconciled, we should not claim to know which occurred.

But if an intellectual-property sale took place, there should potentially be a purchaser.

If a licence existed, there should be a licensor and licensee.

And if the technology moved before administration, there should potentially be an assignment or agreement explaining how.

Intellectual property does not simply migrate because the same scientist later works somewhere else.

Inventing Something Is Not the Same as Owning It

This distinction is essential.

Stephen Ray may have invented the underlying technology.

That does not automatically mean Stephen Ray personally owned the patents.

The patent records identify Lydac as an assignee.

Ray may later have worked with Wellbeing.

That does not automatically transfer Lydac's intellectual property to Wellbeing.

Andrew Chancellor may have been a director of Lydac and subsequently CEO of Wellbeing.

That does not transfer intellectual property either.

These are legally distinct concepts:

inventorship;

patent ownership;

licensing;

commercial exploitation;

and:

scientific know-how.

A compelling scientific history does not establish a chain of legal ownership.

Perhaps Wellbeing Doesn't Need the Old Patent

There is another possibility that deserves serious consideration.

Perhaps the Lydac patent is no longer commercially important.

The European record currently describes EP2240189B1 as not in force.

Technology can also develop far beyond an original patent.

Wellbeing could therefore potentially be relying upon:

later discoveries;

trade secrets;

manufacturing protocols;

laboratory know-how;

newer intellectual property;

proprietary processing techniques;

clinical data;

or scientific expertise that is not itself protected by the original patent.

There is nothing inherently suspicious about that.

Many biotechnology businesses rely upon combinations of patents, know-how and confidential manufacturing processes.

But if that is the situation, it changes the question investors should be asking.

What Exactly Is Proprietary?

If an investor is being presented with a biotechnology opportunity, understanding the company's intellectual-property position is fundamental.

What stops another organisation from reproducing the technology?

Is the process protected by patents?

If so, which patents?

Who owns them?

How long do they remain enforceable?

In which jurisdictions?

If Wellbeing doesn't own them, does it hold exclusive licences?

If there are no relevant enforceable patents, what proprietary know-how protects the business?

And which legal entity actually owns that know-how?

These are not hostile questions.

They are basic due-diligence questions.

And That Matters Because Wellbeing Is Raising Investment

This is where our investigation reconnects directly with Wellbeing's current activities.

In March 2026, Wellbeing announced that it had closed the opening tranche of its 2026 capital round.

It said the round remained open.

According to Wellbeing, investment supports research, expansion of its clinical relationship network in Europe and the United States, documentation work and operating capacity.

Wellbeing also says its historical funding has included:

private investment, patient revenue and selective philanthropy.

When outside capital enters a biotechnology organisation, intellectual-property ownership becomes potentially significant.

Because investors are not merely investing in scientific enthusiasm.

They need to understand what the company actually controls.

What Is an Investor Actually Buying Into?

Imagine being shown a biotechnology company built around a treatment described as emerging from decades of research.

The organisation has a scientist with a long research history.

It has a therapy involving extracellular vesicles.

It has international ambitions.

It has patients.

It has research programmes.

And it is raising capital.

A reasonable investor might ask:

What scientific asset gives this organisation commercial exclusivity?

That question becomes particularly important if the historical patents associated with the scientist were originally owned by another company.

A company that subsequently became insolvent.

A company that has now been dissolved.

Ask for the Intellectual-Property Schedule

There is a straightforward way for a serious investor to resolve much of this uncertainty.

Ask Wellbeing for its intellectual-property schedule.

That should identify, where applicable:

patents;

patent applications;

registered proprietors;

licences;

exclusive rights;

territories;

expiry dates;

royalty obligations;

trade secrets;

proprietary processes;

and agreements governing intellectual property created by consultants or employees.

Then ask:

Which legal entity owns the technology underlying Cell-Free Therapy?

And after that:

What relationship, if any, does that technology have to Stephen Ray's earlier Lydac patents?

Those two answers could resolve a substantial part of this investigation.

If There Is No Connection, Say So

There is an important point here.

Our hypothesis could be wrong.

Perhaps modern CFT has no legally significant relationship with the old Lydac patent.

Perhaps the similarities reflect the continuation of Ray's scientific interests rather than continuation of the patented invention.

If that is the case, Wellbeing should be able to explain where the modern process begins and how it differs from the earlier technology.

That would be useful information.

Likewise, if Wellbeing possesses newer intellectual property, identify it.

If the organisation operates under licence, explain that.

If it relies upon proprietary know-how rather than patents, say so.

The answer does not have to be dramatic.

It simply has to be clear.

Patients Have a Stake in This Too

This investigation should not become solely about investors.

Patients matter.

When patients encounter claims about decades of research, scientific heritage and advanced biological technology, they deserve to understand the provenance of the treatment they are purchasing.

If modern CFT developed from Ray's earlier work, when did the current treatment emerge?

How closely does it resemble the patented process?

What additional development occurred?

What clinical evidence relates specifically to the current formulation or process rather than earlier generations of research?

That final distinction is particularly important.

A long history of research in a scientific field does not automatically amount to a long clinical evidence history for the exact treatment currently being administered.

The Question Is Becoming More Precise

At the beginning of this investigation, we were asking broad questions about Wellbeing.

Now we can ask much narrower ones.

We know Stephen Ray has a documented history involving microvesicle technology.

We know Lydac Neuroscience appears in that patent history.

We know Ray was a director of Lydac.

We know Andrew Chancellor subsequently became a director of the same company.

We know Lydac entered administration and ultimately disappeared.

We know Ray and Chancellor later appear together at Wellbeing.

We know Wellbeing's present treatment narrative prominently involves extracellular vesicles.

And we know Wellbeing is raising private investment.

What we do not yet know is whether one continuous chain of intellectual property connects those facts.

That is what we now need to establish.

Three Documents Could Change This Investigation

There are three categories of evidence I particularly want to see.

First:

the complete patent assignment history.

Second:

the Lydac insolvency records showing the treatment and disposal of intellectual property.

Third:

Wellbeing's current intellectual-property schedule or licensing documentation.

Put those three together and the ownership story should become considerably clearer.

Without them, there is a gap.

What We Are Not Alleging

For clarity, this investigation has not established that Wellbeing is using intellectual property it does not own .

We have not established that intellectual property was improperly transferred from Lydac.

We have not established that Andrew Chancellor acquired Lydac's patents.

We have not established that Stephen Ray transferred technology improperly.

And we have not established that Wellbeing's current CFT falls within the claims of the historic Lydac patent.

Those would be serious conclusions.

The evidence does not presently justify them.

What the evidence does justify is asking how the technology travelled from its documented historical origins to the commercial proposition being presented today.

The Right of Reply

There is a very straightforward opportunity for Wellbeing International Foundation to clarify this.

We would welcome answers to the following questions:

Does Wellbeing consider its present Cell-Free Therapy to derive technically or scientifically from Stephen Ray's earlier microvesicle research?
Does EP2240189B1, or any member of that patent family, relate to the present CFT process?
Does Wellbeing own any patents covering CFT?
If not, does it license relevant intellectual property from another entity?
What happened to the microvesicle intellectual property previously owned by Lydac Neuroscience?
Did Wellbeing, Andrew Chancellor, Stephen Ray or any connected organisation acquire intellectual property from Lydac before, during or after its insolvency?
What intellectual property or proprietary rights are included in the commercial proposition currently being presented to investors?

If there is a straightforward ownership history, publishing it would answer many of the questions raised here.

Conclusion: Follow the Science — Then Follow the Ownership

We started with a treatment.

The treatment led us to a scientist.

The scientist led us to patents.

The patents led us to Lydac Neuroscience.

Lydac led us to Andrew Chancellor.

The company then entered insolvency and disappeared.

But years later, Ray and Chancellor are together again within an organisation promoting Cell-Free Therapy and raising investment.

That does not prove that Wellbeing inherited Lydac's technology.

It does not prove that the old patents protect modern CFT.

And it certainly does not prove wrongdoing.

But it creates a documentary question that can no longer be ignored:

If this is substantially the same scientific lineage, where is the chain of ownership?

Because the answer matters.

It matters to patients being told about the scientific heritage behind the treatment.

It matters to investors evaluating what proprietary assets underpin the business.

And it matters to anyone trying to understand whether Wellbeing is commercialising technology it owns, technology it licenses, technology that is no longer protected—or genuinely new technology developed after Lydac.

The science has a history.

The companies have a history.

The people have a history.

Now we need the ownership history.

And until that chain is established, the central question remains:

Does Wellbeing International Foundation actually own the science behind Cell-Free Therapy — and if it does, where is the documentary trail showing how it got there?

Next: Chapter Ten — Following the Patent Trail

In Chapter Ten, we leave the corporate biographies behind and follow the intellectual property itself: patent by patent, jurisdiction by jurisdiction and assignment by assignment. We will compare Stephen Ray's original claims with Wellbeing's description of modern Cell-Free Therapy and look for the missing legal bridge between Lydac Neuroscience and the technology being promoted today.

Follow the Money: Inside the Lydac Neuroscience Insolvency

Sat, 05 Sep 2026 04:01:40 GMT

The Men Behind Wellbeing — Chapter Eight

Lydac Neuroscience once held intellectual property connected to Stephen Ray's microvesicle research. Andrew Chancellor later became a director. Then the company entered administration. If this science forms part of the lineage behind the Cell-Free Therapy promoted by Wellbeing International Foundation today, understanding what happened when Lydac failed becomes far more than a piece of corporate history.

In Chapter Seven, we established something important.

The connection between Stephen Ray, Andrew Chancellor and Lydac Neuroscience Limited is not simply a collection of similar names or an assumption based on their later involvement with Wellbeing International Foundation.

It exists in the corporate record.

Stephen Ray was a director of Lydac Neuroscience from its incorporation in September 2007 until July 2012.

Andrew Chancellor subsequently became a director in November 2014.

Between those dates, intellectual property associated with Ray's microvesicle research was being pursued through Lydac.

Then something happened.

Lydac entered administration.

It moved into liquidation.

And eventually it disappeared altogether.

That could simply have been the end of an unsuccessful biotechnology company.

Except the scientific story did not disappear with it.

Years later, Stephen Ray and Andrew Chancellor are together again at Wellbeing International Foundation.

Ray is presented as a senior scientific figure.

Chancellor is CEO.

And Wellbeing now promotes a Cell-Free Therapy in which extracellular vesicles form an important part of the scientific explanation.

That is why Lydac's insolvency matters.

We are not investigating the collapse of an obscure company for historical curiosity.

We are trying to understand what happened to the science, the intellectual property and the commercial rights when that company failed .

Because if those rights are connected to what Wellbeing is offering today, the insolvency could contain a missing part of the Wellbeing story.

Lydac Neuroscience Wasn't Just Another Company

Lydac Neuroscience Limited was incorporated on 12 September 2007 .

Its registered business activity was:

Research and experimental development on biotechnology.

Stephen Ray became a director on the day the company was incorporated and remained until 27 July 2012.

That period overlaps directly with the earliest priority dates of the microvesicle intellectual property we have already examined.

The first UK priority application dates from 4 January 2008 .

A second followed on 17 March 2008 .

An international application followed in January 2009.

The resulting patent family included European patent EP2240189B1 — “Microvesicles.”

Stephen Ray is named as inventor.

Lydac Neuroscience Limited is identified as the original assignee.

That means Lydac wasn't merely a company Ray happened to direct.

It sat directly within the documented corporate history of his microvesicle technology.

Then Stephen Ray Left

Ray resigned as a director on 27 July 2012 .

This is an important date because it prevents us from oversimplifying the story.

More than two years passed before Andrew Chancellor became a director.

We therefore should not say that Chancellor simply took over from Ray.

The records do not establish that.

But they do establish that both men occupied directorships in the same biotechnology company at different stages of its existence.

And on 26 November 2014 , Andrew William Chancellor was formally appointed as a director of Lydac Neuroscience Limited.

From this point onward, Chancellor becomes directly relevant to the company's later history.

The Patent Was Granted After Chancellor Arrived

The chronology becomes particularly interesting here.

Chancellor became a director in November 2014.

Then, on 30 December 2015 , European patent EP2240189B1 was granted.

The patent names Stephen Ray as inventor and Lydac Neuroscience as the original assignee.

So by the time this important European patent reached grant, Ray was no longer a director.

Chancellor was.

Again, this does not establish that Chancellor personally owned the patent.

Directors and companies are legally distinct.

But it does establish that Chancellor was involved in Lydac during a period when intellectual property originating from Ray's earlier research remained part of the company's documented history.

That becomes significant when we examine what happened next.

The Company Was Filing Dormant Accounts

One of the more puzzling aspects of Lydac's corporate history is its accounting status.

Companies House records dormant accounts for the financial years ending:

30 September 2015

30 September 2016

and:

30 September 2017.

The last accounts filed before administration were therefore dormant accounts.

That deserves attention.

A company can legitimately be dormant while holding intellectual property.

It may have little or no accounting activity.

It may act principally as an IP-holding vehicle.

Commercial activity may occur elsewhere.

So dormant accounts are not evidence of misconduct .

But they create an obvious question.

How does a company filing dormant accounts subsequently end up in formal administration?

There Had Already Been a Strike-Off Attempt

There is another event in the Companies House history.

On 30 August 2016 , a First Gazette notice for compulsory strike-off was issued.

That action was subsequently discontinued on 1 October 2016 .

Compulsory strike-off proceedings can occur for administrative reasons, including failures to make required filings.

The discontinued action does not establish insolvency or wrongdoing.

But it belongs in the chronology.

By 2016, the company had already attracted regulatory action concerning its status on the register.

Two years later, its problems became considerably more serious.

December 2018: Lydac Enters Administration

On 17 December 2018 , administrators were appointed to Lydac Neuroscience Limited.

The official Gazette identifies:

Ian Robert

and:

Christopher Purkiss

of Kingston Smith & Partners LLP.

The notice describes Lydac's business as:

“Research and experimental development on biotechnology.”

And its principal trading address at the time was:

10 Harley Street, London W1G 9PF.

This is a significant distinction.

Lydac wasn't simply struck off because nobody bothered maintaining the company.

It entered a formal insolvency procedure.

Administrators were appointed.

Creditors existed.

Assets and liabilities had to be considered.

And professional insolvency practitioners took control.

That is where the story changes.

Why Did Lydac Fail?

This is the first major question Chapter Eight needs to answer.

The public chronology tells us that Lydac failed.

It doesn't, by itself, tell us why .

And that distinction is important.

We should not invent an explanation.

We should not assume poor management.

We should not assume investor losses.

We should not assume that the patents were worthless.

And we certainly should not assume misconduct.

Fortunately, insolvency creates paperwork.

And Lydac generated a considerable amount of it.

January 2019: The Statement of Affairs

On 28 January 2019 , Companies House records the filing of a nine-page:

Statement of Affairs.

This is potentially one of the most important documents in the entire investigation.

A statement of affairs can reveal the financial anatomy of an insolvent company.

Assets.

Liabilities.

Creditors.

Estimated realisable values.

Secured claims.

Unsecured claims.

And potentially the shortfall facing creditors.

For most companies, investigators might immediately look for cash, property, vehicles or equipment.

For Lydac, there is another asset category that interests us far more.

Intellectual property.

Where Are the Patents?

This is the question at the heart of Chapter Eight.

We know Lydac had historically been associated with intellectual property.

We have patent records.

We have Stephen Ray named as inventor.

We have Lydac identified as assignee.

So when administrators arrived in December 2018, what happened to those rights?

Were patents listed as company assets?

Were they valued?

Were they still legally owned by Lydac?

Had particular rights expired or lapsed?

Had they been licensed?

Had they already been transferred?

Were they considered commercially valuable?

Or were they effectively worthless by the time administrators arrived?

Those questions cannot responsibly be answered by guessing.

But the insolvency documents give us somewhere concrete to look.

April 2019: A 31-Page Administrator's Proposal

On 9 April 2019 , Companies House records another substantial document:

Statement of Administrator's Proposal.

Thirty-one pages.

This may ultimately prove more important than any corporate biography we have examined.

Because an administrator's proposal can provide the contemporary professional explanation of what happened to a company.

Why administration became necessary.

What assets existed.

Who the creditors were.

What administrators intended to do.

What recoveries might be possible.

And how creditors were expected to fare.

For an investigation like ours, this is potentially the financial autopsy of Lydac Neuroscience.

The Creditors Then Considered the Proposal

The following day, 10 April 2019 , Companies House records the result of a creditors' meeting.

That tells us something else.

This was not merely an internal restructuring exercise.

There were creditors whose financial interests were affected by what happened to Lydac.

Who were they?

How much were they owed?

Were any connected with investment?

Were there director loans?

Professional creditors?

Research costs?

Patent expenses?

Other companies?

We should not answer those questions until the underlying documents establish the facts.

But these are precisely the details we now need to extract.

July 2019: The Administrator Reports Back

On 19 July 2019 , another important filing appeared:

Administrator's Progress Report.

Seventeen pages.

By then, administrators had controlled Lydac for approximately seven months.

That is enough time for something extremely important potentially to have happened.

Assets may have been realised.

And for this investigation, one category matters above everything else.

The intellectual property.

If patents were sold, this is where we might start seeing the transaction.

If intellectual property was assigned, we need the recipient.

If licences were disposed of, we need the counterparty.

If nothing was sold because the rights had no realisable value, that matters too.

Whatever happened, the answer potentially changes the Wellbeing story.

November 2019: Administration Ends

Lydac was not rescued.

On 15 November 2019 , the company left administration and moved into creditors' voluntary liquidation .

The Gazette confirms the appointment of Ian Robert and Christopher Purkiss as liquidators following the company's exit from administration.

That tells us that whatever administrators attempted during the preceding eleven months did not result in Lydac continuing as an independent biotechnology company.

The company was now being wound up.

But Lydac Took Years to Finally Disappear

The liquidation did not conclude quickly.

Companies House records successive liquidators' statements of receipts and payments covering periods ending in:

2020

2021

2022

and:

2023 .

The winding-up process therefore continued for years.

A final meeting return was eventually filed in January 2025.

Then:

9 April 2025 — Lydac Neuroscience Limited was dissolved.

Almost seventeen and a half years after it was incorporated, the company ceased to exist.

But that still doesn't tell us what happened to its science.

A Company Can Die While Its Intellectual Property Survives

This is the key point.

A biotechnology company disappearing does not necessarily mean its technology disappears.

Patents can be sold.

Patent applications can be assigned.

Licences can survive.

Know-how can move.

Research data can be acquired.

Manufacturing processes can be transferred.

Scientists can continue developing ideas elsewhere.

In fact, intellectual property can sometimes be among the most valuable assets remaining when the operating company itself fails.

That is why we cannot simply close the Lydac file in April 2025.

We have to follow what survived.

And This Is Where Wellbeing Comes Back Into the Story

This investigation began with Wellbeing International Foundation.

Today, Wellbeing identifies Andrew Chancellor as its CEO.

Stephen Ray is presented as its Senior Scientific Consultant.

Wellbeing describes Cell-Free Therapy using language involving extracellular vesicles, growth factors and cytokines.

And in 2026, Wellbeing announced that it had closed the first tranche of a capital round intended to support its research programme, clinical network and expansion.

That means the historical intellectual-property question is no longer merely academic.

If the science being promoted today is descended from Ray's earlier microvesicle work, then the ownership history potentially matters to:

patients;

commercial partners;

and especially:

investors.

What Happened Between Lydac and Wellbeing?

There is a danger here of making an assumption.

We must not automatically draw this line:

Lydac → Wellbeing.

We haven't established that.

The science may have changed substantially.

New intellectual property may have been created.

Ray may have developed subsequent technology independently.

Wellbeing may operate under licences.

The older patents may no longer matter.

Or another company may sit somewhere in the ownership chain.

Any of those explanations could be legitimate.

But the existence of possible explanations does not remove the need to identify the actual one.

The Insolvency Could Contain the Missing Link

Suppose the administrators' records show that Lydac still owned microvesicle patents in December 2018.

Then we need to know what happened to them.

Suppose instead the records show that Lydac no longer owned them.

Then we need to move backwards.

When did they leave?

Who acquired them?

For what consideration?

Suppose the administrators valued the intellectual property but couldn't sell it.

That would tell us something else.

And suppose the patents weren't mentioned at all.

That would create another question:

Why wasn't intellectual property historically associated with the company appearing among the assets of a biotechnology business?

Each answer sends the investigation in a different direction.

Follow the Money — But Follow the Ownership

This chapter is called Follow the Money .

But perhaps that title only describes half the investigation.

With biotechnology, we have to follow two things simultaneously.

The money.

And:

the intellectual property.

Where did the money come from?

Who was owed money?

What did creditors recover?

What assets were sold?

But alongside those questions:

Who owned the patents?

Who owned the know-how?

Who acquired the rights?

What survived liquidation?

And where did it go?

Because those questions lead directly back to Wellbeing.

The Andrew Chancellor Question

Andrew Chancellor was a director of Lydac when administrators were appointed.

That is an established corporate fact.

It does not establish that Chancellor caused Lydac's insolvency.

It does not establish that he transferred its intellectual property.

It does not establish that he personally benefited from the insolvency.

And it does not establish that insolvency practitioners criticised his conduct.

We should be absolutely clear about that.

But his position does make the records relevant to our investigation.

Because Chancellor later appears as CEO of Wellbeing International Foundation.

And Wellbeing is now commercially involved in regenerative biotechnology alongside the scientist whose earlier intellectual property was associated with Lydac.

The question is therefore not:

“Did Chancellor do something wrong?”

The correct question is:

“What happened to Lydac's technology while Chancellor was directing the company, and what relationship—if any—does that technology have to Wellbeing today?”

That is a much more important question.

The Stephen Ray Question

The same discipline applies to Stephen Ray.

Ray resigned from Lydac in 2012.

He was no longer a director when the company entered administration six years later.

Nothing we have established suggests that he was responsible for Lydac's subsequent insolvency.

But his intellectual-property history remains central.

If Ray continued developing the technology after leaving Lydac, we need to understand which parts belonged to Lydac and which parts were subsequently created elsewhere.

Inventorship and ownership are not the same thing.

A scientist can invent technology whose legal rights belong to a company.

That distinction could become crucial.

The Investor Question

And now we arrive at the reason this historical investigation matters today.

Wellbeing is raising investment.

If prospective investors are being presented with a business built around proprietary regenerative biotechnology, they need to understand what intellectual property supports that proposition.

Does Wellbeing own patents?

Does it own later patents derived from Ray's work?

Does it hold licences?

Does another entity own the technology?

Does Wellbeing rely primarily on proprietary know-how?

What stops competitors reproducing the process?

And if part of its scientific lineage originated inside Lydac, how did the relevant rights travel from that now-dissolved company to their present owner?

Those are basic due-diligence questions.

What We Can Establish

At this point, several facts are documented.

Lydac Neuroscience was incorporated in September 2007.

Stephen Ray became a director on incorporation.

Ray is named as inventor on microvesicle intellectual property associated with Lydac.

Ray resigned in July 2012.

Andrew Chancellor became a director in November 2014.

European patent EP2240189B1 was granted in December 2015 with Lydac identified as original assignee.

Lydac subsequently filed dormant accounts.

Administrators were appointed in December 2018.

A statement of affairs was filed.

An administrator's proposal followed.

A progress report followed.

The company moved into creditors' voluntary liquidation in November 2019.

And Lydac was finally dissolved in April 2025.

Those facts establish a corporate and intellectual-property chronology.

What We Have Not Established

Equally importantly, we have not established :

that Wellbeing owns the Lydac patents;

that Wellbeing's present CFT is covered by those patents;

that Chancellor acquired Lydac's intellectual property;

that Ray transferred Lydac's technology;

that assets were improperly disposed of;

that creditors were unfairly treated;

or that either Ray or Chancellor committed misconduct in connection with the insolvency.

Those would require substantially more evidence.

But we have established enough to ask where the assets went.

And that is precisely what an investigation should now do.

The Documents We Need Next

The next stage should focus on the documents rather than biographies.

We need the detailed Statement of Affairs .

We need the complete Administrator's Proposal .

We need the Administrator's Progress Report .

We need the administration-to-liquidation documentation.

We need the liquidators' receipts and payments accounts .

And we need to place those records beside the complete assignment history of Ray's microvesicle patent family.

Then we need to compare what those documents tell us with the intellectual-property position presented by Wellbeing today.

That is where the story may finally join together.

Conclusion: Lydac Failed — But Did the Science Move On?

Lydac Neuroscience is gone.

The company that appeared alongside Stephen Ray's early microvesicle patents no longer exists.

But the people continued.

The science continued.

And today, an organisation led by Andrew Chancellor and scientifically associated with Stephen Ray is promoting Cell-Free Therapy and raising investment.

That does not establish a direct ownership chain.

That is precisely the problem.

We can see the beginning of the scientific story.

We can see Lydac in the middle.

We can see Wellbeing today.

What we cannot yet see is the documentary bridge connecting them.

If the technologies are unrelated, that needs establishing.

If the Lydac patents became obsolete, that needs establishing.

If new technology replaced them, we need to identify it.

If the intellectual property was sold or licensed, we need to follow the transaction.

And if today's Cell-Free Therapy substantially descends from the same technology once owned by Lydac, then patients and prospective investors are entitled to ask a very straightforward question:

Who owns the science now?

That is where this investigation goes next.

Next: Chapter Nine — The Missing Asset: Does Wellbeing Actually Own the Science Behind Cell-Free Therapy?

Lydac disappeared, but Stephen Ray's scientific work did not. In Chapter Nine, we return directly to Wellbeing International Foundation and ask whether its present Cell-Free Therapy shares the scientific lineage of Lydac's microvesicle technology. If it does, where is the assignment, licence or ownership trail—and what intellectual property are investors actually being asked to put their money behind?

What Happened to Lydac Neuroscience? The Company Connecting Stephen Ray and Andrew Chancellor

Sat, 05 Sep 2026 03:57:21 GMT

The Men Behind Wellbeing — Chapter Seven

Before Wellbeing International Foundation, before Cell-Free Therapy and before its current investment story, there was another biotechnology company. Stephen Ray helped establish it. His microvesicle patents were associated with it. Years later, Andrew Chancellor became one of its directors. Then the company entered administration, liquidation and ultimately disappeared. Understanding what happened to Lydac Neuroscience may be essential to understanding where the science behind Wellbeing really came from.

For the last several chapters, this investigation has followed the people behind Wellbeing International Foundation.

That trail has taken us backwards.

From Andrew Chancellor's present role as Chief Executive.

To Stephen Ray's scientific history.

Then into the patent records surrounding Ray's earlier work on microvesicles.

And those patents repeatedly led to the same company:

Lydac Neuroscience Limited.

At first, Lydac appeared to be little more than a historical name attached to old intellectual-property records.

It isn't.

Companies House records reveal something considerably more important.

Stephen Ray was a director of Lydac Neuroscience from the day the company was incorporated.

Years later, after Ray had left, Andrew Chancellor became a director of the same company .

Then Lydac collapsed.

Administrators were appointed.

The company moved into liquidation.

And eventually, in April 2025, Lydac Neuroscience ceased to exist.

That creates an important new line of investigation.

Because today Stephen Ray and Andrew Chancellor appear together again at Wellbeing International Foundation.

And Wellbeing is promoting Cell-Free Therapy—a treatment whose scientific explanation places considerable emphasis on extracellular vesicles.

So before we can properly understand Wellbeing's present scientific and commercial proposition, we need to understand the company that appears much earlier in this story.

What exactly was Lydac Neuroscience?

What did it own?

What happened to it?

And ultimately:

What happened to its science?

Lydac Neuroscience Begins in 2007

Lydac Neuroscience Limited, company number 06369154 , was incorporated in England on 12 September 2007 .

Its registered business activity was:

72110 — Research and experimental development on biotechnology.

This was therefore not simply a consultancy or general commercial company.

Its stated purpose placed biotechnology research at the centre of the business.

And on the very day the company was incorporated, Stephen Ray became a director.

Companies House records show Ray remaining in that position until 27 July 2012 .

That date becomes particularly significant when placed beside the patent history.

Within Months, the Patent Trail Begins

The earliest priority date we have identified for Ray's microvesicle technology is:

4 January 2008.

A second UK priority application followed on:

17 March 2008.

Then, on 2 January 2009 , an international application was filed under:

PCT/GB2009/000004.

The resulting patent family includes the international publication WO2009/087361 and European patent EP2240189B1 .

The European patent is titled:

Microvesicles.

Stephen Ray is named as inventor.

And the original assignee is:

Lydac Neuroscience Limited.

That chronology is important.

Lydac was incorporated.

Ray became a director.

Within months, priority applications relating to microvesicle technology began appearing.

The company then became the corporate assignee associated with that intellectual property.

That gives us something far stronger than a loose historical association.

Lydac sat directly within the early commercial history of Stephen Ray's microvesicle science.

What Was Ray Trying to Patent?

The patent documentation describes methods involving microvesicles, including the production of immunologically matched autologous microvesicles .

The specification discusses potential therapeutic and cosmetic applications.

In simplified terms, the technology concerned biological material derived from cells and the signalling components associated with that material.

This is interesting because extracellular vesicles are now central to the scientific language surrounding Wellbeing's Cell-Free Therapy.

But we need to be disciplined here.

I am not claiming that Ray's Lydac patent is identical to the Cell-Free Therapy offered by Wellbeing today .

We have not established that.

Microvesicle and extracellular-vesicle science has developed significantly since these patents were first filed.

Processes can change.

New intellectual property can be developed.

Manufacturing methods can evolve.

And an older patent may cover only particular claims within a much larger modern process.

But the scientific overlap is sufficiently obvious to justify investigating the relationship.

Especially because the scientist is the same.

Stephen Ray Leaves Lydac

On 27 July 2012 , Stephen Ray resigned as a director of Lydac Neuroscience.

This is another point where accuracy matters.

Andrew Chancellor did not immediately replace him.

There was a gap of more than two years.

Corporate records identify Bruno Butti as a director during part of the intervening period.

So it would be inaccurate to write:

“Chancellor took over Lydac from Stephen Ray.”

We do not have evidence for that.

What we can say is more precise—and potentially more interesting.

Stephen Ray was a director during the company's formative period and the development of its early microvesicle intellectual property.

He left in 2012.

Then, in 2014, another person who would later become central to Wellbeing entered the same company's history.

Andrew Chancellor Arrives

On 26 November 2014 , Companies House records the appointment of:

Andrew William Chancellor

as a director of Lydac Neuroscience Limited.

On the same date, Bruno Butti's directorship was terminated.

This is the first hard corporate record directly placing Chancellor inside the company associated with Ray's earlier microvesicle intellectual property.

That is significant because Chancellor's own later accounts of his move into biotechnology place Stephen Ray at the centre of that transition.

In interviews, Chancellor has described meeting Ray and becoming interested in the commercial potential of his research.

He has described conversations evolving into discussions about how the science might be commercialised and brought into clinical use.

Now we have a corporate record that adds another layer to that story.

Chancellor did not merely encounter a scientist with interesting research.

He subsequently became a director of the biotechnology company historically associated with that scientist's microvesicle intellectual property.

But Ray and Chancellor Were Not Directors Together

This distinction deserves repeating.

Stephen Ray resigned:

27 July 2012.

Andrew Chancellor was appointed:

26 November 2014.

Their directorships therefore did not overlap according to the records we have established.

That does not weaken the connection.

It simply defines it correctly.

Both men appear in the history of the same biotechnology company.

At different times.

And years later both appear again inside Wellbeing International Foundation.

That is the documented connection.

Anything beyond that requires additional evidence.

Lydac Moves to Harley Street

Another development followed.

On 16 June 2015 , Lydac changed its registered office to:

10 Harley Street, London W1G 9PF.

Harley Street carries obvious prestige within British medicine.

But an address alone tells us nothing about the scale of clinical or scientific activity taking place there.

The important point for this investigation is chronological.

By mid-2015:

Andrew Chancellor was a director.

Lydac was registered at Harley Street.

And Ray's earlier microvesicle patent family was still progressing.

Then, later that year, something important happened.

The European Microvesicle Patent Is Granted

On 30 December 2015 , European patent EP2240189B1 was granted.

The title:

Microvesicles.

Inventor:

Stephen Ray.

Original assignee:

Lydac Neuroscience Limited.

This creates an unusual corporate timeline.

Ray had left Lydac more than three years earlier.

But the patent originating from the earlier research continued through the patent system.

And by the time the European patent reached grant, Andrew Chancellor was a director of Lydac.

That does not mean Chancellor invented the technology.

The patent identifies Ray as inventor.

It does not mean Chancellor personally owned the patent.

The assignee was the company.

But it does mean Chancellor was directing the company during a period when significant intellectual property originating from Ray's research was reaching patent grant.

That fact becomes important later.

Something Else Was Happening at Lydac

Despite being registered as a biotechnology research company and being associated with patent activity, Lydac's Companies House record shows dormant accounts in the years preceding its collapse.

Dormant accounts were filed for the financial years ending:

30 September 2015

30 September 2016

and:

30 September 2017.

That initially appears strange.

How can a biotechnology company associated with patent development and a Harley Street address be dormant?

But “dormant” should not automatically be interpreted as suspicious.

An intellectual-property holding company may conduct little accounting activity.

Research or commercial work may occur elsewhere.

Patents may be held inside a separate corporate vehicle.

Licensing arrangements can separate intellectual-property ownership from trading activity.

So the dormant accounts do not establish wrongdoing.

They do, however, create a question that becomes much more important when we see what happened next.

A Strike-Off Warning Appears

On 30 August 2016 , a First Gazette notice for compulsory strike-off was issued against Lydac.

The action was subsequently discontinued on 1 October 2016 .

Compulsory strike-off proceedings can arise for relatively ordinary administrative reasons, such as failure to make required filings.

Because the action was discontinued, Lydac remained registered.

Again, there is no basis for turning that into an allegation of misconduct.

But it belongs in the chronology.

By 2016, the company's position on the register had already required attention.

Then, two years later, the situation became much more serious.

December 2018: Lydac Collapses Into Administration

On 17 December 2018 , administrators were appointed to Lydac Neuroscience Limited.

The official Gazette notice identifies the administrators as:

Ian Robert

and:

Christopher Purkiss

of Kingston Smith & Partners LLP.

The notice records Lydac's principal trading address as:

10 Harley Street, London W1G 9PF.

And it describes the company's business as:

Research and experimental development on biotechnology.

This was no longer an administrative strike-off issue.

This was formal insolvency.

Professional administrators had been appointed.

Creditors existed.

Assets and liabilities had to be examined.

And suddenly, something we had discovered earlier in this investigation becomes extremely important.

The patents.

What Happened to the Intellectual Property?

This is where the Lydac story becomes much more than corporate history.

We know Lydac had been associated with Ray's microvesicle intellectual property.

We know Lydac was recorded as assignee on relevant patent records.

So what happened to those rights when administrators arrived?

Were they still owned by Lydac?

Were they valuable?

Had they been licensed?

Had some rights already lapsed?

Had they been assigned elsewhere before administration?

Were they subsequently sold by the administrators?

Were they transferred during liquidation?

Or had the commercially important science moved beyond those original patents entirely?

At this stage, we should not pretend to know.

But the question has become unavoidable.

Administration Generates a Paper Trail

Fortunately, insolvency leaves documents.

Companies House records a substantial series of filings following the appointment of administrators.

On 28 January 2019 , a nine-page Statement of Affairs was filed.

On 9 April 2019 , a 31-page Administrator's Proposal followed.

On 10 April 2019 , the result of a creditors' meeting was filed.

Then, on 19 July 2019 , a 17-page Administrator's Progress Report appeared.

These documents matter because they potentially tell us what Lydac possessed when it failed.

Assets.

Liabilities.

Creditors.

Estimated recoveries.

And potentially:

intellectual property.

This is where the next stage of the investigation has to go.

Administration Did Not Save the Company

Lydac did not emerge from administration as a rescued biotechnology business.

On 15 November 2019 , the administration ended and Lydac moved into:

Creditors' Voluntary Liquidation.

The Gazette records Ian Robert and Christopher Purkiss as liquidators and identifies the transition as an exit from administration.

From that point onward, Lydac was being wound up.

But the process took years.

Liquidators' statements of receipts and payments continued to appear through subsequent reporting periods.

The company remained legally present while the winding-up process continued.

Finally:

9 April 2025.

Lydac Neuroscience Limited was dissolved.

After nearly eighteen years, the company disappeared from the register.

But Intellectual Property Does Not Necessarily Die With a Company

This is perhaps the most important point in Chapter Seven.

A company can disappear.

Its technology does not necessarily disappear with it.

Patents can be sold.

Applications can be assigned.

Licences can continue.

Research data can move.

Know-how can be transferred.

Scientists can continue developing technology elsewhere.

An insolvent biotechnology company may actually possess intellectual property that survives long after the company itself is gone.

That is why we cannot simply conclude:

Lydac failed, therefore the story ended.

The opposite may be true.

The failure of Lydac may be precisely where the next part of the story begins.

Because Stephen Ray Did Not Disappear

Today, Stephen Ray appears at Wellbeing International Foundation.

Wellbeing describes him as its Senior Scientific Consultant .

It credits him with more than thirty years of academic and commercial experience in cell therapy.

And Wellbeing's scientific narrative surrounding Cell-Free Therapy places extracellular vesicles among the biological components of the treatment.

That brings us back to the patents.

Microvesicles.

Extracellular vesicles.

Autologous biological material.

Stephen Ray.

The terminology and scientific history overlap sufficiently to require investigation.

But again:

overlap is not proof that the technologies are legally or technically identical.

That is exactly what we now need to determine.

Andrew Chancellor Did Not Disappear Either

Andrew Chancellor also appears today at Wellbeing International Foundation.

He is its Chief Executive.

His own public account of his move into biotechnology describes meeting Stephen Ray and becoming interested in commercialising the research.

And we now know that Chancellor subsequently became a director of the very biotechnology company associated with Ray's earlier microvesicle patents.

This gives us a chronology that is becoming increasingly difficult to dismiss as irrelevant.

Stephen Ray.

Lydac.

Microvesicle patents.

Andrew Chancellor.

Lydac's insolvency.

Then:

Stephen Ray.

Andrew Chancellor.

Wellbeing International Foundation.

Cell-Free Therapy.

That does not establish a continuous legal ownership chain.

It establishes the need to find one—or establish that none exists.

This Is Why We Are Investigating Lydac

It is important not to lose sight of this.

We are not interested in embarrassing someone because an old company became insolvent.

Businesses fail.

Biotechnology companies fail.

Research companies fail.

Administration itself is not evidence of fraud or wrongdoing.

Our interest in Lydac is much more specific.

Lydac appears to have held intellectual property associated with the science of a man who is now central to Wellbeing's scientific story.

And one of Lydac's later directors is now Wellbeing's CEO.

That makes the fate of Lydac's intellectual property potentially relevant to understanding the origins and ownership of the technology being promoted today.

And Now There Is an Investment Dimension

There is another reason this matters.

Wellbeing is not simply presenting scientific ideas.

In 2026, it announced the opening tranche of a new capital raise.

Wellbeing says the money will support its research programme, clinical relationships, documentation and expansion.

That introduces investors into the story.

And intellectual-property ownership is fundamental to biotechnology investment.

An investor needs to understand what they are investing behind.

Patents?

Licences?

Trade secrets?

Manufacturing know-how?

Clinical data?

A scientific team?

Or technology whose historic patent ownership sits somewhere else?

None of those structures is inherently illegitimate.

But they represent very different investment propositions.

The Question We Cannot Yet Answer

At this stage, I cannot responsibly say:

Wellbeing owns Lydac's intellectual property.

I cannot say:

Wellbeing acquired Lydac's patents.

I cannot say:

Andrew Chancellor acquired the technology during the insolvency.

I cannot say:

Stephen Ray transferred it.

And I cannot yet say:

Wellbeing's current Cell-Free Therapy is covered by the old Lydac patents.

We have not established those things.

But equally, we have not yet found the documentary bridge explaining how the technology moved from its historical corporate setting to the commercial and scientific proposition being presented today.

That is the gap.

The Timeline We Can Establish

What we can establish is already significant:

12 September 2007 — Lydac Neuroscience Limited incorporated; Stephen Ray appointed director.

4 January 2008 — first UK priority application associated with the microvesicle patent family.

17 March 2008 — second UK priority application.

2 January 2009 — international patent application filed.

27 July 2012 — Stephen Ray resigns as director.

26 November 2014 — Andrew Chancellor becomes a director.

16 June 2015 — Lydac's registered office moves to 10 Harley Street.

30 December 2015 — European microvesicle patent EP2240189B1 granted.

17 December 2018 — administrators appointed.

28 January 2019 — Statement of Affairs filed.

9 April 2019 — Administrator's Proposal filed.

19 July 2019 — Administrator's Progress Report filed.

15 November 2019 — Lydac moves from administration into creditors' voluntary liquidation.

9 April 2025 — Lydac Neuroscience Limited dissolved.

That chronology is no longer speculative.

It comes from corporate, insolvency and patent records.

What We Need to Find Next

The next stage of this investigation is now very clear.

We need to open the insolvency file.

Not merely read the filing titles.

We need the actual contents.

We need to know:

Why did Lydac enter administration?

Who were the major creditors?

How much was owed?

What assets did the company possess?

Were patents or intellectual property listed?

What value was placed upon them?

Were they sold?

Were they licensed?

Were they transferred before administration?

Who acquired them?

What did creditors ultimately recover?

And above everything:

Where did the microvesicle intellectual property go?

A Right of Reply

There may be perfectly straightforward answers to all of this.

Andrew Chancellor may be able to explain exactly what happened to Lydac's intellectual property.

Stephen Ray may be able to explain how his subsequent science developed beyond the original patents.

Wellbeing may be able to demonstrate that its current Cell-Free Therapy is based on later technology entirely separate from Lydac's intellectual property.

Or it may possess legitimate licences or assignments that simply aren't apparent from the public material we have examined.

We would welcome that clarification.

Because the objective here is not to manufacture a scandal.

It is to establish the documentary history.

Conclusion: The Company Disappeared. The Science Didn't.

Lydac Neuroscience no longer exists.

Its name now survives primarily in Companies House records, Gazette notices and patent databases.

But the people associated with its history continued.

Stephen Ray continued.

Andrew Chancellor continued.

And the scientific field around extracellular vesicles continued.

Today, Ray and Chancellor are together at Wellbeing International Foundation.

Wellbeing is promoting Cell-Free Therapy.

It is presenting a scientific heritage built around decades of research.

And it is seeking investment to support its future.

That makes the fate of Lydac's intellectual property more than an historical curiosity.

If today's technology is unrelated to the Lydac patents, we need to establish that.

If it evolved from them, we need to understand how.

If those rights were transferred, we need to find the transaction.

If they were licensed, we need to understand the licence.

And if the old patents ceased to matter because entirely new intellectual property replaced them, then we need to identify what that new intellectual property actually is.

The company disappeared.

The science apparently did not.

So now we follow what happened when the money ran out—and what happened to the assets when Lydac Neuroscience collapsed.

Next: Chapter Eight — Follow the Money: Inside the Lydac Neuroscience Insolvency

Lydac entered administration while Andrew Chancellor was its director. In Chapter Eight, we go inside the insolvency process: the Statement of Affairs, the Administrator's Proposal, the creditors, the assets and the liquidation. Most importantly, we begin looking for what happened to the intellectual property that once sat at the centre of Stephen Ray's microvesicle research.

The Men Behind Wellbeing — Chapter Six

Sun, 23 Aug 2026 06:01:31 GMT

Who Owned Stephen Ray’s Science? The Lydac Neuroscience Connection

We found Stephen Ray's microvesicle patent trail. Now another company has emerged from the official records: Lydac Neuroscience Limited. What role did it play, what did it own, and how—if at all—did that intellectual property eventually reach Wellbeing International Foundation?

Patent investigations have a habit of changing direction.

You begin looking for one company.

Then the documents give you another.

That is exactly what has happened here.

In Chapter Five, I established that a Stephen Ray of Bath is named as inventor on a patent family involving microvesicles, autologous cells and potential therapeutic applications.

The earliest priority applications date to 2008 .

But there was another name sitting inside the patent record that deserves considerably more attention.

Not Wellbeing International Foundation.

Not Natural Biosciences SA.

But:

Lydac Neuroscience Limited.

And unlike some of the historical material examined previously, this isn't simply a name appearing in a promotional article.

It appears directly in patent records.

Lydac Neuroscience Limited Appears in the Microvesicle Patent Record

The US application published in January 2011 identifies the invention as:

Microvesicles

It identifies:

Inventor: Stephen Ray (Bath)

and then something extremely important:

Applicant: LYDAC NEUROSCIENCE LIMITED (Bath).

US Patent Application 20110014251 — Microvesicles

That materially advances this investigation.

We are no longer merely trying to infer which company might have been connected to Ray's intellectual property.

We have a company explicitly identified within the patent documentation.

The Canadian Record Strengthens the Connection

There is further evidence.

An official Canadian Intellectual Property Office publication records a patent from the same international family.

It identifies:

RAY, STEPHEN, GB

as inventor.

And:

LYDAC NEUROSCIENCE LIMITED, GB

as the proprietor or assignee.

The record also identifies the international application:

PCT/GB2009/000004

with British priority applications dating from January and March 2008. ( Publications Canada )

That is much stronger evidence than a corporate biography.

It establishes a documentary relationship between:

Stephen Ray

the microvesicle intellectual property

and

Lydac Neuroscience Limited.

Inventor Does Not Necessarily Mean Owner

This corrects an important assumption that readers could easily make.

Stephen Ray being named as inventor does not necessarily mean Stephen Ray personally owned the commercial rights.

Patent systems distinguish between the person who invents something and the legal entity holding rights to exploit that invention.

An employee may invent something owned by their employer.

An inventor may assign their rights to a company.

A company may subsequently sell those rights.

A licence may permit another company to exploit them without transferring ownership.

In this case, the documentary evidence presently available points directly toward Lydac Neuroscience Limited as an important holder of rights associated with the patent family. ( Justia Patents )

That creates an entirely new corporate trail.

So What Was Lydac Neuroscience Limited?

That is now one of the most important unanswered questions in this investigation.

We need to establish:

When was Lydac incorporated?

Who founded it?

Who were its directors?

Who were its shareholders?

Was Stephen Ray a director or shareholder?

Who financed the company?

What other intellectual property did it hold?

Did Andrew Chancellor ever become involved?

What eventually happened to the company?

And critically:

what happened to its intellectual property?

Because if Lydac controlled patents relevant to technology subsequently commercialised elsewhere, the movement of those rights matters enormously.

Natural Biosciences Has Not Disappeared From the Story

This discovery does not mean the Natural Biosciences evidence was irrelevant.

Quite the opposite.

A historical South African publication from 2011 describes:

“Natural Biosciences SA – a company with expertise in stem cell research and treatment”

and discusses Ray's work involving secretory factors produced by cells. ( Netcells )

The same article states that Natural Biosciences was treating patients on a compassionate basis in Germany and Switzerland and working with Netcells Cryogenics in South Africa. ( Netcells )

That is remarkable historical material.

It suggests that by 2011 , Ray's work was not confined simply to patents and laboratory theory.

It was being publicly associated with patient treatment.

But we must distinguish two separate propositions.

Lydac appears in the patent records.

Natural Biosciences appears in historical treatment and commercial material.

The relationship between those two organisations remains to be established.

Two Companies, One Scientist

We therefore have an intriguing situation.

Stephen Ray appears in the intellectual-property history associated with Lydac Neuroscience.

He also appears historically associated with Natural Biosciences SA.

And years later he appears as the senior scientific figure associated with Wellbeing International Foundation.

That gives us at least three corporate or organisational names surrounding the same broad scientific story:

Lydac Neuroscience Limited

↓

Natural Biosciences SA

↓

Wellbeing International Foundation

But I deliberately put no connecting arrows of ownership between them yet.

Because chronology is not proof of succession.

One organisation appearing after another does not establish that it acquired the first organisation's assets.

That connection must be demonstrated.

The Missing Document Is the Assignment

What we need now is remarkably specific.

Patent assignment records.

If Lydac owned the intellectual property and that technology subsequently became part of Wellbeing's commercial operation, there should potentially be a legal mechanism connecting the two.

An assignment.

A sale.

A licence.

An acquisition.

A transfer.

Or another contractual arrangement.

That document—or the absence of one—could become extremely important.

What We Need to Establish

The ownership investigation now has four distinct stages.

Stage One: Inventor

Stephen Ray is named as inventor.

That is documented. ( Justia Patents )

Stage Two: Early rights holder

Lydac Neuroscience Limited appears as applicant in the US record and proprietor/assignee in an official Canadian record. ( Justia Patents )

Stage Three: Natural Biosciences

Historical material connects Ray with Natural Biosciences SA and describes the organisation as involved in stem-cell research and treatment. ( Netcells )

Stage Four: Wellbeing International Foundation

Today, Ray's scientific history forms an important part of Wellbeing's presentation of the origins of its technology.

What remains missing are the legal bridges between those stages.

Another Patent Complicates the Story Further

Searching Ray's patent history produced something else.

The microvesicle application is not the only biological intellectual property associated with a Stephen Ray matching this research area.

Patent databases also identify earlier applications involving the administration of RNA.

One is titled:

Method Of Genotypically Modifying Cells By Administration Of RNA

The applicant is listed as:

Fischer Education Project Limited

with inventors:

Stephen Ray and Michael Fischer. ( Justia Patents )

Another is described as:

Method of Treatment by Administration of RNA.

Again, this broadens the historical intellectual-property footprint.

It suggests Ray's involvement with commercialisable biological inventions predates even the 2008 microvesicle priority applications.

That deserves its own investigation.

The Scientific History Is Becoming Longer

This is important because Wellbeing's current story can easily appear relatively recent.

A regenerative-medicine organisation.

Modern extracellular-vesicle science.

Cell-Free Therapy.

A longevity programme.

A 2026 peer-reviewed pilot.

But the intellectual-property trail we're uncovering stretches considerably further backwards.

RNA-related applications.

Microvesicles.

Lydac Neuroscience.

Natural Biosciences.

Patient treatments reportedly occurring in Europe by 2011.

Then the later commercial relationship involving Andrew Chancellor.

And eventually Wellbeing.

This does not demonstrate that every organisation used precisely the same therapy.

Nor does it establish uninterrupted ownership.

But it demonstrates something increasingly important:

the commercial history surrounding Ray's biological research appears to be much older and more complicated than the current Wellbeing brand.

Patients Were Apparently Being Treated Years Ago

The 2011 South African article deserves particular attention.

It describes Natural Biosciences as treating patients on a compassionate basis in Germany and Switzerland , reportedly with positive results. ( Netcells )

That raises a completely different set of questions.

Which patients?

Which diseases?

How many?

What exactly were they administered?

Who were the treating physicians?

Which clinics were involved?

Under which regulatory framework?

Were outcomes formally recorded?

Were adverse events recorded?

Were results subsequently published?

Were these the patients whose outcomes helped form the basis for later commercial claims?

These questions are potentially more important than the patents themselves.

Where Is the Clinical Dataset?

If patients were receiving related biological interventions by approximately 2011, then potentially fifteen years of clinical experience now separates those reported treatments from the present day.

That raises an obvious question:

Where is the dataset?

If dozens—or perhaps hundreds—of patients have subsequently received versions of this technology, there should potentially be substantial observational evidence.

Diagnosis.

Treatment protocol.

Dosage.

Follow-up.

Outcomes.

Failures.

Adverse events.

Duration of benefit.

Long-term consequences.

That information would be scientifically valuable.

Yet the peer-reviewed longevity pilot we investigated earlier involved only fourteen participants completing a multi-intervention programme.

That creates an intriguing contrast.

A technology with intellectual-property roots extending back toward 2008.

Historical reports of patients being treated by 2011.

Yet comparatively limited peer-reviewed human evidence presented publicly today.

That deserves explanation.

Then Andrew Chancellor Enters the Timeline

This is where our previous chapters reconnect.

Chancellor says he met Stephen Ray and eventually began discussing how Ray's research could be commercialised.

But we now know Ray's intellectual-property and commercial history already extended back years.

So the question becomes more precise:

At what point did Chancellor enter this existing structure?

Was Lydac still operating?

Was Natural Biosciences operating?

Who controlled the patents when Chancellor became involved?

Did Chancellor invest?

Did he acquire rights?

Did he establish a new organisation?

Was Wellbeing created around licensed technology?

Or did the technology pass into another entity first?

These are no longer vague historical questions.

We have names and patent numbers with which to investigate them.

The Investment Question Becomes Even More Important

Wellbeing is now raising investment capital.

That makes the intellectual-property chain particularly important.

An investor considering a biotechnology company should understand precisely what assets the company owns.

If the technology underpinning Cell-Free Therapy derives partly from patents originally held by another company, an investor would reasonably want to know:

Does Wellbeing own those rights today?

Does it have an exclusive licence?

How long does that licence last?

What territories does it cover?

Can it be terminated?

Are royalties payable?

Are patents still active?

Which parts of the current process are actually protected?

And what happens when the patents expire?

Those aren't hostile questions.

They are basic biotechnology due diligence.

The Expiration Question

There is another reason the dates matter.

The earliest British priority applications in this patent family date from 2008 . ( Justia Patents )

Patent terms are jurisdiction-specific and can be affected by later filings, divisionals, maintenance, extensions and other legal factors.

So we should not simply declare that every related patent expires on one particular date.

But a patent family with roots in 2008 naturally raises an important commercial question in 2026:

How much enforceable patent protection remains?

That becomes particularly relevant when valuing a company whose investment proposition may partly depend upon proprietary technology.

The exact status needs checking patent by patent and jurisdiction by jurisdiction.

What We Can Now Establish

The evidence has moved considerably beyond where we were two chapters ago.

We can now establish that Stephen Ray is named as inventor on a microvesicle patent application with roots in British priority filings from 2008. ( Justia Patents )

We can establish that Lydac Neuroscience Limited appears as applicant in the US patent record. ( Justia Patents )

An official Canadian patent publication identifies Lydac Neuroscience Limited as proprietor/assignee of a patent arising from the same PCT application. ( Publications Canada )

Historical material separately connects Ray with Natural Biosciences SA and reports that organisation as involved in stem-cell research and treatment. ( Netcells )

We can also establish that Ray's patent history includes earlier biological inventions involving RNA. ( Justia Patents )

What we cannot yet establish is the complete ownership chain connecting those entities to Wellbeing.

And that distinction matters.

Conclusion: We Found an Earlier Owner

Chapter Five asked:

Who owned the science?

We now have part of the answer.

The documentary record points toward Lydac Neuroscience Limited as an early corporate holder associated with Stephen Ray's microvesicle intellectual property. ( Justia Patents )

That is a significant development.

But it creates a larger mystery.

Because today it is Wellbeing International Foundation promoting Cell-Free Therapy.

Between those two points sit years of corporate history.

Natural Biosciences appears.

Patients were reportedly being treated.

Andrew Chancellor enters the story.

New organisations appear.

Investment capital becomes involved.

And somewhere along that journey, the technology—or technology descended from it—becomes part of today's Wellbeing proposition.

The investigation therefore has a very specific next task.

Follow the ownership.

Not the scientific claims.

Not the testimonials.

Not the biographies.

The legal ownership.

Because if we can determine what happened to Lydac Neuroscience and its intellectual property, we may finally be able to establish how Stephen Ray's science travelled from an early biotechnology company into the organisation now asking both patients and investors to put substantial amounts of money behind it.

Next: Chapter Seven — What Happened to Lydac Neuroscience?

The patent records identify Lydac Neuroscience Limited as an early holder of Stephen Ray's microvesicle intellectual property. Now we investigate the company itself: its directors, shareholders, finances, eventual fate—and where its intellectual property went.

The Men Behind Wellbeing — Chapter Five

Sun, 23 Aug 2026 05:53:52 GMT

Stephen Ray’s Microvesicle Patents: Following the Intellectual Property Behind Cell-Free Therapy

Wellbeing International Foundation credits Stephen Ray with decades of research behind its Cell-Free Therapy. This investigation has now located a patent trail stretching back to 2008. What does it actually prove—and what doesn't it prove?

In the previous chapter, I said the next stage of this investigation would be different.

Instead of following biographies, promotional articles and interviews, I wanted to follow something considerably harder to rewrite.

Patents.

Patent records leave dates.

They identify inventors.

They describe technologies.

They establish priority claims.

And sometimes they allow us to reconstruct the origins of a commercial technology long before the company currently selling it existed.

That search has now produced something important.

There really is a patent trail connected to a Stephen Ray of Bath, Great Britain , involving microvesicles, stem cells, autologous biological material and potential therapeutic applications.

And the history appears to begin much earlier than Wellbeing International Foundation.

US Patent Application 20160032322 — Microvesicles

The Patent Is Real

The US patent record identifies an application titled simply:

“Microvesicles.”

The named inventor is:

Stephen Ray — Bath, Great Britain.

The US publication number is US 2016/0032322 .

But 2016 is misleading if we are trying to establish when the underlying intellectual property originated.

The application explains that it is part of a much older patent family.

It traces backwards through a US application filed in 2010 to an international application:

PCT/GB09/00004

filed on 2 January 2009 .

That application, in turn, claimed priority from two British applications:

GB 0800107.5 — filed 4 January 2008

and

GB 0804932.2 — filed 17 March 2008.

Read the patent history and specification

This is significant.

Because whatever eventually became Wellbeing's present commercial operation, the documented intellectual-property story surrounding Ray's microvesicle work appears to reach back approximately 18 years .

What Did Stephen Ray Claim to Have Invented?

The patent is technically complex, but the central idea can be simplified.

It concerns producing autologous microvesicles .

Autologous means biological material originating from the same individual who ultimately receives it.

The patent describes taking cells, influencing or inducing them in particular ways, harvesting microvesicles produced by those cells and potentially using those microvesicles—or derivatives of them—to affect other cells or for therapeutic purposes. ( Patents Encyclopedia )

That should sound familiar to anyone who has followed this investigation.

Because there are obvious conceptual similarities with the language now surrounding Wellbeing's Cell-Free Therapy.

But similarity is not enough.

We need to be careful about claiming that today's commercial CFT product is identical to what this patent describes.

That connection needs to be established separately.

The Patent Talks About Regeneration and Rejuvenation

The language becomes particularly interesting deeper inside the patent.

The specification discusses potential applications involving:

tissue repair

regeneration

rejuvenation

and various therapeutic uses.

It also contemplates administration of biological products through routes including intravenous administration . ( Patents Encyclopedia )

Again, the resemblance to some of the terminology used today in regenerative medicine is striking.

But there is an essential distinction.

A patent is not clinical proof.

That point cannot be overstated.

A Patent Does Not Prove That a Treatment Works

Patients can easily misunderstand what a patent represents.

A patent is fundamentally an intellectual-property instrument.

It can protect an invention.

It can establish priority.

It can prevent competitors from exploiting protected claims.

It can become a valuable corporate asset.

But obtaining or applying for a patent does not establish that a medical treatment has been demonstrated to be safe and effective in humans.

Patent examination is not the same thing as a randomised controlled clinical trial.

It is not regulatory approval.

It is not independent clinical validation.

It is not evidence that a treatment cures disease.

This distinction becomes extremely important if patents are ever presented to patients or investors as evidence that the underlying therapy is medically proven.

The Patent Goes Much Further Than Today's Marketing

The specification is extraordinarily broad.

It discusses potential applications involving disorders associated with cell deficiency and differentiation.

It refers to traumatic injury.

Brain injury.

Age-related degeneration.

Infertility.

Cancer-related applications.

Cosmetic applications.

Physical enhancement.

Cognitive enhancement.

And tissue repair and rejuvenation. ( Patents Encyclopedia )

But patent documents frequently describe broad possible embodiments and applications.

That does not mean every proposed application has subsequently been demonstrated in human clinical trials.

This is precisely why patents and clinical evidence must remain separate.

An Experiment Raises Another Question

The patent specification also describes experimental work involving animals.

One example discusses age-related cognitive decline and reports an experiment involving microvesicles and laboratory animals.

The patent characterises the results positively and then refers to other work from the laboratory as unpublished . ( Patents Encyclopedia )

That immediately raises another investigative question.

Where is the subsequent scientific publication?

If these experiments formed part of the scientific foundation for a technology eventually administered to paying humans, we need to determine whether the underlying experiments were ever:

peer reviewed;

independently replicated;

published in full;

or followed by controlled human clinical trials.

A patent can tell us an experiment was described.

It cannot substitute for the scientific scrutiny of publishing the underlying research.

The Timeline Has Now Changed

This discovery changes our understanding of the chronology.

We previously knew that Wellbeing's present commercial organisation developed later.

We knew Chancellor says he met Ray and eventually began discussing commercialisation.

But the patent priority record takes Ray's microvesicle work back to 2008 .

That means the science—or at least the intellectual-property claims surrounding it—predates the present Wellbeing operation by years. ( Patents Encyclopedia )

The chronology now looks something like this:

2008 — British priority applications

2009 — international PCT application

2010 — US national-phase application

2015 — later US divisional filing

2016 — US publication

and subsequently further patent-family activity appears in the records. ( Patents Encyclopedia )

This is much more useful than a company biography.

We now have documentary dates.

Natural Biosciences Appears Again

Then something particularly interesting happens.

In Chapter Four, I identified historical material referring to a company called Natural Biosciences SA .

That material described Stephen Ray as leading a team responsible for generating an extensive portfolio of patents and intellectual property associated with Natural Biosciences.

At the time, I deliberately treated that claim cautiously because the material survives through a third-party-hosted presentation rather than a primary corporate archive.

Historical presentation referencing Stephen Ray and Natural Biosciences SA

But we have now found something else.

A separate historical publication from South Africa describes:

“Dr Stephen Ray, chief scientist at Natural Biosciences SA”

and also identifies him at the time as a senior lecturer in Clinical Physiology at Oxford Brookes University.

That publication discusses adipose-derived stem cells and regenerative therapies. ( Netcells )

Historical article identifying Stephen Ray with Natural Biosciences SA

That gives the Natural Biosciences connection considerably more weight.

We now have more than one historical source connecting a Stephen Ray working in this scientific area with Natural Biosciences SA .

But the next question is the important one.

Did Natural Biosciences Own the Patents?

This is where I am not yet prepared to jump ahead of the evidence.

The patent record establishes Stephen Ray as inventor.

Historical material connects Ray with Natural Biosciences SA.

Another historical document claims Natural Biosciences applied for intellectual property developed by Ray's team. ( Patents Encyclopedia )

But those facts do not automatically establish the entire ownership chain.

We now need the assignment records.

Who was the original applicant?

Were the rights assigned?

To whom?

Was Natural Biosciences the owner?

Did another company acquire the intellectual property?

Did Wellbeing subsequently acquire or license it?

Does Ray personally retain any rights?

These are now answerable questions.

Inventor and Owner Are Not the Same Thing

This distinction matters enormously.

A patent can identify Stephen Ray as inventor while the commercial rights belong to somebody else.

Scientists frequently assign inventions to employers.

Universities own patents generated by researchers.

Biotechnology companies acquire patents.

Investors finance companies that own intellectual property.

Licences can grant commercial rights without transferring ownership.

Therefore:

Stephen Ray being named as inventor does not necessarily mean Stephen Ray owns the patent.

We need the ownership trail.

Does Wellbeing Own the Technology?

This is perhaps the most commercially important question raised by the discovery.

Wellbeing's business depends upon technology it presents as proprietary and developed from years of research.

If that technology is protected by patents originating from Ray's earlier work, investors and patients deserve to understand the relationship.

Does Wellbeing International Foundation own those patents?

Does it license them?

Does another company own them?

Are the relevant patents still active?

Which jurisdictions are protected?

Do the claims actually cover the current manufacturing process?

Those are due-diligence questions—not accusations.

And they become particularly important now that Wellbeing is actively presenting itself as an investment opportunity.

The Investment Story Changes

This is where our two investigations begin to intersect.

Earlier, we examined Wellbeing's announcement that it had closed the first tranche of its 2026 investment round.

Investors considering a biotechnology business are not simply investing in a charismatic management team.

One of the most valuable assets in biotechnology can be intellectual property .

If the company's competitive advantage depends upon technology developed by Stephen Ray, then an investor would reasonably want to know:

Who owns it?

How long is it protected?

Where is it protected?

What exactly do the claims cover?

Are there competing patents?

Have rights expired?

Are licences exclusive?

Can the intellectual property be transferred?

And does the company raising the investment actually control the technology upon which its valuation depends?

Those are fundamental investment questions.

Another Important Distinction: Patent Claims Versus Today's CFT

We also need to establish whether the patent technology is actually the technology currently being used.

The patent focuses heavily on microvesicles .

Wellbeing's current terminology discusses Cell-Free Therapy, conditioned media, extracellular vesicles and biological signalling factors.

There may be substantial overlap.

There may also be important differences.

Manufacturing processes evolve.

Scientific terminology changes.

Patent claims may cover only particular methods.

A commercial product may use additional processes developed later.

So I am not yet saying:

“This patent is Wellbeing's Cell-Free Therapy.”

What we can say is:

Stephen Ray is named as inventor on a patent family concerning autologous microvesicles and their potential therapeutic use, with priority dating to 2008.

That is established.

Whether and how those claims map onto today's CFT needs further investigation. ( Patents Encyclopedia )

Something Else Has Become Clear

This discovery also corrects an important weakness in earlier investigations of Stephen Ray.

Ray's scientific footprint is not nonexistent.

There is a genuine intellectual-property record carrying his name in an area directly relevant to microvesicles and regenerative medicine.

That should be acknowledged.

An investigation should correct itself when better evidence appears.

The question is no longer:

Did Stephen Ray ever work on this technology?

The patent evidence strongly supports that he did.

The better questions are:

How scientifically validated was that work?

Who owned it?

What happened to it?

And how did it become today's commercial therapy?

Those are much stronger investigative questions.

Patents Are Evidence of Invention, Not Evidence of Efficacy

This distinction should remain at the centre of everything that follows.

The patent trail strengthens Ray's claim to have been working with microvesicle technology many years ago.

It does not prove Wellbeing's current treatment works.

Those are completely different evidential questions.

To establish efficacy, we still need clinical evidence.

Controlled trials.

Adequate patient numbers.

Appropriate endpoints.

Independent replication.

Transparent adverse-event reporting.

Peer-reviewed results.

Regulatory scrutiny.

The longevity pilot we previously investigated contained only fourteen completing participants and combined multiple interventions, making attribution to Cell-Free Therapy impossible.

A patent from 2008 does not solve that problem.

The Questions Chapter Five Leaves Behind

We now have several concrete investigative targets.

Who originally owned the Ray patent family?

What was Natural Biosciences SA's legal identity?

Who owned Natural Biosciences?

Was Andrew Chancellor involved?

When did Chancellor and Ray begin working together?

Were the patents assigned or licensed?

Where are those rights today?

Does Wellbeing control them?

Are they included among the assets supporting Wellbeing's current investment proposition?

And perhaps most importantly:

What human clinical evidence exists connecting the technology described in these patents with the treatment being sold to patients today?

Those questions can now be investigated using documents rather than promotional claims.

Conclusion: We Found the Patent Trail

For the first time in this part of the investigation, we have reached something concrete.

A Stephen Ray in Bath is named as inventor of a microvesicle patent family.

The priority trail reaches back to 2008 .

The invention discusses autologous microvesicles.

It discusses therapeutic applications.

It discusses regeneration and rejuvenation.

It contemplates intravenous administration.

And historical material independently connects Stephen Ray with Natural Biosciences SA and stem-cell research. ( Patents Encyclopedia )

That is significant.

It means there is genuine historical intellectual property behind at least part of the scientific story being told.

But it also opens a much bigger door.

Because now that we have found the invention, we can start asking:

Who owned it?

Who financed it?

Who acquired it?

Who controls it today?

And what evidence transformed an interesting patented biological concept into a treatment being offered to human patients?

Those questions matter not only to patients.

They matter enormously to investors.

Because if Wellbeing is now asking people to invest in the future of its regenerative-medicine business, one of the first things any serious investor should establish is remarkably simple:

Does the company actually own—or securely control—the intellectual property its future depends upon?

Next: Chapter Six — Who Owns the Science?

The patent exists and Stephen Ray is named as inventor. Now we follow the ownership trail through Natural Biosciences and any subsequent companies to determine who controlled the intellectual property—and whether Wellbeing controls it today.

Andrew Chancellor and Stephen Ray: Where Business Met the Science The Men Behind Wellbeing — Chapter Four

Sun, 23 Aug 2026 05:44:15 GMT

How the partnership between businessman Andrew Chancellor and scientist Stephen Ray helped transform biological research into the commercial operation that became Wellbeing International Foundation.

Every biotechnology company needs two things.

Science capable of producing something valuable.

And somebody capable of turning that science into a business.

In the history of Wellbeing International Foundation, those two roles appear to have been occupied by two very different men.

Stephen Ray brought the science.

Andrew Chancellor brought the business.

That isn't my interpretation alone.

It is remarkably close to the story Chancellor himself now tells.

After years in banking and international recruitment, Chancellor says he met Stephen Ray, became fascinated by his work and eventually began discussing something that would change the direction of both men's careers:

How could Ray's research be commercialised?

FounderAt — Andrew Chancellor discusses meeting Stephen Ray and commercialising the research

That word— commercialise —takes us to the heart of this chapter.

Because this investigation is no longer simply asking where Wellbeing's science came from.

We need to understand how that science became a product.

The Scientist and the Businessman

Wellbeing currently identifies Stephen Ray as its Senior Scientific Consultant .

Its biography credits him with more than thirty years of academic and commercial research experience in cell therapy and refers to previous academic positions at Oxford Brookes University and the Carrick Institute.

Andrew Chancellor, meanwhile, is identified as Chief Executive Officer , with a background beginning in international banking before moving through recruitment and ultimately healthcare and bioscience.

Wellbeing International Foundation — Leadership and research team

The distinction is striking.

Ray's stated expertise is scientific.

Chancellor's is commercial.

And according to Chancellor, those two worlds came together almost accidentally.

Andrew Chancellor Says He Entered a World He Knew Little About

Chancellor has now written publicly about this transition himself.

In an article titled “From Banking to Bioscience: The Unlikely Evolution of Andrew Chancellor,” he describes meeting Ray as the event that pushed him into a scientific world he initially knew little about.

Andrew Chancellor — “From Banking to Bioscience”

That is an important admission rather than necessarily a damaging one.

Biotechnology companies routinely combine scientific founders with commercially experienced executives.

Scientists may understand the technology but lack experience raising capital, building companies, negotiating partnerships or developing international markets.

Businesspeople can provide exactly those skills.

The interesting question isn't why Ray needed Chancellor.

It is:

What exactly did they build together?

From Conversation to Commercialisation

Chancellor gives us part of the answer.

In a recent interview he explained:

“What began as casual conversations evolved into structured discussions about how to commercialise the research responsibly…”

Read Chancellor's full FounderAt interview

That is one of the most important statements we have uncovered about the origins of Wellbeing.

The research apparently existed first.

Then came the commercial question.

How could it be turned into something capable of being delivered to patients?

How could an organisation be built around it?

How could it operate internationally?

How could clinicians become involved?

And ultimately, how could the science generate revenue?

There is nothing inherently improper about any of those questions.

That is how biotechnology businesses are created.

But it means the origins of Wellbeing should be examined not only as a scientific story.

They are also a commercial story .

What Exactly Was Stephen Ray's Research?

This is where the history becomes considerably more important.

Wellbeing attributes the scientific origins of its approach to work carried out by Stephen Ray over many years.

Its current materials describe Ray as having extensive experience in cell therapy and position his research as central to the development of what eventually became Cell-Free Therapy.

The basic concept is that cells release biological signalling substances—including extracellular vesicles, cytokines and growth factors—which may influence repair and cellular behaviour.

Rather than administering the living cells themselves, Wellbeing's approach involves producing and administering a preparation containing substances released by those cells.

This is scientifically interesting territory.

Extracellular vesicles and cellular secretomes are genuine areas of biomedical research.

But the existence of a scientific field does not automatically validate a particular commercial therapy.

That distinction has remained central throughout this investigation.

The Intellectual Property Question

Once Chancellor and Ray began discussing commercialisation, another question inevitably arose.

Who owned the science?

Scientific discoveries intended for commercial development are often protected through intellectual property.

Patents.

Patent applications.

Proprietary laboratory processes.

Trade secrets.

Licensing agreements.

Manufacturing protocols.

If Ray had developed processes capable of producing commercially valuable biological preparations, ownership of those processes could potentially become enormously valuable.

And this is where an older document uncovered during this investigation becomes particularly interesting.

A 2016 Document Points Toward Natural Biosciences SA

I located a presentation preserved online that appears to contain historical Wellbeing-related material dating from approximately 2016.

Within that material, Stephen Ray is described as having led a team responsible for generating:

“an extensive portfolio of patents and intellectual properties”

associated with a company called Natural Biosciences SA .

The same material describes Andrew Chancellor as Chief Executive Officer with responsibility for taking the organisation from a research-and-development group toward a commercial medical-science company.

If authentic, this could be extremely important.

Because suddenly we have another corporate name entering the story:

Natural Biosciences SA.

But I need to be very clear about the evidential status.

This Is a Lead, Not Yet a Finding

The document I found is not currently hosted on an official Wellbeing website.

It appears inside a third-party presentation preserved online.

That means I am not yet treating every statement contained within it as independently established fact .

Before relying upon it conclusively, we need to determine:

Who created the original material?

When was it produced?

Was it genuinely supplied by Wellbeing or its predecessors?

What was Natural Biosciences SA?

Where was it incorporated?

Who were its directors?

Who were its shareholders?

What patents did it own or apply for?

And what relationship did it have with Stephen Ray and Andrew Chancellor?

Until those questions are answered, Natural Biosciences remains an investigative lead.

But potentially a very important one.

Follow the Intellectual Property

This gives us another route into the history.

Rather than merely searching for companies associated with Chancellor, we can follow the technology itself.

If Ray generated patents, those patents should potentially leave records.

Patent applications identify inventors.

They identify applicants.

They contain dates.

They can identify companies.

They can show changes of ownership.

They may identify jurisdictions.

And sometimes they reveal precisely when scientific research became a commercial asset.

That trail could tell us considerably more than executive biographies.

Who Was the Inventor?

The first question is straightforward.

Which patents identify Stephen Ray as an inventor?

Who Owned Them?

Was the applicant Ray personally?

Natural Biosciences SA?

Another company?

Wellbeing?

A laboratory?

An investor-controlled entity?

Where Did the Intellectual Property Go?

If the technology was originally owned elsewhere, was it subsequently licensed or transferred to Wellbeing?

And if so:

When?

For how much?

Under what agreement?

Those are potentially crucial questions when trying to understand who owns the technology underlying a treatment being offered commercially today.

The Corporate History May Predate Wellbeing

This is becoming increasingly important.

Chancellor says he has led Wellbeing for approximately nine years.

Wellbeing's current biography says he has worked in healthcare and bioscience for approximately fifteen years.

That suggests the commercial relationship surrounding this science may predate the present Wellbeing operation.

If Natural Biosciences—or another predecessor organisation—was involved earlier, then the real history of Cell-Free Therapy may extend through several corporate structures.

That isn't necessarily unusual.

Biotechnology projects often migrate through companies as investment rounds change, intellectual property is transferred and new commercial structures are created.

But it means we need to identify those structures.

Then We Found Something Else From 2016

The same historical material contains something potentially even more significant.

It reproduces what appears to be an email exchange involving Andrew Chancellor and an NHS healthcare professional concerning a patient with idiopathic pulmonary fibrosis .

The healthcare professional asks for evidence concerning outcomes in patients with that condition.

The reproduced response from Chancellor says that first consultations were complimentary but appears reluctant to provide information before meeting the prospective patient.

Again, I am deliberately being cautious.

The material requires authentication before I would publish the correspondence as established fact.

But if authenticated, it could show Chancellor interacting with prospective patient enquiries as early as 2016 .

That would make the questions raised in Chapter Two about patient assessment considerably more historically significant.

This would not simply be about what Chancellor does today.

It could potentially establish a patient-facing role extending back a decade.

The Science Was Already Becoming a Business

What is beginning to emerge is a clearer picture of the transition.

Stephen Ray appears to have been developing biological research.

Andrew Chancellor entered the relationship from banking and recruitment.

Chancellor says they began discussing how to commercialise Ray's work.

An organisation developed around that objective.

Patients eventually entered the picture.

And today Wellbeing operates internationally, working with clinicians, laboratories and commercial partners to deliver Cell-Free Therapy.

That is the broad story.

But enormous gaps remain.

Who Funded the Early Development?

Research costs money.

Laboratories cost money.

Patent applications cost money.

Clinical development costs money.

Staff cost money.

International expansion costs money.

So who financed the Chancellor–Ray project during its early years?

Was it Chancellor?

Ray?

Private investors?

Corporate investors?

Patient revenue?

Philanthropic funding?

Another company?

This becomes especially relevant given Wellbeing's recent move into raising investment capital.

If today's investors are being offered an opportunity based partly upon technology developed years earlier, understanding who financed and owns that technology becomes basic due diligence.

Where Does Stephen Ray's Ownership Begin and End?

Another question now needs answering.

Was Stephen Ray merely the scientist?

Or did he hold equity in the businesses commercialising his research?

Was he an inventor?

Shareholder?

Director?

Consultant?

Licensor?

Employee?

Those distinctions matter.

A scientist paid to advise a company occupies a very different commercial position from an inventor who owns the underlying intellectual property.

And if ownership changed over time, we need to understand how.

The Relationship Has Lasted for Years

Whatever the precise corporate arrangements, one thing is clear from Chancellor's own public account.

His relationship with Ray has lasted for years.

Chancellor describes their working relationship in unusually warm terms, saying they came from completely different professional worlds but formed an immediate and enduring partnership.

That makes Ray more than simply another consultant in the Wellbeing story.

He appears to be central to Chancellor's entire transition into bioscience.

Without Ray, there may have been no scientific proposition.

Without Chancellor, there may have been no commercial organisation built around it.

That makes understanding their relationship essential.

The Question Is No Longer “Who Is Andrew Chancellor?”

We now know considerably more about Chancellor.

He came from banking and recruitment.

He met Stephen Ray.

He became interested in Ray's science.

He began discussing its commercialisation.

He eventually became CEO of the organisation delivering the resulting intervention.

The question has changed.

It is now:

What exactly was commercialised?

Who developed it?

Who owned it?

Who financed it?

What companies controlled it?

What evidence supported it at the point patients began paying for it?

And how did those early arrangements evolve into Wellbeing International Foundation?

Those questions take us beyond biographies.

They take us into corporate records, patent databases and historical documents.

Conclusion: Where Science Became a Commercial Proposition

There is nothing unusual about a scientist working with a businessman.

In fact, biotechnology depends upon exactly that partnership.

Scientific discoveries rarely reach patients without capital, management, regulatory expertise and commercial organisation.

But that relationship deserves scrutiny when the resulting intervention is sold to patients for substantial sums while its clinical evidence remains developing.

Stephen Ray appears to provide the scientific foundation of the Wellbeing story.

Andrew Chancellor appears to have provided much of the commercial machinery.

And Chancellor himself acknowledges that their early conversations became discussions about commercialising the research .

That gives us the next investigative target.

Not the marketing.

Not the testimonials.

Not even the treatment.

The intellectual property.

Because patents do something biographies cannot.

They leave dates.

They leave names.

They leave owners.

And they leave a documentary trail.

If the scientific technology behind Cell-Free Therapy passed through Natural Biosciences SA or other companies before reaching Wellbeing, that trail may allow us to reconstruct exactly how the science became the business.

And perhaps, finally, determine who actually owns what patients are being sold today.

Next: Chapter Five — Follow the Patents

Stephen Ray is credited with decades of cell-therapy research. Now we search the patent record: what did he actually invent, who owned the intellectual property, and how did it reach Wellbeing International Foundation?

The Men Behind Wellbeing — Chapter Three

Sun, 16 Aug 2026 08:16:31 GMT

Following Andrew Chancellor’s Corporate Trail: From Recruitment to Regenerative Medicine

Andrew Chancellor’s public biography tells us where he started and where he is today. But what happened in between? This chapter begins following the corporate trail behind the CEO of Wellbeing International Foundation.

By Steven

When investigating the people behind an organisation, biographies can only take you so far.

They tell you what somebody wants the public to know.

They provide the highlights.

They simplify decades of professional history into a few paragraphs.

But they rarely tell you everything.

That is why, after examining Andrew Chancellor's involvement in the patient journey, I wanted to go backwards.

Before Cell-Free Therapy.

Before Wellbeing International Foundation.

Before regenerative medicine.

Who was Andrew Chancellor?

And what does the documentary record tell us about the businessman who eventually became CEO of an organisation operating in experimental and emerging biological medicine?

The answer begins somewhere considerably more conventional.

Financial recruitment.

Andrew Chancellor Before Wellbeing International Foundation

Wellbeing's current biography describes Chancellor as having built a career in banking and recruitment across Europe and Asia before moving into bioscience alongside Stephen Ray.

Today, Wellbeing identifies him simply as its Chief Executive Officer , responsible for the organisation's commercial strategy. ( Wellbeing International Foundation )

Wellbeing International Foundation — About and Leadership

That account can be independently tested.

And when we go back almost a quarter of a century, Andrew Chancellor begins appearing in the financial recruitment press.

In 2004, eFinancialCareers identified an Andrew Chancellor as Managing Director of the Financial and Professional Services Division at Robert Walters , discussing recruitment within corporate finance. ( eFinancialCareers )

By January 2005, the same publication described Chancellor as Managing Director of Financial Services at Robert Walters , commenting on salaries and bonuses within London's corporate-finance market. ( eFinancialCareers )

Then, in February 2007, recruitment publication Onrec identified Andrew Chancellor as the London-based head of the banking and finance team at Robert Walters . ( Onrec )

Onrec — Asian Expertise Filling Corporate Finance Gaps, February 2007

This gives us something valuable.

Independent contemporary evidence supports an important part of Chancellor's stated professional history.

Before regenerative medicine, he was a senior figure within financial recruitment.

A Career Built in Business, Not Medicine

There is nothing sinister about this history.

Quite the opposite.

The documentary evidence suggests Chancellor had achieved senior positions within a major international recruitment company.

But it reinforces the distinction established in the earlier chapters.

His professional foundations were in business and recruitment , not medicine.

The evidence I have found does not show an early career treating patients.

It doesn't show medical-school training.

It doesn't show a career in clinical research.

Instead, it shows somebody working at a senior level within the commercial world.

That distinction becomes important when we examine what happened next.

Because eventually Andrew Chancellor met Stephen Ray.

And Chancellor's professional direction changed dramatically.

The Meeting With Stephen Ray

Chancellor has publicly described meeting Stephen Ray as the moment that ultimately brought him into bioscience.

In a recent interview, he described Ray as the researcher behind Wellbeing's science and explained that the two came from very different professional backgrounds.

What began as discussions about the underlying biology eventually became discussions about how to commercialise the research and build an organisation capable of bringing it into clinical use. ( Founder@ )

FounderAt — Andrew Chancellor on the Origins of Wellbeing

This is one of the most important statements I have found in Chancellor's own account.

Because it provides the bridge.

Science met business.

Ray apparently brought the scientific research.

Chancellor brought commercial experience.

And the discussion became not simply:

Does this science work?

But:

How do we commercialise it?

There is nothing inherently improper about commercialising scientific research.

Virtually every pharmaceutical and biotechnology company ultimately has to answer exactly that question.

But once commercialisation begins, another series of questions follows.

Who owns the technology?

Who owns the intellectual property?

Which companies were established?

Who invested?

Who became directors?

Where was the research conducted?

And how did those early commercial arrangements eventually evolve into today's Wellbeing International Foundation?

That is the corporate trail we now need to reconstruct.

Wellbeing’s Own History Confirms the Transition

Interestingly, Wellbeing's own historical material describes Chancellor's arrival in remarkably similar terms.

The organisation says Chancellor joined the work following a career that had moved through banking and international recruitment.

According to Wellbeing, he became interested in whether the active biology associated with cells could be extracted and reliably reproduced as a therapeutic preparation. ( Wellbeing International Foundation )

Wellbeing — Its Account of the Organisation's Research Heritage

That account is useful because it again places Chancellor's arrival after the underlying scientific work had begun .

He appears in the story as the businessman entering an existing scientific field.

This is consistent with his own description of meeting Ray.

When Did Andrew Chancellor Enter Bioscience?

This is where the timeline becomes interesting.

Wellbeing's public LinkedIn profile states that the organisation was founded in 2015 . ( LinkedIn )

Wellbeing International Foundation — LinkedIn Company Profile

However, recent public biographies of Chancellor describe him as having nearly a decade in bioscience leadership . ( Acquisition International )

Other Wellbeing material describes his involvement in healthcare and bioscience over a longer period.

This does not necessarily represent a contradiction. Organisations evolve, corporate structures change, and scientific projects can exist for years before a particular company is created.

But it leaves an important period that needs to be reconstructed.

What exactly existed before Wellbeing?

The Missing Corporate Bridge

We know where Chancellor was in the mid-2000s.

Financial recruitment.

We know where he is today.

CEO of Wellbeing International Foundation.

And we know that somewhere between those points he met Stephen Ray and became involved in commercialising biological research.

What remains considerably less obvious is the corporate bridge between those worlds.

Which businesses was Chancellor involved with during that transition?

Which were biotechnology companies?

Which involved Stephen Ray?

Who owned them?

Who financed them?

Were investors brought in?

Did those companies own intellectual property?

Did that intellectual property subsequently move?

Were companies dissolved or replaced?

Were new corporate structures established in different jurisdictions?

Those questions matter because today's Wellbeing organisation did not simply appear from nowhere.

There must be a commercial history behind it.

Then a Companies House Record Appeared

During the investigation, one particular UK corporate record attracted my attention.

Companies House contains a company originally called Illuminate Technologies UK Limited , company number 11201475 .

The company is now called ITUKL Realisations Limited .

Its filing history contains a February 2022 entry explicitly referring to:

“Director's details changed for Mr Andrew Chancellor.” ( Company Information Service )

UK Companies House — ITUKL Realisations Limited Filing History

The company subsequently entered administration.

Its Companies House record contains administrator documentation and continuing insolvency-related filings. ( Company Information Service )

At first sight, this looked potentially significant.

An Andrew Chancellor.

A directorship.

A technology company.

And a company that later entered administration.

But this is exactly where an investigation can go badly wrong.

The Andrew Chancellor Identity Problem

There are multiple people named Andrew Chancellor.

A search for the name produces businessmen, academics, doctors and scientists.

LinkedIn search results alone show numerous individuals with that name, including a medically qualified Andrew Chancellor in New Zealand and an Andrew Chancellor with a PhD associated with biomedical research. ( LinkedIn )

That creates a serious evidential problem.

A matching name is not proof of identity.

I cannot responsibly state that the Andrew Chancellor recorded as a director of Illuminate Technologies UK Limited is Wellbeing's Andrew Chancellor unless that connection can be independently established.

A date of birth could establish it.

An address could establish it.

A CV could establish it.

Another corporate filing could establish it.

An archived biography could establish it.

But the name alone cannot.

For that reason, the Illuminate record currently remains:

IDENTITY MATCH NOT YET ESTABLISHED.

That distinction is important.

Why Publish an Unconfirmed Lead?

Because this investigation is also intended to demonstrate how evidence should be handled.

It would be extremely easy to write:

“Andrew Chancellor was director of a technology company that went into administration.”

It would certainly make a dramatic headline.

But without proving that the director is the same Andrew Chancellor, it could also be completely wrong.

Investigative journalism cannot work that way.

First find the evidence.

Then authenticate it.

Then attempt to disprove your own theory.

Only after that should you publish the conclusion.

So Illuminate remains a lead.

Not a finding.

Even a Confirmed Directorship Would Not Prove Responsibility

There is another equally important safeguard.

Suppose we eventually prove that Wellbeing's Andrew Chancellor was indeed a director of Illuminate.

That still would not establish that he caused the company's insolvency.

Businesses fail for countless reasons.

Funding disappears.

Customers leave.

Markets change.

Technology fails.

Investors withdraw.

Management strategies fail.

Economic circumstances intervene.

The correct questions would then become:

When was Chancellor appointed?

What position did he hold?

When did he leave?

Was he still involved when the financial problems developed?

What did the administrators identify as the causes of failure?

Were any directors criticised?

Were transactions challenged?

Did administrators allege misconduct?

Was Chancellor personally criticised?

Only those documents could establish the significance—if any—of his involvement.

The Public Andrew Chancellor Profile Is Growing

Something else has happened recently.

Chancellor's public media profile has expanded.

In 2026, articles carrying his byline have appeared in business publications discussing international expansion, leadership and healthcare management.

Acquisition International describes him as CEO of Wellbeing International Foundation and specifically references his career across banking, international executive recruitment and bioscience leadership . ( Acquisition International )

Acquisition International — Andrew Chancellor on Global Expansion

EU Business News provides essentially the same career description. ( EU Business News )

EU Business News — Andrew Chancellor on Human-Centred Growth

This consistency is useful.

It strengthens the broad outline of his professional history.

But it still doesn't fill the missing corporate years.

Chancellor Is Now Telling His Own Story

There is another development worth noting.

Chancellor now has his own author profile on Vocal.

The biography describes him primarily as a figure in international recruitment and executive search .

Among the pieces published under his name is one titled:

“From Banking to Bioscience: The Unlikely Evolution of Andrew Chancellor.”

Another discusses Wellbeing's history and sports-related treatment claims. ( Vocal )

Andrew Chancellor's Vocal Author Profile

Again, this is useful material.

But it is important to distinguish self-published or promotional biography from independent evidence .

Chancellor's own account tells us how he describes his history.

Contemporary recruitment reports tell us what can independently be established.

Companies House tells us which corporate appointments can be proven.

Court and insolvency records tell us what happened when businesses encountered problems.

Those different types of evidence should never be treated as interchangeable.

The Corporate Investigation Now Changes Direction

At this stage, we have established something quite clearly.

Andrew Chancellor did not emerge from a traditional medical career.

He emerged from the commercial world.

Contemporary reporting places him in senior financial recruitment roles at Robert Walters during the 2000s. ( eFinancialCareers )

His own account says that meeting Stephen Ray ultimately led to discussions about commercialising scientific research. ( Founder@ )

Wellbeing's own history broadly confirms that transition. ( Wellbeing International Foundation )

And today Chancellor leads the organisation's commercial strategy. ( Wellbeing International Foundation )

The beginning and the end of the story are therefore relatively clear.

The middle is not.

The Questions We Need to Answer Next

The next stage is no longer about Andrew Chancellor's CV.

It is about the businesses surrounding the science.

Which companies first connected Chancellor and Stephen Ray?

Who owned those companies?

Where did their money come from?

What intellectual property did they control?

Which laboratories were involved?

Which investors participated?

What happened to those businesses?

And most importantly:

How did the science being discussed between Chancellor and Ray become the commercial Cell-Free Therapy operation being promoted today?

That is where the corporate history becomes relevant to the medical investigation.

Conclusion: Follow the Companies, Not the Biography

Andrew Chancellor's move from recruitment into biotechnology is not evidence of wrongdoing.

Nor is commercialising scientific research inherently suspicious.

Biotechnology exists because scientists, entrepreneurs and investors work together to turn discoveries into products.

But when an organisation eventually asks patients to spend substantial sums on an emerging biological intervention, understanding the commercial history behind that organisation becomes legitimate due diligence.

Who developed the science?

Who financed it?

Who owned it?

Who commercialised it?

Which companies came before the current organisation?

And what happened to them?

Those questions cannot be answered by a polished executive biography.

They require documents.

Corporate filings.

Historical records.

Accounts.

Directorships.

Shareholdings.

And where appropriate, insolvency and court records.

That is precisely where this investigation now goes.

Because somewhere between Andrew Chancellor the financial recruiter and Andrew Chancellor the CEO of a regenerative-medicine organisation lies the story we still need to uncover.

And the next person standing directly in the middle of that story is:

Stephen Ray.

Next: Chapter Four — Chancellor & Ray: Where Business Met the Science

What happened when a businessman specialising in finance and recruitment met the scientist behind Wellbeing's biological research—and which companies, intellectual property and commercial relationships came out of that partnership?

THE MEN BEHIND WELLBEING — Chapter Two

Sun, 16 Aug 2026 08:13:41 GMT

The Gatekeeper

An investigation into Andrew Chancellor, Wellbeing International Foundation and the question of who actually determines whether a prospective patient is suitable for Cell-Free Therapy.

There is a moment when every discussion about regenerative medicine stops being theoretical.

A real patient makes contact.

They may be frightened. They may be living with a chronic or degenerative condition. They may have exhausted conventional treatment options. Or they may simply be searching for something that could improve their quality of life.

And they ask the question that matters most:

Can this treatment help me?

For an organisation such as Wellbeing International Foundation, the answer to that question carries considerable responsibility.

Cell-Free Therapy isn't simply an interesting scientific concept. It is something being offered to paying patients.

During the prospective-patient enquiry examined as part of this investigation, the potential cost reached approximately £37,000 .

So before somebody commits that kind of money, another question becomes extremely important:

Who decides whether they are suitable for treatment?

That question takes us directly back to Wellbeing's Chief Executive Officer, Andrew Chancellor .

Wellbeing Says It Selects Its Patients

Andrew Chancellor has publicly explained that Wellbeing does not simply accept everyone who approaches the organisation.

In an interview discussing the company's philosophy and patient selection, Chancellor said:

“If the data suggests they will not benefit, we decline them.”

Read the Andrew Chancellor interview at FounderAt

At first glance, this sounds reassuring.

An organisation offering an expensive emerging biological intervention should not accept someone simply because they can afford it. If the treatment is unsuitable, the responsible answer should be no.

But Chancellor's statement immediately raises another question:

Who exactly is “we”?

Who Reviews the Patient Data?

If Wellbeing is capable of deciding that a prospective patient is unlikely to benefit, somebody must presumably evaluate information about that patient.

What information?

Medical records? Diagnosis? Blood tests? Medication? Previous treatments? Age? Disease progression? Biological markers?

And then somebody has to interpret that information.

That is where the distinction between administration and medicine becomes important.

A patient coordinator can collect medical records. An administrator can arrange an appointment. A commercial representative can explain prices and logistics. A CEO can explain the organisation's technology.

But determining whether a particular person is medically suitable for an intervention is something different.

So who makes that decision at Wellbeing?

Andrew Chancellor's Role at Wellbeing International Foundation

As established in Chapter One, Wellbeing does not publicly identify Andrew Chancellor as a physician.

Its own biography describes a career beginning in international banking before moving into recruitment and, considerably later, healthcare and bioscience.

Wellbeing International Foundation — Leadership biographies

Wellbeing identifies Chancellor as its Chief Executive Officer .

It separately identifies Stephen Ray as its senior scientific figure.

And importantly, it separately identifies Dr Gerhard Boonstra as its senior medical consultant.

Wellbeing states that Boonstra obtained his medical degree from Stellenbosch University before working in emergency medicine and general practice.

Wellbeing International Foundation — About the team

That appears to establish a sensible division of responsibility:

Chancellor — commercial leadership.

Ray — science.

Boonstra — medicine.

But the patient journey raises the question of how clearly those divisions operate in practice.

Patient Screening Is Not the Same as Clinical Assessment

This distinction is essential.

There is nothing unusual about a non-medically qualified employee speaking to patients. It happens throughout healthcare.

A receptionist may ask why you need an appointment. A patient coordinator may obtain your medical history. A private hospital employee may explain treatment costs. A clinical-trial coordinator may collect information before a physician becomes involved.

None of that makes those people doctors.

The important question is what happens next.

There is a significant difference between:

“Tell me about your medical condition so I can pass the information to our doctor.”

and:

“Based upon your medical condition, we believe this treatment could help you.”

The first is information gathering.

The second may amount to a clinical judgement depending upon exactly what is said, the context and the applicable law.

That distinction lies at the centre of this investigation.

What Happens During the Wellbeing Patient Assessment?

This investigation has examined prospective-patient communications involving Wellbeing.

Initially, I was primarily interested in what was being said about Cell-Free Therapy.

Now I am equally interested in who was saying it and at what stage of the process .

The chronology needs to be reconstructed carefully.

When the patient's medical conditions were discussed, who asked the questions?

Who received the medical information?

Who interpreted it?

Who discussed the possibility of improvement?

Who explained why Cell-Free Therapy might be appropriate?

Who determined that the patient could proceed?

And critically:

When did a registered physician first become involved?

Those questions matter considerably more than someone's job title.

Where Does Andrew Chancellor's Role End?

There is nothing inherently problematic about Chancellor speaking to prospective patients.

As CEO, he may know Wellbeing's technology extremely well.

He can explain how the organisation operates. He can discuss its research. He can explain the treatment process. He can discuss costs. He can collect information that will subsequently be assessed by a physician.

The crucial boundary is whether he personally goes further.

Does Chancellor assess an individual's medical condition?

Does he interpret their symptoms or diagnosis?

Does he express an opinion about their likelihood of benefiting?

Does he determine whether they qualify?

Does he recommend that they proceed?

If he does, on whose clinical authority is that judgement made?

Those are questions the evidence needs to answer.

Where Does the Doctor Enter the Process?

This brings us back to Dr Gerhard Boonstra.

Wellbeing's own description identifies Boonstra as a medically qualified member of its senior team.

That makes the timing of medical involvement particularly important.

Does Dr Boonstra—or another appropriately qualified physician—review every prospective patient's case?

If so, when?

Before the initial consultation?

Before suitability is discussed?

Before a price is presented?

Before money changes hands?

Or later in the treatment pathway?

These are not trivial procedural details.

They help establish whether clinical assessment drives the commercial process—or follows it.

Who Has Final Authority?

There is an extremely straightforward question Wellbeing could answer:

Who possesses final authority to approve a patient for Cell-Free Therapy?

Is it Chancellor?

Dr Boonstra?

Another physician?

A clinical committee?

A combination of scientific and medical personnel?

If Chancellor believes someone is suitable but the physician disagrees, who has the final say?

Conversely, if a physician believes the intervention is inappropriate, can anyone within the commercial organisation override that decision?

A clearly separated clinical process should make those answers straightforward.

What Does “Benefit” Actually Mean?

There is another important element within Chancellor's statement:

“If the data suggests they will not benefit, we decline them.”

What exactly does benefit mean?

Improvement in symptoms? Improved mobility? Reduced pain? Changes in blood biomarkers? Changes in biological-age algorithms? Improved quality of life?

Something else?

And what data allows Wellbeing to predict this?

If the organisation possesses a reliable method for determining which patients are likely to respond to Cell-Free Therapy, that could itself be scientifically important.

Which raises another question:

Has that predictive method been independently validated?

What Evidence Supports Patient Selection?

If patient selection is data-driven, there should presumably be evidence supporting the selection criteria.

How many previous patients contributed to the dataset?

What medical conditions were included?

How were outcomes measured?

What constituted success?

What constituted failure?

Were unsuccessful treatments included?

How accurately does the system predict response?

Has the methodology been published?

Has it been independently tested?

Without those answers, the phrase “the data suggests” sounds reassuring but tells prospective patients surprisingly little.

The £37,000 Cell-Free Therapy Question

The financial element makes all of this considerably more important.

During the prospective-patient enquiry examined in this investigation, a programme costing approximately £37,000 was discussed.

That requires an important qualification.

I am not claiming £37,000 is Wellbeing's universal current price. Wellbeing currently explains that programmes are personalised and pricing depends upon the treatment proposed.

The figure relates to the specific enquiry examined during this investigation.

But imagine the position of the patient.

Someone is potentially telling you that an emerging biological intervention may help you.

Then you are asked to consider spending tens of thousands of pounds.

At that moment, the authority and qualifications of the person discussing your potential benefit matter enormously.

Hope Is Not an Ordinary Product

Patients seeking emerging treatments are not necessarily ordinary consumers.

Some may be seriously ill. Some may have exhausted conventional medicine. Some may be living with chronic pain or disability. Others may simply fear the consequences of ageing.

Whatever their circumstances, they may be particularly receptive to hope.

That creates a responsibility for organisations operating in emerging medicine.

Scientific possibility must not become confused with established clinical probability.

“This mechanism is scientifically interesting” is not the same as:

“This is likely to help you.”

And the qualifications of the person explaining that difference matter.

The Commercial Conflict in Private Medicine

There is another uncomfortable reality.

The organisation deciding whether the patient is suitable may also financially benefit if that patient proceeds.

This issue is not unique to Wellbeing.

It exists throughout private medicine.

Private hospitals make money from procedures. Dentists make money from treatments. Cosmetic clinics make money from interventions. Fertility clinics make money from IVF.

One important safeguard is the separation between commercial incentives and professional clinical judgement.

A regulated clinician has professional responsibilities towards the patient.

That is why determining who actually makes Wellbeing's clinical decisions is so important.

Who Decides That the Patient Should Spend £37,000?

Earlier in this investigation I asked:

Where does the £37,000 go?

Now there is another question:

Who decides that the patient should spend it?

If that decision follows an independent assessment by an appropriately qualified physician, Wellbeing should be able to demonstrate that pathway clearly.

If the commercial discussion occurs first and the physician becomes involved considerably later, prospective patients deserve to understand that too.

Transparency would resolve much of this uncertainty.

Questions Wellbeing International Foundation Can Answer

There is a straightforward way to establish what actually happens.

I would like Wellbeing International Foundation to explain who conducts its initial prospective-patient consultations; whether Andrew Chancellor personally collects or discusses individual medical histories; whether he expresses opinions about an individual's likelihood of benefiting from Cell-Free Therapy; whether he has authority to approve or reject patients; which registered physician performs the formal clinical assessment; and at what stage that assessment occurs.

There are further questions.

Does the medical assessment happen before treatment is recommended?

Does it happen before a price is quoted?

Who has final authority over clinical suitability?

What data is used to determine whether somebody is likely to benefit?

Has that selection methodology been independently validated?

And in which jurisdiction is the responsible physician registered?

Clear answers would substantially clarify the patient pathway.

What This Investigation Is — and Is Not — Alleging

Precision matters.

I am not alleging that Andrew Chancellor falsely represents himself as a doctor . I have found no evidence that he does.

I am not suggesting that a CEO cannot speak with patients.

And I am not presently claiming that Chancellor has unlawfully practised medicine.

That would be a legal conclusion requiring considerably more evidence. The applicable jurisdiction, precise words used, nature of any assessment and relevant regulatory definitions would all matter.

The question being investigated is narrower:

What role does Andrew Chancellor personally perform when Wellbeing determines whether an individual patient should receive Cell-Free Therapy?

Why the Patient Recording Matters

This is where evidence gathered during the investigation becomes potentially important.

A recollection can be disputed.

A summary can be interpreted differently.

A contemporaneous recording potentially provides something much more useful:

chronology and exact words.

What did the patient say?

What did Chancellor say?

Which medical conditions were discussed?

What questions were asked?

What potential benefits were discussed?

Was an opinion about suitability expressed?

When was treatment proposed?

When did price enter the conversation?

And was a physician involved before those things happened?

That evidence should be presented carefully, accurately and in context.

There is no need to tell readers what they should think.

Let the evidence show them what happened.

Conclusion: Who Is the Gatekeeper?

Andrew Chancellor does not need a medical degree to run Wellbeing International Foundation.

That has never been the issue.

The question is whether his role remains that of a chief executive when an individual patient's medical circumstances are being considered.

Because somebody inside Wellbeing acts as the gatekeeper.

Somebody ultimately decides:

Yes.

Or:

No.

Somebody determines whether the person on the other side of that conversation should proceed towards an expensive intravenous biological intervention.

Patients deserve to know who that person is.

They deserve to know that person's qualifications.

They deserve to understand the evidence being used.

And they deserve to understand any commercial interests surrounding the recommendation.

For someone contemplating spending tens of thousands of pounds in search of better health, those aren't technical questions.

They are fundamental ones.

And until the patient pathway is completely clear, one question remains at the centre of this investigation:

Who is actually making the medical decision?

Next: Chapter Three — Following Andrew Chancellor's Corporate Trail

Before regenerative medicine came banking and recruitment. What does the documentary record tell us about the businessman who became Wellbeing's CEO?

For Chancellor's stated background and Wellbeing's leadership structure: Wellbeing International Foundation — About .

For Chancellor's comments about patient selection: FounderAt — Andrew Chancellor interview .

THE MEN BEHIND WELLBEING

Sun, 16 Aug 2026 08:05:45 GMT

Chapter One: Andrew Chancellor

The Businessman Behind the Biologics

From international banking and recruitment to the leadership of a regenerative-medicine organisation

When investigating an organisation selling an emerging medical intervention, there are two very different questions worth asking.

The first is obvious:

Does the science support the treatment?

The second receives considerably less attention:

Who are the people turning that science into a business?

That second question brought me to Andrew Chancellor, Chief Executive Officer of Wellbeing International Foundation.

Today, Chancellor sits at the head of an organisation promoting Cell-Free Therapy, an intervention involving biological material processed from a patient's own cells and subsequently administered intravenously.

He speaks publicly about regenerative medicine.

He discusses patients.

He discusses the potential of the technology.

And he represents an organisation operating at the intersection of biotechnology, private healthcare and investment.

Yet Chancellor's route into this world did not begin in medicine.

According to Wellbeing's own biography, it began in banking .

Wellbeing International Foundation — Leadership biographies

Before Regenerative Medicine

Wellbeing describes Chancellor as an experienced international businessman.

His early career was spent in international banking in South Africa and the United Kingdom.

He subsequently moved into recruitment and executive search, operating businesses across London, Paris, Hong Kong, Singapore and Sydney.

Historical recruitment-industry reporting supports at least part of that account.

In 2007, an Andrew Chancellor was identified by recruitment publication Onrec as the London-based head of banking and finance at Robert Walters, discussing the international recruitment of corporate-finance professionals.

Onrec — “Asian expertise filling corporate finance gaps”

It is a substantial commercial career.

But it is important to understand what it isn't.

It isn't a conventional medical career.

Where Are the Medical Qualifications?

This is where precision becomes essential.

I have found no evidence in Wellbeing's published biography identifying Andrew Chancellor as a medical doctor.

No medical degree is listed.

No medical school is identified.

No clinical speciality is provided.

And Wellbeing does not describe him as a physician.

That does not mean Chancellor should not be CEO of Wellbeing.

Chief executives of healthcare and biotechnology businesses do not have to be doctors.

Some of the world's largest healthcare companies are run by executives whose expertise lies in finance, management or business development.

The relevant question is therefore not:

Why is Wellbeing run by someone who isn't a doctor?

The more important question is:

What does Chancellor actually do when medicine and individual patients become involved?

That distinction will become increasingly important.

Wellbeing Separates the Roles

Interestingly, Wellbeing's own leadership structure appears to make the distinction between commercial, scientific and medical expertise.

Chancellor is identified as:

Chief Executive Officer.

Stephen Ray is identified separately as:

Senior Scientific Consultant.

And Dr Gerhard Boonstra is identified as:

Senior Medical Consultant.

Wellbeing's biography for Boonstra specifically identifies his medical education, stating that he obtained his medical degree from Stellenbosch University before working in emergency medicine and general practice.

Wellbeing International Foundation — About the team

On paper, the structure therefore appears straightforward.

Chancellor — business.

Ray — science.

Boonstra — medicine.

But how those boundaries operate in practice is another matter.

How Did a Banker Enter Regenerative Medicine?

The answer appears to begin with Stephen Ray.

Chancellor has spoken publicly about meeting Ray and becoming fascinated by the underlying science.

Their relationship eventually developed beyond scientific discussion.

Chancellor describes conversations about how the research could be commercialised and brought into clinical use.

FounderAt — Interview with Andrew Chancellor

That word matters.

Commercialised.

Because it helps explain what Chancellor appears to have brought to the relationship.

Ray brought scientific research.

Chancellor brought decades of business experience.

Together, the question became whether that research could be transformed into something capable of being delivered commercially.

That eventually contributed to the organisation we are investigating today.

Learning Medicine From the Outside

Chancellor has also discussed the difficulty of entering such a scientifically complex industry.

He describes having to understand the science and medicine sufficiently to lead the organisation responsibly, and speaks about learning through extensive reading, questioning and research.

There is nothing inherently wrong with that.

A chief executive running a biotechnology company should understand the science behind the product.

But it tells us something important about Chancellor's route to expertise.

Based upon the public information I have examined, his knowledge of regenerative medicine appears to have developed through his involvement in the industry and self-directed learning rather than through conventional medical education and clinical training.

Again, that is not inherently problematic for a CEO.

It becomes relevant only when we examine the extent of his involvement with patients.

From Commercialisation to Clinical Delivery

Wellbeing says Chancellor has now spent approximately fifteen years working within healthcare and bioscience.

During that time, his role appears to have evolved considerably.

He is no longer simply the businessman helping a scientist commercialise an idea.

He is now the CEO and one of the principal public representatives of the organisation.

He discusses Cell-Free Therapy.

He explains biological mechanisms.

He discusses patient outcomes.

He talks about clinical delivery.

And significantly, he has spoken publicly about Wellbeing's approach to deciding which prospective patients should receive treatment.

This is where the story changes.

“We Decline Them”

In a public interview, Chancellor explained that Wellbeing does not simply accept everybody willing to pay.

He said:

“If the data suggests they will not benefit, we decline them.”

Read the full Andrew Chancellor interview at FounderAt

On its face, that sounds responsible.

An organisation offering an expensive biological intervention should not accept someone it believes is unlikely to benefit simply because that person can afford the treatment.

But the statement raises an obvious question.

Who is “we”?

Who evaluates the data?

Who reviews the patient's medical condition?

Who determines whether that person is likely to benefit?

Who decides whether they qualify?

And who carries the medical responsibility for that decision?

The Difference Between Business and Medicine

This is the boundary at the centre of my investigation into Andrew Chancellor.

A CEO can explain his company.

A CEO can discuss published scientific research.

A CEO can discuss strategy.

A CEO can talk about the theoretical potential of technology.

Administrative staff can also collect medical records and information from prospective patients.

But evaluating an individual's medical condition is different.

Assessing contraindications is different.

Predicting whether a particular patient is likely to benefit is different.

Determining whether an individual is clinically suitable for an intravenous biological intervention is different again.

Those functions require us to ask exactly where Wellbeing draws the line between commercial screening and clinical assessment .

Why This Matters

Cell-Free Therapy isn't being discussed in the same financial category as a vitamin supplement or wellness consultation.

During the prospective-patient enquiry examined as part of this wider investigation, a programme costing approximately £37,000 was discussed.

That figure should be understood carefully.

I am not suggesting that £37,000 is Wellbeing's universal current tariff. Wellbeing currently describes its programmes as individually priced.

It is the approximate price arising from the enquiry examined during this investigation.

Nevertheless, it changes the importance of the conversation.

Someone considering spending tens of thousands of pounds on an emerging biological intervention may place enormous weight upon what they are told about their chances of benefiting.

That makes the identity and qualifications of the person providing that assessment extremely important.

The Patient Changes Everything

Until this point, Chancellor's unusual career transition is merely interesting.

Banker becomes recruiter.

Recruiter meets scientist.

Businessman becomes involved in biotechnology.

Eventually businessman becomes CEO.

There is nothing inherently improper about any of that.

But once the CEO begins interacting directly with prospective patients, another level of scrutiny becomes appropriate.

What questions does he ask?

What medical information does he receive?

Does he interpret that information?

Does he discuss whether CFT could help a particular condition?

Does he express an opinion about whether the individual is suitable?

Does he recommend proceeding?

And most importantly:

Has a registered physician independently assessed the patient before any such conclusion is communicated?

Those are factual questions.

They should have factual answers.

Where Is the Doctor?

This is why Wellbeing's separate identification of Dr Gerhard Boonstra becomes so important.

If Boonstra—or another appropriately qualified and registered physician—reviews every patient's medical records, assesses suitability and makes the final clinical decision before treatment is recommended, that is significant context.

It should be reported.

But we need to establish when that happens.

Before Chancellor speaks with the patient?

Afterwards?

Before suitability is discussed?

Before the treatment price is presented?

Before payment?

Immediately before treatment?

The sequence matters.

Because a doctor approving treatment after a commercial decision has effectively already been made is very different from a doctor independently deciding at the beginning that the intervention is clinically appropriate.

What This Investigation Is Not Claiming

There is an important line I will not cross without evidence.

I am not claiming Andrew Chancellor is pretending to be a doctor.

I have found no evidence that he describes himself as one.

I am not claiming merely being a non-medically qualified CEO of a biotechnology organisation is improper.

It isn't.

And I am not presently alleging that Chancellor is unlawfully practising medicine.

That would require analysis of exactly what he did, what was said, where it occurred and the applicable regulatory law.

The question at this stage is considerably simpler:

What role does Andrew Chancellor personally play in determining whether individual patients receive Cell-Free Therapy?

The Evidence Will Decide

That question cannot be answered by speculation.

Fortunately, this investigation does not have to rely solely upon corporate biographies.

I have examined prospective-patient communications involving Wellbeing.

Those interactions potentially allow us to reconstruct what happens when someone approaches the organisation seeking help.

That evidence needs to be treated carefully.

Exact words matter.

Chronology matters.

Context matters.

If Chancellor merely gathers information before referring a patient to a doctor, that needs to be made clear.

If the evidence demonstrates something more substantial, that needs to be made equally clear.

The objective is not to make the evidence fit the story.

The evidence must determine the story.

A Simple Question

Andrew Chancellor's career is certainly unusual.

International banking.

Executive recruitment.

Bioscience.

Regenerative medicine.

CEO.

But unusual does not mean improper.

The question that matters is what happened when the businessman crossed from building the business into interacting with the people purchasing its medical services.

Because ultimately, a prospective patient doesn't care whether the person speaking to them once worked in banking.

They care whether the person telling them that an expensive biological intervention might help them is qualified to make that judgement.

And that brings us to the next part of this investigation.

Not Andrew Chancellor the banker.

Not Andrew Chancellor the recruiter.

Not even Andrew Chancellor the CEO.

But Andrew Chancellor sitting opposite a prospective patient.

And one question:

Who is actually making the medical decision?

NEXT — CHAPTER TWO

The Gatekeeper

Inside the patient-selection process: who decides whether someone qualifies for Cell-Free Therapy?

THE BUSINESS OF LONGEVITY – Chapter Nine The £37,000 Question

Sun, 09 Aug 2026 08:50:38 GMT

Patients Pay for the Treatment. But What Exactly Are They Funding?

The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.

THE BUSINESS OF LONGEVITY – Chapter Eight The Investor Pitch

Sun, 09 Aug 2026 08:47:25 GMT

When Emerging Science Becomes an Investment Opportunity

There is a moment in the development of almost every biotechnology company when the conversation changes.

Scientists talk about evidence.

Doctors talk about patients.

But investors talk about the future.

That difference is important.

Scientific research asks whether something works.

Investment asks what something could eventually become worth.

Between those two questions exists an enormous commercial opportunity—and an equally important area of risk.

During this investigation into Wellbeing International Foundation, I discovered that the organisation had moved beyond simply offering Cell-Free Therapy and conducting research.

It was also raising private capital.

Wellbeing announced that it had successfully closed the first tranche of its 2026 investment round.

That announcement changed the direction of my investigation.

Because once emerging medical science becomes an investment proposition, another question becomes unavoidable:

What exactly are investors being asked to believe?

Why Biotechnology Needs Investors

There is nothing unusual about a biotechnology company raising money.

Quite the opposite.

Developing new medical technologies can require enormous amounts of capital.

Laboratories cost money.

Researchers cost money.

Clinical studies cost money.

Manufacturing costs money.

Regulatory approval costs money.

International expansion costs money.

Without investors willing to accept considerable risk, many important medical innovations would never progress beyond the laboratory.

Investment itself is therefore not the issue.

The issue is understanding the proposition being presented to those investors.

The Public Announcement

Wellbeing's announcement confirmed that the first tranche of its 2026 fundraising had been completed.

According to the organisation, capital would support areas including research, development, international expansion and operational capacity.

What the public announcement did not reveal was the detailed financial proposition behind the transaction.

From the information publicly available, we cannot independently determine:

how much was raised;
the valuation placed upon the company;
who invested;
what percentage of ownership changed hands;
which securities were issued;
what financial projections were presented;
what returns were discussed;
what exit strategy investors were shown.

For a privately held business, there is nothing inherently unusual about keeping such information confidential.

But it means the public announcement tells us that an investment has occurred without allowing us to independently evaluate the investment itself.

What Is Being Purchased?

This is perhaps the most basic question an investor should ask.

What am I actually buying?

Shares in Wellbeing International Foundation?

Shares in another company?

Preference shares?

Convertible debt?

An interest in intellectual property?

A holding company sitting above the operating businesses?

Without the investment documents, there is no responsible basis upon which to assume the answer.

And the answer matters enormously.

The value of a biotechnology investment may ultimately depend upon ownership of patents, technology, manufacturing processes and licensing rights.

If the company receiving investment does not directly own those assets, the investor needs to understand exactly what contractual rights connect them.

This is why professional investors conduct detailed legal due diligence before investing.

The brand name alone tells them very little.

Then Came Peer Review

The investment story becomes particularly interesting when viewed alongside another development.

Wellbeing's longevity programme has now appeared in the peer-reviewed scientific journal Frontiers in Aging.

That is a genuine scientific achievement.

The study exists.

It was peer reviewed.

It was published.

But as examined earlier in this investigation, the study remains preliminary.

Only fourteen participants completed the programme.

There was no untreated control group.

There was no placebo group.

Participants underwent multiple interventions simultaneously.

The research involved individuals commercially connected with organisations delivering the programme.

And the authors themselves acknowledged that larger controlled studies would be required.

Scientifically, those limitations matter.

Financially, however, two words can become extraordinarily powerful:

Peer reviewed.

Published Does Not Mean Proven

This distinction is essential.

Peer review means that research has undergone scholarly evaluation before publication.

It does not mean that a commercial medical intervention has been definitively proven effective.

Clinical confidence generally develops through a much larger body of evidence.

Independent replication.

Randomised controlled trials.

Larger patient populations.

Appropriate control groups.

Long-term follow-up.

Clinically meaningful endpoints.

Reproducible results.

A small pilot study may justify further investigation.

It cannot, by itself, provide the same level of evidence as a mature clinical-development programme.

That distinction becomes particularly important when scientific credibility contributes to commercial valuation.

The Commercial Power of Two Words

Imagine two presentations to an investor.

The first says:

We are developing an experimental longevity programme.

The second says:

Our longevity programme has been published in a peer-reviewed scientific journal.

Both statements could be completely accurate.

But they create very different impressions.

The second immediately sounds more established.

More credible.

More scientifically mature.

Potentially more investable.

That is why the precise language contained within investment materials matters.

Are investors clearly told that the research involves fourteen participants?

Are they told there was no placebo or untreated control group?

Are they told that multiple interventions were administered simultaneously?

Are the commercial connections of the researchers explained?

Are they told that independent replication remains necessary?

Or is "peer reviewed" presented without that wider context?

At present, I cannot answer those questions.

I have not seen Wellbeing's private investment memorandum or investor presentation.

That limitation must be made absolutely clear.

What We Do Not Have

Several documents would transform this investigation.

The investor deck.

The information memorandum.

The term sheet.

Subscription documents.

Financial forecasts.

The capitalisation table.

Risk disclosures.

Shareholder agreements.

Those documents would allow us to compare three different narratives.

What patients are told.

What the scientific paper actually says.

What investors are told.

If those three narratives are consistent, that would provide important reassurance.

If materially different claims are being made to different audiences, understanding those differences would become extremely important.

Until the documents are available, however, no such conclusion should be drawn.

The Longevity Investment Story

There is another reason this deserves scrutiny.

Longevity has become an extraordinarily attractive commercial concept.

People are living longer.

Wealthy consumers increasingly spend significant amounts attempting to remain healthier for longer.

Researchers are studying cellular senescence, epigenetic ageing, gene therapy, regenerative medicine and biological-age measurement.

Investors naturally see opportunity.

If even a small proportion of the promises surrounding longevity science eventually translate into effective therapies, the commercial market could become enormous.

That creates legitimate excitement.

It can also create a dangerous temptation.

Valuing tomorrow's possibility as though it were today's reality.

The Difference Between Potential and Performance

Investors do not normally buy companies because of what they are today.

They invest because of what they believe those companies may become tomorrow.

That means valuations frequently depend upon assumptions.

Future patients.

Future clinics.

Future countries.

Future intellectual property.

Future revenues.

Future clinical evidence.

Future regulatory approvals.

There is nothing inherently wrong with that.

Every early-stage investment contains uncertainty.

But the more a valuation depends upon future events, the more carefully those assumptions should be tested.

Scientific uncertainty therefore becomes financial uncertainty.

Science Risk Is Investment Risk

This is one of the most important connections in the entire investigation.

Imagine that future independent clinical trials fail to reproduce the encouraging findings reported in the pilot study.

What happens to the investment case?

What happens if regulators classify the therapy differently?

What happens if manufacturing requirements become more demanding?

What happens if the intellectual property proves difficult to protect?

What happens if competitors develop stronger clinical evidence?

What happens if patient demand falls?

These are not simply scientific questions.

They are investment risks.

When a biotechnology company's value is connected to its science, weaknesses in the evidence become potential weaknesses in the valuation.

Questions I Would Ask Before Investing

If I were considering investing my own money, I would want straightforward answers.

What is the company worth today?

How was that valuation calculated?

What revenue does the company currently generate?

How much comes from patients?

Is the business profitable?

How much cash does it hold?

How quickly is that cash being spent?

How much additional funding will be required?

Which company owns the intellectual property?

What exactly am I buying?

What percentage will I own?

Who controls the company after I invest?

What clinical evidence supports the growth projections?

What regulatory risks exist?

What happens if the science fails?

And finally:

How do I eventually get my money back?

These are not hostile questions.

They are the basic questions upon which serious investment decisions are made.

The Exit Question

Every investment ultimately requires an exit.

Perhaps the company is sold.

Perhaps another investor buys the shares.

Perhaps it eventually lists on a stock exchange.

Perhaps dividends are paid.

Perhaps the technology is licensed.

Whatever the strategy, investors normally need to understand how today's investment could eventually produce tomorrow's return.

That makes the absence of publicly available information concerning valuation, ownership and investment terms particularly significant for an outside observer.

It does not mean investors themselves lack that information.

They may have received extensive documentation privately.

It simply means we cannot independently evaluate it.

What Can Be Said Today

At this stage, there is no evidence available to this investigation demonstrating that Wellbeing has misled its investors.

That point matters.

Without seeing the private investor materials, it would be irresponsible to suggest otherwise.

What can be established is considerably narrower.

Wellbeing is raising private capital.

It is developing and commercialising a longevity programme.

Its programme now has a peer-reviewed scientific publication.

That publication remains preliminary and contains significant methodological limitations.

The detailed investment proposition is not publicly available.

Those are the facts.

What they mean depends upon information we have not yet obtained.

Two Products

Perhaps the most interesting conclusion is that Wellbeing may now effectively have two propositions.

One is offered to patients.

A longevity programme.

The other is offered to investors.

The future commercial value of that programme.

Those are fundamentally different products.

Patients are buying what exists today.

Investors are buying what they believe might exist tomorrow.

The credibility of both ultimately depends upon the same thing.

Evidence.

Conclusion

This investigation began by asking whether Cell-Free Therapy works.

That question led to the scientific paper.

The scientific paper led to the company.

The company led to its directors.

The directors led to corporate history.

The corporate history led to ownership.

And ownership eventually led to investment.

Each step has revealed another layer.

The investment round itself is not evidence of anything improper.

It is evidence that Wellbeing's story has moved beyond medicine.

It is now also a financial story.

And whenever scientific possibility becomes financial opportunity, due diligence becomes essential.

Because investors are not simply investing in today's company.

They are investing in a version of the future.

The question is whether the evidence available today supports the future they are being asked to believe in.

THE BUSINESS OF LONGEVITY – Chapter Seven Who Really Owns Wellbeing?

Sun, 09 Aug 2026 08:44:29 GMT

Following the Ownership, Control and Money Behind the Foundation

When investigating a company, identifying the people running it is relatively straightforward.

Chairmen have biographies.

Chief executives give interviews.

Scientists publish papers.

Directors appear on websites.

Ownership is different.

Behind almost every private business sits another layer consisting of shareholders, holding companies, investment agreements, intellectual property and voting rights.

Those relationships determine something far more important than who appears on the company website.

They determine who ultimately controls and benefits from the business.

As this investigation into Wellbeing International Foundation moved from science into corporate finance, that distinction became increasingly important.

We know considerably more about who represents Wellbeing publicly than we do about who ultimately owns its economic value.

And that leads to a very simple question.

Who really owns Wellbeing?

Management Is Not Ownership

One of the easiest mistakes to make when researching a private company is assuming that the people running it are necessarily the people who own it.

They may be.

But they do not have to be.

Directors manage companies.

Executives operate them.

Shareholders own economic interests in them.

Investors provide capital.

Intellectual property may belong to yet another company entirely.

That distinction becomes particularly important when an organisation begins raising outside investment.

New capital can change ownership.

It can change voting rights.

It can change control.

And sometimes it can change who ultimately receives the greatest financial benefit if the company succeeds.

The Wellbeing Question

Wellbeing International Foundation publicly identifies its leadership team and provides information about its scientific and commercial activities.

What is considerably harder to establish from public information is the complete ownership structure behind the organisation.

Who are the shareholders?

What percentage does each hold?

Who possesses voting control?

What happened to those percentages following the 2026 investment round?

Are there different classes of shares?

Do investors have preferential economic rights?

These are routine questions during professional investment due diligence.

From the public information presently available, however, the complete answers are not obvious.

That distinction matters.

It would be incorrect to say ownership has been deliberately concealed merely because information is not publicly accessible.

The accurate position is simpler:

A complete picture of ultimate ownership cannot currently be established from the public material examined during this investigation.

The Word "Foundation"

The organisation's name continues to deserve attention.

Wellbeing International Foundation.

For many readers, the word Foundation naturally suggests charitable, philanthropic, educational or scientific activity.

But a name does not tell us who owns an organisation or how its economic interests are structured.

Wellbeing itself has publicly discussed private investment, patient revenue, international expansion and commercial growth.

Those activities immediately make ownership relevant.

If investors have provided capital, what did they receive in return?

Equity?

Preference shares?

Convertible instruments?

Debt?

An economic interest in another company?

Without the underlying investment documentation, it would be irresponsible to assume the answer.

But it remains an important question.

The 2026 Investment Round

Wellbeing announced that it had successfully closed the first tranche of its 2026 investment round.

The announcement presented the fundraising as another step in the organisation's development.

What was not publicly disclosed was the detailed financial structure behind that transaction.

We do not currently have public confirmation of:

the amount invested;
the company valuation;
the identities of participating investors;
the percentage of equity issued;
the securities investors received;
voting rights attached to those securities;
the resulting ownership percentages.

None of this is necessarily unusual for a privately held company.

Private transactions are frequently confidential.

However, confidentiality creates an unavoidable limitation for anyone attempting to independently understand who owns and controls the organisation.

Ownership Is More Than Shares

There is another complication.

Finding the shareholders does not necessarily answer the entire ownership question.

Economic control can exist through many different arrangements.

Ordinary shares.

Preference shares.

Voting agreements.

Convertible debt.

Holding companies.

Licensing agreements.

Intellectual-property ownership.

Contractual rights.

An organisation may operate the business while another entity owns the technology upon which that business depends.

That is why sophisticated investors examine the entire structure rather than simply looking at a shareholder list.

They follow the economic value.

Follow the Intellectual Property

For an emerging biotechnology company, this may be the most important question of all.

Who owns the science?

Wellbeing's commercial potential appears closely connected to Cell-Free Therapy and the biological processes surrounding it.

If those technologies ultimately prove successful, the intellectual property could potentially become extremely valuable.

That makes ownership crucial.

Are the relevant rights owned directly by Wellbeing International Foundation?

By a research company?

By individual scientists?

By a separate intellectual-property company?

Are they licensed?

Are investors buying into the entity that actually owns those rights?

These questions should not be answered through speculation.

They require patents, licensing agreements, corporate filings and investment documents.

Until those records are available, the correct position is simply that the complete intellectual-property ownership structure has not yet been independently established.

Patient Revenue Adds Another Layer

There is another financial relationship that makes this structure particularly interesting.

Wellbeing has acknowledged that patient revenue has historically contributed to funding its activities.

That means money potentially enters the organisation from several directions.

Patients.

Investors.

Selective philanthropic engagement.

Each group provides money for a fundamentally different reason.

Patients expect a service.

Investors expect financial returns.

Philanthropic supporters generally expect their contribution to advance a particular mission.

Understanding where those funds enter the corporate structure—and where they ultimately go—is therefore important.

Which entity receives patient payments?

Which pays for research?

Which owns the intellectual property?

Which received investment capital?

Which retains profits?

Those relationships would reveal considerably more about the business than a corporate biography ever could.

Why Bermuda Matters

This investigation inevitably returns to Bermuda.

Not because incorporating there demonstrates anything improper.

It does not.

Bermuda is a long-established international business jurisdiction used by many legitimate global organisations.

The importance of Bermuda is practical.

Public disclosure requirements differ between jurisdictions.

A researcher examining a UK company may be able to access incorporation documents, director histories, accounts, confirmation statements, charges and certain ownership information relatively easily.

An offshore private structure may provide considerably less information to an ordinary member of the public.

That makes reconstructing ultimate beneficial ownership more difficult.

Again, difficulty obtaining information is not evidence that something is being hidden.

But it does place greater importance on voluntary transparency.

What Investors Would Normally Want to Know

Imagine being invited to invest substantial money in a biotechnology company.

Before transferring funds, most experienced investors would ask:

Who currently owns the business?

What percentage am I buying?

What valuation am I investing at?

Who controls the voting rights?

What happens if more shares are issued?

Who owns the intellectual property?

Does the company I am investing in actually own the assets upon which its valuation depends?

What happens if another company in the group fails?

How do I eventually exit?

These are not aggressive questions.

They are fundamental investment questions.

Presumably, Wellbeing's investors receive significantly more private information than is available publicly.

If that investment documentation can eventually be obtained, it could answer many of the questions raised by this investigation.

What We Can Establish

It is important to separate facts from unknowns.

From Wellbeing's own public communications, we can establish that the organisation operates commercially, generates patient revenue, has attracted private investment and intends to expand its international activities.

Its scientific programme is also becoming increasingly important to the organisation's public identity.

What remains much harder to independently establish from public material is:

ultimate beneficial ownership;
individual shareholder percentages;
voting control;
the post-investment ownership structure;
the valuation attached to the 2026 fundraising;
ownership of the core intellectual property;
financial relationships between the relevant entities.

Those gaps do not establish misconduct.

They establish the limits of what can currently be independently verified.

And those limits themselves are relevant when evaluating transparency.

Why Patients Should Care Too

Ownership may initially appear to be an issue solely for investors.

It isn't.

Corporate ownership influences incentives.

A philanthropically funded research organisation operates under different financial pressures from a venture-backed biotechnology company.

A founder-controlled company may make different decisions from one controlled by outside investors.

A business dependent upon patient revenue faces different incentives from one funded predominantly through research grants.

None of those structures is automatically better or worse.

But understanding which model applies helps patients understand the organisation they are trusting.

Follow the Economic Interest

Throughout this investigation, one principle has repeatedly proved useful.

Do not stop at the brand.

Do not stop at the biography.

Do not even stop at the company.

Follow the economic interest.

Who provides the money?

Who owns the assets?

Who controls the decisions?

Who carries the risk?

And who benefits if the company succeeds?

Those questions lie at the heart of understanding almost every commercial enterprise.

They become even more important when the business operates at the intersection of experimental science, private healthcare and investment.

Conclusion

This investigation began with a medical treatment.

Then came the scientific paper.

Then the corporate history.

Then the investment round.

Each discovery revealed another layer.

We can identify many of the people publicly associated with Wellbeing International Foundation.

What we cannot yet independently reconstruct is the complete economic ownership sitting behind the organisation.

That does not justify assumptions.

It justifies further investigation.

Because ultimately, knowing who runs a company tells us only part of the story.

Knowing who owns the value tells us considerably more.

And that is where the money trail becomes impossible to ignore.

THE BUSINESS OF LONGEVITY – Chapter Six

Sat, 01 Aug 2026 08:41:26 GMT

Behind the Foundation

Following the Corporate Structure

Throughout this investigation, one lesson has become increasingly clear.

Understanding the science is only part of the story.

To understand the business, you first have to understand the structure behind it.

Every organisation has a legal framework.

Every investment has an ownership structure.

Every intellectual property portfolio belongs to someone.

Those are not controversial observations.

They are the starting point of every corporate investigation.

As I moved beyond scientific papers and into company records, a new set of questions began to emerge.

Who owns the intellectual property?

Which company receives patient revenue?

Which entity raises investment?

Where does one company end and another begin?

Answering those questions proved considerably more difficult than expected.

Looking Beyond the Brand

Most people encounter Wellbeing International Foundation through its website.

They see a healthcare organisation promoting regenerative medicine, longevity science and innovative biological therapies.

That is the public face of the business.

The legal structure, however, is something entirely different.

Behind every recognised brand sits a network of companies, directors, registrations, contracts and corporate relationships.

Sometimes that network is remarkably simple.

Sometimes it spans multiple countries and multiple legal entities.

Understanding that structure is not about suspicion.

It is about clarity.

Why Corporate Structure Matters

Corporate structures exist for many legitimate reasons.

Businesses separate activities to manage risk.

Intellectual property may be held in one company.

Clinical operations in another.

Research in a third.

Investment and finance in yet another.

Large pharmaceutical companies have done this for decades.

There is nothing unusual about it.

The important question is not whether multiple entities exist.

The important question is whether people can understand how they relate to one another.

For patients, that means understanding who is providing the treatment.

For investors, it means understanding where the assets sit.

For regulators, it means understanding who is responsible for what.

Transparency benefits everyone.

The Bermuda Question

One aspect of Wellbeing's corporate structure immediately attracted attention.

The organisation identifies Bermuda as its headquarters.

Bermuda is a respected international financial centre and home to many multinational businesses.

Companies choose Bermuda for a wide range of legitimate commercial reasons, including international operations, legal certainty and corporate flexibility.

The jurisdiction itself is not the issue.

The challenge is that privately held companies incorporated there often publish considerably less financial information than publicly listed businesses.

That means outsiders attempting to understand ownership, financial performance or capital structure have fewer publicly available documents to work with.

It does not imply secrecy.

It does, however, make independent due diligence more challenging.

Following the Money

One of the recurring themes throughout this investigation has been investment.

Wellbeing publicly announced that it had completed the first tranche of its 2026 funding round.

The announcement confirmed that capital had been raised to support continued growth.

What it did not disclose publicly included:

the amount raised;
the valuation of the business;
the identities of investors;
the investment structure;
ownership changes resulting from the fundraising.

For a privately owned company, there is nothing inherently unusual about keeping those details confidential.

Nevertheless, anyone attempting to understand the business is left with an incomplete picture.

Without those details, it becomes difficult to assess how the organisation is financed or how ownership may have evolved over time.

Intellectual Property

Throughout the biotechnology industry, intellectual property is often the most valuable asset a company owns.

Patents.

Research.

Manufacturing processes.

Trade secrets.

Licensing agreements.

These assets frequently represent far more value than laboratories or office buildings.

That naturally raises another important question.

Where is Wellbeing's intellectual property held?

Is it owned directly by the Foundation?

A separate holding company?

A licensing entity?

A research subsidiary?

At present, those relationships are not fully explained within the publicly available information.

Understanding where those assets sit is a key part of understanding the business itself.

Why Transparency Matters

Throughout this investigation I have been careful to distinguish between missing information and evidence of wrongdoing.

They are not the same thing.

A private company is under no obligation to publish every aspect of its corporate affairs.

Equally, when an organisation operates within healthcare, raises private investment and promotes innovative therapies, transparency inevitably becomes more important.

Patients place trust in the treatment.

Investors place trust in the management.

Both groups benefit from clarity.

Transparency does not weaken confidence.

It strengthens it.

The Questions That Remain

Despite months of research, several important questions remain unanswered.

Which entity ultimately owns the core intellectual property?
Which company receives patient payments?
Which legal entity raised the investment announced in 2026?
How are the various companies connected?
Where does operational control sit?
How does the Bermuda headquarters interact with companies in other jurisdictions?

These are not accusations.

They are simply the next stage of responsible due diligence.

Looking Ahead

If this chapter has shown anything, it is that understanding a modern biotechnology company requires more than reading scientific journals or corporate biographies.

It requires understanding the legal architecture behind the organisation.

The companies.

The directors.

The ownership.

The flow of investment.

The movement of intellectual property.

In the next chapter, we begin mapping that architecture in greater detail.

Who owns what?

Who controls what?

And ultimately, who benefits if the business succeeds?

Those answers may prove just as important as the science itself.

THE BUSINESS OF LONGEVITY – Chapter Five

Sat, 01 Aug 2026 08:38:02 GMT

Eneco

When Innovation Meets Bankruptcy

Every emerging technology industry shares one thing in common.

It attracts investors.

Whether the technology is artificial intelligence, renewable energy or regenerative medicine, the promise of future innovation often attracts substantial financial backing long before commercial success has been proven.

Sometimes those investments change the world.

Sometimes they disappear without trace.

Sometimes they become trapped in years of legal disputes that reveal just how complicated the business of innovation can become.

That is exactly what happened with Eneco Inc.

As I continued tracing the corporate history of Wellbeing International Foundation's Chairman, Max Lewinsohn, I discovered that one chapter stood out from all the others.

Unlike earlier companies, the story of Eneco is preserved in extraordinary detail.

Bankruptcy filings.

Federal court proceedings.

Asset sale orders.

Intellectual property disputes.

Years of litigation.

For an investigator, it is one of the richest documentary records in this entire series.

A Business Built on Ideas

Eneco was not a conventional manufacturing company.

Its value lay largely in intellectual property.

Its commercial future depended on innovative energy technologies and the expectation that those ideas could eventually become profitable products.

That business model is familiar.

Across emerging industries, investors routinely provide capital years before a product reaches full commercial maturity.

The investment is not based solely on current performance.

It is based on future potential.

That potential can be extremely valuable.

It can also be extremely risky.

When the Money Runs Out

Like many ambitious technology companies, Eneco eventually faced financial pressure.

According to publicly available court records, the business required additional funding to continue developing and commercialising its technology.

That funding never arrived in sufficient quantity.

The company entered Chapter 11 bankruptcy protection in the United States before later being converted into Chapter 7 liquidation.

For shareholders, that marked the end of the company.

For the courts, it marked the beginning of a much longer story.

The Real Asset

When a technology company collapses, the buildings are rarely its greatest asset.

The intellectual property is.

Patents.

Research.

Trade secrets.

Licensing rights.

Those assets often become the focus of intense legal disputes because they may still hold significant commercial value even after the company itself has failed.

The Eneco court record demonstrates exactly how complex those disputes can become.

Ownership.

Priority.

Creditors.

Investors.

Competing commercial interests.

Years after the company ceased trading, the intellectual property continued to generate litigation.

Where Max Lewinsohn Appears

Public court documents identify Max Lewinsohn in connection with Eneco and with Maximillian & Co., an investment vehicle involved during the bankruptcy proceedings.

His name appears throughout parts of the documentary record because of that involvement.

That fact alone should not be interpreted as evidence of wrongdoing.

Large corporate insolvencies frequently involve directors, investors, advisers, creditors and competing commercial interests.

Participation in litigation does not determine liability.

The importance lies in understanding the documented role each party played rather than drawing assumptions from their presence within court proceedings.

That is precisely why this investigation relies on original legal documents rather than internet commentary.

Innovation Carries Risk

One of the most valuable lessons from the Eneco story has little to do with the individuals involved.

It is about innovation itself.

Emerging technologies are expensive.

Research takes time.

Commercial success is uncertain.

Even promising ideas can fail if funding disappears before the business becomes financially sustainable.

That lesson applies far beyond the energy sector.

It is equally relevant to biotechnology, regenerative medicine and longevity research.

Scientific promise does not automatically translate into commercial success.

Why This Matters

Readers may reasonably ask why a bankruptcy involving an energy technology company is relevant to an investigation into longevity medicine.

The answer lies not in the industries themselves.

It lies in corporate experience.

When investors evaluate a management team, they rarely look only at today's company.

They examine previous ventures.

Corporate restructurings.

Bankruptcies.

Litigation.

Successful exits.

Commercial failures.

Not because history predicts the future.

But because history provides context.

Understanding that context is an essential part of responsible due diligence.

The Documentary Record

One of the defining principles of this investigation has been simple.

Every important conclusion should be supported by original documentation.

The Eneco chapter is built upon:

United States Bankruptcy Court records;
published court judgments;
asset sale proceedings;
publicly available litigation documents;
corporate filings.

Those records provide a far more reliable account than retrospective opinion ever could.

Looking Ahead

Eneco marks an important turning point in this investigation.

The documentary evidence becomes richer.

The legal record becomes deeper.

The commercial questions become more significant.

Yet one question remains unanswered.

How does a career that includes complex technology ventures, corporate restructurings and extensive litigation eventually lead to the leadership of Wellbeing International Foundation?

The next chapter leaves the courtroom behind and follows something even more important.

The corporate structure itself.

Who owns the business?

Where is the intellectual property held?

How is investment organised?

And why was Bermuda chosen as the centre of that structure?

THE BUSINESS OF LONGEVITY – Chapter Four

Sat, 01 Aug 2026 08:33:40 GMT

Dominion International

The Company That Started the Paper Trail

Every long corporate career leaves behind a paper trail.

Sometimes that trail tells the story of success.

Sometimes it tells the story of failure.

More often, it tells a far more complicated story than any corporate biography ever can.

As I continued investigating the business behind Wellbeing International Foundation, I found myself moving further away from regenerative medicine and deeper into corporate history.

That search led to one company that appears repeatedly in the early career of Wellbeing's Chairman, Max Lewinsohn.

Dominion International.

It is not a household name today. Yet it represents the first significant chapter in the public corporate record that ultimately leads to the leadership of Wellbeing International Foundation.

This article is not about assigning blame for events that occurred decades ago.

It is about understanding the documented history behind one of the individuals now responsible for guiding a company operating within one of the world's fastest-growing healthcare sectors.

Why Look Back?

Whenever investors examine a business, they begin with the management team.

Before analysing products or financial forecasts, they ask a simple question:

Who is running the company?

The answer rarely begins with the present.

It begins with the past.

Corporate history provides context.

It shows how leaders have navigated success, failure, growth and crisis throughout their careers.

That process is not unusual.

Banks perform it.

Institutional investors perform it.

Private equity firms perform it.

Investigative journalists should do exactly the same.

Dominion International

Public records identify Dominion International as a financial services and property group operating during the late twentieth century.

Like many businesses of its era, the company expanded during a period of significant economic optimism.

Expansion, however, was followed by financial difficulty.

Eventually, Dominion International collapsed.

Its failure resulted in insolvency proceedings and references within the public record to proceedings under the Company Directors Disqualification Act 1986 .

Those references immediately raised several important questions.

What happened?

What findings were made?

What role did the directors play?

At this stage of the investigation, those questions remain more important than any conclusions.

Separating Fact from Reputation

One of the challenges in investigating historic corporate failures is distinguishing between documented fact and decades of repeated commentary.

Newspaper articles often summarise events.

Online discussions repeat fragments of information.

Corporate biographies naturally focus on achievements rather than setbacks.

None of those sources should be accepted without verification.

For that reason, this investigation is being built around primary evidence wherever possible.

The objective is to obtain and review:

Companies House records;
court judgments;
Insolvency Service documents;
regulatory notices;
official filings;
historical corporate records.

These documents provide a far more reliable account than retrospective opinion.

Why This Matters

It would be easy to assume that events from the late twentieth century have little relevance today.

That would be a mistake.

Corporate history does not exist to predict future conduct.

It exists to provide context.

Many respected business leaders have experienced failed ventures before later building successful organisations.

Equally, previous insolvencies, restructurings and regulatory proceedings form part of the experience that directors bring to future roles.

Understanding that experience is a normal part of due diligence.

It should not be controversial.

The Questions Still to Be Answered

As this investigation continues, the focus is now shifting from general history to specific evidence.

Among the questions still being examined are:

What business model was Dominion International pursuing?
What events led to its collapse?
What conclusions did the courts ultimately reach?
What role did individual directors play?
What lessons can be drawn from the official record?

These are questions of fact, not opinion.

They deserve answers supported by documents rather than speculation.

Looking Ahead

Dominion International represents the earliest significant chapter in this investigation.

It establishes the beginning of a corporate timeline.

The next chapter moves forward into the early 2000s with Eneco Inc. , where the documentary record becomes substantially more detailed.

Unlike Dominion, Eneco generated years of bankruptcy proceedings, court judgments and intellectual property litigation.

Those records provide a rare opportunity to examine a corporate story almost entirely through original legal documents.

As always, this investigation will follow one simple principle.

No assumptions.

No sensationalism.

No conclusions beyond the evidence.

Because in the end, the documents tell the story far better than anyone else can.

Looking Beyond the Biography of Max Lewinsohn

Sun, 26 Jul 2026 06:00:57 GMT

The Chairman - Wellbeing International Foundation LTD

When we visit a company's website, we are presented with a carefully prepared introduction to its leadership team.

These biographies are designed to inspire confidence. They summarise careers, achievements and experience, presenting the individuals entrusted with guiding the organisation.

There is nothing unusual about that.

Every successful business does it.

But good investigative journalism asks a different question.

What does the public record tell us beyond the biography?

That question led me to the Chairman of Wellbeing International Foundation, Max Lewinsohn .

As my investigation into the business of longevity expanded beyond science and into investment, one thing became increasingly clear.

Patients may be interested in treatments.

Investors are interested in leadership.

When private capital is being raised to support an emerging medical business, the experience and corporate history of those leading that business become just as important as the science itself.

This article is not an accusation.

Nor is it an attempt to rewrite history.

It is an examination of the public record and an effort to understand the career of one of the key figures behind Wellbeing International Foundation.

The Public Biography

Wellbeing International Foundation describes Max Lewinsohn as a Chartered Accountant with more than forty years of international business experience.

According to the company's published biography, he has advised and guided numerous public companies and has held senior positions across finance, technology and investment.

It is an impressive résumé and undoubtedly reflects extensive experience in corporate finance.

Experience, however, is only one part of any business story.

Every long corporate career contains successes, setbacks and difficult decisions.

The question is whether the publicly available biography reflects the complete picture.

Why Corporate History Matters

Business history is not about assigning blame.

Companies fail.

Markets change.

Technology evolves.

Economic conditions deteriorate.

Many respected entrepreneurs have experienced failed businesses before later creating successful ones.

Failure alone tells us very little.

However, corporate history provides valuable context.

When investors evaluate a company, they routinely examine the track record of its directors.

Banks perform due diligence.

Institutional investors commission background reports.

Prospective shareholders ask difficult questions.

Patients rarely do.

Perhaps they should.

When a healthcare organisation asks people to place their trust in innovative therapies, understanding the experience of those leading the company is entirely reasonable.

Dominion International

One of the earliest significant companies associated with Max Lewinsohn was Dominion International.

Contemporary reports describe Dominion as a financial-services and property group that ultimately collapsed during the 1990s.

Public reports also refer to proceedings brought under the Company Directors Disqualification Act following the company's failure.

At the time of writing, I am obtaining the original court papers, Insolvency Service records and regulatory documents relating to those proceedings.

The objective is simple.

To establish, from the original evidence:

Mr Lewinsohn's exact role;
the findings made by the court;
the reasons for any reported disqualification;
and the wider circumstances surrounding the company's collapse.

Those documents—not newspaper headlines—will determine the conclusions reached in this investigation.

Eneco

More than a decade later, Max Lewinsohn's name again appears within extensive legal proceedings involving Eneco Inc., an American technology company attempting to commercialise energy-related intellectual property.

Court records show that Eneco entered Chapter 11 bankruptcy protection before later being converted into Chapter 7 liquidation.

The subsequent sale of intellectual property resulted in years of litigation involving investors, creditors and competing claims over valuable technology.

Mr Lewinsohn appears within those proceedings through his involvement with Maximillian & Co., and the court papers provide a detailed account of the commercial disputes that followed.

The existence of litigation should never be interpreted as evidence of wrongdoing.

Complex commercial disputes frequently arise following corporate insolvencies.

What matters is understanding the documented facts rather than relying upon speculation.

That is precisely what this investigation seeks to do.

A Career Across Many Businesses

Public records indicate that Mr Lewinsohn has been associated with numerous businesses spanning finance, technology, investment and education.

Some were successful.

Some ceased trading.

Others entered insolvency procedures.

That is not unusual over a career lasting more than four decades.

The significance lies not in the existence of corporate failures, but in understanding the complete corporate history rather than only the highlights presented within a biography.

Experience should always be viewed in its entirety.

Why This Matters Today

Today, Max Lewinsohn chairs an organisation operating within one of the fastest-growing sectors of modern healthcare.

Longevity medicine is attracting global attention, increasing patient demand and significant private investment.

That naturally places greater importance on transparency.

Prospective investors may reasonably wish to understand the experience of those entrusted with managing their capital.

Patients considering innovative treatments may equally wish to understand the corporate leadership behind the organisation providing those services.

These are not unreasonable questions.

They are part of responsible due diligence.

The Investigation Continues

This chapter is not intended to reach final conclusions.

It is intended to identify the questions that now require documentary answers.

Over the coming weeks, this investigation will examine:

Companies House filings;
court judgments;
insolvency records;
bankruptcy proceedings;
director appointments;
regulatory documents;
historical corporate filings.

Only after those original documents have been reviewed will it be possible to build a complete picture of Mr Lewinsohn's corporate career.

Good investigations do not begin with conclusions.

They begin with evidence.

And as this series has already demonstrated, the deeper one looks into the business of longevity, the more important the documents become.

The science brought me here.

The business persuaded me to keep digging.

In the next chapter, we move beyond the biographies and begin analysing the documentary evidence itself—company by company, filing by filing and judgment by judgment.

Peer Reviewed... But Does It Actually Prove Anything?

Sun, 26 Jul 2026 05:57:29 GMT

A closer examination of Wellbeing International Foundation's published longevity study

For years, the regenerative medicine industry has been driven by hope, innovation and compelling patient testimonials. Scientific research has often followed behind the marketing, leaving patients to decide whom to trust in an increasingly complex field.

So when Wellbeing International Foundation announced that its longevity programme had been published in the peer-reviewed journal Frontiers in Aging, it appeared to represent a significant milestone. To many readers, "peer reviewed" carries an understandable implication: that the treatment has now been scientifically proven.

But does it?

After carefully reviewing both the published paper and Wellbeing's accompanying announcement, the answer is more nuanced than the headlines might suggest.

The study is genuine.

The journal is genuine.

The peer-review process is genuine.

However, that does not necessarily mean the treatment itself has been proven effective.

A Genuine Scientific Publication

Unlike many promotional claims found throughout the regenerative medicine sector, this research genuinely exists within the scientific literature.

Published in Frontiers in Aging in June 2026, the paper underwent formal peer review before publication. That immediately places it on a higher scientific footing than organisations relying solely on testimonials or marketing material.

Publication, however, is only the beginning of scientific scrutiny—not its conclusion.

Throughout medical history, many promising early studies have later failed to withstand larger, independent clinical trials. Peer review establishes that research is worthy of discussion; it does not establish that a treatment has been conclusively proven.

Who Conducted the Research?

Whenever evaluating a scientific paper, one of the first questions investigators should ask is straightforward:

Who carried out the research?

In this case, the study was authored by researchers employed by Wellbeing International Foundation together with employees of xLongevity.

In other words, the organisations responsible for delivering and promoting the programme also designed, conducted and published the research.

That is not unusual within pharmaceutical or biotechnology research, nor does it invalidate the findings.

However, it does mean the study should not be viewed as independent confirmation.

The authors openly declared these commercial relationships within the publication, allowing readers to assess the findings with appropriate context.

Fourteen Participants

Only fourteen volunteers completed the seventeen-week programme.

That is an exceptionally small sample from which to draw broad conclusions.

Pilot studies are designed to explore possibilities and generate future research questions.

They are not intended to provide definitive clinical proof.

The Fundamental Scientific Limitation

The most significant limitation of the study is surprisingly simple.

It is impossible to determine which part of the programme produced the reported improvements.

Participants did not receive Cell-Free Therapy alone.

Instead, they completed a comprehensive programme including:

dietary modification;
structured exercise guidance;
intermittent fasting;
sleep optimisation;
nutritional supplementation, including NMN, GlyNAC, taurine, creatine, curcumin and CoQ10;
two infusions of autologous cell-conditioned media.

Every participant received every intervention.

There was:

no placebo group;
no untreated control group;
no group receiving lifestyle changes without the infusions;
no randomisation;
no blinding.

As a result, even if genuine improvements occurred, the study cannot identify which intervention—or combination of interventions—was responsible.

Biological Age Versus Chronological Age

Perhaps the most eye-catching claim promoted after publication was that participants finished the programme several years "biologically younger."

This is an attractive headline.

However, it is important to understand what was actually measured.

The researchers did not demonstrate that participants physically became younger.

Instead, they used biological-age algorithms based upon laboratory biomarkers.

These so-called ageing clocks estimate biological age using mathematical models.

They are valuable research tools, but they are not direct measures of rejuvenation.

The study did not demonstrate:

increased lifespan;
reduced mortality;
disease prevention;
tissue regeneration;
improved physical performance;
improved cognitive function.

It demonstrated changes in laboratory markers over a relatively short period.

Those findings are scientifically interesting.

They are not proof that ageing has been reversed.

Understanding the Numbers

Wellbeing's accompanying announcement highlights participants finishing approximately:

5.8 years younger according to one biological-age clock;
4.1 years younger according to another.

These figures are technically accurate within the context presented.

However, they describe the participants' final estimated biological age relative to their chronological age.

The actual change observed during the study was considerably smaller.

That distinction is important.

Without careful explanation, readers could reasonably assume that participants reversed more than five years of ageing in just seventeen weeks.

That is not what the published paper demonstrates.

Ethics and Transparency

Another aspect of the study deserves discussion.

The paper explains that two registered physicians concluded, using UK Health Research Authority guidance, that NHS Research Ethics Committee approval was not required.

However, the publication does not clearly identify:

an independent ethics committee overseeing the study;
the physicians who reached that conclusion;
the country in which the infusions were administered;
the laboratory manufacturing the investigational product;
the accreditation of that manufacturing facility.

None of these omissions necessarily imply any wrongdoing.

Nevertheless, when healthy volunteers receive an investigational intravenous biological product, greater transparency would strengthen confidence in the research.

Commercial Connections

One of the strongest aspects of the paper is also one of its most important disclosures.

The authors openly state that they were employed by organisations involved in delivering the programme.

That openness should be recognised.

At the same time, it reinforces why independent replication is essential.

Medical history contains countless examples of encouraging pilot studies that could not be reproduced by independent researchers.

Replication—not publication alone—is ultimately what establishes scientific confidence.

What the Study Actually Demonstrates

To the authors' credit, the paper itself is measured in its conclusions.

It does not claim to have cured ageing.

It does not claim definitive proof.

Instead, it presents preliminary findings and openly acknowledges that larger, properly controlled clinical trials are required.

That is precisely how early-stage scientific research should be presented.

The published paper is, in many respects, more cautious than some of the marketing that has surrounded regenerative medicine in recent years.

Conclusion

This study represents an important milestone for Wellbeing International Foundation.

It demonstrates that a complex, multi-component health programme was associated with improvements in several biological markers among fourteen participants.

What it does not demonstrate is that Wellbeing's Cell-Free Therapy alone produced those improvements.

Nor does it prove biological rejuvenation or establish clinical effectiveness.

Ultimately, scientific credibility is built through repeated, independent verification conducted by researchers with no commercial involvement in the treatment being evaluated.

Until those studies are completed, this publication should be regarded for what it is: an interesting and encouraging pilot study that raises important questions—but does not yet provide definitive answers.

Good science rarely deals in certainty.

It progresses by asking better questions.

This paper is an important contribution to that process, but it should be viewed as the beginning of the conversation rather than the end of it.

How a Stem Cell Company Became an Investment Opportunity

Sun, 26 Jul 2026 05:51:24 GMT

THE BUSINESS OF LONGEVITY

Introduction

When I first began looking into Wellbeing International Foundation, my aim was simple.

I wanted to understand one thing.

Does Cell-Free Therapy actually work?

Like many people, I expected the story to centre on regenerative medicine, clinical research, and patient outcomes.

But the deeper I went, the more the focus began to shift.

What initially appeared to be a medical story increasingly revealed another dimension.

This was not only about science.

It was also about business.

This article is not an allegation of misconduct.

Nor is it a challenge to the validity of ongoing research.

Instead, it is an attempt to understand how an emerging medical concept transitions into a commercial structure capable of attracting private capital.

That distinction is important.

Because patients and investors often evaluate the same organisation in very different ways.

Patients want to know whether a treatment is effective.

Investors want to know whether a company can scale.

Those two perspectives are not always supported by the same evidence.

A New Narrative Emerges

Wellbeing International Foundation positions itself as a leader in regenerative medicine and longevity science.

Its public communications emphasise extending healthspan, advancing biological research, and developing innovative therapeutic approaches.

On the surface, this is a familiar and legitimate ambition.

Medical progress depends on organisations willing to fund research and explore new frontiers.

However, as I reviewed more material, a second narrative began to appear alongside the scientific one.

Alongside references to biology and clinical work, there were repeated themes of:

expansion
growth
capital
investment
clinical networks
commercial partnerships

These are not the language of a laboratory.

They are the language of enterprise.

This is not unusual in itself.

Most biotechnology companies must eventually operate as commercial entities if their research is to reach patients at scale.

The key question is not whether commercialisation exists.

It is whether the scientific progress and the business development are aligned in timing and substance.

The Scientific Milestone

In June 2026, Wellbeing announced that its longevity programme had been published in the peer-reviewed journal Frontiers in Aging.

This was a meaningful milestone.

Peer review remains an important part of scientific validation.

It indicates that independent reviewers considered the work suitable for publication.

However, it does not confirm clinical effectiveness.

As discussed in the previous article, the study itself was a small pilot involving fourteen participants, no control group, multiple simultaneous interventions, and several acknowledged limitations.

The authors were appropriately cautious in their conclusions.

From a scientific standpoint, the findings were exploratory rather than definitive.

From a commercial standpoint, however, the publication carried a different weight.

It allowed the company to state that its programme had been peer-reviewed.

In a competitive healthcare and longevity market, that distinction carries significant reputational value.

A Different Kind of Announcement

Several months earlier, another update appeared on the company’s website.

It attracted far less public attention.

Unlike the scientific publication, this announcement focused on finance.

Wellbeing confirmed that it had completed the first tranche of its 2026 investment round.

The statement described strong investor interest and noted that the funds would support research, international expansion, clinical infrastructure, and operational development.

None of this is unusual.

Scientific research is expensive.

Clinical expansion requires capital.

Innovation depends on funding.

However, what stood out was not what was said, but what was not.

The announcement did not disclose:

the total amount raised
the company valuation
the identity of investors
the type of securities issued
the level of equity dilution
current revenue figures
audited financial statements

Instead, readers were told that these details remained private.

For a privately held company, this may be entirely standard practice.

But it also limits the ability of external observers to independently assess financial strength and risk.

The Meaning Behind “Foundation”

One of the more interesting aspects of this investigation is the company’s name itself.

The term “Foundation” is commonly associated with charitable organisations, research institutes, or non-profit entities.

There is no legal requirement preventing a commercial company from using the term.

However, names influence perception.

At the same time as presenting itself as a foundation, the organisation also discusses investment rounds, patient revenue, international expansion, and commercial growth.

These concepts are not inherently contradictory.

Many organisations combine research, clinical work, and commercial activity.

Nevertheless, it raises reasonable questions for patients and investors alike about structure.

How is the organisation legally organised?

Which entities hold intellectual property?

Where does revenue flow?

How is future growth financed?

These are not accusations.

They are questions of clarity.

Bermuda and Public Disclosure

Another relevant factor is jurisdiction.

Wellbeing states that it is headquartered in Bermuda.

Bermuda is a recognised international financial centre used by many legitimate global companies.

There is nothing unusual in that.

However, privately held companies incorporated in such jurisdictions often disclose less financial information publicly than listed companies in more regulated public markets.

As a result, external observers may have limited access to independently verified financial data.

This does not imply wrongdoing.

It simply means that much of the available information comes directly from company communications rather than public filings.

In such environments, transparency becomes especially important for building trust.

Following the Money

At some point, every scientific programme intersects with financial reality.

Research requires funding.

Facilities require infrastructure.

Teams require salaries.

No meaningful innovation occurs without capital.

The question is therefore not whether money is involved.

It is what that money is being used to support.

Is investment backing a treatment that has already been clinically validated?

Or is it funding the development of a technology still in early-stage evaluation?

These are fundamentally different propositions.

Understanding that difference is essential for anyone evaluating both risk and potential.

Conclusion

This investigation began with a question about stem cells.

It has evolved into a broader examination of how longevity science becomes a commercial enterprise.

The science remains central.

But so too do the structures, disclosures, and financial decisions that surround it.

Innovation requires investment.

Investment requires transparency.

And transparency begins with scrutiny.

In the next chapter, we turn to one of the key individuals behind Wellbeing International Foundation.

His background spans finance, corporate development, and international business.

But as with all investigations, the public narrative is only the surface.

The deeper story lies in the details beneath it.

The Ten Questions Every Patient Should Ask Before Spending £40,000 on Experimental Medical Treatment

Sat, 18 Jul 2026 08:01:53 GMT

"The most powerful question in medicine is often the one that is never asked."

Over the course of this investigation we have examined publicly available company records, reviewed scientific claims, analysed an undercover consultation and explored the importance of published clinical evidence.

Throughout the series we have deliberately avoided telling readers what to think.

Instead, we have asked questions.

Because informed decisions begin with informed questions.

Whether you are considering regenerative medicine, stem cell therapy, extracellular vesicles or any other innovative treatment, the same principles apply.

Before committing your health—and potentially tens of thousands of pounds—we believe every patient deserves clear answers.

Here are the ten questions we believe matter most.

1. Who Am I Actually Paying?

Before transferring any money, ask:

Which legal company will receive my payment?
Which country is that company incorporated in?
Which company appears on my invoice?
Who signs my contract?

Knowing exactly who you are doing business with is the first step in protecting yourself.

2. Who Decided I Was Suitable?

Ask:

Who reviewed my medical history?
Who accepted me for treatment?
Is there a formal assessment process?
Are patients ever declined?

Understanding how treatment decisions are made is just as important as understanding the treatment itself.

3. What Published Clinical Evidence Supports This Recommendation?

Request:

Peer-reviewed human clinical studies.
Independent publications.
Long-term outcome data.
Safety information.
Published complication rates.

Hope is important.

Evidence is essential.

4. What Are The Risks?

Every medical treatment carries uncertainty.

Ask openly:

What complications have been recorded?
How often do they occur?
What happens if treatment fails?
What follow-up is provided?

No reputable healthcare provider should be uncomfortable discussing risk.

5. What Alternatives Exist?

A balanced consultation should explain more than one option.

Ask:

What happens if I do nothing?
Are there conventional treatments available?
Why is this treatment recommended instead?

Good decisions are made by comparing choices—not hearing only one.

6. Can I Take Time To Think?

Large financial decisions should never feel rushed.

Ask for time.

Go home.

Read.

Research.

Discuss the information with your family, GP or specialist.

If a treatment is appropriate today, it should still be appropriate after careful consideration.

7. What Happens If I Change My Mind?

Before paying, understand:

refund policies;
cancellation rights;
written terms and conditions;
dispute procedures.

These questions are easier to ask before payment than afterwards.

8. Who Regulates This Treatment?

Ask:

Which professional bodies oversee the treatment?
Which regulations apply?
What standards are followed?
Is the clinic independently inspected?

Understanding the regulatory framework provides valuable context.

9. Can I Verify The Information Independently?

Look beyond marketing material.

Search for:

independent publications;
clinical trial databases;
scientific reviews;
regulatory guidance;
company records.

Reliable information should be capable of independent verification.

10. Am I Making This Decision Because Of Evidence… Or Hope?

Perhaps the most difficult question of all.

When people are living with chronic illness, pain or life-changing diagnoses, hope becomes incredibly powerful.

Hope is human.

Hope drives innovation.

Hope inspires research.

But hope should never replace informed decision-making.

The strongest decisions are those supported by both optimism and evidence.

The Lesson We Learned

This investigation was never about proving whether a treatment works.

Nor was it about criticising innovation.

Medical progress depends upon researchers who challenge established thinking.

New ideas are essential.

What we learned, however, is that asking better questions often produces better decisions.

Corporate history matters.

Transparency matters.

Clinical evidence matters.

Independent verification matters.

Most importantly…

Patients matter.

A Final Word

Every patient deserves respect.

Every patient deserves honesty.

Every patient deserves the opportunity to ask difficult questions without feeling uncomfortable.

The purpose of this investigation has never been to discourage innovation.

It has been to encourage informed decision-making.

Because when healthcare, hope and significant financial commitments come together, there should never be any hesitation in asking one more question.

Sometimes the most valuable treatment you receive is not an injection, a procedure or a promise.

Sometimes it is the confidence that comes from knowing you asked every question that mattered.

And if this series encourages even one patient to pause, ask those questions and make a better-informed decision, then it has achieved exactly what it set out to do.

Who Decides You're Suitable for Treatment? A Question Every Patient Should Ask

Sat, 18 Jul 2026 07:59:41 GMT

When people consider an innovative medical treatment, the first question is usually obvious.

The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.

Before Spending £40,000 on Medical Treatment, Here's One Thing Many Patients Forget to Check

Sat, 18 Jul 2026 07:56:53 GMT

When people are considering an expensive medical treatment, it's completely understandable that they focus on one thing.

Will it help me?

They read testimonials.

They watch videos.

They speak to consultants.

They search online for stories from other patients.

But there is another area that deserves just as much attention.

The business behind the treatment.

Looking Beyond the Science

Imagine you're about to invest £30,000, £40,000 or even more in a treatment that offers hope for a serious medical condition.

Most people would naturally want to understand:

How the treatment works.
Who developed it.
What previous patients experienced.

But there are other questions that are just as important.

Who owns the company?

Which legal entity are you actually contracting with?

Where is that company based?

Which country's laws protect you if something goes wrong?

These are not questions of science.

They are questions of consumer protection.

Public Records Tell Their Own Story

One of the simplest due diligence checks anyone can carry out is to review publicly available corporate records.

In the UK, Companies House provides information on directors, company status, filing history and corporate changes.

Those records do not tell you whether a treatment works.

Nor do they tell you whether a business is trustworthy.

What they do provide is valuable background information that helps consumers understand the history of the organisation they are considering doing business with.

A Corporate History Is Not a Verdict

During our own research into companies operating in the regenerative medicine sector, we found that some key individuals had been associated with multiple businesses over a number of years.

Some of those companies remain active.

Others have been dissolved.

Some have been subject to compulsory strike-off procedures.

One entered liquidation before being dissolved.

It is important to be absolutely clear.

None of those facts, taken individually, demonstrate wrongdoing.

Companies close every day for perfectly legitimate commercial reasons.

Entrepreneurs often establish and close companies throughout their careers.

Public records simply provide context.

Why Context Matters

If you were buying a £40,000 car, you would probably research the dealer.

If you were investing £40,000 into a business, you would likely review its financial background.

Medical treatment deserves no less careful consideration.

Understanding the corporate history of a business is not about suspicion.

It is about making informed decisions.

Questions Worth Asking

Before making any significant financial commitment, consider asking:

Which company am I paying?
Which legal entity signs my contract?
Where is that company incorporated?
Which country's legal system applies?
Who carries responsibility if I need to make a complaint?
Can I independently verify the business history of the organisation?

Any reputable organisation should understand why patients ask these questions.

Transparency Builds Confidence

Good businesses have nothing to fear from informed customers.

In fact, transparency often strengthens trust.

When organisations openly explain their structure, ownership and responsibilities, prospective patients are able to make decisions with greater confidence.

That benefits everyone involved.

Due Diligence Is Not Distrust

One of the biggest misconceptions is that asking questions means you don't trust a business.

The opposite is true.

Responsible consumers ask questions because they are making responsible decisions.

Whether you are buying a home, investing your savings or considering an innovative medical treatment, understanding who you are dealing with is simply good practice.

Final Thoughts

Hope is an important part of medicine.

Innovation drives healthcare forward.

But neither should replace careful research.

Before making any life-changing financial decision, take the time to understand not only the treatment itself, but also the organisation offering it.

The answers you receive may give you greater confidence.

And if they raise further questions, those questions deserve to be answered before any commitment is made.

An informed patient is not a difficult patient.

An informed patient is a protected patient.

Behind the Brand - Wellbeing International Foundation Ltd.

Sat, 11 Jul 2026 04:28:42 GMT

What Our Investigation Discovered – And Why It Raises Even More Questions

Three articles.

Hundreds of pages of research.

Public records.

Corporate databases.

Professional profiles.

Company websites.

Legal documents.

What began as a simple investigation into one international regenerative medicine provider quickly became something much bigger.

It became an investigation into transparency.

Not whether regenerative medicine works.

Not whether patients improve.

Not whether companies have good intentions.

Instead, we found ourselves asking a much simpler question.

Who exactly is standing behind Wellbeing International Foundation Ltd. asking patients to place their trust—and often tens of thousands of pounds—in their hands?

The investigation changed direction

When we first began our research, we expected to spend most of our time examining treatments.

Instead, we spent far more time trying to understand corporate structures.

Legal entities.

Jurisdictions.

Responsibilities.

Relationships between clinics, laboratories and management companies.

The more we looked, the more we realised something important.

Patients rarely investigate the company behind the treatment.

Most investigate the treatment itself.

Why that matters

Healthcare is built on trust.

Patients trust doctors.

They trust clinics.

They trust websites.

They trust testimonials.

But trust becomes even stronger when it is supported by transparency.

Understanding who you are dealing with is not a sign of scepticism.

It is part of making an informed decision.

The ability to identify the legal entity providing the service, understand where it is based, and know which laws govern the relationship should never be viewed as an inconvenience.

It should be considered part of responsible healthcare.

We found questions—not conclusions

Throughout this series, we deliberately resisted the temptation to jump to conclusions.

Investigations should never begin with an outcome already decided.

Instead, they should begin with evidence.

Where we found evidence, we reported it.

Where we found uncertainty, we explained it.

Where questions remained unanswered, we asked them openly.

That approach matters.

Because unanswered questions are not proof of wrongdoing.

Equally, unanswered questions deserve thoughtful answers when patients are making significant medical and financial decisions.

The importance of independent verification

Modern healthcare organisations often operate internationally.

They may work with partner clinics.

Independent laboratories.

Consultants.

Medical specialists.

Administrative companies.

Marketing organisations.

There is nothing inherently unusual about any of those arrangements.

The important question is whether patients can clearly understand how those pieces fit together.

Transparency is not about satisfying journalists.

It is about giving patients confidence that they fully understand who they are trusting.

But this investigation has uncovered something much bigger…

As we assembled the evidence for this series, another story slowly began to emerge.

One that we hadn't originally intended to investigate.

It isn't about one company.

It isn't even about one clinic.

It's about how modern international healthcare businesses are structured—and how difficult it can sometimes be for an ordinary patient to follow the corporate trail from a website to the legal entity ultimately responsible for their care.

That journey deserves closer examination.

And that's exactly where our investigation now turns.

Coming Next: Following the Corporate Trail

Over the coming weeks, we'll begin a new investigation into Wellbeing International Foundation Ltd.

This time, we'll go beyond websites and marketing material.

We'll follow the paperwork.

The contracts.

The invoices.

The consultations.

The legal entities.

The laboratories.

And the people behind them.

Among the questions we'll be investigating are:

Which legal company actually contracts with patients?
Which organisation receives payment?
Which entity carries legal responsibility?
Who employs the people involved in patient care?
How are international partnerships structured?
Which laboratories provide the products or services?
What regulatory oversight exists at each stage of the patient journey?
What protections are available if treatment does not go as planned?

And perhaps the biggest question of all:

Can an ordinary patient easily discover these answers before committing their health and their life savings?

A new direction

The next stage of this investigation will be different.

We'll move beyond public records.

We'll examine first-hand experiences.

We'll analyse contracts and documentation.

We'll compare what patients are told with what can be independently verified.

Most importantly, we'll continue applying the same principle that guided this entire series:

Follow the evidence.

Not assumptions.

Not speculation.

Evidence.

Because in healthcare, informed decisions begin with informed questions.

And sometimes, the most important discoveries aren't the answers we find—

They're the questions we realise still need asking.

Our investigation is only just beginning.

What's Really Behind a Modern Stem Cell Clinic?

Sat, 11 Jul 2026 04:22:24 GMT

Understanding the people, systems and infrastructure that patients rarely see

When most people think about stem cell therapy or regenerative medicine, they picture a consultation room, a doctor and perhaps a laboratory.

In reality, that's only a tiny part of the picture.

Modern regenerative medicine is one of the most complex areas of healthcare. Behind every consultation lies an extensive network of specialists, governance, regulation, quality control and administration that most patients never see.

Understanding that infrastructure isn't just interesting—it can help you make better decisions when choosing where to place your health, and often a significant financial investment.

It starts long before the patient arrives

Every reputable regenerative medicine provider should have systems in place before a patient even walks through the door.

Those systems typically include:

Clinical governance.
Medical leadership.
Patient assessment procedures.
Laboratory partnerships.
Regulatory compliance.
Quality assurance.
Data protection.
Financial and legal oversight.

These aren't optional extras.

They're the foundations that support safe and accountable healthcare.

Doctors are only one part of the team

A successful regenerative medicine programme is rarely built around one individual.

Behind the scenes, patients would normally expect to find a multidisciplinary team that may include:

Consultant physicians.
Medical directors.
Specialist clinicians.
Registered nurses.
Laboratory scientists.
Quality managers.
Patient coordinators.
Administrative staff.
Compliance specialists.
Customer support teams.

Each plays a different role in ensuring treatments are delivered consistently and responsibly.

The laboratory is often the heart of the operation

Whether treatments involve stem cells, cell-free therapies, biologics or other regenerative products, laboratory standards are critical.

Patients may reasonably wish to understand:

Where are products prepared?
Who is responsible for quality control?
What standards are followed?
How is sterility maintained?
What safeguards exist to ensure consistency?

Many providers work with specialist laboratories rather than operating their own.

There is nothing unusual about that.

The important point is that patients should understand who those laboratories are and what role they play in the treatment process.

Healthcare is heavily regulated for a reason

Unlike many industries, healthcare operates within strict regulatory frameworks designed to protect patients.

Depending on the countries involved, a regenerative medicine provider may need to comply with multiple legal and professional requirements.

Patients may wish to ask:

Which country's regulations apply?
Which professional bodies oversee the clinicians?
What standards govern the laboratory work?
How are complications reported?
What systems exist for patient safety?

Clear answers to these questions help build confidence.

Quality doesn't happen by accident

Some of the most important work within a healthcare organisation happens away from patients.

Quality assurance teams monitor systems, review procedures, investigate incidents and continually improve the service.

Although much of this work is invisible, it is fundamental to maintaining high standards.

Without robust governance, even experienced clinicians can find themselves working within systems that lack consistency or accountability.

Looking beyond the treatment itself

Patients often focus on outcomes.

Understandably so.

But asking questions about the organisation itself can be just as important.

For example:

Who employs the clinical staff?
Which company provides the treatment?
Who carries legal responsibility?
What professional insurance exists?
How are complaints handled?
Who oversees patient safety?

These questions don't imply that something is wrong.

They simply help patients understand the organisation they are placing their trust in.

Transparency builds confidence

Many excellent healthcare providers openly explain how they operate.

They identify their clinical leadership.

They describe their laboratory partnerships.

They explain their governance arrangements.

They provide clear information about the legal entities involved in patient care.

That level of openness allows prospective patients to make informed choices.

It also demonstrates confidence in the systems supporting the treatment.

Before making your decision...

If you're considering regenerative medicine, don't just ask about success rates or testimonials.

Ask about the organisation itself.

Ask how it operates.

Ask who is responsible.

Ask how quality is maintained.

Ask who stands behind the treatment—not just medically, but organisationally.

Because the strongest healthcare providers are built on far more than promising therapies.

They're built on transparent governance, experienced professionals, robust systems and a willingness to answer the questions that every patient has the right to ask.

Before You Spend Thousands on Medical Treatment, Ask One Simple Question…

Sat, 11 Jul 2026 04:19:36 GMT

Do you really know who you're dealing with?

When people consider travelling overseas or spending significant sums on private regenerative medicine treatments, they often focus on one thing:

Will the treatment work?

It's an understandable question.

But during our own investigation into one international regenerative medicine provider, we found ourselves asking a different question altogether.

Wellbeing International Foundation Ltd. Who is the company behind the treatment?

Surprisingly, finding a clear answer wasn't as straightforward as we expected.

This article isn't about making accusations or suggesting wrongdoing.

It's about explaining why understanding the legal identity of a healthcare provider should be just as important as understanding the treatment itself.

Every investigation starts somewhere

Like many patients, our first step was online.

Professional websites.

Social media.

Public company profiles.

One publicly available company profile described the organisation as an international private business headquartered in Hamilton, Bermuda, with a workforce of between 11 and 50 employees.

On the face of it, everything appeared professional.

Naturally, that led to the next question.

Could that information be independently verified?

Looking beyond the marketing

Whenever a business promotes expensive healthcare services, there are usually public records that help people understand who they are dealing with.

Depending on where a business is incorporated, these may include information about:

Directors.
Registered offices.
Corporate filings.
Financial accounts.
Company history.
Ownership.
Other associated companies.

These records don't tell the whole story, but they often provide reassurance that a business has a clear and identifiable corporate structure.

So we began looking.

An unexpected challenge

Our research quickly highlighted an issue that many prospective patients may never consider.

Identifying the legal entity behind Wellbeing International Foundation Ltd. wasn't as simple as identifying the brand being promoted.

That distinction matters.

A trading name, website or marketing brand isn't always the same as the legal company that enters into contracts, receives payment or carries legal responsibility.

For patients, understanding that difference can be extremely important.

Why the legal entity matters

Imagine investing tens of thousands of pounds in treatment.

Before doing so, most people would probably want to know:

Which company will issue the invoice?
Which company am I entering into a contract with?
Which country's laws govern that agreement?
If I have a complaint, who is legally responsible?
Which organisation actually employs the people caring for me?

These aren't difficult questions.

They're sensible questions.

In almost every significant financial decision we make—buying a home, investing money or taking out insurance—we expect to know exactly who we're dealing with.

Healthcare should be no different.

Transparency builds confidence

It's important to say that international businesses often operate through multiple companies, partner organisations and specialist service providers.

That, in itself, isn't unusual.

Nor does it suggest anything improper.

However, transparency allows patients to understand how those organisations fit together.

When corporate information is clear and easy to verify, confidence grows.

When it is difficult to identify, patients may reasonably decide to ask a few more questions before proceeding.

Questions worth asking

If you're considering any private regenerative medicine provider, you may wish to ask:

What is the full legal name of the company I am contracting with?
Where is that company registered?
Which country's laws apply to my agreement?
Who employs the people involved in my treatment?
Where can I independently verify the company's corporate information?

These questions aren't designed to challenge anyone.

They're designed to help patients make informed decisions.

This investigation is only beginning

The purpose of our research isn't to tell readers what to think.

It's to encourage them to look beyond glossy brochures and polished websites.

In the coming articles, we'll explore what a genuine international regenerative medicine operation typically requires behind the scenes—from clinical governance and laboratory standards to regulatory oversight and corporate accountability.

Because before placing your health and your finances in someone else's hands, one question is always worth asking:

Do I really know who I'm dealing with?

Building Trust Through Transparency

Fri, 03 Jul 2026 11:22:58 GMT

How Public Claims Shape Patient Confidence in International Healthcare

When people seek medical treatment, they are not simply buying a service.

They are placing their health—and often their hope—in the hands of an organisation they may know very little about.

That is why trust is one of the most valuable assets any healthcare provider possesses.

Trust is influenced by many factors. Clinical expertise, patient experience, scientific evidence and professional standards all play an important role. Equally important, however, is transparency.

Patients increasingly research healthcare providers online before making contact. They compare treatments, read testimonials, examine websites and try to understand the organisations behind the services being offered.

The information presented publicly often forms a patient's first impression.

As part of our ongoing investigation into Wellbeing International Foundation, we have explored the organisation's published description of its international partner clinic network and examined what information prospective patients can independently verify before entering the enquiry process.

Our previous articles focused on the visibility of the claimed clinic network and the question of accountability within an international treatment model.

This final article asks a broader question.

How should healthcare organisations communicate their scale, structure and partnerships in a way that supports patient confidence?

First Impressions Matter

Modern healthcare organisations invest significant effort in presenting themselves professionally.

Websites often describe international reach, specialist expertise, research collaborations and partnerships with healthcare professionals.

There is nothing unusual about this.

Patients naturally look for reassurance.

An organisation that appears established, experienced and internationally connected may inspire greater confidence than one providing little public information.

However, confidence is strongest when those public claims can be independently understood and verified.

If a website describes a global network, patients may reasonably expect to see evidence of that network.

If it refers to partner clinics, readers may expect those clinics to be identifiable.

If physicians play a central role, patients may wish to know who those physicians are before making contact.

Transparency transforms broad claims into information that patients can evaluate for themselves.

Scale Versus Visibility

One of the themes emerging from this investigation is the distinction between describing a healthcare network and publicly identifying its individual components.

Wellbeing International Foundation presents itself as operating internationally through partner clinics located across several countries.

That description creates an impression of organisational scale.

During our review, however, we found comparatively limited publicly available information identifying the individual clinics that make up the network.

This observation should not be interpreted as evidence that those clinics do not exist.

Rather, it illustrates the difference between describing a network and enabling the public to independently understand that network.

Many healthcare providers choose to publish detailed information about each participating location.

Others provide that information only after prospective patients make direct contact.

Both approaches are possible.

The difference lies in the amount of information available before the patient begins their journey.

Transparency Supports Better Decisions

Patients considering private healthcare frequently compare providers.

They ask questions such as:

Where will my treatment take place?

Who are the clinicians?

How long has the clinic operated?

Who regulates the facility?

What happens after treatment?

How is follow-up care organised?

The easier it is to answer those questions, the easier it becomes for patients to make informed decisions.

Transparency benefits not only patients but also healthcare professionals referring patients, journalists examining public claims and researchers studying emerging treatments.

Independent verification is not an obstacle to trust.

It is one of its strongest foundations.

Why Public Information Matters

Healthcare decisions often involve significant financial, emotional and medical considerations.

Some patients travel internationally.

Some spend substantial sums of money.

Others may be exploring treatment after exhausting conventional options.

In each case, reliable information becomes particularly important.

Patients should not have to rely solely on marketing material.

They should be able to examine publicly available information and understand the organisation responsible for their care.

This principle applies broadly across healthcare.

Whether considering a local private clinic or an international medical provider, access to clear information supports better decision-making.

Lessons Beyond One Organisation

Although this investigation has focused on Wellbeing International Foundation, the issues discussed extend well beyond any single organisation.

The questions raised are relevant wherever healthcare is delivered through international partnerships, referral networks or multiple independent providers.

They encourage all healthcare organisations to consider how much information is made available to prospective patients before treatment begins.

Simple measures—such as publishing clinic directories, identifying participating clinicians, explaining organisational structures and outlining patient pathways—can significantly improve transparency.

These practices help patients understand not only the treatment being offered but also the people and organisations responsible for delivering it.

An Invitation for Dialogue

Investigative journalism is most valuable when it encourages constructive discussion rather than confrontation.

Throughout this series, we have sought to distinguish carefully between confirmed facts, observations based on publicly available information and questions that remain open.

We recognise that organisations may hold information that is not immediately visible on public websites.

For that reason, Wellbeing International Foundation remains welcome to clarify any aspect of its published clinic network, organisational structure or patient pathway.

Constructive engagement benefits everyone, particularly prospective patients seeking accurate information.

Looking Forward

Healthcare continues to evolve rapidly.

New technologies, international collaborations and innovative therapies are creating opportunities that would have seemed impossible only a generation ago.

As these developments continue, transparency will become even more important.

Patients will increasingly expect to understand not only the science behind a treatment but also the organisation delivering it.

Clear communication, accessible information and openness about clinical partnerships help build confidence long before treatment begins.

Innovation and transparency should never compete with one another.

They should work together.

Final Reflection

This investigation began with a simple question about a publicly described partner clinic network.

Along the way, it evolved into something broader.

It became an examination of how healthcare organisations communicate with the people who trust them with their health.

The purpose has never been to discourage innovation or to question individual patient experiences.

Instead, it has been to explore a principle that applies across all areas of healthcare:

When organisations make significant public claims about their reach, partnerships or clinical networks, those claims should be supported by information that patients can understand and, wherever possible, independently verify.

Transparency is not merely good public relations.

It is an essential part of informed healthcare.

Patients deserve clarity.

Clinicians deserve clarity.

The public deserves clarity.

Because when trust is built on openness, everyone benefits.

Who Is Responsible? Understanding the Role of "Partner Clinics" in International Healthcare

Fri, 03 Jul 2026 11:19:41 GMT

Accountability Matters Just as Much as Innovation

Healthcare is built on trust.

Whether a patient is undergoing routine treatment or considering an innovative regenerative therapy, one principle remains constant: they should understand who is responsible for every stage of their care.

That responsibility extends beyond the doctor carrying out the procedure. It includes the clinic where treatment takes place, the organisation coordinating the patient's journey, the laboratories involved in processing biological material and, where appropriate, the companies promoting or managing the treatment pathway.

As part of our continuing investigation into Wellbeing International Foundation, we have been examining how the organisation describes its international partner clinic network and what information is available to prospective patients before they begin treatment.

Our first article explored whether the Foundation's publicly described network of partner clinics could be independently identified using publicly available information.

This second investigation examines a different question.

If treatment is delivered through independent partner clinics, who is ultimately responsible for each stage of the patient's care?

It is an important question because accountability is one of the foundations of modern healthcare.

What Is a "Partner Clinic"?

The phrase "partner clinic" appears regularly throughout the Foundation's public material.

At first glance, the meaning seems straightforward.

Most readers are likely to assume it refers to an independent medical clinic working alongside the Foundation to deliver treatment.

However, the term itself can cover a wide range of different relationships.

A partner clinic might be:

an independently owned private medical practice;
a specialist healthcare provider;
a physician operating under their own licence;
a referral centre;
a clinic providing consultations only; or
a location where treatment is administered on behalf of another organisation.

Each of these arrangements carries different legal, clinical and regulatory responsibilities.

Without further explanation, the public cannot know which model applies.

That uncertainty is not unique to one organisation. It is a common issue whenever healthcare involves multiple independent parties operating across different countries.

The Patient Journey

To understand why this matters, consider a typical international treatment pathway.

A patient may first contact a healthcare organisation through its website.

Medical records are reviewed.

Consultations may take place remotely.

Blood or other biological material may be collected in one country.

That material may then be transported elsewhere for laboratory processing.

Once complete, treatment may be administered in a different clinic by another medical professional.

Several organisations may therefore play a role in a single patient's treatment.

Each has responsibilities.

Understanding where one responsibility ends and another begins is an important part of informed decision-making.

Questions Patients Naturally Ask

Patients considering international healthcare commonly ask practical questions.

Who is my treating doctor?

Where is my treatment taking place?

Who employs the doctor?

Which organisation carries professional indemnity?

Who do I contact after treatment?

If complications arise, which organisation is responsible for follow-up care?

Where should concerns or complaints be directed?

These are not confrontational questions.

They are sensible questions that help patients understand how their care is organised.

Most healthcare providers expect them.

Why Organisational Transparency Matters

Transparency benefits everyone involved in healthcare.

Patients gain confidence by understanding who will be treating them.

Doctors can better explain referral pathways.

Healthcare professionals can communicate more effectively with one another.

Researchers and journalists can independently verify public information.

Regulators can better understand organisational structures where necessary.

Transparency is therefore not simply about marketing.

It is about helping people make informed choices.

Cross-Border Healthcare Brings Additional Complexity

International healthcare often involves more than one jurisdiction.

Different countries have different professional regulators, healthcare laws, licensing systems and complaint procedures.

When several organisations work together across borders, understanding who performs each role becomes increasingly important.

Patients may reasonably wish to know:

Who collected my biological material?

Where was it processed?

Who verified its quality?

Who administered the treatment?

Who is responsible for my ongoing care?

These are ordinary questions whenever treatment extends beyond a single healthcare provider.

What We Were Able to Establish

From the publicly available material reviewed during this investigation, it is clear that Wellbeing International Foundation describes an international treatment model involving partner clinics and laboratory processing.

The Foundation also presents itself as working with healthcare professionals in multiple locations.

These are statements reflected within its own published material.

What was less clear from the information reviewed was the detailed structure of those individual clinical relationships.

For example, we did not identify a publicly available explanation describing the specific role of each partner clinic within the overall treatment pathway.

That observation does not mean such information is unavailable elsewhere.

It simply means it was not readily identifiable within the publicly accessible material examined for this investigation.

Opportunities for Greater Clarity

Many of the questions raised throughout this article could be addressed through greater public transparency.

For example, healthcare organisations operating international networks may choose to publish:

participating clinic names;
clinic addresses;
lead physicians;
the role each clinic performs;
information explaining how patients are allocated to clinics;
governance arrangements;
follow-up care pathways.

Providing this information helps prospective patients understand how care is organised before making significant healthcare decisions.

It also supports independent verification of publicly described clinical networks.

Why This Discussion Matters

This investigation is not about criticising innovation.

Healthcare continues to evolve, and new therapies often involve collaboration between clinicians, laboratories and specialist organisations.

That collaboration is not, in itself, unusual.

What matters is that patients understand the structure behind the treatment they are considering.

Knowing who performs each stage of care, where treatment takes place and which organisation is responsible helps patients make informed decisions with confidence.

Transparency does not weaken healthcare.

It strengthens it.

Final Thoughts

International healthcare is becoming increasingly common.

As treatment models become more sophisticated, involving multiple organisations and cross-border collaboration, transparency becomes even more important.

Patients should be able to understand not only the treatment itself but also the network of organisations responsible for delivering it.

Innovation builds hope.

Accountability builds trust.

And trust remains one of the most valuable medicines any healthcare organisation can offer.

The Invisible Clinic Network

Fri, 03 Jul 2026 11:15:28 GMT

When a Healthcare Network Is Difficult to VerifyWhy Can’t the Public Identify Wellbeing International Foundation’s 23 Partner Clinics?

When a healthcare organisation tells the public it operates through a large international network of partner clinics, most people would expect those clinics to be easy to identify.

Patients would expect names.

They would expect locations.

They would expect doctors.

They would expect some clear route to understanding where treatment is delivered and who is responsible for their care.

That expectation is not unreasonable. In healthcare, transparency is not simply a matter of marketing. It is part of trust .

This investigation began with a simple public-interest question.

Wellbeing International Foundation publicly describes a delivery network of more than twenty partner clinics across the United States and internationally. Its website refers to multiple locations, including cities across America and other parts of the world.

At first glance, that creates the impression of a significant medical network.

But when we began looking for the individual clinics behind that claim, the public record became far less clear.

This article is not about whether any treatment works.

It is not about individual patients.

It is not an allegation that clinics do not exist.

It asks something much simpler:

If Wellbeing International Foundation says it has more than twenty partner clinics, why are those clinics not clearly listed for the public to see?

The Claim

The Foundation’s own public material presents a picture of international reach.

It refers to a network of partner clinics across the United States and beyond. Cities listed include Austin, Dallas, Detroit, Los Angeles, Louisville, New Orleans, New York, Philadelphia, Reno, San Francisco, Seattle, St Louis and Virginia Beach.

These are real places.

But they are cities, not clinic names.

A city does not tell a patient where to go.

It does not identify the doctor.

It does not identify the clinic owner.

It does not provide a licence number, address, medical director or direct contact point.

That distinction matters.

There is a major difference between saying treatment is available in “Dallas” and naming the actual Dallas clinic responsible for delivering it.

For a patient, that difference is everything.

What We Looked For

Our investigation focused only on publicly available information.

We reviewed the Foundation’s website, public promotional material and the information available to prospective patients before making direct contact with the organisation.

We looked for:

clinic names;

clinic addresses;

doctors attached to each location;

medical directors;

public appointment pages;

location-specific phone numbers;

clinic websites;

and a directory of partner clinics.

What we found was a public description of a network.

What we did not find was a clear public directory identifying the clinics that make up that network.

That does not prove the clinics do not exist.

It does not prove treatment is not being delivered.

It simply means that, based on the public information reviewed, a patient may struggle to independently identify the clinics before entering the enquiry process.

That is the issue.

Why This Matters

Healthcare is not like buying an ordinary product.

Patients may be vulnerable.

They may be seriously ill.

They may be making emotional decisions.

They may be spending large sums of money.

They may be travelling internationally.

Before committing to treatment, patients should be able to understand the basic structure of the organisation they are dealing with.

Where will I be treated?

Who will treat me?

Who regulates that clinic?

Who carries medical responsibility?

Who do I contact if something goes wrong?

Those are not hostile questions.

They are normal questions.

They are the questions any responsible patient, family member or referring doctor should ask.

A transparent healthcare organisation should welcome them.

Cities Are Not Clinics

One of the clearest findings from this review is the difference between a geographic claim and a clinical directory.

A map with city names may suggest scale.

But it does not provide verification.

If a healthcare provider says it has a partner clinic in Seattle, the public should ideally be able to identify the clinic.

If it says it has a partner in New York, the public should be able to see who that partner is.

If it says it has a network across the United States, patients should be able to understand whether those clinics are active, permanent, contracted, occasional or independently owned.

Without that information, the phrase “partner clinic” remains unclear.

Does it mean a formal clinic relationship?

Does it mean an independent physician?

Does it mean a treatment location?

Does it mean a past arrangement?

Does it mean a referral contact?

The public cannot know unless the organisation explains it.

The Accountability Question

The lack of a public clinic directory also raises a second issue: accountability.

If treatment is delivered through independent partner clinics, who is responsible for each stage of the patient journey?

The Foundation?

The clinic?

The doctor?

The laboratory?

Another company?

This becomes especially important in cross-border healthcare, where biological material may be collected in one location, processed elsewhere and administered in another jurisdiction.

Patients should not have to guess who is responsible.

They should be able to understand the chain of care.

That is not only a legal issue.

It is a patient safety issue.

What Transparency Could Look Like

The questions raised in this investigation could be answered very simply.

The Foundation could publish a clear partner clinic directory.

That directory could include:

the name of each clinic;

the city and address;

the lead physician or medical director;

the clinic’s website;

the role of each clinic in the treatment process;

whether the location is currently active;

and how patients are matched to clinics.

Providing this information would not weaken the Foundation’s position.

It would strengthen it.

Transparency builds confidence.

It allows patients to verify claims.

It allows journalists to check facts.

It allows doctors to understand referral pathways.

It allows regulators to see how the network is structured.

If the clinic network is as extensive as described, then public identification of those clinics should support the claim rather than undermine it.

What We Are Not Saying

It is important to be clear.

This article does not claim Wellbeing International Foundation has no partner clinics.

It does not claim patients have not received treatment.

It does not claim individual doctors are not involved.

It does not claim wrongdoing.

What it does say is that the public-facing information reviewed does not appear to provide a clear list of the clinics behind the claimed network.

That is a fair and legitimate subject for scrutiny.

When a healthcare organisation makes a significant public claim, that claim should be capable of independent verification.

Questions for Wellbeing International Foundation

We believe the following questions deserve clear public answers:

What are the names of the 23 partner clinics?

Where is each clinic located?

Which clinics are currently active?

Who are the treating physicians at each location?

Are the clinics owned by the Foundation or independently operated?

What formal relationship exists between the Foundation and each clinic?

How are partner clinics selected?

How are patients matched to clinics?

Who is responsible for patient consent?

Who carries medical liability if something goes wrong?

These questions are not accusations.

They are basic transparency questions.

Right of Reply

Wellbeing International Foundation is invited to respond to any aspect of this article.

If the organisation wishes to provide the names and locations of its partner clinics, clarify how the network operates, correct any factual point or explain its patient pathway, we will review that information and update this article where appropriate.

This investigation is based solely on publicly available information.

We remain open to new evidence, clarification and correction.

Final Summary

This investigation began with one simple question:

Where are the 23 partner clinics?

The Foundation publicly presents itself as operating through a sizeable international network. Yet, based on the public information reviewed, the individual clinics behind that network do not appear to be clearly identified in a way that allows easy independent verification.

That matters because healthcare depends on trust.

Trust depends on transparency.

And transparency begins with patients knowing who is treating them, where they are being treated and who is responsible for their care.

Until those clinic names, doctors and locations are publicly identified, the question remains:

Where exactly is the clinic network?

Selling Words: How Wellbeing International Turns Athlete Testimonials Into Medical Suggestion

Sat, 27 Jun 2026 07:09:02 GMT

Selling Words...

The Wellbeing International Foundation blog article, “Performance, Recovery, and Resilience: Why Athletes Are Turning to Wellbeing International Foundation,” is not written like a hard medical paper.

It is written like soft persuasion.

That is what makes it dangerous.

The article does not directly say, “we regenerate athletes’ joints.”

It does not directly say, “we extend sporting careers.”

It does not directly say, “we prevent injury.”

Instead, it builds an emotional bridge.

Athletes.

Recovery.

Resilience.

Energy.

Movement.

Long-term wellbeing.

Then it asks the reader to walk across that bridge without ever being shown the evidence underneath.

The Claims Hidden Inside The Language

The article repeatedly uses careful, attractive phrases.

Athletes are said to describe “renewed energy,” “easier movement,” “better recovery rhythms,” and a sense of being more physically in sync.

This may sound harmless.

But in the context of a company promoting cell-free therapy, these are not neutral words. They are commercial signals.

They invite the reader to believe that the treatment is doing something measurable inside the body.

Yet the article provides no clinical trial data showing that athletes receiving this therapy recover faster than athletes who do not.

No randomised controlled trial.

No comparative injury data.

No independent long-term follow-up.

No objective performance outcomes.

Just stories.

Doug Baldwin: The Testimonial That Undermines The Message

The most important comparison is Doug Baldwin.

Wellbeing has used Baldwin’s testimonial as part of its promotional material. He stated that he was pleased with his infusions and believed they improved his healing time.

That is his personal experience, and he is entitled to describe it.

But personal experience is not proof.

Baldwin reportedly underwent regenerative treatment in 2017.

In 2018, he endured an injury-plagued season.

He battled multiple physical problems, including knee, shoulder, elbow, hip and groin issues.

In early 2019, he required further surgeries.

He failed a physical.

He was released by the Seattle Seahawks.

He then retired from professional football.

This does not prove the treatment failed.

But it absolutely destroys the suggestion that his testimonial can be used as evidence of long-term athletic recovery, joint preservation, career extension or meaningful sporting resilience.

If anything, Baldwin’s timeline shows exactly why testimonial marketing is so unreliable.

A man may feel better at one point.

A company may quote that feeling.

But the body’s real outcome may tell a far more complicated story.

“These Are Not Medical Claims”

The article attempts to protect itself by saying these accounts are not medical claims.

But this is where the contradiction appears.

If they are not medical claims, why are they being used in an article about performance, recovery and resilience?

If they are merely personal stories, why are they placed beside language about cell-free therapy, long-term wellbeing and athletes relying on physical performance?

The article wants the benefit of medical implication without the burden of medical proof.

That is the entire problem.

It dresses advertising in the tone of evidence, while carefully avoiding the responsibility that evidence demands.

The Missing Question

The article asks why athletes are turning to Wellbeing International.

But it never answers the more important question:

What measurable benefits have been proven in athletes?

Not felt.

Not believed.

Not reported in testimonials.

Proven.

Did treated athletes return faster from injury?

Did they require fewer surgeries?

Did they suffer fewer relapses?

Did their cartilage improve on imaging?

Did their careers last longer?

Did objective markers of inflammation improve compared with controls?

Did performance measurably increase?

The article provides no answers.

Because the article is not built on outcomes.

It is built on words.

The FDA Warning Matters

Regenerative medicine is not automatically illegitimate.

Research in this field is real.

But commercial claims must not outrun clinical evidence.

The FDA has warned that regenerative medicine products, including exosome-related products, are not approved for orthopedic conditions such as knee pain, shoulder pain, tendonitis, disc disease, back pain, hip pain, neck pain or osteoarthritis.

That warning matters because this is exactly the type of space where athletes and injured people can be emotionally vulnerable.

They want recovery.

They want movement.

They want one more season.

They want one more chance.

And where there is desperation, soft marketing becomes extremely powerful.

The Testimonial Machine

The article repeatedly relies on testimonials.

A former NFL player.

A runner.

A person with mobility problems.

A client with disc issues.

Manual workers.

Active grandparents.

These people may genuinely believe they improved.

But belief is not clinical evidence.

Pain fluctuates.

Recovery happens naturally.

Physiotherapy helps.

Surgery helps.

Rest helps.

Lifestyle changes help.

Expectation changes perception.

That is why proper medicine does not rely on testimonials.

It relies on controlled evidence.

Without that, nobody can separate treatment effect from placebo, timing, rehabilitation, natural recovery or simple hope.

Selling The Feeling

The article’s real product is not evidence.

It is feeling.

The feeling of being more capable.

The feeling of being lighter.

The feeling of recovery.

The feeling of hope.

But medicine cannot be allowed to sell feeling as proof.

Especially when the audience may include injured athletes, chronic pain sufferers, neurological patients and people who have already exhausted conventional options.

For these people, hope is not cheap.

Hope can cost thousands.

The Baldwin Problem Will Not Go Away

Doug Baldwin’s story should have made Wellbeing more careful, not more confident.

If a high-profile athlete receives treatment, believes it helps, but is then out of sport after injuries and surgeries, that story should be treated with caution.

It should not be used to imply sporting success.

It should not be used to imply long-term protection.

It should not be used to imply resilience.

The honest version would say:

Doug Baldwin reported feeling benefit after treatment. However, he later suffered significant injuries, underwent surgery, failed a physical and retired from professional football. His testimonial should not be taken as proof that the therapy regenerates joints, prevents injury, accelerates recovery or extends athletic careers.

That would be responsible.

But that is not the message being sold.

Conclusion: Words Are Not Evidence

The Wellbeing article is carefully written.

Too carefully.

It avoids making direct medical promises while surrounding the reader with language that implies medical benefit.

Recovery.

Resilience.

Energy.

Mobility.

Long-term wellbeing.

Athletic performance.

But where are the trials?

Where is the data?

Where is the independent evidence?

Where is the proof that athletes receiving this treatment do better than athletes who do not?

Until those answers are provided, the article should be seen for what it is:

not science,

not proof,

not clinical evidence,

but marketing.

A collection of carefully chosen words designed to make testimonials feel like medicine.

And that is the oldest trick in the wellness industry.

Sell the story.

Sell the hope.

Sell the placebo.

But never show the proof.

Selling the Placebo: The Doug Baldwin Testimonial and the Problem With Hope as Evidence

Sat, 27 Jun 2026 07:04:58 GMT

When a company sells a medical treatment through testimonials, the stories it chooses matter.

They are not neutral.

They are selected.

They are framed.

They are placed in front of frightened, desperate or hopeful people for a reason.

On the Wellbeing International Foundation website, one of the most powerful testimonials comes from former Seattle Seahawks wide receiver Doug Baldwin. He is not presented as an ordinary patient. He is presented as an elite athlete, a Super Bowl winner, a man whose body was once his profession.

His testimonial says he was pleased with his infusions. He says he believed the treatment improved his healing time with nagging injuries. He also says he was looking forward to the overall benefit to his long-term health.

That is powerful language.

But then comes the uncomfortable part.

Doug Baldwin reportedly travelled for regenerative treatment in 2017. In 2018, his body began to break down. That season he battled multiple injuries, including knee, shoulder, elbow, hip and groin problems. By early 2019, he had undergone shoulder and knee surgery. Shortly afterwards, the Seattle Seahawks released him after a failed physical. In May 2019, Baldwin indicated he was retiring from the sport.

This does not prove the treatment harmed him.

But it does destroy the marketing illusion.

Because if a testimonial is being used to imply healing, regeneration, recovery, protection or long-term physical benefit, then the full story matters. A man who received the treatment and was out of professional sport within roughly two years is not proof of regeneration. It is proof of how weak testimonial medicine can be.

And that is the danger.

A testimonial captures a feeling at a moment in time. It does not prove causation. It does not prove repair. It does not prove cartilage regeneration. It does not prove joint restoration. It does not prove long-term benefit.

It proves only that someone believed they felt better.

That may be real.

But belief is not medicine.

Hope is not evidence.

And the placebo effect is not a product.

The regenerative medicine industry has become expert at selling emotional certainty where scientific certainty does not yet exist. The formula is simple: take a recognisable athlete, attach the language of healing, recovery and performance, then allow the public to fill in the blanks.

The customer sees the name.

The customer sees the career.

The customer sees the words “improved healing”.

And the customer thinks: if it helped him, perhaps it can help me.

But did it help him?

That is the question the marketing does not answer.

Because the public facts show something very different from a clean success story. They show a world-class athlete still struggling with injuries, needing surgery, failing a physical and retiring from elite sport far earlier than he wanted.

Again, this does not prove failure of the treatment.

But it certainly does not prove success.

And that is the whole point.

Testimonials are not clinical trials. They are not independent medical evidence. They are not controlled. They are not blinded. They are not followed properly. They do not account for physiotherapy, surgery, rest, natural healing, elite medical support, painkillers, training changes, or the simple human desire to believe that an expensive treatment has worked.

This is where the placebo becomes commercial.

A patient pays for hope.

The body may feel different.

Pain may fluctuate.

Energy may improve.

Optimism may return.

But unless the claim is tested, measured and proven, the company is not selling science. It is selling interpretation.

And interpretation is dangerous when dressed up as medicine.

The FDA has repeatedly warned that regenerative medicine products, including stem cell and exosome-related products, have not been approved for orthopedic conditions such as knee pain, shoulder pain, tendonitis, osteoarthritis, back pain, neck pain or joint disease. The agency has also warned that patients may be misled by products that have not been shown to be safe or effective.

That warning matters here.

Because Doug Baldwin’s testimonial is not sitting in a private diary. It is sitting on a commercial-facing website, surrounded by other stories of recovery, neurological improvement, pain relief, athletic performance and renewed health.

That changes the purpose of the story.

It becomes part of the sales machine.

The public deserves to see the full picture.

Doug Baldwin may have genuinely believed the treatment helped him. That belief should not be mocked. Elite athletes live with pain most people cannot imagine. If he felt better at the time, that experience was real to him.

But a patient’s belief is not proof.

And a company using that belief to sell treatment has a responsibility to present the limitations honestly.

The honest version would say:

Doug Baldwin reported feeling benefit after treatment. However, he later suffered a serious run of injuries, underwent surgery, failed a team physical and retired from professional football. His testimonial should not be understood as proof that the treatment regenerates joints, prevents injury, extends athletic careers or produces long-term health benefits.

That would be honest.

But that is not how hope is sold.

Hope is sold by selecting the brightest sentence and removing the shadow behind it.

And that is why this matters.

Because the people buying these treatments are often not NFL athletes. They are ordinary people with arthritis, neurological disease, chronic pain, injury, fear and desperation. They do not have elite medical teams. They do not have NFL salaries. They do not have the luxury of spending thousands on a treatment that may only deliver belief.

They deserve evidence.

They deserve caution.

They deserve the truth.

The Doug Baldwin testimonial should not be treated as proof of regenerative medicine success.

It should be treated as a warning about testimonial marketing.

Because when the full timeline is examined, the story does not show a miracle.

It shows the oldest sales tool in medicine:

take hope, wrap it in celebrity, and sell the placebo.

The 1993 Illusion: How Wellbeing International Rewrites Scientific History

Sat, 27 Jun 2026 06:59:28 GMT

Dr Stephen Ray: Scientist, But Not A Medical Doctor

The blog claims Wellbeing’s “journey” began in 1993, but public company-facing records list Wellbeing International Foundation as founded in 2015. ( wellbeinginternationalfoundation.blogspot.com ) It presents Dr Stephen Ray as central to the science, while Wellbeing’s own site calls him “Senior Scientific Consultant,” not a medical doctor. ( Wellbeing International Foundation ) The cited 2019 secretome paper is preclinical/in vitro and animal work, not a human clinical proof of commercial treatment efficacy. ( Springer ) FDA and ISSCR guidance both warn against commercial use of unproven regenerative therapies outside properly regulated evidence pathways. ( U.S. Food and Drug Administration )

The 1993 Illusion: How Wellbeing International Rewrites Scientific History

The Wellbeing International Foundation article titled “The Visionaries at Wellbeing International Foundation Pioneering Cell-Free Therapy: Behind the Science” reads like the origin story of a medical breakthrough.

It presents visionaries.

It presents discovery.

It presents decades of research.

It presents Dr Stephen Ray as a central scientific figure.

It presents 1993 as though Wellbeing International itself was somehow there at the beginning of a revolutionary stem-cell discovery.

But when the claims are examined carefully, the story begins to fall apart.

The 1993 Problem

The article states that the “journey” of Wellbeing International Foundation began in 1993.

That is extraordinary wording.

Because public-facing records list Wellbeing International Foundation as founded in 2015.

So what actually began in 1993?

Was Wellbeing International operating?

Was it treating patients?

Was it running regulated clinical trials?

Was it publishing human medical outcomes?

Was it licensed as a clinic?

Or is 1993 being used as a borrowed date — a way of attaching a modern commercial operation to decades of wider scientific development that it did not own?

That distinction matters.

Stem-cell science did not begin with Wellbeing International.

Extracellular vesicle research did not begin with Wellbeing International.

The idea that cells communicate through secreted factors did not begin with Wellbeing International.

Yet the article appears to place the company inside that historic scientific timeline, as though the organisation itself was part of the foundational discovery.

That is not evidence.

That is branding.

Dr Stephen Ray: Scientist, But Not A Medical Doctor

The article places heavy weight on Dr Stephen Ray.

It describes his scientific background, his experience, his academic work and his role in developing the company’s protocols.

But there is a crucial point the public must understand.

Dr Stephen Ray is not presented by Wellbeing International’s own website as a medical doctor treating patients.

He is listed as a Senior Scientific Consultant.

In our own recorded conversation, Dr Steve Ray stated clearly that he is not a medical doctor.

That matters.

Because the public reading this article could easily come away with the impression that they are dealing with a medically led clinical breakthrough.

But where is the medical registration?

Where is the clinic in his name?

Where are the regulated human clinical trials proving the treatment works for the conditions being implied?

Where are the patient outcome studies?

Where is the evidence that this commercial therapy has been proven safe and effective through proper clinical pathways?

The article does not answer those questions.

Instead, it relies on authority language.

Academic experience.

Scientific acumen.

Faculty positions.

Collaborations.

Prestigious institutions.

But reputation language is not clinical proof.

Preclinical Science Is Not Commercial Proof

The article refers to published work showing that stem-cell secretome can accelerate tissue repair.

This is where the public needs to be extremely careful.

A laboratory study is not the same as a proven human treatment.

A mouse model is not the same as a regulated therapy.

Cell assays are not the same as clinical recovery.

Preclinical research may be interesting.

It may be promising.

It may justify further investigation.

But it does not justify selling certainty to sick or injured people.

This is one of the oldest tricks in the wellness industry:

take early-stage science,

translate it into emotional language,

then allow the customer to believe the treatment is already proven.

But promising biology is not proof of medical benefit.

The Missing Clinical Trial Problem

The article talks about safety, efficacy, ethical practice and clinical success.

But where are the trials?

Where are the randomised controlled studies?

Where are the independent peer-reviewed human trials showing that Wellbeing International’s specific treatment reverses disease, repairs joints, restores neurological function or extends sporting careers?

Where are the published outcomes from real patients?

Where is the dose-response data?

Where is the long-term safety data?

Where is the independent medical oversight?

Where are the adverse event records?

The article does not provide them.

Instead, it gives us testimonials.

Jimmy Graham.

Jameis Winston.

Max Lewinsohn.

Stories.

Feelings.

Anecdotes.

Belief.

But testimonials are not clinical evidence.

The “Patient 007” Problem

The article describes Max Lewinsohn as “patient number 007,” a man who came for treatment after a damaged knee and later became Chairman.

This is not presented as a warning.

It is presented as a success story.

But from an investigative perspective, it raises an obvious question:

How does a patient become a leader of the organisation selling the treatment?

That does not automatically mean anything improper happened.

But it does mean the story should be examined with caution.

When patient belief becomes commercial leadership, testimonial and business interest become difficult to separate.

The public deserves transparency.

Was this treatment independently assessed?

Were objective results published?

Was there imaging?

Was there medical follow-up?

Was there a controlled comparison?

Or was this simply a patient experience turned into a corporate origin myth?

Borrowed Prestige

The article repeatedly mentions prestigious research networks and institutions.

University College London.

Oxford.

Boston Children’s Hospital.

Toronto Sick Children’s Hospital.

University of Florida.

These names carry enormous weight.

But the reader must ask:

What exactly was the relationship?

Was Wellbeing International formally running clinical trials with these institutions?

Were these institutions validating the commercial treatment?

Were they supervising patient care?

Were they approving Wellbeing’s marketing claims?

Or were individual scientists connected to separate academic research that has now been used to create an aura of credibility?

Prestige by association is not proof.

A university name in a paragraph does not turn a commercial treatment into evidence-based medicine.

From Science To Sales Language

The article uses powerful phrases:

“revolutionary approach”

“true agents of repair”

“clinical success”

“profound results”

“transform lives”

“restore health and vitality”

These are not neutral scientific terms.

They are sales language.

They create expectation.

They suggest benefit.

They imply treatment effect.

And they do this while avoiding the one thing that would actually matter:

proper clinical proof.

What The Regulators Say

The FDA has warned that regenerative products, including stem-cell and exosome-related products, are not approved for many conditions commonly marketed by clinics, including orthopedic, neurological, cardiovascular and pulmonary conditions.

The ISSCR has also warned against the commercial use of unproven regenerative interventions outside proper clinical research or tightly regulated medical innovation.

That is the context in which this article must be read.

Not as a harmless blog post.

Not as science education.

But as part of a commercial narrative promoting an unproven regenerative therapy.

Conclusion: The Story Is Not The Science

The article wants readers to believe they are looking at the history of a medical breakthrough.

But what they are really seeing is a carefully constructed origin story.

1993 gives the impression of deep history.

Dr Stephen Ray gives the impression of scientific authority.

Prestigious institutions give the impression of validation.

Athlete and patient testimonials give the impression of clinical success.

But when the structure is stripped back, the same questions remain unanswered.

Where are the regulated clinical trials?

Where is the proven efficacy?

Where is the medical licensing?

Where is the transparent clinic?

Where is the independent evidence?

Where is the proof that this treatment does what the marketing implies?

Until those answers are provided, this article should not be treated as science.

It should be treated as reputation-building.

A story designed to make commercial therapy look like medical destiny.

Not proof.

Not clinical validation.

Not a breakthrough.

Just another carefully polished chapter in the sale of hope.

THE PART OF THIS INVESTIGATION THAT BROKE MY HEART

Fri, 19 Jun 2026 05:09:46 GMT

People often ask me why I continue investigating companies operating within the stem cell and regenerative medicine industry.

When I first began looking into this world, I believed I was investigating science. I expected to spend my time examining medical claims, analysing research papers, reviewing company structures and understanding the regulatory frameworks that surround emerging therapies. In many ways, that is exactly what I did.

But somewhere along the journey, the investigation changed.

Or perhaps I did.

The deeper I went, the less this became a story about science and the more it became a story about people.

Real people.

People living with Parkinson's disease, Multiple Sclerosis, Motor Neurone Disease, chronic pain, cancer, dementia and countless other conditions that slowly chip away at their independence, their confidence and, in some cases, their future. People who wake up each day carrying burdens most of us can scarcely imagine. People who have been told there is no cure, no simple answer and no guarantee that tomorrow will be any better than today.

What struck me most was not their illness.

It was their hope.

Hope is one of the most powerful forces a human being possesses. It keeps people moving forward when logic tells them to stop. It allows families to endure impossible circumstances and gives strength to those facing challenges that would otherwise seem unbearable.

When life is going well, hope is something we take for granted.

When illness arrives, hope becomes priceless.

And perhaps that is what broke my heart.

As the investigation progressed, I found myself reading stories late into the night. I listened to recordings. I reviewed testimonials. I spoke to people searching desperately for one more opportunity, one more breakthrough, one more chance to regain something their condition had taken away.

Some simply wanted relief from pain.

Some wanted more time.

Others wanted the chance to see their children grow up, to remain independent, to preserve their dignity or to hold on to a life they felt slowly slipping away.

It became impossible to view them as customers.

I saw fathers.

Mothers.

Grandparents.

Husbands.

Wives.

Children.

Human beings searching for a reason to believe that things could get better.

The more stories I encountered, the more one question began to trouble me.

At what point did desperation become a marketplace?

Because beyond the science, beyond the marketing and beyond the corporate structures, there is an uncomfortable reality that is difficult to ignore. Somewhere within parts of this industry, there appears to be a willingness to view suffering not as a tragedy, but as an opportunity.

An opportunity to sell.

An opportunity to market.

An opportunity to profit.

There is something profoundly unsettling about that.

Not because businesses should not make money. Of course they should. Innovation costs money. Research costs money. Medical progress costs money.

But there is a difference between offering hope and selling it.

There is a difference between exploring possibilities and presenting them as probabilities.

And there is a difference between supporting vulnerable people and building a business around their vulnerability.

The people seeking these treatments are often portrayed as naïve or gullible. My experience suggests otherwise.

Many are intelligent, accomplished and successful individuals. They are business owners, professionals, academics and parents who have spent their entire lives making sensible decisions. They have navigated careers, built companies, raised families and overcome challenges most people would struggle to comprehend.

What changes is not their intelligence.

It is their circumstances.

Illness changes the way people evaluate risk. Chronic pain changes the way people think about money. Fear changes the way people assess possibility.

When someone is healthy, they seek certainty.

When someone is frightened, they seek hope.

That distinction matters more than many people realise.

Hope can make extraordinary claims sound believable.

Hope can make distant possibilities feel tangible.

Hope can persuade people to take risks they would never normally consider.

And hope can convince someone to spend life-changing sums of money because the alternative feels too painful to accept.

For me, the hardest part of this investigation has never been reading scientific papers or reviewing company records. It has never been tracing offshore entities, examining corporate structures or understanding complex biological concepts.

The hardest part has been what comes afterwards.

Because not every victim loses money.

Some lose trust.

Some lose faith.

Some lose years of their lives pursuing promises that never materialise.

And some are left carrying a burden far heavier than financial loss — the belief that somehow they should have known better.

I have spoken to families who emptied savings accounts. Families who borrowed money. Families who genuinely believed they had finally found an answer, only to discover later that what they had purchased was disappointment.

That disappointment is rarely measured in pounds or dollars.

It is measured in sleepless nights.

In regret.

In self-blame.

In the painful realisation that somebody may have taken advantage of the most vulnerable moment of your life.

I wish I could tell you these stories are uncommon.

I no longer believe they are.

That is why I continue.

Not because I enjoy exposing companies.

Not because I enjoy conflict.

And certainly not because I have any personal vendetta against any individual organisation.

I continue because somebody has to speak for the people who are rarely heard.

The people who feel embarrassed.

The people who signed agreements they now regret.

The people who blame themselves when they should not.

The people who no longer have the strength, resources or energy to fight.

The people who quietly disappear once the money is gone and the promises have faded.

Investigative journalism is often portrayed as a profession driven by scepticism. There is some truth in that. Good investigators ask difficult questions and challenge accepted narratives.

But the longer I do this work, the more convinced I become that the best investigative journalism is not driven by scepticism at all.

It is driven by compassion.

It is driven by a belief that ordinary people deserve protection from those willing to exploit them.

It is driven by a belief that truth matters.

And it is driven by a belief that justice should not depend upon wealth, influence or power.

I am realistic enough to know that one article will not change an industry. One investigation will not close every loophole. One journalist will not solve every problem that exists within a rapidly evolving sector of medicine.

But if shining a light on these issues causes one family to pause, ask questions, seek independent advice and avoid becoming another cautionary tale, then every hour spent investigating has been worthwhile.

Because behind every case file is a person.

Behind every payment is a family.

And behind every promise is a responsibility.

The day we stop remembering that is the day we become part of the problem ourselves.

That is a line I refuse to cross.

THE SAME STORY, TOLD ON DIFFERENT CONTINENTS

Fri, 19 Jun 2026 05:03:23 GMT

How an American enforcement action exposed a pattern we were already seeing in Europe

Some investigations take an unexpected turn.

Ours began with a single company.

Like many journalists examining the rapidly expanding world of stem cell and regenerative medicine treatments, we started by asking questions about claims being made to patients, the evidence supporting those claims, and the increasingly complex corporate structures operating behind the scenes.

At first, it appeared to be a story about one organisation.

One company.

One set of claims.

One group of patients.

But then something happened.

During our research, we came across an enforcement action by American regulators against a company called Stem Cell Institute of America.

It was a completely different business.

Different owners.

Different country.

Different patients.

Different regulators.

And yet, as we read through the allegations, an uncomfortable feeling emerged.

We had seen much of this before.

Not the names.

Not the locations.

The patterns.

The same patterns that had already begun to emerge throughout our own investigation.

That moment changed the direction of our work entirely.

Because the question was no longer whether concerns existed around a single provider.

The question became far more troubling.

Why were investigators, scientists and regulators on opposite sides of the Atlantic describing the same warning signs?

The FTC alleged that Stem Cell Institute of America promoted expensive stem cell procedures to people suffering from chronic pain and degenerative conditions using claims that regulators argued were not supported by reliable scientific evidence.

For anybody unfamiliar with the regenerative medicine sector, that may sound like an isolated allegation.

But the more deeply we examined the wider industry, the less isolated it appeared.

Across dozens of websites, promotional videos, patient testimonials and sales presentations, the language remained remarkably consistent.

Not identical.

Consistent.

The science was always described as revolutionary.

The treatment was always positioned as being at the forefront of medicine.

Patients were encouraged to believe they were accessing something that conventional healthcare had not yet caught up with.

And almost always, the target audience was the same.

People in pain.

People with chronic illness.

People living with degenerative conditions.

People who had already exhausted conventional options.

In other words, people most likely to grasp hold of hope.

There is, of course, nothing wrong with hope.

Hope has driven medical innovation throughout history.

Without hope there would be no clinical trials, no breakthroughs and no progress.

But hope becomes dangerous when it begins masquerading as evidence.

That distinction sits at the centre of virtually every controversy surrounding the regenerative medicine industry.

The public often assumes that because something sounds scientific, it must therefore be scientifically proven.

The two are not the same.

A treatment may be based upon genuine scientific concepts while still lacking sufficient evidence to support the claims being made about it.

That gap is where many of the industry's most persistent controversies appear to live.

What struck us most was not simply the language being used.

It was the extraordinary consistency with which certain themes appeared.

Whether examining businesses operating in the United Kingdom, Europe or North America, investigators repeatedly encountered testimonials presented alongside scientific terminology.

They encountered ambitious claims attached to emerging technologies.

They encountered complex explanations that were difficult for patients to independently verify.

And perhaps most notably, they encountered prices that often ran into tens of thousands of pounds.

For somebody suffering from a progressive illness, a neurological disorder or chronic pain, such costs can be life changing.

The decision to proceed is rarely a simple financial transaction.

It is often an emotional one.

Patients are not merely purchasing treatment.

They are purchasing possibility.

That reality places an enormous ethical burden on anybody operating in this space.

The stronger the claim, the stronger the evidence should be.

The greater the promise, the greater the responsibility to substantiate it.

Yet again and again, experts consulted during investigations appear to return to the same question.

Where is the clinical evidence?

Not the theories.

Not the laboratory research.

Not the patient stories.

The evidence.

The properly conducted human clinical trials demonstrating safety and effectiveness.

Because ultimately that is the dividing line between medicine and marketing.

As our investigation expanded, we began to realise that the most important story was no longer about any individual company.

It was about the emergence of an international industry that appears to operate faster than regulators can respond.

An industry built around some of the most exciting scientific developments of modern medicine.

But also one increasingly attracting scrutiny from scientists, regulators, consumer watchdogs and investigative journalists.

The American case was not significant because it involved one clinic.

It was significant because it demonstrated something larger.

When investigators separated by thousands of miles begin asking the same questions, those questions deserve attention.

And when those questions continue to appear across multiple companies, multiple countries and multiple regulatory systems, they become impossible to ignore.

The regenerative medicine revolution may one day transform healthcare.

Scientists around the world are working tirelessly to make that future a reality.

But until evidence catches up with ambition, patients deserve something that should never be negotiable.

Transparency.

Accountability.

And proof.

Not promises.

How vulnerable patients become customers in the growing regenerative medicine industry

Fri, 19 Jun 2026 04:57:56 GMT

WHEN TWO INVESTIGATIONS START ASKING THE SAME QUESTIONS

Most investigations begin with a single thread.

A website that doesn't quite add up.

A claim that seems difficult to verify.

A company structure that appears more complicated than it needs to be.

Or simply a nagging feeling that there is more to the story than first meets the eye.

Our investigation into Wellbeing International Foundation began much the same way.

At first, the focus was straightforward. We wanted to understand the company behind the marketing. We wanted to know who was operating it, where it was operating from, and how it presented itself to patients seeking treatment. Like any investigation, the process started with documents, corporate records, addresses and publicly available information.

What we did not expect was to discover that another investigation, conducted entirely independently and from a completely different starting point, would end up arriving at many of the same questions.

That investigation, published by a newspaper following undercover work and expert analysis, focused primarily on the therapies being promoted and the claims being made to potential patients. Covert recordings, scientific experts and legal opinions all formed part of a detailed examination of how regenerative medicine treatments were being presented and marketed.

While their investigation concentrated on the science, ours followed the paper trail.

Yet despite approaching the subject from different directions, both investigations appeared to encounter remarkably similar concerns.

The newspaper investigation examined claims surrounding extracellular vesicles and other regenerative medicine concepts, alongside statements suggesting potential benefits for conditions such as Parkinson's disease and Multiple Sclerosis. Experts interviewed as part of that investigation questioned whether sufficient scientific evidence existed to support some of the claims being made and expressed concern about the difficulties patients face when attempting to distinguish between emerging science and established medical treatment.

Meanwhile, our own investigation was uncovering a different set of questions.

As we examined the company's corporate structure and operational footprint, we found ourselves looking closely at locations used within promotional material and public-facing communications. One address linked to the organisation appeared to be a multi-occupancy serviced office facility rather than a dedicated treatment centre. Another, located on London's prestigious Harley Street, appeared to function primarily as a consulting address rather than a specialist regenerative medicine facility operated directly by the company.

These observations do not, in themselves, imply misconduct.

Many legitimate businesses operate from serviced offices and consulting suites. Such arrangements are common and entirely lawful.

However, when a company promotes advanced therapies that can cost patients substantial sums of money, questions naturally arise regarding the scale and nature of the infrastructure supporting those treatments.

Patients are entitled to understand who is providing the treatment, where it originates, how it is delivered and who ultimately bears responsibility for the process.

Those questions become increasingly important when operations appear to span multiple jurisdictions and involve a network of different entities, locations and service providers.

What struck us most throughout the investigation was the recurring gap between what patients are told and what they can independently verify.

Promotional material frequently references sophisticated concepts such as extracellular vesicles, secretomes, regenerative signalling and cellular communication. To scientists, these terms describe areas of ongoing research and investigation. To the average patient, however, such language can be difficult to interpret and even harder to challenge.

Most people do not possess a background in molecular biology or regenerative medicine. They are forced to place trust in those presenting the information to them.

That trust carries an enormous responsibility.

It also creates a simple but important question.

Can the claims being made be supported by robust and independently verifiable clinical evidence?

It is a question that appeared repeatedly throughout both investigations.

The newspaper investigation approached it through scientific scrutiny.

Our investigation approached it through transparency and accountability.

Yet both ultimately arrived at the same destination.

A growing list of unanswered questions.

Perhaps that is what makes the overlap between these investigations so significant.

Not that two groups reached identical conclusions.

But that two entirely separate investigations, working independently and examining different aspects of the same organisation, found themselves asking many of the same things.

Questions about evidence.

Questions about transparency.

Questions about accountability.

Questions about oversight.

And questions about whether vulnerable patients are always being given the full picture before making life-changing decisions.

As regenerative medicine continues to grow as a global industry, these questions are unlikely to disappear.

Indeed, they are becoming more relevant with each passing year.

Patients facing serious illness deserve clear information, realistic expectations and complete transparency. They deserve to understand not only what is being offered, but also the evidence supporting it and the organisations standing behind it.

That should not be controversial.

It should be the foundation upon which trust is built.

Because while hope can be powerful, hope alone is not enough.

Patients deserve answers.

And until those answers are provided, the questions will continue to be asked.

Hope, Testimonials and Cell-Free Therapy: When Patient Stories Become a Marketing Strategy

Sat, 13 Jun 2026 06:13:57 GMT

Every successful healthcare company understands one simple truth:

People trust people.

Not scientific papers.

Not regulatory documents.

Not clinical statistics.

People trust stories.

That reality has become one of the most powerful marketing tools in modern healthcare, particularly in emerging sectors such as regenerative medicine, stem cell therapies, exosome treatments and so-called Cell-Free Therapy programmes.

Patients searching for solutions to chronic illness, pain, neurological conditions, injuries or age-related decline are often looking for hope.

And hope is most easily delivered through personal stories.

Our investigation into Wellbeing International Foundation revealed a marketing strategy that appears heavily focused on patient experiences, athlete endorsements and testimonial-driven promotion.

The question is not whether these stories are genuine.

The question is whether consumers fully understand the difference between a testimonial and evidence.

The Power of Personal Experience

A patient describing improved mobility after treatment is compelling.

An athlete discussing recovery from injury is persuasive.

A person talking about reduced symptoms creates an emotional connection that scientific studies rarely achieve.

This is why testimonials have become one of the most valuable assets in healthcare marketing.

Potential patients naturally identify with people who appear similar to themselves.

Someone suffering from pain looks for another person who experienced pain.

Someone living with a neurological condition seeks stories from others facing the same challenge.

When positive experiences are presented, they create optimism.

And optimism influences decision-making.

That is precisely why regulators pay attention to testimonials.

The Wellbeing Testimonial Network

During our investigation, we discovered that Wellbeing International Foundation operates a dedicated website focused entirely on testimonials and patient experiences.

Unlike a traditional review platform, this website is controlled by the organisation itself and forms part of its wider marketing infrastructure.

The website presents stories from patients, athletes and public figures discussing their experiences with Cell-Free Therapy.

The message is clear.

Real people.

Real stories.

Real results.

At least that is the impression being created.

The challenge is that personal experience and scientific proof are not the same thing.

The Difference Between Stories and Evidence

A testimonial tells us what one individual believes happened.

Scientific evidence attempts to determine whether the treatment actually caused the outcome.

The distinction is crucial.

For example:

A patient may report less pain.

An athlete may report faster recovery.

An individual may report feeling healthier.

All of these experiences may be genuine.

But without controlled clinical investigation, nobody can know whether the treatment itself caused those outcomes.

Other factors may be involved.

Natural healing.

Lifestyle changes.

Rehabilitation.

Placebo effects.

Concurrent treatments.

Changes in medication.

Simple coincidence.

This is why medicine relies on controlled studies rather than anecdotes.

Stories generate questions.

Evidence provides answers.

The Athlete Effect

One of the most striking features of Wellbeing's marketing is the use of professional athletes and sports personalities.

Athlete endorsements carry enormous influence.

Consumers often assume elite athletes have access to the best doctors, trainers and medical advice.

As a result, endorsements create credibility.

The problem is that sporting success does not automatically translate into scientific validation.

A former NFL player discussing treatment outcomes may be entirely sincere.

But their experience still represents a single anecdote.

Athletes can influence public perception.

They cannot replace clinical evidence.

Testimonials and Regulatory Concerns

Healthcare regulators around the world have repeatedly warned about the use of testimonials in medical advertising.

The concern is straightforward.

Patients may interpret personal experiences as proof of effectiveness.

In reality, testimonials are among the weakest forms of scientific evidence.

The UK Advertising Standards Authority has consistently stated that testimonials do not remove the requirement for advertisers to possess robust evidence supporting any objective claims being made.

In simple terms:

A claim does not become true simply because somebody says it happened.

Evidence is still required.

The Psychology of Hope

There is another reason testimonials are so effective.

They bypass rational analysis.

A scientific study requires effort to understand.

A patient story does not.

Stories are emotional.

They create empathy.

They create possibility.

They create hope.

For individuals facing chronic conditions, that hope can be incredibly powerful.

The danger is that hope may sometimes lead people to overlook important questions.

Questions such as:

What evidence supports this treatment?

Has it been independently evaluated?

What do regulators say?

What risks exist?

How many people did not experience improvement?

Testimonials rarely answer these questions.

The Missing Stories

One issue common to almost every testimonial-based marketing campaign is the absence of negative experiences.

Visitors encounter success stories.

Positive outcomes.

Recovery journeys.

Happy patients.

What they rarely encounter are:

Patients who experienced no improvement.

Patients who were disappointed.

Patients who saw no measurable change.

Patients who felt the treatment was not worth the cost.

This creates an inherent imbalance.

The consumer sees only one side of the picture.

Why Separate Testimonial Websites Matter

The existence of a dedicated testimonial website is significant.

Rather than housing success stories within the main corporate website, Wellbeing created an entirely separate destination focused exclusively on positive experiences.

This strategy provides several marketing advantages.

It allows the organisation to:

Create additional online visibility.
Dominate searches relating to reviews and testimonials.
Present positive stories without competing information.
Build emotional engagement with prospective patients.

From a marketing perspective, it is effective.

From a consumer protection perspective, it raises important questions.

The Bigger Question

Perhaps the most important issue is not whether the testimonials are true.

Perhaps the real question is:

What role should testimonials play in healthcare decision-making?

Should a patient spend thousands of pounds based primarily on stories?

Or should those stories merely act as a starting point for deeper investigation?

Most healthcare experts would argue for the latter.

Stories may inspire curiosity.

But evidence should guide decisions.

Conclusion

Wellbeing International Foundation's testimonial-focused marketing strategy reflects a broader trend across the regenerative medicine industry.

Patient stories have become one of the most powerful tools available to healthcare marketers.

They create trust.

They create emotional connection.

They create hope.

But they do not create evidence.

Consumers considering any medical treatment should remember that testimonials represent individual experiences, not scientific conclusions.

A story can be compelling.

A story can be sincere.

A story can even be true.

But in medicine, truth is established through evidence, not emotion.

And that is a distinction every patient deserves to understand before making life-changing healthcare decisions.

Selling Hope: How Wellbeing International Foundation Built a Global Marketing Ecosystem Around Cell-Free Therapy

Sat, 13 Jun 2026 06:09:27 GMT

In today's digital world, consumers rarely buy a product after visiting a single website.

Instead, they research.

They search Google.

They read reviews.

They look at testimonials.

They seek out independent articles.

They watch videos.

They investigate success stories.

And increasingly, companies understand this behaviour better than consumers themselves.

The result is a sophisticated marketing strategy designed not simply to sell a product, but to surround potential customers with a network of reassuring information.

Our investigation into Wellbeing International Foundation suggests the organisation has built precisely this type of ecosystem around its Cell-Free Therapy programme.

The question is not whether this marketing is effective.

The question is whether patients can clearly distinguish between independent information and company-controlled promotion.

The Search for Credibility

Medical treatments are difficult to sell.

Consumers are naturally cautious.

Patients want reassurance before spending thousands of pounds on healthcare interventions.

This is especially true in regenerative medicine, where treatments often involve complex scientific terminology that most people do not fully understand.

Faced with uncertainty, consumers look for signals of trust.

These signals typically include:

Testimonials
Professional endorsements
Media coverage
Scientific references
Athlete stories
Independent reviews

The more of these signals a company can create, the more credible it appears.

This appears to be a central feature of Wellbeing International Foundation's marketing approach.

The Dedicated Testimonial Website

One of the most unusual discoveries during our investigation was the existence of a completely separate website devoted exclusively to testimonials.

Most healthcare companies simply include a testimonial section on their primary website.

Wellbeing went further.

The organisation created an entirely separate platform focused on success stories, athlete experiences, and patient outcomes.

The website shares the same corporate identity and contact information as Wellbeing International Foundation.

It is not an independent review platform.

It is not operated by a consumer organisation.

It is not controlled by a regulator.

It is a company-controlled promotional asset.

That distinction matters.

Because visitors may assume they are reading independent experiences when in reality they are consuming marketing material curated by the organisation itself.

The Athlete Strategy

Professional athletes appear prominently throughout Wellbeing's marketing.

The names of former NFL players, professional surfers, and other sporting figures are used to create credibility around Cell-Free Therapy.

This is a powerful strategy.

Athletes are viewed as individuals who depend upon their bodies for performance.

When consumers see a former professional athlete discussing treatment, many assume extensive due diligence has already taken place.

The problem is that celebrity endorsement is not scientific evidence.

An athlete's positive experience may be genuine.

But it remains a personal experience rather than a controlled clinical outcome.

The distinction is important.

Consumers often confuse authority with evidence.

The Rise of Sponsored Media

During our investigation, we also identified multiple favourable articles discussing Wellbeing International Foundation appearing across various online publications.

These articles often present themselves in a journalistic style.

They discuss innovation.

They discuss leadership.

They discuss scientific advancement.

They discuss global expansion.

At first glance, readers may assume they are reading independent journalism.

Closer examination frequently reveals a different picture.

Many of these articles originate from press releases, sponsored content, business promotion platforms, or syndicated distribution networks.

This is increasingly common across the healthcare industry.

The challenge for consumers is identifying the difference between:

Independent journalism.

And promotional content presented in a journalistic format.

The two can look remarkably similar.

The Authority Loop

What emerges is a fascinating marketing structure.

A consumer discovers Wellbeing.

They visit the corporate website.

They find a testimonial website.

They encounter athlete endorsements.

They locate positive media coverage.

They read favourable business articles.

They discover interviews.

They see references to scientific innovation.

Each element reinforces the next.

The result is what marketing professionals sometimes call an authority loop.

Every piece of content points toward the same conclusion:

This organisation must be legitimate because so many sources appear to support it.

Yet many of those sources ultimately originate from the same marketing ecosystem.

The Emotional Power of Testimonials

Testimonials occupy a unique place within healthcare marketing.

Scientific studies appeal to logic.

Testimonials appeal to emotion.

A clinical trial might discuss statistical significance.

A testimonial discusses hope.

And hope is powerful.

Especially when dealing with:

Chronic illness
Neurological conditions
Injury recovery
Ageing
Pain
Quality of life concerns

Patients are not simply purchasing a treatment.

They are often purchasing possibility.

This is why regulators pay such close attention to testimonial marketing.

A powerful story can influence decision-making more effectively than a scientific paper.

The Independent Evidence Question

One question repeatedly emerged throughout our investigation:

Where is the independent evidence?

Not the testimonials.

Not the athlete stories.

Not the promotional articles.

Not the business profiles.

The independent evidence.

Consumers researching healthcare products should always ask:

What do independent clinical studies show?

What do regulators say?

What do independent specialists conclude?

What evidence exists beyond marketing material?

These questions become even more important when treatments carry significant financial costs.

The Creation of Trust

Trust is one of the most valuable assets in healthcare.

Companies know this.

Marketers know this.

Public relations professionals know this.

The challenge is that trust can be created in different ways.

It can be earned through evidence.

Or it can be manufactured through perception.

The two are not always the same thing.

The existence of multiple websites, testimonial platforms, athlete endorsements, favourable business articles, and a broad online presence creates a powerful impression of credibility.

Whether that credibility is supported by sufficient independent evidence is a separate question.

The Bigger Picture

Wellbeing International Foundation is not unique.

Many organisations operating within the regenerative medicine sector use similar strategies.

The industry increasingly relies on:

Influencers
Testimonials
Success stories
Sponsored content
Brand ambassadors
Patient experiences

The result is an environment where consumers can easily become overwhelmed by positive messaging.

The danger is that marketing begins to replace investigation.

Stories begin to replace evidence.

Emotion begins to replace scrutiny.

Conclusion

Our investigation suggests that Wellbeing International Foundation has developed a sophisticated marketing ecosystem designed to surround prospective patients with positive information.

A dedicated testimonial website.

Athlete endorsements.

Business publication coverage.

Success stories.

Corporate branding.

Each component strengthens the others.

None of this proves wrongdoing.

None of it proves that treatments are ineffective.

But it does raise an important question.

When patients are evaluating expensive healthcare interventions, are they seeing independent evidence?

Or are they seeing different parts of the same marketing machine?

For consumers considering any regenerative medicine treatment, that distinction may be one of the most important questions they can ask.

The Illusion of Infrastructure: Inside Wellbeing International Foundation's Global Footprint

Sat, 13 Jun 2026 06:06:01 GMT

Wellbeing International Foundation publicly lists its headquarters

In the world of regenerative medicine, image is everything.

Patients researching advanced therapies often look for reassurance before committing to expensive treatments. They want to see laboratories, clinics, medical professionals, scientific expertise, and an organisation that appears large enough to inspire confidence.

For many prospective patients, Wellbeing International Foundation appears to tick all of those boxes.

The company promotes Cell-Free Therapy (CFT), references a Bermuda headquarters, highlights a German laboratory, maintains a presence associated with Harley Street in London, and claims access to a network of partner clinics across multiple countries.

On paper, it presents the image of a global regenerative medicine organisation.

But when we began examining the infrastructure behind the marketing, a different picture started to emerge.

Looking Beyond the Marketing

Most patients do not investigate corporate structures.

They see an international organisation and naturally assume that the company owns clinics, employs medical professionals, operates treatment facilities, and controls the infrastructure being promoted.

However, our investigation found surprisingly little evidence that Wellbeing International Foundation directly owns the facilities associated with its public image.

Instead, the organisation appears to rely heavily on a combination of offshore registration, partner clinics, third-party laboratories, and external treatment locations.

That distinction is important.

Because there is a significant difference between operating a healthcare network and marketing services delivered through a network of independent partners.

The Bermuda Headquarters

Wellbeing International Foundation publicly lists its headquarters as:

Williams House
20 Reid Street
Hamilton HM11
Bermuda.

At first glance, this sounds impressive.

The reality appears less straightforward.

Williams House is a commercial office building located in Hamilton's financial district. Public business directories show the address being used by numerous fund administrators, investment firms, insurance companies, corporate service providers, and offshore entities.

What we did not find was evidence that the building contains:

A medical clinic
A treatment centre
A biotechnology laboratory
An infusion facility
A patient consultation centre

Based on publicly available information, Williams House appears to function as a commercial office address rather than a medical facility.

This raises an obvious question.

If the headquarters is not a clinic and not a laboratory, what operational activity actually occurs there?

Why Bermuda?

Bermuda has long been known as one of the world's leading offshore financial centres.

Thousands of international companies are registered there, attracted by regulatory structures, tax advantages, and international business services.

Operating from Bermuda is not illegal.

Many legitimate companies are based there.

However, when an organisation is marketing medical-related services, patients are entitled to understand why an offshore jurisdiction has been selected and what practical operations are being carried out from that location.

The more important question may not be why Wellbeing is registered in Bermuda.

The more important question is what Wellbeing actually does there.

The German Laboratory

Wellbeing's website refers to a GMP-certified laboratory in Germany.

This laboratory appears central to the Cell-Free Therapy process.

Yet public information does not clearly establish whether the laboratory is:

Owned by Wellbeing International Foundation
Operated by Wellbeing International Foundation
Controlled by Wellbeing International Foundation
Or simply contracted by Wellbeing International Foundation

That distinction matters enormously.

A company that owns and operates a laboratory has direct responsibility for quality control, staffing, compliance, and processing.

A company that uses a third-party laboratory operates under a very different model.

Patients deserve to know which model applies.

The Harley Street Effect

Perhaps no address carries more prestige in private healthcare than Harley Street.

For generations, Harley Street has been associated with elite medicine, specialist consultants, and private healthcare providers.

It is therefore unsurprising that many healthcare businesses highlight Harley Street connections within their marketing.

But there is an important distinction that patients should understand.

A Harley Street address does not automatically mean a company owns a clinic.

Many Harley Street addresses are:

Serviced offices
Virtual offices
Consulting rooms
Mail handling facilities
Shared office suites

The presence of an address alone tells us very little.

The key question is always:

What actually happens there?

Without transparency, patients are left to fill in the blanks themselves.

The Partner Clinic Network

Perhaps the most revealing part of Wellbeing's own description is its reference to a network of partner clinics.

Notice the language carefully.

The company does not refer to "our clinics."

Instead, it refers to partner clinics.

That wording suggests a referral or partnership model rather than direct ownership.

Again, there is nothing inherently wrong with this structure.

Many healthcare companies work through partnerships.

The issue is transparency.

Consumers should know:

Who owns the clinic?
Who employs the doctor?
Who administers treatment?
Who carries liability?
Who is responsible if complications occur?

These questions become especially important when treatments can cost tens of thousands of pounds.

The Testimonial Machine

The company's separate testimonial website adds another layer to the picture.

The website is dedicated entirely to success stories from patients and athletes who report positive experiences after treatment.

The site uses the same Bermuda address and branding as the main organisation.

The result is a marketing ecosystem that creates a powerful impression of scale and success.

Yet testimonials cannot answer questions about ownership, infrastructure, accountability, or evidence.

A positive story may influence a patient emotionally.

It does not explain who ultimately controls the treatment process.

The Accountability Gap

This is where the investigation becomes most important.

When a patient enters a traditional healthcare environment, accountability is usually clear.

There is a clinic.

There is a doctor.

There is a regulator.

There is an identifiable legal entity.

But what happens when treatment involves:

An offshore headquarters
A third-party laboratory
Independent partner clinics
Multiple jurisdictions
International payment flows

The structure becomes far more complex.

Patients may not fully understand who is responsible for each part of the process.

That uncertainty creates an accountability gap.

Questions That Deserve Answers

Our investigation leaves several important questions unanswered:

Who owns Wellbeing International Foundation?

How many employees work at the Bermuda headquarters?

Does the organisation own any treatment facilities?

Does it own the German laboratory?

Who receives patient payments?

Who contracts directly with patients?

Which entity carries legal responsibility if treatment outcomes are disputed?

How are partner clinics selected and monitored?

What regulatory oversight applies across multiple jurisdictions?

These are reasonable questions for any organisation operating in the healthcare sector.

Conclusion

Wellbeing International Foundation presents itself as an international regenerative medicine organisation with a Bermuda headquarters, a German laboratory, Harley Street connections, and a network of partner clinics.

Our investigation found that the publicly listed Bermuda headquarters appears to be a commercial office building rather than a medical facility. Public information also suggests that key elements of the treatment process may be delivered through third-party laboratories and partner clinics rather than facilities directly owned by the organisation.

None of this proves wrongdoing.

But it does raise questions.

In healthcare, trust should be built on transparency.

Patients should know who owns the infrastructure, who provides the treatment, who receives the money, and who carries responsibility.

Until those questions are clearly answered, the image of a global medical organisation may remain just that — an image.

Today, the process often works differently.

Many press release services now distribute content directly to online publishing platforms.

Articles can appear on websites that resemble traditional news outlets, even though the content was supplied by the organisation being discussed.

This creates an important distinction.

Publication does not necessarily mean independent reporting.

In many cases, it simply means the content has been distributed through a media network.

The Appearance of Authority

The average reader rarely examines how an article was published.

Most people focus on:

The headline
The publication name
The professional appearance of the website

Very few readers investigate whether the content was:

Independently researched
Written by a journalist
Submitted by a public relations agency
Distributed through a press release service

As a result, promotional content can gain credibility simply by appearing on a recognised platform.

The Questions That Often Go Unasked

Independent journalism is built upon scrutiny.

A journalist is expected to challenge claims, seek opposing viewpoints, verify information, and present balanced reporting.

When reading healthcare-related content, readers should look for evidence that these steps have taken place.

Important questions include:

What evidence supports the claims?
What do independent experts say?
What limitations exist?
What risks have been identified?
What do regulators think?
Is there any disagreement within the scientific community?

When these questions are absent, readers should consider whether the content is designed to inform or persuade.

The Language of Public Relations

Press releases are intended to create positive impressions.

Because of this, they often rely on carefully selected language.

Common examples include:

Industry-leading
Innovative
Groundbreaking
Revolutionary
Trusted
Pioneering

Such descriptions may be accurate.

However, they are also promotional.

Their purpose is to strengthen reputation and encourage confidence.

Journalism, by contrast, relies on evidence rather than adjectives.

Why Search Engines Matter

Search engines reward content.

The more content that exists discussing a particular organisation, the more visible that organisation becomes online.

This creates a powerful marketing opportunity.

A company may distribute multiple articles across different websites.

Each article reinforces similar messages.

Over time, potential customers searching online encounter article after article discussing the same organisation.

This repetition can create the impression of widespread independent recognition.

Yet many of those articles may ultimately originate from the same source.

Healthcare Requires Higher Standards

This issue becomes particularly important when discussing healthcare treatments.

Patients researching medical options are often vulnerable.

They may be seeking solutions for serious illnesses, chronic conditions, pain management, or quality-of-life concerns.

In these situations, transparency matters.

Readers deserve to know:

Who created the content.
Who paid for the content.
Whether the article was independently researched.
Whether commercial interests are involved.

Without that transparency, consumers may struggle to distinguish between information and promotion.

A Simple Rule for Readers

When you encounter an impressive healthcare article online, pause before accepting it at face value.

Ask yourself:

Who wrote this?

Who benefits if I believe it?

Who paid for it?

Was it independently investigated?

The answers may not change the facts being presented.

But they will help you understand the context.

And in healthcare, context can be just as important as the claims themselves.

The Bottom Line

Press releases are not inherently bad.

Sponsored content is not inherently bad.

Corporate communications are not inherently bad.

The problem occurs when readers mistake promotional material for independent journalism.

The internet contains more information than at any point in human history.

It also contains more marketing.

Understanding the difference may be one of the most important skills modern consumers can develop.

Editorial Note

This article examines general publishing practices within digital media and healthcare marketing. It is intended to encourage transparency, critical thinking, and informed evaluation of healthcare-related information found online.

WHO IS REALLY WRITING THE STORY?

Fri, 05 Jun 2026 11:55:33 GMT

The Growing Trend of Self-Published Healthcare Content Disguised as Independent Authority

The internet has transformed the way people research healthcare.

Before making decisions about treatments, therapies, clinics, and medical providers, many patients turn to Google in search of answers. They read articles, watch videos, browse websites, and consume large amounts of content in the hope of finding trustworthy information.

But a growing problem is emerging.

Many of the articles appearing in search results are not written by independent journalists, healthcare professionals, or scientific researchers.

Instead, they are being written by the very organisations that stand to benefit financially from the treatments being discussed.

The question is simple:

Are patients reading independent information, or are they reading marketing?

The Rise of Self-Published Authority

Modern digital publishing has created opportunities for anyone to become a publisher.

Companies no longer need to wait for journalists to write about them.

They can publish articles directly onto content platforms, business websites, online magazines, and media distribution networks.

There is nothing inherently wrong with this practice.

Businesses have every right to tell their story.

The issue arises when promotional content begins to resemble independent reporting.

Many readers see a professionally written article on a recognised platform and naturally assume the content has been researched and verified by an independent source.

In reality, that may not always be the case.

The Appearance of Credibility

Healthcare marketing has become increasingly sophisticated.

Rather than relying solely on traditional advertising, organisations now focus on creating educational content.

These articles often discuss:

Scientific developments
Medical innovation
Patient success stories
Industry leadership
Future breakthroughs

On the surface, the content appears informative.

However, readers should always ask an important question:

Who wrote the article?

If the answer is the organisation itself, then the content should be viewed through a different lens.

The Language of Promotion

One of the easiest ways to identify promotional content is through the language used.

Marketing articles frequently contain phrases such as:

Revolutionary
Groundbreaking
Visionary
Innovative
Transformational
Pioneering

These words create excitement.

They build confidence.

But they are not evidence.

Independent journalism tends to focus on verification.

Marketing focuses on persuasion.

The difference is important.

What Independent Reporting Looks Like

A genuine investigative journalist is trained to ask difficult questions.

They seek multiple viewpoints.

They examine strengths and weaknesses.

They challenge claims.

They look for evidence.

An independent article discussing a healthcare treatment would typically explore:

Clinical evidence
Regulatory status
Risks and limitations
Independent expert opinions
Contradictory findings
Unanswered questions

When these elements are missing, readers should proceed with caution.

The Search Engine Effect

Search engines reward content.

The more articles that exist about a company, the more visible that company becomes online.

Over time, a collection of positive articles can create the impression of widespread support and validation.

Consumers may see multiple articles discussing the same organisation and conclude that independent media outlets have extensively covered the story.

Yet many of those articles may ultimately originate from the same source.

Different websites.

Different headlines.

Different formats.

The same underlying message.

This phenomenon has become increasingly common in sectors such as:

Regenerative medicine
Stem cell therapies
Wellness treatments
Longevity medicine
Alternative healthcare

Why Transparency Matters

Transparency is not about accusing organisations of wrongdoing.

It is about helping readers understand where information originates.

Every healthcare article should prompt a few simple questions:

Who wrote this?
Who funded this?
Was it independently researched?
Does the author have a commercial interest?
Is opposing evidence presented?

These questions are especially important when treatments involve significant costs or vulnerable patients seeking hope.

A Better Informed Public

Patients deserve accurate information.

They deserve transparency.

And they deserve to know whether they are reading journalism, advertising, public relations, or corporate content marketing.

The solution is not censorship.

The solution is awareness.

By understanding how online authority is created, consumers can make more informed decisions and better evaluate the claims presented to them.

The internet contains extraordinary amounts of valuable information.

It also contains marketing.

The challenge for modern consumers is learning the difference.

Editorial Note

This article discusses general publishing practices within healthcare marketing and digital media. It is intended to encourage transparency, critical thinking, and informed decision-making when evaluating online healthcare information.

Who Is Actually Treating You? The Question Every Stem Cell Patient Should Ask

Fri, 29 May 2026 11:17:51 GMT

This is a subtitle for your new post

When people search for stem cell therapies, exosome treatments, extracellular vesicle (EV) therapies and regenerative medicine programmes, they are usually searching for one thing.

Hope.

Hope that pain may be reduced.

Hope that mobility may improve.

Hope that symptoms may ease.

Hope that quality of life may return.

The regenerative medicine industry understands this.

Its websites are filled with stories of innovation, scientific discovery and medical possibility.

Patients are shown impressive laboratories.

They are introduced to leadership teams.

They read articles discussing breakthroughs and future therapies.

They see testimonials from people claiming life-changing results.

But throughout our investigation into this rapidly expanding sector, one question repeatedly emerged.

A question so simple that many consumers never think to ask it.

Who is actually treating you?
Not who owns the company.
Not who wrote the article.
Not who appears in the interview.
Not who answers the telephone.

The actual medical professional responsible for your care.

Because when things go right, everyone is happy.

The real test comes when things go wrong.

The Confusion At The Heart Of Modern Regenerative Medicine

Many consumers assume that the company they are dealing with is also the clinic providing the treatment.

That assumption is not always correct.

In some cases, businesses promote treatments that are ultimately delivered by separate practitioners, separate clinics, separate laboratories or even separate organisations operating in different countries.

This can create a confusing chain of responsibility.

Patients may know the company brand.

They may know the sales representative.

They may know the person who arranged the consultation.

Yet they may know surprisingly little about the person who will ultimately be responsible for their medical care.

That should concern every consumer.

The Most Important Name On The Form

When undergoing any medical procedure, one name matters more than any other.

The clinician responsible for treatment.

Who examined you?
Who reviewed your medical history?
Who assessed the risks?
Who decided you were suitable?
Who obtained informed consent?
Who authorised the procedure?
Who takes responsibility if complications occur?

These are not technical questions.

They are fundamental patient-safety questions.

Yet many consumers entering the regenerative medicine marketplace focus almost entirely on the treatment being sold rather than the medical professional providing it.

The Power Of Branding

Modern healthcare marketing is highly sophisticated.

A consumer may encounter:
A professional website.
A polished executive interview.
A scientific-looking article.
A patient testimonial.
A business profile.
A social media campaign.
A corporate leadership team.

All of these elements create trust.

The problem is that branding can sometimes become more visible than the medicine itself.

Consumers begin to trust the organisation without fully understanding who is clinically accountable.

In healthcare, that distinction matters enormously.

What Happens If Something Goes Wrong?

It is an uncomfortable question.

But it is the question every patient should ask before handing over money.

What happens if complications occur?
Who do you contact?
Who carries professional indemnity insurance?
Who investigates concerns?
Who reviews adverse outcomes?
Who accepts responsibility?

If a company cannot clearly explain these processes, consumers should proceed with caution.

Transparency should be a basic requirement in healthcare.

Not an optional extra.

The Difference Between Marketing Responsibility And Medical Responsibility

Many businesses in the regenerative medicine sector are exceptionally good at marketing.

They produce articles.

They publish testimonials.

They conduct interviews.

They explain complex science in simple language.

There is nothing wrong with that.

The problem arises when marketing visibility becomes confused with clinical responsibility.

A person may be highly visible within an organisation while having no direct responsibility for patient treatment.

Likewise, the person carrying medical responsibility may be largely invisible to the consumer.

Patients deserve clarity.

They deserve to know exactly who is responsible for their care.

The Questions Consumers Should Demand Answers To

Before proceeding with any treatment, ask:

Who is the treating clinician?

What qualifications do they hold?

Which professional body regulates them?

Where are they licensed?

What experience do they have?

Who carries responsibility if complications occur?

Who holds the medical records?

Who carries professional indemnity cover?

Who regulates the facility?

What complaints process exists?

If clear answers are unavailable, consumers should stop and investigate further.

Why Vulnerable Patients Need Extra Protection

The regenerative medicine industry attracts people searching for solutions.

Many have chronic illness.

Many have long-term pain.

Many have exhausted conventional options.

Many are frightened.

Many are desperate.

That vulnerability creates an ethical responsibility.

Healthcare businesses should be held to higher standards than ordinary commercial enterprises.

The more vulnerable the patient, the greater the responsibility to provide transparency.

Not less.

The Accountability Gap

Perhaps the greatest risk facing consumers today is what investigators increasingly refer to as the accountability gap.

Patients know who marketed the treatment.

Patients know who sold the treatment.

Patients know who promoted the treatment.

But when problems arise, identifying who is actually responsible can become much harder.

That gap benefits nobody except those who prefer not to answer difficult questions.

Healthcare should never operate in a grey area.

Patients deserve certainty.

Patients deserve accountability.

Patients deserve answers.

Trust Must Be Earned

Trust is essential in medicine.

Without trust, healthcare cannot function.

But trust should never be based solely on websites, testimonials, articles or corporate branding.

Trust should be earned through:

Transparency.

Evidence.

Professional qualifications.

Regulatory oversight.

Clear accountability.

And honest communication.

Anything less places patients at risk.

The Bottom Line

The regenerative medicine industry may well play an important role in the future of healthcare.

Research continues.

Science evolves.

New discoveries emerge every year.

But before committing your health, your hopes and your money to any treatment programme, ask one simple question:

Who is actually treating me?

Not who owns the company.

Not who appears in the marketing.

Not who wrote the article.

The person who accepts medical responsibility for your care.

Because when hope is being sold, accountability matters.

And in healthcare, accountability starts with knowing exactly who is responsible when the promises end and the treatment begins.

Follow The Money: Why Patients Should Investigate Who Is Behind Regenerative Medicine Companies

Fri, 29 May 2026 11:09:30 GMT

When most people research a medical treatment, they focus on one thing:

Will it work?

It is an understandable question.

After all, patients seeking stem cell therapies, exosome treatments, extracellular vesicle (EV) therapies and regenerative medicine programmes are often looking for hope. Many are dealing with chronic illness, long-term pain, neurological disorders or conditions for which conventional medicine offers limited answers.

Yet during our investigation into the regenerative medicine sector, another question repeatedly emerged:

Who is actually making money from these treatments?

It may sound cynical.

But in healthcare, following the money can often reveal more than following the marketing.

The Business Behind The Promise

The regenerative medicine industry has grown rapidly over the past decade.

Websites promote revolutionary science.

Patients are shown success stories.

Executive interviews discuss the future of medicine.

Articles describe breakthrough therapies and cutting-edge biological treatments.

What consumers rarely see, however, is the commercial structure operating behind the scenes.

Who owns the business?

Who controls the finances?

Who receives the treatment fees?

Who employs the staff?

Who carries the liability?

Who is responsible if things go wrong?

These questions are rarely featured in promotional materials.

Yet they are often among the most important questions a patient can ask.

Healthcare Or Commercial Enterprise?

Many consumers assume they are dealing directly with a medical clinic.

In reality, some organisations operating within the regenerative medicine sector may function through a complex mixture of companies, consultants, laboratories, overseas providers, treatment coordinators and referral networks.

This does not automatically indicate wrongdoing.

But it can make accountability difficult to understand.

Patients should be able to identify:

Who they are paying.
Who is treating them.
Who is medically responsible.
Who regulates the service.
Who carries professional indemnity cover.

If those answers are unclear, caution is warranted.

The Leadership Question

One area that often receives little scrutiny is the background of company leadership.

Consumers naturally focus on doctors.

But directors, founders and executives can have enormous influence over how treatments are marketed, priced and sold.

When examining leadership teams, consumers should consider:

Business history.
Previous company directorships.
Dissolved companies.
Legal disputes.
Regulatory issues.
Financial history.
Professional qualifications.

None of these factors automatically prove misconduct.

However, they can help consumers understand who they are trusting.

Healthcare requires a higher standard of transparency than most industries.

The Power Of Authority

Many regenerative medicine businesses invest heavily in creating authority.

Professional websites.

Executive biographies.

Thought leadership articles.

Media interviews.

Business awards.

Industry recognition.

Partnership announcements.

All of these elements contribute to an image of credibility.

The danger is that consumers may confuse business authority with medical authority.

Being a successful entrepreneur does not automatically make someone a medical expert.

Being a skilled executive does not automatically validate a treatment.

Being featured in interviews does not constitute clinical evidence.

Patients must learn to separate branding from proof.

The Cost Of Hope

Regenerative medicine treatments are rarely cheap.

Patients may spend:

Several thousand pounds.
Tens of thousands of pounds.
Travel costs.
Accommodation expenses.
Follow-up treatment fees.
Consultation charges.

For many families, these costs represent significant financial commitments.

Some patients use savings.

Others borrow money.

Some delay conventional treatments while pursuing alternative options.

The financial risk can therefore be substantial.

That is precisely why transparency matters.

The more money involved, the greater the responsibility to provide clear and accurate information.

Questions That Every Patient Should Ask

Before committing to any treatment, consumers should consider the following:

Who owns the company?
Who benefits financially from my treatment?
Who is medically qualified?
Who is clinically responsible?
Where is the treatment actually performed?
Who regulates the service?
What evidence supports the claims?
What risks have been identified?
What happens if complications arise?
What happens if the treatment fails?

These questions should never be viewed as confrontational.

They are sensible due diligence.

The Difference Between Hope And Evidence

One recurring theme throughout the regenerative medicine industry is the use of powerful emotional narratives.

Stories of recovery.

Stories of transformation.

Stories of renewed quality of life.

Such stories can be inspiring.

But they can also be persuasive sales tools.

Patients must remember that testimonials are not clinical trials.

Personal experiences do not replace scientific evidence.

Anecdotes do not establish effectiveness.

And emotional marketing should never be mistaken for proof.

Why Transparency Builds Trust

Trustworthy organisations should welcome scrutiny.

They should provide clear answers.

They should explain:

Their structure.
Their regulation.
Their leadership.
Their evidence base.
Their responsibilities.

The more transparent a company is, the easier it becomes for patients to make informed decisions.

Opacity, complexity and confusion benefit nobody except those who prefer not to answer difficult questions.

The Bottom Line

Regenerative medicine may well play an important role in the future of healthcare.

Research continues.

Scientific understanding develops.

New discoveries emerge.

However, consumers should never allow excitement about future possibilities to replace proper investigation today.

Before spending large amounts of money on any stem cell, exosome or regenerative medicine treatment, follow the money.

Understand who is behind the business.

Understand who benefits financially.

Understand who carries responsibility.

And most importantly, understand the difference between a medical promise and a proven medical outcome.

Because in healthcare, trust should never be purchased through marketing.

It should be earned through transparency, evidence and accountability.

The Credibility Trap: How Corporate Success Can Be Mistaken For Medical Expertise

Fri, 29 May 2026 11:01:11 GMT

One of the biggest dangers facing patients searching for alternative medical treatments today is not necessarily the treatment itself.

It is the credibility trap.

Across the world, thousands of patients are turning to regenerative medicine, stem cell therapies, exosome treatments and other forms of experimental biological interventions in the hope of finding solutions where conventional medicine has failed.

Many of these patients are intelligent, cautious people.

They conduct research.

They read articles.

They watch interviews.

They study websites.

They investigate company backgrounds.

Yet despite their efforts, many still fall into the same trap.

They mistake corporate credibility for medical credibility.

The Modern Healthcare Sales Machine

The private healthcare industry has changed dramatically over the past decade.

Medical businesses no longer rely solely on doctors and clinics to attract patients.

Today they use sophisticated marketing techniques borrowed from the corporate world.

Executive interviews.

Business magazine profiles.

Leadership articles.

Success stories.

Personal branding campaigns.

Social media influence.

Professional public relations.

Corporate storytelling.

The result is a carefully constructed image of authority.

The consumer begins to feel reassured.

The company appears successful.

The leadership appears confident.

The website appears professional.

The messaging appears consistent.

Before long, trust begins to develop.

But consumers should stop and ask themselves an important question:

What exactly am I trusting?

Being Successful In Business Is Not The Same As Being Qualified In Medicine

This distinction is often overlooked.

Many healthcare organisations are led by individuals with impressive backgrounds in business, finance, recruitment, sales, investment, technology or corporate management.

There is absolutely nothing wrong with that.

Businesses need capable leaders.

Healthcare organisations need effective management.

The problem occurs when commercial experience becomes confused with clinical expertise.

A successful entrepreneur is not automatically a medical expert.

A company director is not automatically a scientist.

A talented salesperson is not automatically a clinician.

An impressive executive profile is not evidence of medical effectiveness.

Yet consumers often absorb these signals subconsciously.

If someone appears successful, many assume they are also trustworthy in every other area.

Psychologists refer to this as the "halo effect."

The regenerative medicine sector appears particularly vulnerable to this phenomenon.

The Authority Effect

Investigations into private healthcare marketing repeatedly reveal the same pattern.

Consumers are introduced to a company through positive content.

They read an executive interview.

They discover articles discussing innovation.

They find success stories.

They see references to advanced science.

Gradually, authority is established.

The consumer begins to believe they are dealing with experts.

However, authority can be manufactured.

Real authority comes from:

Clinical evidence
Scientific validation
Regulatory oversight
Peer-reviewed research
Medical qualifications
Transparent governance

Everything else is marketing.

The Missing Questions

When patients are considering expensive regenerative treatments, they often focus on the treatment itself.

What they should also be investigating is the structure behind the business.

Questions worth asking include:

Who owns the company?
Who runs the company?
Who makes treatment decisions?
Who carries medical responsibility?
Who regulates the treatment?
Who carries professional liability?
Who handles complaints?
Who answers when things go wrong?
Many patients never ask these questions.
They assume someone else already has.
That assumption can be costly.

Hope Creates Vulnerability

The regenerative medicine marketplace is unique because many of its customers are vulnerable.

People suffering from chronic illness.

People living with pain.

People caring for disabled children.

People with neurological conditions.

People facing progressive disease.

People who have been told there are limited treatment options available.

Hope is powerful.

And powerful emotions can influence decision-making.

This is not a criticism of patients.

It is human nature.

When someone believes a treatment might change their life, they naturally want to believe the people offering it are credible.

That is exactly why consumers must slow down and investigate thoroughly.

Follow The Evidence, Not The Personality

One of the oldest rules in investigative journalism is simple:

Follow the evidence.

The same principle applies to healthcare.

Consumers should not be persuaded by:

Personal charisma
Corporate titles
Impressive websites
Executive interviews
Social media profiles
Inspirational stories

Instead they should ask:

Where is the evidence?

What clinical data exists?

What independent research supports the claims?

What do regulators say?

What risks have been identified?

What outcomes have been documented?

Evidence should always outweigh personality.

Why Transparency Matters

Trustworthy organisations should welcome scrutiny.

They should welcome questions.

They should welcome independent examination.

Patients should never feel uncomfortable asking:

Are you regulated?

Are you registered?

Who is medically responsible?

What qualifications do your practitioners hold?

What evidence supports your treatment?

What are the risks?

What happens if the treatment fails?

These questions are not hostile.

They are responsible.

Any organisation handling healthcare decisions should be able to answer them clearly and transparently.

The Bottom Line

Corporate success can be impressive.

Professional branding can be impressive.

Strong leadership can be impressive.

But none of these things prove medical effectiveness.

Consumers must be careful not to confuse business credibility with scientific credibility.

The two are not the same.

Before committing significant amounts of money to any stem cell, exosome or regenerative medicine programme, take a step back.

Look beyond the website.

Look beyond the interviews.

Look beyond the testimonials.

Look beyond the personalities.

Focus on the evidence.

Because when healthcare is involved, the most important question is not who sounds convincing.

It is who can prove what they are claiming.

And in medicine, proof matters far more than presentation.

The Breakthrough Without the Doctors? How Branding, Prestige and Hope Built a Regenerative Medicine Empire

Fri, 15 May 2026 09:34:22 GMT

For months, investigators have examined the digital footprint, corporate structure, public marketing, and leadership profiles connected to Wellbeing International Foundation Ltd.

What began as a routine investigation into regenerative medicine marketing slowly evolved into something far more troubling.

Not because investigators uncovered a traditional clinic.

But because they struggled to find one at all.

Instead, what emerged appeared to be a sophisticated ecosystem built around perception:

scientific language,
emotional marketing,
prestige branding,
offshore structures,
and vulnerable people searching desperately online for hope.

And at the centre of it all sits a question investigators still cannot fully answer:

How does an organisation present itself as a global leader in regenerative medicine while appearing to operate without the transparent medical infrastructure the public naturally assumes exists?

The Image of Scientific Authority

To the average visitor, the presentation is compelling.

The branding projects professionalism and confidence.
The terminology sounds advanced and scientific.
The messaging speaks of innovation, ethical healing, and regenerative breakthroughs.

For worried families or chronically ill patients, it creates a powerful impression:
This looks like the future of medicine.

But investigations rarely stop at appearances.

As investigators dug deeper into the structure behind the branding, a very different picture began to emerge.

One built not around visible hospitals, laboratories, and large clinical teams — but around business structures, consultancy relationships, and carefully managed perception.

Following the Leadership Trail

One of the first major questions investigators asked was simple:

Who is actually running this operation?

Public biographies connected to Managing Director Andrew Chancellor describe a background rooted primarily in:

banking,
executive recruitment,
commercial strategy,
and business development.

Investigators found little evidence publicly linking Chancellor to traditional clinical medicine, hospital management, laboratory leadership, or frontline healthcare before his involvement in regenerative medicine ventures.

Again, this alone does not imply wrongdoing.

Business professionals exist throughout healthcare industries.

But when a company positions itself as a groundbreaking scientific authority, the public reasonably expects visible medical leadership at the centre of the operation.

Instead, investigators repeatedly encountered structures built around:

advisers,
consultants,
external affiliations,
international partnerships,
and commercial positioning.

The visible clinical backbone remained difficult to identify.

The Clinic That Appears Difficult to Find

As scrutiny intensified, investigators attempted to establish the organisation’s direct clinical footprint.

Where were the hospitals?
Where were the laboratories?
Where were the permanently employed specialist doctors?
Where was the visible medical infrastructure operating directly under the organisation itself?

Investigators struggled to find clear answers.

Instead, what appeared publicly visible was:

a Bermuda-linked corporate structure,
satellite connections to Harley Street,
consultancy relationships,
and broad claims surrounding regenerative medicine innovation.

This distinction matters enormously.

Because vulnerable patients often assume they are engaging directly with fully established medical institutions when the reality may instead involve a network of affiliated entities, overseas partnerships, external clinics, and commercially structured operations spanning multiple jurisdictions.

Harley Street: The Power of Prestige

Few addresses in global healthcare carry more psychological influence than Harley Street.

For generations, the London district has represented elite private medicine, specialist expertise, and medical authority.

That reputation alone holds extraordinary marketing power.

But investigators caution that a Harley Street address does not automatically equal clinical depth or institutional infrastructure.

Throughout the district, serviced offices, consultation suites, and rented professional spaces are widely available.

The postcode itself has become a branding asset.

And in industries driven heavily by perception and trust, perception can become commercially invaluable.

Investigators therefore began examining whether associations with Harley Street may be functioning as part of a wider legitimacy framework — helping project scientific authority even where transparent in-house infrastructure remains difficult to independently verify.

The Digital Hunt for Vulnerable People

The investigation then moved online.

Beneath the public-facing branding, investigators identified what appeared to be carefully structured search-engine targeting systems designed to attract vulnerable audiences searching online for autism-related therapies and alternative medical solutions.

Dedicated autism-related landing pages.
Emotionally charged wellness language.
Search-engine optimisation structures targeting highly sensitive medical queries.

Investigators examining sections of the site architecture identified what appeared to be deliberate keyword-targeting strategies aimed at intercepting vulnerable families at the very beginning of the customer journey.

The significance of this cannot be overstated.

Because the sales process no longer begins in a consultation room.

It begins on Google.

Late at night.
Desperate searches.
Exhausted parents.
Chronically ill patients.
Families searching for miracles.

That is where the funnel appears to start.

Selling Possibility Without Making Promises

One of the most sophisticated aspects of the marketing observed during this investigation is the careful use of implication.

Explicit guarantees appear limited.
Direct promises are often avoided.

Instead, the language repeatedly centres around:

transformation,
hope,
healing,
innovation,
regeneration,
and advanced therapies.

This creates an emotionally powerful atmosphere while remaining legally safer than direct medical claims.

It is a marketing strategy increasingly common within controversial wellness sectors:
suggest possibility,
avoid certainty,
sell aspiration,
maintain plausible deniability.

The result is an ecosystem where vulnerable people may psychologically interpret far more than is ever explicitly stated.

Why Regulators Often Move Slowly

One of the most difficult realities investigators encountered is that operations like these often exist within highly complex legal grey zones.

Law enforcement agencies and regulators face enormous challenges because:

structures span multiple countries,
companies operate through offshore jurisdictions,
consultants replace direct employment,
affiliate clinics create distance,
and carefully worded disclaimers avoid explicit guarantees.

As a result, proving criminal wrongdoing can become extremely difficult even where ethical concerns continue mounting.

Operations may present themselves as:

educational,
wellness-focused,
consultative,
or experimental rather than directly claiming guaranteed outcomes.

That ambiguity slows enforcement dramatically.

Meanwhile, vulnerable patients continue entering the system.

The Bigger Question Facing Modern Medicine

This investigation is not an attack on legitimate regenerative medicine research.

Stem cell science continues to hold enormous scientific potential.

Nor does this investigation claim to determine the effectiveness or ineffectiveness of individual treatments.

But it does raise serious concerns about the modern intersection between:

medicine,
branding,
digital marketing,
offshore business structures,
and vulnerable human psychology.

Because in today’s online world, perception itself has become monetised.

A prestigious address can create authority.
Scientific terminology can create trust.
Testimonials can create emotional persuasion.
Luxury branding can create legitimacy.
Search-engine targeting can capture desperation.

And together, those elements can create something extremely powerful:
the appearance of medical certainty in the minds of vulnerable people searching for hope.

The Final Question

At the centre of this investigation lies one final question — perhaps the most important of all:

When organisations market themselves as world-leading forces in regenerative medicine, should they be expected to provide complete transparency regarding:

their doctors,
their laboratories,
their clinics,
their regulatory oversight,
and the true structure behind the branding?

Because when desperate people place their trust, their health, and often enormous sums of money into systems promising hope, image alone should never be enough.

Especially when investigators continue asking the same question over and over again:

Where is the medicine behind the marketing?

The Clinic With No Clinic? Inside the Corporate Structure Behind Wellbeing International Foundation Ltd

Fri, 15 May 2026 09:31:52 GMT

As investigators continued examining the structure behind Wellbeing International Foundation Ltd,

Publicly, the organisation presents itself as a pioneering force in regenerative medicine — a groundbreaking operation positioned at the forefront of advanced stem cell science, ethical healing, and innovative therapies.

The branding is polished.
The language is ambitious.
The imagery projects scientific authority and medical sophistication.

But behind the carefully managed presentation, investigators repeatedly encountered the same unanswered question:

Where is the actual clinic?

A Medical Leader — Without Medical Leadership?

For any organisation presenting itself as a transformative force within advanced medicine, the public naturally expects to find certain fundamentals:

specialist doctors,
clinical directors,
laboratory scientists,
regulated treatment facilities,
and transparent medical oversight.

Yet investigators examining publicly available company information, biographies, and operational structures struggled to identify a visible in-house clinical core.

Instead, the structure appears heavily weighted toward:

business development,
consultancy relationships,
investment-linked operations,
external affiliations,
and commercial leadership.

According to public biographies published online, Managing Director Andrew Chancellor’s background is described primarily in banking, executive recruitment, commercial strategy, and business development rather than medicine or clinical practice.

Additional interviews and promotional profiles similarly reference commercial and recruitment sectors prior to involvement in regenerative medicine and bioscience ventures.

That fact alone does not imply wrongdoing.

Business professionals operate within healthcare industries every day.

However, it does raise an important public-interest question:

How does an organisation market itself as a world-leading regenerative medicine authority while its visible leadership structure appears rooted predominantly in business rather than transparent clinical expertise?

The Missing Infrastructure

As the investigation deepened, further concerns emerged regarding the apparent absence of substantial clinical infrastructure directly owned or operated by the organisation itself.

Investigators struggled to identify evidence of:

owned hospitals,
permanent treatment facilities,
in-house laboratories,
or a transparent roster of permanently employed specialist doctors directly operating under the company structure.

Instead, the organisation appears to rely heavily upon:

consultants,
associates,
advisers,
external clinics,
and international affiliate relationships.

This distinction is critical.

Because vulnerable patients searching online for hope often believe they are engaging directly with fully established medical institutions when in reality they may instead be entering complex commercial networks operating across multiple countries and jurisdictions.

That gap between perception and reality sits at the centre of growing concerns surrounding the regenerative medicine industry worldwide.

The Power of Harley Street

One of the most striking elements investigators encountered was the organisation’s connection to Harley Street — one of the world’s most recognised medical addresses.

For generations, Harley Street has been associated with elite private healthcare, specialist medicine, and medical prestige.

But investigators caution against confusing a prestigious address with clinical infrastructure.

Serviced offices, meeting rooms, consultation spaces, and satellite business facilities are widely available throughout Harley Street.

The postcode itself carries enormous commercial value.

Simply operating from, renting space within, or holding consultations in Harley Street does not automatically make an organisation a world-leading medical institution.

Yet from a branding perspective, the association can be extremely powerful.

The combination of:

luxury presentation,
scientific language,
professional consultation environments,
and a Harley Street address

can create an overwhelming perception of legitimacy in the minds of vulnerable patients.

Investigators therefore began asking a difficult question:

Are some regenerative medicine organisations leveraging the reputation of Harley Street itself to project a level of scientific authority that exceeds the visible reality of their underlying infrastructure?

Offshore Structures and Bermuda

The investigation also uncovered links to Bermuda — an offshore jurisdiction commonly used within international business structures.

Again, offshore registration is not inherently improper.

Many legitimate global companies operate through offshore entities for legal and financial reasons.

However, within sectors involving expensive experimental medical treatments and vulnerable patients, offshore structures naturally raise additional questions regarding:

accountability,
transparency,
jurisdiction,
regulatory oversight,
and legal responsibility.

Patients considering life-changing therapies deserve to know:

who regulates the treatments,
where complaints can be pursued,
which legal systems apply,
and who ultimately carries responsibility if something goes wrong.

Yet investigators repeatedly encountered structures appearing significantly more international and corporate than medically transparent.

The Business of Hope

One theme continued emerging throughout this investigation:

Hope itself has become an industry.

The regenerative medicine sector now operates within a highly emotional marketplace involving:

autism,
neurological disorders,
chronic pain,
autoimmune disease,
anti-ageing,
and degenerative conditions.

Families facing serious diagnoses are often desperate for answers.
Patients living with chronic illness are often willing to try anything.
Conventional medicine can leave many people emotionally exhausted.

That creates a uniquely powerful commercial environment.

And within that environment, branding matters enormously.

Investigators observed repeated use of language centred around:

breakthroughs,
transformation,
healing,
advanced therapies,
innovation,
and life-changing treatment possibilities.

Importantly, many claims appear carefully phrased to imply hope without making direct guarantees.

That distinction matters.

Because emotionally suggestive language can be enormously persuasive even when explicit medical promises are avoided.

Why Authorities Often Struggle to Intervene

One of the most frustrating aspects of the regenerative medicine sector is how difficult it can be for regulators and law enforcement agencies to intervene quickly.

Why?

Because many operations function within carefully managed legal grey areas.

The structure itself creates complexity:

multiple jurisdictions,
offshore companies,
affiliate clinics,
consultants instead of direct employees,
carefully worded disclaimers,
and implied rather than explicit claims.

As a result, fraud investigators often face enormous evidential challenges before enforcement action can even begin.

Operations may present themselves as educational, experimental, consultative, or wellness-focused rather than directly claiming guaranteed medical outcomes.

That legal ambiguity allows many organisations to continue operating while scrutiny slowly builds around them.

Meanwhile, vulnerable patients continue searching online for hope.

The Question That Demands an Answer

This investigation does not claim that regenerative medicine itself lacks scientific potential.

It unquestionably remains an important area of ongoing research.

Nor does this investigation seek to make criminal allegations unsupported by evidence.

But it does raise serious public-interest concerns about the widening gap between:

scientific appearance,
commercial branding,
and transparent clinical accountability.

If an organisation presents itself as a revolutionary medical leader, the public deserves clear answers regarding:

who the doctors are,
where the clinics are,
where the laboratories are,
who regulates the treatments,
and who carries responsibility when vulnerable patients place their trust — and often enormous sums of money — into the system.

Because in medicine, image should never outweigh evidence. And branding should never outrun accountability.